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Summary 
It is increasingly apparent that cancer cells exhibit major intraclonal and interclonal 
heterogeneity that impacts on disease behaviour, response to treatments as well as clinical 
outcomes for patients.  Understanding this diversity is critical to gain insights that ultimately 
influence treatment decisions in the era of personalised medicine.  There is an increasing need 
to identify unique and relevant diagnostic and prognostic protein biomarkers to allow better 
stratification.  Identification of aberrant gene expression patterns is one way in which 
additional insights into cancer causation can be discovered and can also inform novel 
therapeutic targets. 
In this study we sought to focus on a group of proteins that are predominantly present in the 
germline but not in somatic cells.  It is now well established that cancer cells exhibit aberrant 
expression of germline factors.  Cancer testis antigens (CTAs) are one such family of proteins 
that exhibit increased presence in a variety of cancers and are also potentially immunogenic.  
As meiotic cell division is restricted to germline cells such as the testis, we hypothesised that 
identification and characterisation of genes that govern this process may yield additional 
clinically useful biomarkers that are also relevant to disease biology and behaviour.   
With the aid of a pre-existing computational and bioinformatics approach, we first identified a 
subset of genes, some of which were likely to be involved in meiosis, and interrogated normal 
and cancerous cells to ascertain their expression pattern.  This allowed us to identify a distinct 
cohort of candidate genes that appeared to be predominantly expressed in the germline and 
cancer.  Immunohistochemistry using normal and (predominantly colorectal) cancer tissues 
was performed for further evaluation.  Significantly, we identified two novel proteins 
(C20orf201 and TEX19) as putative meiosis-associated proteins that may have enhanced 
presence in cancer and the potential to be immunogenic.   
In summary, this research into germline restricted genes in cancer vs normal tissues has 
identified two previously uncharacterised proteins that are likely to be relevant for the 
biology, behaviour or therapy of some cancers and has also identified a cohort of further 
genes that warrant further scientific exploration.   
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1. Introduction 
1.1. Cancer 
1.1.1. The burden of cancer 
Cancer is one of the most prevalent causes of human mortality and the proportion of deaths 
from the disease is projected to increase to an extent it may collectively become the commonest 
cause (Mathers and Loncar, 2006; Seigel et al., 2015).  Cancer is predominantly but not 
exclusively a disease of old age and as human longevity improves so the levels of cancer 
increase but the burden of disease varies across different regions of the World, impacted to 
some degree by economic prosperity (Mathers et al., 2009; Siegel et al., 2015).  There are 
important gender differences in cancer incidence but, overall, colorectal cancer is the second 
most common cancer diagnosed in the UK and ovarian cancer is the fifth most common cause 
of cancer-related death in women after breast, lung, colorectal and pancreatic cancer (Hossack, 
2012; Seigel et al 2015). 
1.1.2. Cancer definition and oncogenesis 
The diverse functions within the human body require the coordinated expression of distinct 
genes in time and place; a process governed by homeostatic mechanisms occurring throughout 
the body.  Cancer, as with other diseases, can be seen as a failure of homeostasis, where cells 
divide uncontrollably and can develop the ability to invade and metastasise to other regions of 
the body.  Although cancer usually arises from a primary site or group of cells, the process of 
oncogenesis (or carcinogenesis) is a drawn out process, where the cells acquire a sequential 
series of changes (e.g., genetic and epigenetic alterations) that ultimately lead to the cancer 
phenotype (Stratton et al., 2009).  This process typically takes place over a period of years and 
is the main reason cancer becomes more common as we get older.  Exceptions to this general 
‘rule’ are the few cancers which can be considered to arise from a single (genetic) event: for 
example, NUT midline carcinomas and many paediatric cancers fall into this group (French, 
2012; Horton et al., 2007; Pui et al., 2011).  In addition the occurrence of chromothripsis has 
also been suggested to occur in up to 3% of human malignancies, whereby the vast array of 
genetic alterations can be accounted for by a single catastrophic genetic event, rather than a 
progressive series of alterations (Stephens et al., 2011). 
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1.1.3. Hallmarks of cancer 
Several distinct phenotypes have been described for cancers, which are considered necessary 
for cancer formation.  In a seminal review six ‘hallmarks’ of cancer were described – see Figure 
1.1 (Hanahan and Weinberg, 2000).  Four additional characteristics have now been added to 
this list – see Figure 1.2 (Hanahan and Weinberg, 2011).  Cancer cells must be able to: evade 
apoptosis, growth suppressive signals and immune attack; sustain proliferative signals and 
replicate indefinitely; invade surrounding tissues and induce angiogenesis in order to grow, 
spread and metastasize; and adjust their metabolic cellular machinery to serve their cause.   
 
 
 
 
 
 
 
 
 
 
Figure 1.1. The original six hallmarks of cancer proposed in 2000.    
These hallmarks can be seen to arise from either increased or abnormal function of genes that directly 
promote these attributes, or reduction in the function of genes that guard against their development. 
Adapted from Hanahan and Weinberg (2011). 
 
The process of metastasis, whereby a cell or group of cells escape from the primary tumour and 
travel to distant sites within the body where they set up ‘colonies’ is a leading cause of death 
from cancer.  Understanding the key drivers or events that lead to development of these 
attributes and/or developing treatments which target multiple hallmarks is important.  Two key 
drivers of the oncogenic process, which can also be considered additional ‘hallmarks’, are 
depicted in Figure 1.2 – these are genomic instability/mutability and tumour-promoting 
inflammation (Hanahan and Weinberg, 2011; Mantovani et al., 2008; Negrini et al., 2010).  
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Figure 1.2. The additional hallmarks and enabling characteristics of cancer.   
Four new features (7-10 in the above figure) of cancer were added to the original six hallmarks (labelled 
1-6 in the above figure) that had previously been described (see Figure 1.1).  Deregulation of cellular 
metabolism and avoiding immune destruction are considered as additional hallmarks; whereas genomic 
instability and cancer-promoting inflammation are considered as mechanisms to promote or enable the 
other hallmarks to develop.  Adapted from Hanahan and Weinberg (2011).   
 
 
Many of these attributes or hallmarks of cancer can be ascribed to the activation of tissue-
specific genes; a fact that should aid the development of new treatment strategies (Wang et al., 
2014).  There is little doubt that evading immune attack is of fundamental importance for most, 
if not all, cancers.  There are various immunotherapeutic approaches, which aim to reverse what 
can been seen as the immune system’s failure in preventing cancer formation; some of these 
will be discussed later in this chapter.  Such approaches are often targeted at the products of 
tissue specific genes, which are activated out of context and in tissues in which there are not 
normally found (Hunder et al., 2008; Robbins et al., 2015; Wang et al., 2014). 
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1.1.4. Classification 
The most common type of cancers are the carcinomas.  These are cancers that arise from 
epithelial cells, or the cells lining the internal viscera.  Epithelial cells are not only a common 
cell type, but as they line the viscera, they are frequently exposed to compounds that could 
potentially initiate genetic/epigenetic change.  Two illustrative examples of this are: lung 
cancer, which is more common in people who smoke; and skin cancer, whose risk is increased 
by increased exposure to the Sun’s ultraviolet ionising (i.e. free-radical promoting and DNA 
damaging) radiation.  Other types of cancer are the sarcomas, which arise from the 
mesenchymal tissue.  The mesenchyme, or more specifically the mesenchymal stem cells, can 
differentiate into muscle, fat, nerves, cartilage, tendons, bone, blood vessels and the fibrous 
connective tissue that supports other cells.  Sarcomas only make up 1% of all cancers but over 
10% of cancers in children and young adults (Bleyer et al., 2008).  Haematological 
malignancies make up the final group of cancers and include: myeloma (which arises from the 
plasma cells in the blood), the myeloproliferative disorders (overproduction of mature blood 
cells), leukaemias (which arise from the white blood cells) and lymphomas (which arise from 
lymphoid tissue).  
1.1.5. Genes and cancer development 
The differentiation and division of cells is tightly controlled to maintain tissue homeostasis and 
normal cellular and as a result visceral, structure and function.  Three classes of genes (tumour 
suppressor, oncogenes and genomic stability genes) can be considered as contributing to cancer 
development, through genetic mutations, chromosomal rearrangements or overexpression, 
which disrupts their normal function.  Firstly, tumour suppressor genes (or anti-oncogenes) 
encode proteins that inhibit cell proliferation and/or induce apoptosis.  It can be seen that loss 
or reduction of tumour suppressor gene function can lead to deregulated and uncontrolled 
proliferation of cells, which is a hallmark of cancer.  Proto-oncogenes are normal genes that 
produce proteins that promote cellular proliferation; they can through a genetic change become 
an oncogene.  Oncogenes have the potential to also promote uncontrolled cellular proliferation 
by overriding the inhibitory signals (i.e. of tumour suppressor gene products) in the cellular 
milieu.  A third class of genes, the genomic stability genes, can be viewed as a subcategory of 
tumour suppressor genes.  These genes are involved in DNA repair and chromosome 
recombination and contribute to tumourigenesis by failure to maintain genome integrity; their 
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function is also altered by genetic or epigenetic change.  So, oncogenes promote cancer 
development, and tumour suppressor genes along with genome stability genes guard us against 
its formation (Hanahan and Weinberg, 2011; Vogelstein and Kinzler, 2004).  Table 1.1 
summarises examples of well-characterised tumour suppressor genes and Table 1.2 shows 
examples of some oncogenes.   
 
Table 1.1.  Examples of tumour suppressor and genome stability genes and their associated cancer 
types.   
Gene Function Common cancer types 
APC Promotes beta-catenin degradation, thus influencing 
cell adhesion and transcriptional activation of other 
genes (Aoki and Taketo, 2007) 
Colorectal carcinomas; Desmoid 
tumour  
BRCA1 DNA repair and maintaining genome stability (Silver 
and Livingston, 2012) 
Breast and ovarian carcinomas 
RB1 G1 checkpoint control inhibiting cellular proliferation 
(Giacinti and Giordano, 2006) 
Retinoblastoma; sarcoma; breast, 
lung and bladder carcinomas 
TP53 Cell cycle arrest; autophagy regulation; induction of 
apoptosis (Ryan, 2011) 
Broad range of cancer types – 
mutation present in ~50% of 
cancers 
WT1 Transcriptional regulator, influences RNA 
metabolism and MET (Hohenstein et al., 2015) 
Wilms’ tumour 
PTEN Acts as a phosphatase to influence cell signalling and 
thus influence cellular proliferation, migration and 
apoptosis; also genome stability (Milella et al., 2015) 
Melanoma; brain tumours; lung 
endometrial; prostate and kidney 
carcinomas 
MET – mesenchymal-to-epithelial transition 
 
 
Knudson’s two hit hypothesis was proposed over 40 years ago in regard to the RB1 gene, 
whereby there needs to be a loss of function in both alleles to promote cancer development 
(Knudson, 1971).  Such loss of function mutations can be inherited, that is through the germline, 
or acquired after birth and can be referred to as a loss of heterozygosity.   It remains a useful 
way of seeing how inherited genetic factors can combine with environmental factors to result 
in cancer. 
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Table 1.2 Examples of oncogenes, their broad functions and associated cancer types. 
Gene Function Common cancer types 
SHH Evading apoptosis and promoting proliferation (Ng 
and Curran, 2011) 
Medulloblastoma and 
numerous carcinomas 
KRAS* GTPase signal transduction promoting cell 
proliferation (Malumbres and Barbacid, 2003; Vale et 
al., 2012) 
Lung, pancreatic and intestinal 
carcinomas  
MYCBP Transcription factor that promotes cell proliferation 
(Vafa et al., 2002) 
Numerous types of carcinomas 
and central nervous system 
tumours 
NOTCH1 Inter-cellular communication; evasion of apoptosis 
and cell proliferation.  Also, tumour suppressor 
functions (Radtke and Raj, 2003) 
Skin cancer among other 
cancer types 
FOS Forms part of Activator Protein-1 complex; acts as a 
transcription factor to promoting cell proliferation and 
evasion of  apoptosis (Milde-Langosch, 2005) 
Sarcomas and numerous types 
of carcinoma. 
ERBB2* Cell surface receptor that triggers cell proliferation 
through tyrosine kinase activity and other 
mechanisms (Moasser, 2007) 
Breast and ovarian carcinomas 
*Currently in use as biomarkers.  ERBB2 (also known as HER2) is used as a prognostic indicator for 
breast cancer treatment (Constantinidou and Smith, 2011) and likewise KRAS mutation testing guides 
which patients will benefit from anti-EGFR therapy in colorectal cancer (Vale et al., 2012). 
 
1.1.6. The heterogeneous nature of cancer 
It has been known for some time that different forms of cancer, despite common characteristics, 
are very varied in their biological make-up.  However, it has only been relatively recently that 
we have fully appreciated the extensive heterogeneity of human cancers (Swanton et al., 2010).  
There can be huge differences, both genetic and epigenetic, not only between cancers of the 
same type but even within individual tumours.  Such intra-tumour or intraclonal heterogeneity 
has far reaching implications for cancer diagnosis and treatment.  In terms of predictive 
biomarkers for instance, do we try and predict the outcome for patients from a single biopsy?  
New approaches to cancer diagnosis, such as biopsy techniques and/or resected specimen 
processing, will most likely become increasingly important and more widely used in the future 
to meet the demands of personalised medicine and deal with the analysis of tumour 
heterogeneity that will be required.  The use of functional imaging is likely to become of 
increasing importance and may prove a useful way of targeting biopsies as well as 
characterising tumours pre-operatively (Schmitz et al., 2016). 
Chapter 1: Introduction 
7 
 
The ideal cancer biomarker would be easily detectable and present either exclusively or to a 
vastly different degree than in normal tissues, making it both sensitive and specific for disease.  
There is an additional advantage of biomarkers that are present exclusively in the cancer, in that 
they may also be the target for (immune-based) therapies.  If the targets of such treatments are 
not present in healthy tissues in the body and specific targeting occurs, then no or minimal side 
effects would be expected.  Histological characteristics, and cell-surface markers, commonly 
used to stratify patients into ‘risk’ categories at present often do not adequately reflect the 
degree of tumour heterogeneity.  New biomarkers are required to help overcome this problem.  
Another, perhaps surprising fact, is that the gene expression profiles of tumours remain fairly 
stable from early to advanced stages of disease (Visvader, 2011).  Tumour heterogeneity and 
immune-based cancer treatments will be discussed again later, with emphasis on colorectal 
cancer, but the importance of cancer stem cells and how they relate to tumour heterogeneity 
will now be highlighted in the following section. 
1.1.6.1. The importance of cancer stem cells 
In normal physiology, stem cells are specialist cells which have the ability to give rise to cells 
that constitute an organ.  Stem cells can be quiescent but their activation following injury is of 
great importance in restoring homeostasis and organ function following injury or damage due 
to disease.  When a sperm cell fertilises an ovum, the initial cell (and those of the first few cell 
divisions) is totipotent; that is these cells can differentiate to produce an entire organism and 
the extra-embryonic tissue of a trophoblast (Jaenisch and Young, 2008).  Adult stem cells are 
often capable of differentiating into different cell types that make up an organ or tissue (i.e. 
they are multipotent) but they can be bipotent or unipotent (Visvader and Clevers, 2016).  Stem 
cells and their progenitor cells act in a hierarchical manner to produce differentiated cells that 
constitute an organ.  For example, an intestinal stem cell will differentiate into the various cells 
of the intestinal crypt, or a liver stem cell will help reconstitute the liver parenchyma.  The same 
concept is believed to apply to cancer; that is a small proportion of the cells within a given 
tumour have the ability to maintain and regenerate the cancer.  These cells are termed cancer 
stem cells (CSCs) or cancer stem-like cells (Plaks et al., 2015).   
The function of adult stem cells is incompletely understood in normal physiology; the situation 
in cancer and CSC function is even more complex and indeed continues to be debated.  The cell 
which initially undergoes oncogenic genetic change (i.e. the ‘cell of origin’), may not be related 
to the CSC: indeed, this is believed to be the case for the majority of cancers (Visvader, 2011).  
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The cell of origin can be viewed as the cancer initiating event, whereas the CSCs are the cancer-
sustaining cells.  Any cell within the cellular hierarchy (of stem cells and their progenitors) can 
potentially act as a cell of origin for cancer.  As reviewed by Visvader, the majority of the 
proposed cells of origin for different cancers are progenitor cells (Visvader, 2011).  There is a 
rapid turnover of intestinal crypt cells, thus the progenitor cells may not exist for long enough 
to acquire the mutations necessary to result in cancer.  Consistent with this, the cells of origin 
in intestinal cancer are in fact stem cells, which acquire APC and Wnt signalling gene mutations 
(Visvader, 2011).  Difficulties in establishing the cells of origin in cancer are in part due to 
methodological challenges but there may also be numerous cells of origin that lead to a situation 
where a self-sufficient tumour exists.  There may also be numerous CSCs within a tumour and 
this can contribute to tumour heterogeneity and at the same time pose great challenges for 
successful cancer treatment (see Figure 1.3). 
 
 
 
 
 
 
 
 
Figure 1.3. The contribution of cancer stem cells to tumour generation and heterogeneity.   
There numerous ways in which cancer stem cells (CSCs) can contribute to tumour heterogeneity and 
tumour generation.  There may be a single CSC subset and non-CSCs are not capable of tumour 
generation (A).  There may be several distinct CSCs within the tumour, each capable of clonal expansion 
and independently able to generate the tumour (B).  There may be CSCs which have been dormant for 
some time which become reactivated following an activation signal depicted by red arrow (C).  These 
reactivated CSCs could result in local or distant tumour recurrence following activation, potentially 
many years following initial treatment.  Finally, as the tumour grows and the cancer progresses, existing 
CSCs may undergo further genetic or epigenetic change (indicated by red star) resulting in distinct 
subsets of CSCs (D).  Clonal expansion of the more aggressive CSC (depicted by green circle) will 
become the dominant driver for tumour generation and resistance to further therapy.  In addition, 
changing of cell surface markers may result in a change of CSC phenotype. Adapted from, Visvader 
and Lindeman (2012).   
A 
B 
C D 
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As the vast majority of chemo-therapeutic strategies are aimed at rapidly dividing cells, this 
causes a major problem for successful cancer treatment as CSCs may be quiescent or slow-
cycling and protected by the niche in which they reside (Borovski et al., 2011; Plaks et al., 
2015; Visvader and Lindeman, 2012).  The agents used are often successful at reducing the 
tumour burden (i.e. killing the rapidly dividing cells which make up the bulk of many solid 
tumours) but the CSCs may still survive and retain the ability to regenerate the cancer following 
therapy.  Recurrent tumours are often altered in that they are more resistant to the initial therapy 
as cellular selection or tumour adaptation, via genetic or epigenetic change of an existing CSC 
for example, has taken place (see again Figure 1.3).  Thus, targeting CSC is of vital importance 
in successful cancer treatment, especially if they have recurred and/or are refractory to surgical 
removal. 
The mechanism of CSC formation remains poorly understood.  There are two principal 
possibilities: either a differentiated cell dedifferentiates and regains stem-like properties, or a 
normal adult stem cell is transformed into an abnormal (cancerous) one.  The dedifferentiating 
model is more widely accepted, not least as pluripotent stem cells can be induced from 
terminally differentiated cells via epigenetic manipulation (Friedmann-Morvinski and Verma, 
2014).  Such induced pluripotent stem cells (iPSC) have many potential applications, not only 
in understanding cancer biology but also in the emerging field of regenerative medicine (Matsa 
et al., 2014).  Others have argued more strongly in favour of the latter model of carcinogenesis 
in which oncogenes are seen as the cellular ‘reprogammers’ (Vicente-Duenas et al., 2013).  It 
is possible that there is an overlap between the theories of initiating events or differences 
between cancer types but targeting CSCs is undoubtedly important if dramatic improvements 
in cancer survival are to be achieved.  In addition to understanding and therapeutically 
overcoming the mechanisms by which CSC survive (Flemming, 2015; Pattabiraman and 
Weinberg, 2014; Plaks et al., 2015), further complexity may be revealed by the existence of 
multiple CSCs within any given tumour.   
Before going on to introduce cancer biomarkers and how they are linked to the identification 
of novel targets for cancer therapy, the concept of field cancerization will be mentioned.  This 
concept has implications for biomarker discovery (e.g., when comparing ‘normal’ to cancerous 
tissue) and relevance to tissue sampling, which formed a substantial part of the work of this 
research.  The concept of field cancerization is also inextricably linked to CSCs and tumour 
heterogeneity through the clonal expansion theory. 
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1.1.6.2. Field Cancerization 
The concept of field cancerization (or field carcinogenesis) was first proposed over half a 
century ago (Slaughter et al., 1953) and has evolved considerably over the years (Frede et al., 
2014; Lochhead et al., 2015).  It is believed to result from the clonal expansion of a cell that 
has acquired mutations in tumour suppressor and/or proto-oncogenes.  The resulting cell 
population from this ‘rogue’ cell can cover a large area.  Although histologically the tissue 
looks the same as normal tissue, there is a (genetic) predisposition within it to develop cancer.  
The concept can apply to an area around a solid established tumour as well as a premalignant 
state before cancer has developed.  It helps explain the existence of synchronous tumours that 
can occur in many organs and it may also be the cause of cancer recurrence following surgery 
even when the surgical margins were ‘clear’ of cancer.  There is growing evidence that field 
cancerization is important in the development of CSCs (Frede et al., 2014).  For example, in 
the intestine, crypt fission events may be tipped in favour of cancer-promoting lineage 
(containing KRAS mutations) through mutations in the stem-cell compartment, leading to clonal 
expansion across a potentially large area of mucosa (Snippert et al., 2014).  When considering 
colorectal cancer, field changes have been seen over 17 cm from the primary tumour (Dawson 
et al., 1987) but there is probably a tapering effect in that more mutations are present, or the 
genotype more closely resembles that of the cancer, the closer you move towards the cancer 
(Hawthorn et al., 2014).  The evidence for this tapering is limited and requires clarification by 
future research.  If clonal expansion occurs from mutations in the stem cell compartment, then 
there would need to be multiple ‘fields’ within the area of field change for the tapering effect 
to take place. 
1.1.7. Cancer prevention, stratification and the importance of biomarkers 
Understanding the causative factors for different cancers is key to prevention.  Reducing 
environmental exposure to known carcinogens forms the basis for many health prevention 
strategies, such as the “Stop Smoking Wales” campaign.  Vaccination against viruses known to 
be carcinogenic is another approach, which can be considered a form of anti-cancer 
immunotherapy (Cohen et al., 2013; Frazer, 2004).  In addition to preventative strategies, 
cancer mortality rates can be further reduced by early diagnosis.  This requires tests that can be 
used to diagnose cancer.   
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A biological marker, or biomarker, has been defined as: “A characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacological responses to a therapeutic intervention” (Biomarkers Definitions Working 
Group., 2001).   
Cancer-specific biomarkers can be used to facilitate diagnostic testing.  Other cancer 
biomarkers may be better for monitoring response to treatment and/or predicting the likely 
natural course of the disease and thus guide which treatment strategy is most appropriate.  A 
clinical endpoint is a characteristic or variable that reflects how a patient feels, functions or 
survives (Biomarkers Definitions Working Group., 2001).  Some cancer biomarkers will have 
application as surrogates for clinical endpoints, which can be used to assess their suitability in 
the clinical setting or how effective new treatment strategies are.  This is particularly important 
when the actual clinical endpoint, e.g., mortality or cancer recurrence, may occur after a long 
period of time.  Developing good surrogate markers is tremendously useful in the realm of 
clinical translational research and also forms the basis of personalised treatment strategies. 
Good diagnostic biomarkers also form the basis of many cancer screening programmes, which 
are aimed at diagnosing cancer in the stage before it has become symptomatic.  Screening tests 
can be aimed at high risk patient groups or an entire subset of the population (e.g., within a 
given age range).  A good screening test should be reproducible, preferably non-invasive, cost-
effective and both sensitive and highly specific for the disease (Smith et al., 2015).  Even a 
slight reduction in specificity could lead to treatment and/or tests at significant costs, as well as 
anxiety and potential harm to the patient. 
So, in addition to diagnosing and screening patients for the presence of cancer, cancer 
biomarkers can also be used for staging, prognostication and guiding therapy.  Despite the 
efforts to establish useful cancer biomarkers, relatively few are in common clinical use and the 
path to discovery is typically a long one (Ludwig and Weinstein, 2005; Pavlou et al., 2013).  
Table 1.3 provides a list of some biomarkers that are in current clinical use; there remain fewer 
than 30 cancer biomarkers in common clinical use.  The stages of biomarker development can 
be split into pre-analytical, analytical, statistical or bioinformatics input, validation and then 
finally commercialisation and approval (Diamandis, 2014; Ludwig and Weinstein, 2005; 
Pavlou et al., 2013).  Reasons for the failure to develop more biomarkers are multifactorial and 
lie at every stage of the biomarker development process.  The significant costs throughout this 
process are also a hindrance.  The search for new biomarkers is as important as ever, especially 
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as we move increasingly towards an era of personalised cancer treatments (Aris and Barrio, 
2015; Kraus et al., 2014).  Indeed, predictive biomarkers form the basis for the development of 
personalised treatments; at present breast cancer treatment is probably the best example of 
where treatment is tailored depending on tumour characteristics (Cho et al., 2012). 
1.1.7.1. Sources and development of cancer biomarkers 
Tumour biopsy, urine, sputum, ascitic fluid, faeces, buccal mucosa or airways brushings and 
even exhaled breath can all be used as a source of biomarker detection (Hensing and Salgia, 
2013; Srinivas et al., 2001).  Blood is often the ideal source and many of the existing biomarkers 
in clinical use are proteins detected in the serum – see Table 1.3.  Protein biomarkers can be 
cell surface receptors, tumour antigens, proteins with post-translational modifications, as well 
as peptides released or excreted into or from the body (Ludwig and Weinstein, 2005).   
Table 1.3.  Examples of biomarkers in current clinical use  
Biomarker Type Biological source, cancer type and clinical use 
AFP Glycoprotein Serum test for staging of testicular cancer 
BRAF DNA mutation 
analysis 
Pathological tumour specimen.  Predicts response to BRAF 
inhibitors in patients with melanoma. 
CA19-9 Protein Serum test for monitoring pancreatic cancer 
CA125 Glycorotein Serum test for monitoring and stratifying risk of ovarian cancer 
CEA Protein Serum test for monitoring colorectal cancer 
ER + PR Proteins Pathological tumour specimen.  Prognostic indicator and therapy 
selection for patients with breast cancer 
HER2 
(ERBB2) 
Protein (IHC) + 
DNA (FISH) 
Pathological tumour specimen.  Prognostic indicator and therapy 
selection for patients with breast cancer 
KRAS DNA mutation 
analysis 
Pathological tumour specimen.  Prognostic indicator and therapy 
selection for patients with colorectal cancer 
PSA Protein Serum test for screening and monitoring prostate cancer 
AFP - α-fetoprotein; CA – cancer antigen; CEA – carcinoembryonic antigen; PSA – prostate specific 
antigen; HER2 – human epidermal growth factor receptor 2; KRAS – gene that encodes the KRAS 
protein; ER – oestrogen receptor; PR – progesterone receptor; BRAF – gene that encodes the B-Raf 
protein.  (Gonzalez de Castro et al., 2013; Ludwig and Weinstein, 2005; Pavlou et al., 2013). 
 
The rapid development of various “-omics” techniques has expanded the possibilities of 
developing other types of cancer biomarkers; though few have come to clinical fruition they 
still hold great promise.   Such alternate biomarkers include: DNA- and RNA-based changes 
(including microRNAs and epigenetic alternations such as DNA methylation), autoantibody 
detection, and circulating tumour cells or free DNA (cfDNA) (Gonzalez de Castro et al., 2013; 
Hensing and Salgia, 2013; Ludwig and Weinstein, 2005; Yoon et al., 2014).  Some have 
advocated ‘multiplexing’ or using pattern-based biomarkers, whereby several biomarkers are 
combined to increase the diagnostic or stratification accuracy (Ludwig and Weinstein, 2005; 
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Ullah and Aatif, 2009).  In a similar vein, multiple tumour antigens, which can themselves be 
biomarkers, can be targeted simultaneously to improve the efficacy of immunotherapeutic 
approaches.   
Tumour antigens and immunotherapy will now be discussed.  It can be seen how tumour 
antigens often overlap with biomarker discovery and research, as cell surface markers that 
enable cancer to be detected and recognised via screening or diagnostic molecular tests, may 
also be the very same targets for anti-cancer pharmaceuticals.    
1.2. Tumour antigens and immunotherapy 
Abnormal proteins arising and/or occurring in increased abundance as a result of cancer that 
are capable of eliciting an immune response are collectively termed tumour-associated antigens 
(TAAs).  Genetic or epigenetic changes in any of the three tumourigenic gene classes described 
above may result in a TAA.  Peptides of TAAs have the ability to induce the immune system 
as they may not be recognised as ‘self’ antigens.  Harnessing the body’s own immune-system 
to fight cancer is a very attractive anti-cancer treatment modality (Mellman et al., 2011).  To 
be useful for cancer immunotherapy, TAAs should ideally be: 1) restricted to the tumour and 
not present in healthy tissues; 2) present throughout the relevant cancer or cancer type 
predictably (i.e. not in a sporadic or hap-hazard fashion); and 3) targeted by cytotoxic T 
lymphocytes (Krishnadas et al., 2013). The identification and characterisation of TAAs has 
become a large area of research in the field of cancer immunotherapy (Mellman et al., 2011).  
The third attribute of TAA, being able to stimulate an immune response by activating T-cells, 
is crucially important when it comes to developing immunotherapies to target cancer (Coulie et 
al., 2014; Krishnadas et al., 2013). 
1.2.1. Types of tumour-associated antigens 
Human TAAs can be classified into different types according to their presence or patterns of 
gene expression within the body (Neller et al., 2008; Srinivasan and Wolchok, 2004): 
 Overexpressed (and universal antigens such as telomerase and survivin) are peptides 
derived from over-expressed genes that are found to be associated with T-cell responses.  
The low level of expression in normal cells should not stimulate the immune system to 
recognise these antigens.  
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 Oncofetal antigens are present during embryonic development but not present in adult 
tissues. 
 Differentiation antigens are present in specific tissues and associated with a particular 
state of differentiation. 
 Cancer/testis antigens (CTAs) are found in the normal testis and malignant tumours. 
Because of their unique expression pattern, CTAs are becoming useful biomarkers as 
well as targets for immunotherapy such as cancer vaccines (Krishnadas et al., 2013; 
Whitehurst, 2014).  This class of TAA will be discussed in more detail below. 
 Some gene mutations result in the translation of proteins with an altered amino-acid 
sequences that result in cancer-specific antigenic peptides capable of eliciting an 
immune response.  The genetic change may or may not be in a tumour suppressor gene 
or proto-oncogene; the important point being that the immune system will not have 
‘seen’ the protein before.  These unique antigens are also referred to as neoantigens 
(Schumacher and Schreiber, 2015).   
 Viral antigens or antigens occurring as a result of an infectious agent that can cause 
cancer are also considered an additional class of cancer antigens. 
1.2.2. Immunotherapeutic approaches 
Globally, infections are thought to result in around 2 million cases of cancer each year (de 
Martel et al., 2012).  Many of these cases are related to viral infections, such as human 
papilloma virus (HPV), Epstein-Barr virus (EBV) and viral induced hepatitis.  Vaccination 
against such viruses is a highly effective method of cancer prevention and a vaccination 
programme against HPV has recently been introduced in the UK to protect women against 
cervical cancer.   Therapeutic vaccines directed against TAAs have had limited success in 
treating cancer.  It is believed part of this limited success is due to targeting patients with 
advanced and metastatic disease; vaccines may hold the greatest benefit at halting the 
progression of pre-malignant or early stage disease (Gray et al., 2008).  However, patients with 
early stage disease can often be treated successfully by alternate means and immunotherapeutic 
approaches are unfortunately often a last and/or experimental resort. 
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Allogeneic bone marrow transplantation is a well-established and effective treatment of certain 
haematological cancers.  This can be considered a form of immunotherapy as it is thought to 
involve an immediate immune reaction against the residual cancer through the action of 
antibodies within the donor cells (Mellman et al., 2011).  Adoptive therapy, or adoptive cell 
transfer, follows a similar principal but here autologous cells are used (Essand and Loskog, 
2013; Gattinoni et al., 2006).  The patient’s own lymphocytes are cultured and expanded ex 
vivo before being transferred back into the patient to permit auto-immune destruction of the 
cancer – see Figure 1.4.  Dramatic results have been achieved in some instances, most notably 
in malignant melanoma (Hunder et al., 2008) but also in subsets of patients with other tumour 
types, for example, cervical cancer (Stevanovic et al., 2015). 
Monoclonal antibodies targeting TAAs have been widely investigated, with some agents 
gaining regulatory body approval for specific patient groups (Luke and Hodi, 2013; Mellman 
et al., 2011).  Recombinant cytokines have also been shown to be effective in treating cancer 
in patients with immunogenic tumours and who are predisposed to autoimmunity.  Predicting 
or identifying which patients will respond best to this form of immunotherapy, however, has 
proved not to be straightforward (Mellman et al., 2011).  Antibody drug conjugates (ADCs) are 
an additional example of a personalised immunotherapeutic approach (Leal et al., 2014).  Here, 
a drug conjugate containing a toxic payload is attached using a linker molecule to an antibody 
that specifically recognises cancer cells.  The toxic payload of the drug conjugate is internalised 
only by the (cancer) cells which contain cell surface antigens recognised by the antibody.  This 
limits potentially unpleasant systemic toxic side effects and in fact enables the use of substances 
that it would be too harmful if administered via traditional routes.  An example of a toxic 
substance that has been used in an ADC approach with varying success in a number of cancer 
types is monomethyl auristatin E (MMAE) (Bendell et al., 2014; Ott et al., 2014; Younes et al., 
2012). 
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1.2.3. Immunosuppression within cancer 
For an effective immune response to occur there needs to be antigen presentation by antigen 
presenting cells (APCs) such as dendritic cells, followed by a T-cell response against this 
antigen – see Figure 1.5.  In addition the immunosuppressive signals, produced by the cancer, 
need to be overcome.  These signals are varied and multifactorial, resulting in highly effective 
evasion of the immune system’s surveillance of the tumour and its microenvironment.  For 
example, paracrine mediators and cytokines released by cancer may directly suppress the APCs 
or inhibit access of the T-cells to certain regions of the tumour (Mellman et al., 2011).  Immune 
checkpoints also exist on the surface of T-cells, which have the effect of limiting their 
proliferation or cytotoxic capabilities (Nirschl and Drake, 2013; Topalian et al., 2015).  
Overcoming this immunosuppression is a major challenge in the development of 
immunotherapies against cancer.   
 
Figure 1.4.  Schematic representation of adoptive therapy.   
Tumour infiltrating lymphocytes are cultured and expanded ex vivo and transferred back into the 
patient after they have received non-myeloablative chemotherapy (Gattinoni et al., 2006; Rosenberg 
and Restifo, 2015).  IL-2 – Interleukin-2. 
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Figure 1.5.  Proposed responses to cell surface antigens.   
The transfer of peptides from cell surface proteins can influence numerous stages and facets of the 
immune response.  Aberrant cell behaviour and desensitisation of effector cells, not depicted above, has 
also been proposed as additional responses.  The influence of regulatory T-cells is important in 
establishing an immunosuppressive tumour microenvironment.  Adapted from (Davis, 2007). 
 
Immunotherapeutic approaches, such as the use of monoclonal antibodies, in the treatment of 
melanoma have by and large witnessed the greatest success in recent years (Luke and Hodi, 
2013).  For example, Ipilimumab is a monoclonal antibody that has been approved for use in 
both the UK and USA in the treatment of advanced melanoma.  Rather than targeting cancer 
cells, this form of immunotherapy targets a protein, CTLA-4, that has an inhibitory effect on 
cytotoxic T-cells.  So, this is a way of enhancing the ability of the T-cells to then attack the 
cancer cells.  Trials are ongoing for this use of this antibody in other cancer types. 
A large part of the work presented within this thesis is targeted at the identification of new 
genes which may encode CTAs – one important class of TAAs introduced above.  CTAs will 
be discussed in more detail below but before this it is important to review the process of 
spermatogenesis, as well as highlight the differences between meiotic and mitotic cellular 
division.  CTAs obtained their name because of their discovery in normal testis as well as cancer 
(Chen et al., 1997a).  Meiosis takes place only in the testis and there are particular genetic 
processes, some discussed below, which enable this type of cell division but functionally are of 
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potential significance if genes that govern these processes are reactivated in cancer (for 
example, see MacFarlane et al., 2014; Simpson et al., 2005; Whitehurst, 2014).  Interpretation 
of immunohistochemistry (IHC) of normal testis is aided by a basic understanding of the 
structure and function of the testis: IHC experiments are presented later in this thesis.  
Furthermore, some basic inferences as to the possible functions of proteins present in a certain 
region of the testis or seminiferous tubules can be made, which can direct avenues for further 
research into particular genes.  It will also be seen how the blood-testis barrier is of relevance 
in terms of CTAs as immunotherapeutic targets and in addition the relationship to other tissue 
barriers forms part of the basis for the subclassification of different classes of CTAs. 
1.3. Spermatogenesis 
Spermatogenesis is the process by which the male gametogenic cells produce spermatozoa, or 
sperm (Lie et al., 2013).  The process begins in puberty and after an early peak gradually 
reduces but unlike in females, where gametogenesis discontinues at the menopause, it does 
continue into old age (Eskenazi et al., 2003).  The functional structures of the testis in which 
spermatogenesis occurs are the seminiferous tubules.   
Spermatogenesis is under direct influence from androgens such as testosterone, at least in part 
mediated by paracrine signalling from the Sertoli cells within the seminiferous tubules (Chen 
and Liu, 2015; Smith and Walker, 2014; Yan et al., 2008).  Androgen production itself is 
controlled by the gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone 
(LH), which are released from the anterior pituitary.  LH acts via receptors on Leydig cells, 
which are located between the seminiferous tubules, to stimulate them to produce testosterone.   
1.3.1. Spermatozoa maturation and sub-compartmentalisation 
The spermatogonia which reside in the basal compartment of the seminiferous tubules are the 
progenitor cells for spermatogenesis.  The undifferentiated spermatogonia form the 
spermatogonial stem cells (SSCs).  SSCs are thought to divide into either a new SSC, thus 
resulting in self-renewal of the stem cell compartment (see Figure 1.6) or result in a type A1 
spermatogonial cell.  The A1 spermatogonia then undergo a further mitotic division before 
producing primary spermatocytes via a meiotic division (Chen and Liu, 2015; Lui and Cheng, 
2012; Zhang and Wu, 2015).  When the primary spermatocytes have undergone the first meiotic 
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division (see Section 1.4.3) they become secondary spermatocytes.  Following the second 
meiotic division, four haploid cells will result: initially round spermatids.  These spermatid cells 
will then elongate to generate mature spermatids that are released into the lumen of the tubules 
as spermatozoa, or sperm.  The process of release of spermatozoa from the adluminal 
compartment into the lumen is called spermiation.  Thousands of sperm are produced every 
hour and millions are stored, primarily within the epididymis, prior to ejaculation.  The 
acrosome is an organelle that forms a cap-like structure in the front of mature spermatozoa.  A 
complex biological process known as the acrosome reaction, which enables invasion of an 
ovum, is an essential process for fertilization.  Some genes discussed later in this thesis are 
involved in the acrosome reaction. 
1.3.2. The Blood-Testis Barrier 
The regional areas of the seminiferous tubules are split into basal and adluminal compartments 
by the blood-testis barrier (BTB).  The BTB is formed by the tight junction between adjacent 
Sertoli cells (see Figure 1.6) and provides the developing germ cells with a site of immune 
privilege (Lie et al., 2013).  The spermatogonia and SSCs reside in the basal compartment, 
whereas meiosis and subsequent development of the spermatocytes occur within the adluminal 
compartment.   
The Sertoli cells form a physical barrier to prevent large molecules, such as proteins, moving 
between the tubules and neighbouring blood vessels.  However, even spermatogonial cells 
which reside in the basal compartment ‘outside’ the BTB do not result in the production of self-
antigens.  This is because the germline cells (each side of the BTB) lack the major 
histocompatibility complex (MHC) molecules required for the ability to present peptides 
produced within them for recognition by the immune system (Guillaudeux et al., 1996).  The 
BTB is a dynamic structure that is constantly reformed and dismantled; in part this is believed 
to be the mechanism which permits germ cells to progress towards the lumen between the 
supporting Sertoli cells (Lie et al., 2013).  Testosterone along with cytokines such as 
transforming growth factor-β (TGF-β) regulate the kinetics of protein endocytosis and recycling 
in the Sertoli cells that is necessary for this dynamic process to occur (Yan et al., 2008).  So, 
the BTB is achieved not only by there being tight junctions between adjacent Sertoli cells 
creating an anatomical or physical barrier but also through physiological and immunological 
means (Mital et al., 2011). 
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Figure 1.6. Cross section through the seminiferous tubule.  
(A) A haemotoxylin and eosin stain of a seminiferous tubule in cross section indicating the structure of 
the seminiferous tubules and the morphological differences between developing gametogenic cells.  (B) 
Vertical representation of this cross section – sperm develop and migrate between Sertoli cells within 
the seminiferous tubules.  The spermatogonial cells are seen furthest from the lumen of the tubule in the 
basal compartment (lowermost arrow).  As the sperm develop there is considerable change in the 
morphology of the developing cells as they undergo first of all mitosis and then meiosis within the 
adluminal compartment to produce mature spermatids that are capable of fertilisation.  Note also the 
existence of the blood-testis barrier immediately above the basal compartment, which is formed by 
adjacent Sertoli cells but mediated via several mechanisms – see main text for details.  A primary 
function of this barrier is to prevent the developing germ cells from autoimmune attack.  Adapted from 
(Lui and Cheng, 2012). 
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1.3.2.1. Lack of HLA molecules potentially increases immunogenicity in cancer 
The lack of MHC (or human leucocyte antigen – HLA) molecules within the gametogenic cells 
is brought about at least in part through post-transcriptional means (Guillaudeux et al., 1996).  
The lack of such auto-antigen presentation by germ cells of the testis is of fundamental 
importance in protecting developing germ cells from immune attack but also of fundamental 
importance when one considers the CTA class of tumour antigens.  It means that if the antigen 
is produced elsewhere in the body then the immune system will, or at least should, recognise 
them as ‘foreign’ and mount an immune response.  Even if this immune response is weak or 
absent, it at the very least opens up the possibility of harnessing the immune system’s capability 
of destroying cells with these ‘non-self’ TAAs.  CTAs, and the relevance of the BTB in CTA 
biology, will be discussed again below in Section 1.5.   
1.3.2.2. Similarities with other blood-tissue barriers 
Tight junctions form at the interface between any selective epithelial-endothelial interface; they 
allow, for example, the selective transfer of nutrients and ions from the gut lumen into the blood 
stream, or excretion and reabsorption of ions and waste products within the kidney.  Highly 
specialised blood-tissue barriers occur at certain regions of the body, most notably in the eye, 
placenta, central nervous system and testis.  The blood-testis barrier has unique features but 
also shares similarities to the other specialised blood-tissue barriers in the body (Li et al., 2012).  
For instance, connexins form the basic structural unit of the tight junctions whether these are in 
the eye, central nervous system or testis, and P-glycoprotein, which plays a crucial role in 
maintaining the blood-brain barrier, also acts at the BTB (Fromm, 2004; Li et al., 2012; Mruk 
et al., 2011).  Interestingly, the efflux pump activity of P-glycoprotein, which has a 
physiological role at these blood-tissue barriers, can be hijacked by cancers to increase their 
resistance to chemotherapy and lead to a worse prognosis (Mao et al., 2015; Sharom, 2011).  
Inhibitors of the action of these proteins are being developed in the hope of improving outcome 
for patients with multi-drug resistant cancers (Kapse-Mistry et al., 2014).  Due to the existence 
of the blood-brain barrier this makes the brain and central nervous system (CNS) a region of 
the body with relative immune privilege and this fact forms the rationale for the classification 
of CTAs, as described in Section 1.5. 
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1.4. Cell cycle and division in eukaryotes 
1.4.1. Cell division in eukaryotes 
Two types of cell division occur in eukaryotic cells: mitosis and meiosis.  Both types of cell 
division occur during spermatogenesis as mentioned above.  Meiosis is unique to 
spermatogenesis in males and so a more extensive overview will be provided.   
Mitosis occurs throughout the human body as part of normal tissue homeostasis in which the 
chromosome complement is maintained in its diploid state producing identical daughter cells 
(Civelekoglu-Scholey and Cimini, 2014).  Meiosis, however, only occurs in specialist 
(reproductive) cells of the germline and the cells become haploid in relation to their 
chromosome complement (Duro and Marston, 2015).  Both types of cell division are tightly 
regulated and involve DNA replication followed by chromosomal segregation.  Meiosis occurs 
in the foetal ovary but in adults is confined, as an entire process, to the testis.   
1.4.2. Mitotic cell cycle 
This type of cell division produces two identical daughter cells from a single parent cell 
(Civelekoglu-Scholey and Cimini, 2014).  It is essential for maintaining homeostasis and 
normal regional cellular function.  At any one time, the majority of cells are not undergoing 
mitosis; that is, they are quiescent.  This is known as the G0 phase and the duration of this can 
vary greatly between cell types.  Mitogenic signals promote exit from G0 and progression 
towards mitosis.  Once a cell progresses out of this phase it is committed to completing at least 
one cell cycle and producing two identical diploid daughter cells; assuming, that is, it passes 
the various cell cycle checkpoints that safeguard against errors in DNA processing (Malumbres 
and Barbacid, 2009).  The cell cycle is split into interphase and M-phase – see Figure 1.7.  
Oncogenic signals may also promote exit from G0 and cause uncontrolled cell proliferation, 
which is a fundamental hallmark of cancer (Hanahan and Weinberg, 2011).  Cyclin dependent 
kinases (CDKs) control progression through the normal cell cycle.  Mutations in the genes that 
activate or inhibit CDKs, or indeed the genes that encode them, can lead to not only 
uncontrolled cellular proliferation but also changes in chromosome number (i.e. chromosomal 
instability) as well as genetic instability (Malumbres and Barbacid, 2009). 
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Figure 1.7.  The cell cycle.   
The adult cell cycle is split into interphase and an M-phase or division phase.  Interphase is split into 
three separate phases: G1 where the cell grows and prepares for DNA replication; S-phase where DNA 
synthesis occurs; and G2 which is a second growth phase where the cell prepares for the division phase.  
M-phase is itself subdivided into five phases, which retain the same terminology in both meiosis and 
mitosis.  These five phases of cellular division are: prophase; prometaphase (not depicted above); 
metaphase; anaphase; and telophase.  Meiosis involves two separate divisions to produce four haploid 
daughter cells, whereas mitosis produces two identical daughter cells.  Mitotic daughter cells will ‘exit’ 
the cell cycle and enter a quiescent G0 phase and await a mitogenic signal to re-enter G1. 
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1.4.3. Meiosis 
Meiosis only occurs in gametogenic cells of the body.  Meiosis results in cells (i.e. ova or 
spermatozoa) that are haploid – this is essential for sexual reproduction in mammals and many 
other organisms.  These specialist cells are found only within the ovaries and testis.  When the 
two gametes fuse during the fertilisation process they produce a zygote, which once again 
becomes a diploid cell.  The resulting offspring, which develops from the zygote, has thus 
inherited one distinct copy of each chromosome, known as a homologue, from both parents.  
There are important differences in when meiosis occurs in males and females – see Figure 1.8.  
Most notably, in men the process is not initiated until puberty.  In females the ova are produced 
in the foetus and meiosis is arrested in prophase 1 before birth until puberty.  
 
  
 
 
 
 
 
 
 
Figure 1.8.  Differences in meiosis between males and females.   
In a woman all the ova she will ever produce are produced in the foetus.  After this and until puberty, 
meiosis is arrested in prophase 1 at which point meiosis will resume until she reaches the menopause.  
For men, however, meiosis is initiated at puberty and they will continue to produce sperm for the rest of 
their lives, although the rate of sperm production declines gradually at they become older. 
Adapted from, Baillet and Mandon-Pepin (2012). 
 
1.4.4. The stages of meiosis 
Meiosis is a complex and tightly controlled process (Schvarzstein et al., 2010).  Comparison to 
mitosis of the stages involved is depicted in Figure 1.9.  Both mitosis and meiosis are split into 
five phases and meiosis occurs in two separate divisions termed meiosis I and meiosis II.  As is 
the case during mitosis, before cellular division occurs the DNA must first replicate and the cell 
prepares for the division.  Significant cellular structural changes occur, such as breakdown of 
the nuclear membrane and cytoskeletal rearrangement, during both mitosis and meiosis but the 
WOMEN 
INITIATION AND PROGRESSION 
MEIOSIS RESUMES ARREST IN PROPHASE 1 INITIATION 
MEN 
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chromosome segregation and rearrangements that occur in meiosis are unique and more 
complex resulting in genetically distinct daughter cells (Civelekoglu-Scholey and Cimini, 2014; 
Duro and Marston, 2015; Schvarzstein et al., 2010).  Following DNA replication two rounds of 
chromosome segregation occur during meiosis: during meiosis I reductional chromosome 
segregation occurs, and during meiosis II equational segregation of the chromosomes takes 
place (Duro and Marston, 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. Comparison between the mitotic and meiotic cell cycles.   
Both meiosis and mitosis involve growth phases occurring before and after the S phase in which DNA 
synthesis/replication occurs prior to cellular division.  Mitotic cells spend the majority of their time in 
this interphase and/or outside of the cell cycle in a phase called G0 when they are not dividing.  In 
meiosis, pictured here below mitosis, four daughter cells have been produced with half as many 
chromosomes as the parent cell.  These haploid cells will be able to fuse with haploid cells from the 
other parent and produce a zygote through the process of fertilisation.  The process of meiosis is split 
into two stages: in meiosis I, or the first meiotic division, the chromosome number is maintained; in 
meiosis II chromosome segregation this time results in four haploid daughter cells.  The stages of each 
cell division (for both meiosis and mitosis) are split into five distinct phases: interphase, prophase, 
prometaphase, metaphase, anaphase, and telophase.  Adapted from (Saltsman, 2005). 
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1.4.5. DNA double-strand breaks and meiotic recombination 
Formation of DNA double-strand breaks (DSBs) occurs early on during meiosis and is 
necessary for meiotic recombination to occur, which is essential for correct homologue 
alignment and bivalent formation (Baudat et al., 2013; Longhese et al., 2009).  The most 
marked differences to mitosis occur during prophase I.  During this phase homologous 
chromosomes pair and then synapse.  The pre-meiotic S-phase during which chromosome 
replication takes place is prolonged; during this time inter-homologue interactions take place 
to subsequently permit recombination events and chromosome segregation.  The synapsis of 
homologous chromosomes during prophase I is brought about by a large proteinaceous 
structure called the synaptonemal complex (see Figure 1.10).  The pairing of homologous 
chromosomes prior to this synapsis is promoted by the polarised and condensed chromosomal 
arrangement.  When visualised microscopically the chromosomes are thought to resemble a 
bouquet of flowers and so this is referred to as the bouquet formation (Harper et al., 2004; 
Klutstein and Cooper, 2014).  This formation is caused by the transient clustering of telomeres 
on the inside of the nuclear envelope.  Only recently the function of the telomeres as important 
tethering factors for the centromeres during meiosis has been elucidated (Klutstein et al., 2015). 
 
 
 
 
 
 
Figure 1.10. The synaptonemal complex.  
There are seven known constituent meiosis-specific proteins that form the synaptonemal complex (SC).  
The formation of the SC, arranged in a ladder-like formation, begins early in prophase I.  The central 
element (CE) is formed by four proteins: SYCE1 coalesces with SYCE3, and TEX12 with SYCE2.  
SYCE1 and SYCE3 have the ability to self-assemble and are thought to act as the structural framework 
binding other SC proteins (Fraune et al., 2012).  The transverse filaments are composed of parallel 
homodimers of SYCP1; the N-terminal domain associates with the proteins of the CE and the C-terminal 
domain with the lateral element (LE) proteins.  The LE proteins are SYCP2 and SYCP3.  Adapted from, 
(Fraune et al., 2012). 
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The primary purpose of meiotic recombination is to generate inter-homologue connections, 
which, together with sister centromere monopolarity, permit the reductional division.  However, 
crossover recombination events also serve as the mechanism for creating unique, genetically 
distinct, gametes and as a consequence contribute to genetic and thus biological diversity.  
Recombination events do not occur randomly but are concentrated in specific regions of the 
genome, known as hotspots.  The PRDM9 protein has been identified as being able to bind to 
some of these hotspots and thus regulates the site for some meiotic recombination initiation 
(Baker et al., 2014; Baudat et al., 2013).  DSBs are generated in meiosis by a topoisomerase II-
like enzyme SPO11.  SPO11 is a highly conserved protein without known physiological roles 
outside of meiosis/meiotic recombination.  It acts as a dimer to catalyse the breakage of both 
DNA strands and is removed from the DNA by endonucleolytic cleavage by the MRN complex 
of proteins (de Massy, 2013; Lam and Keeney, 2014).  It will be seen that several of these genes 
will be mentioned again later in the thesis and it is useful here to outline the context of their 
roles in normal physiology.   
RAD51 is a recombinase that is central to mitotic recombination events; it is a homologue of 
the prokaryotic protein RecA (San Filippo et al., 2008).  It is also required for homologous 
recombination (HR) during meiosis but another RecA homologue, DMC1, is also critical.  
DMC1 is meiosis-specific and the precise mechanism of action is unclear but it acts in concert 
with RAD51 to perform HR during meiosis.  Both proteins catalyse the exchange of DNA 
strands from one DNA duplex to another (Handel and Schimenti, 2010).  DMC1, together with 
two other meiosis-specific proteins Hop2 and Mnd1, helps drive the bias that exists in meiosis 
to increase the probability of choosing a homologous chromatid over a sister chromatid with 
which to exchange strands and thus ensure correct bivalent formation (Brown and Bishop, 2014; 
Kang et al., 2015).  The recombinase proteins interact with single-stranded DNA (ssDNA) to 
from a nucleoprotein structure known as the presynaptic filament.  The presynaptic filament 
engages a neighbouring strand of DNA and searches for homology in it – this is referred to as 
homology search.  Successful homology search is thus required for homologous recombination 
following DSB formation – see Figure 1.11.  It has been suggested that the presynaptic filament 
formed by DMC1 drives the initial homology search in preference of a DNA strand from the 
homologous chromatid and RAD51 performs the second end capture but various models have 
been proposed (Brown and Bishop, 2014).  Other accessory proteins, such as the Hop2-Mnd1 
heterodimer in meiosis, are also critical for successful HR (Brown and Bishop, 2014; Kang et 
al., 2015; San Filippo et al., 2008). 
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Figure 1.11.  Repair of DSBs by homologous recombination in meiosis.   
Homologous recombination in meiosis can result in crossover (CO) and non-crossover (NCO) events.  
SPO11 cleaves the DNA to form a DSB; this is the trigger for the initiation of homologous 
recombination.  Single-stranded DNA (ssDNA) is formed at the 3’ end following resection of the DNA 
in a 5’ to 3’ fashion.  This overhanging ssDNA is the substrate for the HR protein machinery which 
form a nucleoprotein filament known as the presynaptic filament; permitting invasion of the 3’ end into 
its homologue.  DNA synthesis ensues using the homologue as a template.  The DSBs can be repaired 
via the double-strand brake repair (DSBR) or synthesis-dependent strand annealing (SDSA) pathway.  
DSBR involves the capture of the second overhanging ssDNA strand to form two Holliday junctions.  
This can result in either a crossover or a non-crossover recombination event.  Gap-filling DNA synthesis 
and ligation are required to complete the process in both types of repair.  There are in fact four distinct 
repair pathways for DSB repair in meiosis as inter-sister, as well as inter-homologue recombination 
events can occur, although there is a preference for the latter.   
Adapted from (Handel and Schimenti, 2010).  
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1.4.6. DNA repair and human disease 
DNA is under constant insult from different sources and there are numerous and highly effective 
pathways for repairing damaged DNA (Abbotts et al., 2014).  Defects in these repair pathways, 
either inherited or acquired, can lead to an increased susceptibility to cancer as they will lead 
directly to genetic instability.  There are also specific repair pathways for repairing DSBs as 
seen in meiosis; including non-homologous end joining (NHEJ) and HR (Chapman et al., 2012; 
Longhese et al., 2009; Lord and Ashworth, 2012).  HR, which occurs in the S and G2 phases 
of the cell cycle, is less error prone than NHEJ.   
Certain inherited genetic disorders carry an increased risk of developing cancers.  Fanconi 
anaemia is an uncommon but interesting example as links to various DNA repair pathways have 
been discovered through a drive to better understand the disease (Longerich et al., 2014).  
Although patients can succumb to bone marrow failure in childhood, patients with Fanconi 
anaemia have a dramatically increased risk of developing acute myeloid leukaemia as well as 
other forms of cancer (Longerich et al., 2014).  Lynch syndrome is another example of an 
inherited disorder that leads to an increased risk of developing cancer.  Here, mutations in 
various mismatch repair genes result in suboptimal DNA repair, thus contributing to genomic 
instability and an increased risk of developing many types of cancer (Al-Sohaily et al., 2012).  
This condition will be mentioned again below in connection to colorectal cancer – see Section 
1.6.  Mutations in the same genes can also be acquired and lead to chromosomal instability and 
cancer in the same fashion.   
BRCA2 is an example of a tumour suppressor gene; when a mutation is inherited or acquired 
patients have an increased risk of developing cancer (most notably breast and ovarian cancer, 
as is the case for its sister gene BRCA1 - see Table 1.1).  BRCA2 is a large protein that when a 
gene mutation results in a defective form, contributes greatly to genomic instability.  This is 
largely due to the fact that healthy BRCA2 interacts directly with the recombinase RAD51 via 
its BRC motif and assists with HR repair events in somatic cells by promoting the binding of 
RAD51 to ssDNA (Thorslund et al., 2010).  Thus, an increased probability of cancer results 
over time as suboptimal repair mechanisms exist to cope with the exogenous DNA damaging 
insults that occur throughout life.  BRCA2 also interacts, via a separate binding site, to DMC1 
and it is thought to be required for the co-localisation of both recombinases in meiosis 
(Thorslund and West, 2007).  The RAD51-associated protein 1, RAD51AP1, is also thought to 
be involved in the co-localisation of these recombinases (Dunlop et al., 2011).  PALB2 
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(encoded by another important tumour suppressor gene, PALB2) is required for the localisation 
of BRCA2 to damaged regions of chromosomes (Xia et al., 2006) and also acts in synergy with 
RAD51AP1 to promote D-loop formation by the recombinase (Dray et al., 2010).  Thus, it can 
be seen how there may be interactions between numerous factors that ultimately result in 
genetic instability due to a failure of adequate DNA repair and as a consequence can contribute 
to oncogenesis.  Some of these DNA repair genes will be mentioned again later in the thesis.  I 
will now go on to discuss an important class of TAAs, the cancer/testis antigens. 
1.5. Cancer-testis antigens 
1.5.1. Discovery and classification 
The term cancer/testis antigen (CTA) was coined in 1997 to describe a class of TAA that had 
limited presence in somatic tissues (Chen et al., 1997a).  At this point several cancer/testis (CT) 
genes had already been discovered; including the first members of the melanoma-associated 
antigen family (e.g. MAGE-A1 and MAGE-A3) as well as PAGE and two members of the GAGE 
gene family (Boel et al., 1995; Gaugler et al., 1994; Van den Eynde et al., 1995; van der 
Bruggen et al., 1991).  It is now known that CT genes are more often present as large paralogous 
families of antigens such as the MAGE genes and the SSX class of CT genes that were 
discovered soon afterwards (Chomez et al., 2001; Gure et al., 1997).  Many of the early 
discoveries were in patients with melanoma, which is a cancer that has many tissue specific 
gene activations associated with it leading to more prominent adaptive immune responses in 
vivo (Blankenstein et al., 2012).  NY-ESO-1 encodes one of the most immunogenic TAA that 
shares little homology with other known proteins: it was discovered in a patient with 
oesophageal squamous carcinoma (Chen et al., 1997b) and later used for a successful 
immunotherapeutic approach in a patient with metastatic melanoma (Hunder et al., 2008). 
The CTAs are a diverse class of TAAs (Fratta et al., 2011; Whitehurst, 2014).  The genes which 
encode these antigens, termed CTA genes or cancer/testis (CT) genes, are expressed in the testis 
and malignant tissues.  Bona fide CT genes have expression silenced in normal tissues other 
than the testis, but then become activated in cancer (Hofmann et al., 2008; Scanlan et al., 2004).  
The expression of CT genes has been shown to vary greatly between different types of cancer: 
melanoma, ovarian and lung cancer for instance have generally higher expression levels than 
colorectal or haematological cancers (Almeida et al., 2009; Caballero and Chen, 2009).  They 
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have attracted a great deal of interest in the field of oncology and tumour immunology (Cheng 
et al., 2011; Costa et al., 2007; Drake et al., 2014; Fratta et al., 2011; Simpson et al., 2005).  
CTAs have attracted such interest owing to their expression profiles, coupled with the fact that 
germ cells do not have HLA molecules enabling them to present antigens for immune 
recognition (as mentioned in Section 1.3).  This increases their immunogenicity (i.e. ability to 
stimulate an adaptive immune response) making them particularly attractive targets for both 
cancer vaccines and adoptive therapy (Hunder et al., 2008; Valmori et al., 2007).  Their 
expression profile also makes them highly attractive as cancer-specific biomarkers that could 
improve diagnosis, stratification or current screening methods (see Section 1.1.7). 
Current knowledge of CT gene expression patterns is summarised on ‘CTDatabase’ (Almeida 
et al., 2009).  Over 250 genes from over 100 separate gene families have been identified 
although not all of these meet the strict CT gene expression criteria (Hofmann et al., 2008).  CT 
genes can be subclassified based on their chromosomal location or alternatively how restricted 
their expression profile is.  Many of the known CT genes are encoded by the X-chromosome 
and are expressed in the basal layer of the seminiferous tubules, i.e. in the spermatogonial cells 
(Chomez et al., 2001).  CT genes located on the autosomes are known as non-X-CT genes.  As 
discussed above, meiosis is a special type of cell division limited to the germ cells.  It has been 
known for some time that meiosis-specific genes (e.g. SCP-1, HORMAD1) can encode a CTA 
(Chen et al., 2005; Tureci et al., 1998a).  A subcategory of CT genes, termed meiCT genes, that 
are specifically associated with meiosis have more recently been described (Feichtinger et al., 
2012b; Sammut et al., 2014).  Due to transcriptional silencing of the X-chromosome during 
meiosis in males (Turner, 2007) meiCT genes would be expected to be autosomally encoded.  
This is indeed the case for the majority of the meiCT genes described.   
It has been observed that some cancers co-express numerous CT genes, whereas others from 
the same or different cancer types do not (Burgdorf et al., 2008; Choi and Chang, 2012; Daudi 
et al., 2014).  The promotor regions of many germline genes are demethylated in the testis 
allowing them to become active during spermatogenesis.  Moreover, the methylation of these 
genes in somatic tissues is believed to be a primary silencing mechanism (Shen et al., 2007).  
Global hypomethylation of DNA is a common feature of cancer (Feinberg and Vogelstein, 
1983); a feature that could lead to the activation of CT genes outside of their normal site of 
expression.  This is believed to be the reason for the co-expression of CT-genes observed in 
some tumours.  Furthermore, treatment of cancer cell lines with the demethylating agent, 5-aza-
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2’-deoxycytidine, has been shown to lead to increased expression of many CT genes adding 
further support for this idea (Adair and Hogan, 2009; Almatrafi et al., 2014).  Other epigenetic 
influences, such as histone deacetylation, are likely to also be important mechanisms for ectopic 
activation of CT genes as demethylation treatment does not consistently result in expression 
(Almatrafi et al., 2014; Fratta et al., 2011). 
1.5.1.1. Subclassification based on somatic tissue expression profile 
In addition to being classified as CT-X and non-X-CT genes based on their chromosomal 
locations, CT genes can also be subclassified into three broad groups based on their expression 
profiles in normal tissues (Hofmann et al., 2008): 
 As mentioned above a bona fide CT gene would be expressed in cancer and testis only: 
these CT genes are termed testis restricted.  However, as the placenta is a specialised 
tissue that is both a site of immune-privilege and also contains germline cells/genes it 
too can be considered as a restricted site.  That is, if a gene is expressed in the testis, the 
placenta and cancer it would still be considered as belonging to this tightly restricted 
class.  It has been proposed that CTAs may play a role in various phases of placenta 
development (Jungbluth et al., 2007).   Extravillous trophoblast invasion and 
implantation, as well as angiogenesis, are fundamental processes involved in placental 
development (Pollheimer et al., 2014).  It is possible that the same functions (of cancer-
germline gene products) that promote placental development also promote oncogenesis 
through similar mechanisms (see Section 1.5.3). 
 A second group, termed testis/brain (or testis/CNS) restricted are present in the testis, 
CNS and cancer only, with no expression in other normal somatic tissues.   
 The third group has predominant expression in testis (and found in cancer) but limited 
expression in somatic tissues.  ‘Limited expression’ could be considered as very low 
(e.g., 100-fold lower) expression compared to testis and/or limited to two other normal 
tissue types (Caballero and Chen, 2009; Feichtinger et al., 2012b; Hofmann et al., 
2008).  Genes with such low expression titres in normal tissue might still be excellent 
targets for immunotherapeutic approaches and remain viable biomarkers for cancer but 
clearly their potential strength in both these regards would be less than the truly 
restricted category of CT genes.  As the ovaries do not offer a site of immune privilege 
in the same way (as the placenta, testis, or even CNS do) then genes expressed here are 
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generally considered the same as other somatic tissues in terms of categorisation.  
However, some germline genes would be expected to be expressed exclusively in the 
ovaries in females and they have been considered a third site of restricted expression by 
some (Scanlan et al., 2002).  Many of the meiCT genes were shown to have significant 
upregulations in ovarian cancer when clinical data-sets were meta-analysed (Feichtinger 
et al., 2012b; Sammut et al., 2014), though the reasons for this are not clear as the 
cellular origin of ovarian cancer is believed to be extra-ovarian in many cases (Berns 
and Bowtell, 2012; Sorensen et al., 2015). 
1.5.2. CTAs as cancer biomarkers  
As is the case with numerous other new biomarkers, despite their promise no CTAs have been 
widely adopted and/or endorsed, for example, by the regulatory authorities in the UK or USA.  
However, examples of CTAs that have been proposed as useful biomarkers and/or shown to be 
predictive of prognosis or treatment response include: ATAD2, MAGE-A3, -A6 and -A9 for 
breast cancer (Ayyoub et al., 2014; Kalashnikova et al., 2010; Xu et al., 2014); NY-ESO-1 in 
non-small cell lung cancer, hepatocellular carcinoma and gastrointestinal stromal tumours 
(John et al., 2013; Perez et al., 2011; Xu et al., 2012); MAGE-C1 in multiple myeloma (de 
Carvalho et al., 2012).  It may remain the case that such biomarkers do establish themselves 
within personalised treatment strategies, rather than for internationally used markers for 
diagnosis or screening.  It has recently been shown that expression of a panel of germline genes 
can be used to predict a worse outcome and guide therapy in lung cancer patients (Rousseaux 
et al., 2013b).  Importantly activation of this specific cohort of germline genes was an 
independent predictor of a poor outcome, even in patients that would have otherwise (i.e., by 
existing stratification methods such as TNM staging) not been predicted to have such a poor 
prognosis.  Thus, such approaches have tremendous potential to be of real clinical benefit to 
patients by guiding the need for more aggressive treatment strategies and/or informing the 
clinician that the treatment is not going to work and consequently saving money, as well as the 
potential unpleasant side effects to the patient. 
1.5.3. Possible roles in oncogenesis 
As mentioned above, the targeting of testis-restricted CTAs for cancer treatment would be 
expected to have no or minimal deleterious side effects in non-cancerous healthy tissue, as the 
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proteins are not found there.  However, there is a second distinct reason why the study of CTAs 
and CT genes is important.  This is that they, and in particular the meiCT genes and their 
products, could be having a powerful oncogenic influence on the cancer.  The products of some 
of these genes would normally serve to drive the meiotic chromosome dynamics and 
differentiation of developing gametes; related functions if aberrantly expressed in somatic 
tissues could be driving significant genetic (and epigenetic) changes, a possibility that remains 
largely unexplored (McFarlane et al., 2015).  For example, it has been suggested that 
aneuploidy, which is a very common feature in cancer, could be brought about in somatic cells 
by the action of these normally silent germline genes (Fratta et al., 2011; Rousseaux et al., 
2013a; Wang et al., 2014; Whitehurst, 2014).  In a seminal study in Drosophila melanogaster 
genome wide expression profiling in a brain tumour model system revealed that a significant 
proportion of upregulated genes were germline in origin, and inactivation of some members 
suppressed tumour growth (Janic et al., 2010).  This provided direct evidence that these 
germline factors were promoting oncogenesis.  Moreover, it was subsequently shown that 
several of these genes displayed statistically significant upregulations when clinically-derived 
(cancerEST and cancerMA) datasets were meta-analysed, thus adding support to the idea that 
a soma-to-germline transition is a hallmark of many cancers (Feichtinger et al., 2014).  
Although the precise mechanisms for the oncogenic-promoting effects of germline genes is 
unknown, it is believed that many of the effects result from changes in broader genome 
epigenetics that occur as a direct result of germline- or testis-specific gene activation in cancer 
(Wang et al., 2011; Whitehurst, 2014).  
Possible and identified functions of CTAs and/or roles in oncogenesis include: 
 Contributing to genetic and chromosomal instability.  Conserved meiotic functions, 
such as meiotic recombination, could lead to chromosomal rearrangements leading 
directly to such instability in a self-perpetuating manner (Cheng et al., 2011; Fratta et 
al., 2011; McFarlane et al., 2015; Simpson et al., 2005).  The synaptonemal complex 
(see Figure 1.10) is a large protein structure that forms a stable connection between two 
homologous chromosomes during prophase in meiosis 1.  SCP1 is an integral member 
of this complex and was first identified as a CTA in 1998 and since found to be present 
in several cancer types (Haffner et al., 2002; Lim et al., 1999; Tureci et al., 1998a).  
Other examples of CTAs found in cancer that could be contributing to unstable genetic 
alterations by driving meiotic-like chromosome dynamics include: the meiotic regulator 
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STRA8, the metalloprotease ADAM2 known to play a role in spermatogenesis, the 
cohesin subunits SMC1β and RAD21L, the meiotic hot spot activator PRDM9, and 
SPO11 which creates DSBs as mentioned above (Feichtinger et al., 2012b; Koslowski 
et al., 2002; Litvinov et al., 2014; Sammut et al., 2014).  HORMAD1 is a meiosis-
specific protein that is needed for formation of the synaptonemal complex and has been 
implicated in directing the site of DSB formation involving MEI4 as well as promotion 
of homologue alignment (Daniel et al., 2011; Kumar et al., 2015).  Recently, it has been 
shown that overexpression of HORMAD1, which localised to the nucleus of breast 
cancer cells, suppresses RAD51-dependent HR, thus promoting genomic instability and 
a bias towards NHEJ as a means of DNA repair (Watkins et al., 2015).  Initial data also 
suggest that HORMAD1 expression will be a useful way of tailoring effective treatment 
options (Watkins et al., 2015). 
 Alteration of chromosome number.  Creation of aneuploidy, which is a cancer-wide 
phenomenon, would be promoted by activation of germline genes through the same 
functions that cause large chromosomal rearrangements and/or altered cohesion (i.e., 
sister monopolarity) during gametogenesis (Fratta et al., 2011; Simpson et al., 2005; 
Whitehurst, 2014).  Genome amplification provides cancer cells with a survival 
advantage (for example by providing a ‘buffer’ against damaging gene mutations) and 
can explain many of the hallmarks of cancer as well as resistance to anti-cancer therapy 
(Coward and Harding, 2014).  It has been suggested that cancer cells hijack the 
gametogenic programme by expressing meiotic factors to create a polyploid state that 
promotes immortality and genome plasticity (Erenpreisa et al., 2014). 
 Acting as transcriptional regulators or activators.  It is known that some CTAs act as 
transcriptional activators, often for other germline genes but also for Myc-mediated 
oncogenes and genes involved in epithelial-mesenchymal transition (EMT) (Daudi et 
al., 2014; Kim et al., 2009; Minges et al., 2013; Whitehurst, 2014).   Activation of 
oncogenes or disrupted function of tumour suppressor genes would be directly 
oncogenic.  The co-activation of other germline genes serves as an additional 
mechanism (to DNA hypomethylation described above), for how some cancers co-
express multiple CT genes, whereas others none or very few.  LUZP4 has recently been 
shown to interact with a major mRNA export receptor and act as an adaptor for mRNA 
export (Viphakone et al., 2015).  This would provide a mechanism for the transcription 
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activation of other genes and as it is commonly expressed in melanoma may be acting 
as an important oncogenic driver in this cancer type.  Testis-specific factors can also 
have other reprogramming influences on the epigenome of somatic cells to promote a 
malignant phenotype (reviewed in, Wang et al., 2011). 
 Promotion of mitotic activity, thus enhancing proliferation which is seen as a 
fundamental hallmark of cancer.  For example, TEX14 and CASC5 have been important 
for kinetochore assembly and so may be actively driving mitotic division when 
expressed in the tumour (Whitehurst, 2014).  CAGE has also been shown to promote 
proliferation of cancer cells by increasing levels of cyclins involved in progression to S 
phase of the mitotic cell cycle (Por et al., 2010).  On the other hand, another CTA 
BORIS has been shown to have growth inhibitory effects and may have tumour-
suppressor functions in vivo (Tiffen et al., 2013); although, contrarily, in an acute 
leukaemia cell line the opposite effect was seen and it was thought this was mediated 
through epigenetic changes influencing NOTCH signalling (Zampieri et al., 2014). 
 Influencing cellular signalling, inducing EMT and maintenance of cancer stem-like cell 
characteristics.  The localisation of certain CTAs within the CSC compartment is of 
particular interest (Wen et al., 2014; Yamada et al., 2013); though whether they actively 
support the CSC niche or whether they are activated as a consequence of other 
genetic/epigenetic changes in that region of the tumour remains uncertain.  In any case, 
it raises the possibility of targeting these proteins to kill the resistant CSCs that are 
believed to be a primary cause of cancer recurrence following standard treatments.  
However, the fact that CTAs have been shown to be able to induce EMT makes a 
putative role in carcinogenesis possible and certainly worthy of further exploration 
(Yang et al., 2015).  The gastric carcinogenic bacterium Helicobacter pylori (H. pylori), 
known to be important in EMT, can lead to activation of the CT gene MAGE-A3 raising 
the possibility of an oncogenic mechanism (Fukuyama et al., 2012).  Increased levels 
of PAI-1, a plasminogen activator inhibitor gene, have been shown to be associated with 
both a worse outcome in gastric cancer and H. pylori infection in healthy individuals 
(Norsett et al., 2011).  Downregulation of PAI-1 was seen when the CT-gene CAGE 
was downregulated (Kim et al., 2013).  It has not been shown whether H. pylori 
activates CAGE in the gastric mucosa but would be worth investigating in order to assess 
a possible mechanism promoting EMT and gastric carcinogenesis. 
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 Alteration of cellular adhesion and proteolytic activity.  This putative function of CTAs, 
which would enhance cell motility and migration, may have important implications for 
the invasive properties of a tumour.  For example, ADAM2 which has been shown to 
be upregulated in prostate cancer (Romanuik et al., 2009), belongs to a family of 
proteolytic enzymes implicated in extravillous trophoblast invasion (Pollheimer et al., 
2014) and also specifically has a role in fertilisation (Evans, 2001; Pollheimer et al., 
2014).  Proteins involved in implantation of the embryo and development of the placenta 
which is a highly vascular structure might also be expected to promote angiogenesis if 
expressed in a tumour.  Indeed, in a chorioallantoic membrane assay, the application of 
recombinant CAGE protein was shown to lead to the induction of angiogenesis (Kim et 
al., 2013) providing direct support for this possibility.  CAGE has also been shown to 
induce the activity of matrix metalloproteinases and promote the motility and invasion 
of cancer cells in both culture and in xenograft models of carcinogenesis (Kim et al., 
2009; Kim et al., 2013).  Overexpression of SSX2 in a breast cancer cell line enhanced 
proliferation and invasive potential of the cells and it was suggested this effect resulted 
via an influence on oestrogen receptor signalling pathways (Chen et al., 2012).  NY-
ESO-1 has also been shown to induce the migration but not proliferation of a 
hepatocellular cell line, though the mechanism for this is uncertain (Xu et al., 2012).  It 
was proposed that NY-ESO-1 may promote metastasis of tumour cells due to this 
positive effect on cell migration. 
 Evasion of apoptosis, another hallmark of cancer, may also occur as a result of CT gene 
expression in cancer.  For example, overexpression of MAGE-A4 has been shown to 
induce apoptosis in spontaneously transformed normal keratinocytes (Bhan et al., 
2012).  A testis-specific serine/threonine kinase (TSSK4) has also been shown to induce 
apoptosis in various cell lines (Wang et al., 2015).  CAGE, a CTA found to be present 
in many cancers, has been shown to inhibit p53 activity which has broad and potent 
tumour suppressive activity including the induction of apoptosis (Kim et al., 2010).  
Similarly, MAGE proteins have been shown to be negative regulators of p53 function 
(Ladelfa et al., 2012).  It has also been shown that downregulation of CAGE expression 
led to enhanced apoptotic activity and increased susceptibility in an ex vivo model to 
chemotherapeutic agents (Kim et al., 2010).  In a xenograft model of tumourigenesis, 
CAGE also displays invasive and angiogenic responses (Kim et al., 2013).   
Chapter 1: Introduction 
38 
 
 Promoting immortality by maintenance of telomere length.  Telomeres are specialised 
ribonucleoprotein structures that exist on the ends of chromosomes.  Reduction in 
telomere length can render a cell senescent but also contributes to genomic instability 
and in this way promotes cancer formation (Bertorelle et al., 2014; O'Sullivan and 
Karlseder, 2010).   Telomeres shorten very slightly in somatic cells with each round of 
cell division but some cell types (e.g., stem cells and germ cells) are particularly active 
in maintaining telomere length (e.g., through increased telomerase activity).  Cancer 
cells by their very nature are usually rapidly dividing; this should make them susceptible 
to cellular senescence induced by a reduction in telomere length.  However, many 
cancers actively maintain telomere length by increasing telomerase activity in a similar 
fashion to that seen in stem cell populations (Bertorelle et al., 2014).  There is another 
pathway independent of telomerase activity employed in a proportion of human cancers, 
termed alternative lengthening of telomeres (ALT).  It has recently been shown that 
ALT telomeres are dependent on meiotic factors for their maintenance via a mechanism 
inextricably linked to their normal function in meiotic recombination (Cho et al., 2014).  
This study provides clear evidence of how cancers can become ‘addicted’ to germline 
genes as had been proposed previously (Janic et al., 2010; McFarlane et al., 2014; 
Rousseaux et al., 2013a; Simpson et al., 2005; Wang et al., 2011) and moreover, 
provides direct evidence of a link to cellular biology seen in meiosis. 
Thus, it can be seen that despite relatively little being known about the detailed function of most 
CTAs, many of the hallmarks of cancer can be explained by the proposed and known functions 
that have been put forward.  Focusing on the normal function of the CTAs, for example, their 
role within the placenta or during gametogenesis, may lead to a greater understanding of their 
role in cancer and to new avenues in which to focus further research. 
We had particular interest in colorectal cancer (CRC) as it is a common and important cancer 
type with varying but generally low expression of these antigens.  Could it be that a subset of 
CRC does express some germline genes that could potentially be of benefit either diagnostically 
or therapeutically?  Ovarian cancer is an important cause of morbidity and mortality in women 
and we were interested in this cancer type as well, which acts as a useful comparison.  The 
following discussion will introduce colorectal and ovarian cancer, and briefly outline what is 
known about CT gene expression in these cancer types but deals with CRC in more detail as 
more data is presented later in the thesis on this cancer type.   
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1.6. Colorectal cancer and CT genes 
Colorectal cancer (CRC) is among the most common malignancies in both men and women 
worldwide and a leading cause of cancer related mortality (Mathers et al., 2009; Siegel et al., 
2015).  When treated early by surgical or endoscopic resection, the disease carries a relatively 
good prognosis, but when it presents in a more advanced stage the prognosis is generally poor.   
All too often, because of the frequent lack of symptoms in the early stages, the disease presents 
at a late stage.  This latter group of patients are often offered chemotherapy to either palliate 
symptoms or increase chances of cure when patients are undergoing surgical resection.  The 
introduction of bowel screening programmes (e.g., faecal occult blood or immunochemical 
testing) attempts to reduce the proportion of patients presenting with advanced stages of disease 
by picking it up before symptoms occur (Smith et al., 2015; Stracci et al., 2014).   Radiotherapy 
is commonly given as adjuvant treatment for tumours within the rectum.   
Before going on to discuss the pathogenesis of colorectal cancer, it is important to briefly 
outline the normal structure and histology of the colon.  This is of relevance later in the thesis 
when immunohistochemistry results, of both normal as well as cancerous colonic tissue, are 
presented. 
1.6.1. Structure of the normal colon 
The embryonic hindgut gives rise to left-sided colon structures; that is, the distal transverse 
colon, descending colon, sigmoid colon and rectum.  The midgut gives rise to the right colon 
(i.e. caecum, ascending and proximal transverse colon) as well as the small bowel distal to the 
ligament of Treitz (Stranding, 2015).  The right and left colon merge at the splenic flexure and 
the left colon merges with the rectum in the pelvis at the rectosigmoid junction.  Cancers most 
commonly occur in the sigmoid colon and rectum, each accounting for approximately 30% of 
cases of colorectal cancer (Albuquerque et al., 2011).   
 
The layers of the gastrointestinal tract conform to the same broad histological features 
throughout the gastrointestinal (GI) tract – see Figure 1.12.  On the luminal surface of the GI 
tract is a mucosal epithelial layer; it is from this layer that the majority of cancers (i.e. all 
carcinomas) arise.  Beneath this is the supporting lamina propria, then a thin layer of muscle 
termed the muscularis mucosae.  Deep to this is the submucosa, which contains blood vessels 
and lymphatics, before a deeper and larger muscular layer termed the muscularis propria.  
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Finally, beneath this is an adventitial layer of serosa or peritoneum (Stranding, 2015).  Large 
mucosal folds or ridges, called haustra, are formed by contraction of the muscularis propria.  
There is also an outer longitudinal layer of muscle, which is organised into three bands termed 
taeniae coli; these run from the rectum to the caecum and all three terminate on the appendix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12.  Layers of the GI tract.  
The colonic mucosa is composed of a single layer of columnar epithelium.  One of the primary functions 
of the colon is to absorb water and the surface area of the colon is increased by involutions of the surface 
epithelium into crypts.  The normal crypt architecture, roughly similar to a “rack of test tubes” is 
maintained throughout the colon.  The crypts contain a more heterogenous mix of cells than the surface 
epithelium, including the stem cell compartment. Taken from (Strong and de la Motte, 2015). 
 
 
1.6.2. Colorectal cancer pathogenesis 
There are several pathways to the development of CRC that have been characterised in some 
detail over the past three decades (Al-Sohaily et al., 2012).  The majority of CRCs are sporadic 
and most of these conform broadly to the Vogelstein model of carcinogenesis (see Figure 1.13); 
that is they arise from successive acquired mutations in genes such as APC and KRAS and lead 
to CRC via the chromosomal instability (CIN) pathway (Al-Sohaily et al., 2012; Fearon and 
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Vogelstein, 1990).  Sporadic cases of CRC usually occur in later life, with an average age at 
diagnosis of around 70 years and the vast majority of patients being diagnosed over the age of 
50 years. The microsatellite instability (MSI) pathway and CpG Island Methylator Phenotype 
(CIMP) pathway are the other pathways described, together accounting for approximately one 
third of all cases of CRC (Al-Sohaily et al., 2012; Kang, 2011).  So, at least three distinct 
‘routes’ to CRC exist but in reality there is a complex overlap between genetic and 
environmental factors that leads to disease development.   
Although over half of CRCs develop within the left (or distal) colon and rectum, tumours that 
develop via the MSI pathway have a propensity to develop within the proximal colon.  The 
exact reasons for this phenomenon are not known but may be related to the level of β-catenin 
signalling within the colon (Albuquerque et al., 2011). 
 
 
 
 
 
 
 
 
 
Figure 1.13 The Vogelstein model of carcinogenesis or “Vogelgram”.   
An initial insult to the colonic epithelium leads to genetic change; mutation in the APC gene is often an 
early event.  Subsequent acquired genetic (e.g., mutations in genes such as p53 and KRAS) and 
epigenetic changes (e.g., demethylation of DNA sequences) leads to greater and greater genetic 
instability.  Small polyps grow is size, develop severely dysplasia and eventually become cancerous, 
when they have the ability to invade and metastasize. Adapted from (Hopkins Colon Cancer Center, 
2015) and (Rao and Yamada, 2013).   
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1.6.2.1. Genetic predisposition 
A minority of CRC cases are due to inherited genetic defects that lead to an increased likelihood 
of developing the disease.  Collectively the inherited syndromes associated with CRC account 
for at least 5% of all cases of the disease, but as yet ill-defined inherited factors may explain a 
much larger proportion of the overall disease burden (Gala and Chung, 2011; van Wezel et al., 
2012).  Identifying patients who have an inherited disorder predisposing them to CRC is often 
not easy, and relies on obtaining a detailed family history.  However, the diagnosis of an 
inherited disorder is important as it not only has implications for the management of the disease 
but also for relatives of the individuals who may for instance be offered regular colonoscopic 
screening and/or genetic counselling/testing.  There are two main types of inherited disorder 
that lead to an increased risk of colorectal cancer: 
 Familial adenomatous polyposis (FAP) is an autosomal dominant condition caused by 
mutation of the APC gene that results in loss of normal function leading to the 
development of hundreds of colonic polyps and the almost inevitable development of 
CRC before the age of 40 years.  Patients known to have this condition usually undergo 
surgery to remove their entire large bowel before their third decade of life (Gala and 
Chung, 2011). 
 The most common inherited disorder associated with CRC is Lynch Syndrome or 
Hereditary Non Polyposis Colorectal Cancer (HNPCC) (Al-Sohaily et al., 2012; 
Hewish et al., 2010).  Lynch syndrome is also inherited in an autosomal dominant 
fashion and is caused by germline mutations in DNA mismatch repair (MMR) genes.   
There are numerous MMR genes that are implicated in Lynch syndrome but common examples 
of genes that are mutated include: mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), mutS 
homolog 6 (MSH6) and postmeiotic segregation increased 2 (PMS2) (Hewish et al., 2010; 
Poulogiannis et al., 2010; Soreide et al., 2006).  Failure of MMR through such gene mutations 
leads to a state termed microsatellite instability (MSI).  Somatic mutations in the same or other 
MMR genes can lead to CRC via the MSI pathway in much the same way that germline 
mutations do (Boland and Goel, 2010; Soreide et al., 2006; Vilar and Gruber, 2010).  
Mismatches in nucleotide base pairing are common during DNA replication and the MMR 
system is of vital importance in recognising and repairing these mistakes.  Microsatellites are 
repetitive sequences of DNA that occur throughout the genome and are particularly susceptible 
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to errors during DNA replication (Jansen et al., 2012; Soreide et al., 2006).  If the errors are not 
corrected in genes involved, for example, in cell growth or replication then this can lead to a 
phenotype that promotes tumourigenesis (Shah et al., 2010).  MSI leads to mutations in β-
catenin and TGFβRII more commonly than genes such as KRAS and p53 that are frequently 
mutated in the Vogelstein model/CIN pathway described above (Hsieh and Yamane, 2008).  
Overall 15-20% of all CRCs develop via the MSI pathway, of which a proportion of patients 
will come from a family with Lynch syndrome.  Failure of MMR, as seen in Lynch Syndrome, 
leads to an increased susceptibility to cancer more generally.  Indeed, Lynch Syndrome is 
associated with an increased risk of various malignancies, including: endometrial, ovarian, 
brain, skin as well as tumours of the upper gastrointestinal and urological systems (Al-Sohaily 
et al., 2012).  The Amsterdam criteria and Bethesda guidelines are the two commonly used 
tools to identify patients at high risk of an inherited genetic disorder from their family history; 
specific genetic testing is then performed to reach a diagnosis (Weissman et al., 2011).  The 
term HNPCC is no longer favoured, largely because it ignores the fact that the condition is 
associated with an increased risk of many other malignancies and also because these patients 
can develop polyps within the colon. 
Once the diagnosis of CRC is established, the treatment of colorectal cancer is similar 
regardless of the genetic background with surgical resection when possible affording the best 
chance of cure.  Treatment is, however, becoming more personalised. Although biological 
agents are used for selected patients with advanced disease, immunotherapy is not as commonly 
utilised for the treatment of CRC as it is for other types of cancer (Boghossian et al., 2012; 
Dalerba et al., 2003; Noguchi et al., 2013a).  Recent advances in our understanding of tumour 
immunology have reignited interest in such therapeutic strategies across a range of tumour types 
including CRC for both early at late stage disease (Boncheva et al., 2013; Hanna, 2012; 
Markman and Shiao, 2015; Rosenberg and Restifo, 2015; Schumacher and Schreiber, 2015; 
Sondak and McArthur, 2015; Topalian et al., 2011).  As CTAs contain amongst the most 
immunogenic antigens, there is a drive to establish whether germline genes are activated in 
colorectal and other cancers.  Some of what is known about CT gene expression will now be 
outlined - see (Sammut et al., 2013) for a more comprehensive review. 
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1.6.3. CT gene expression in colorectal cancer 
Previous studies have indicated that CT genes are not widely or universally expressed in all 
tumour types (Almeida et al., 2009; Caballero and Chen, 2009; Cheng et al., 2011; Costa et al., 
2007; Fratta et al., 2011; Hofmann et al., 2008; Simpson et al., 2005; Viphakone et al., 2015).  
CRC falls within the group of tumours that have limited CTA gene expression but considerable 
variability is seen between studies.  Moreover, this generalised classification does not account 
for the possibility that there is a sub-group of CRCs that do have a high incidence of CTA gene 
expression that could provide valuable clinical targets that currently remain unexplored.  Given 
the patient-specific tailored therapy that advanced immunotherapy approaches represent it 
could be the case that a cohort of patients might benefit from the therapeutic potential of CTA 
genes, assuming that CTA gene expression is associated with antigen production that can be 
therapeutically harnessed.  Some tumours have been found to co-express CTA genes (Wang et 
al., 2002), and thus, it may be the case that the majority of CRCs do not express any CTA genes, 
but rather a minority express several.  Two possible reasons for co-expression of CT genes were 
outlined above (see Section 1.5).  The MAGE family of genes serve as an example of both co-
expression and the variability of expression profiles seen between studies.  These facts will be 
revisited later in the thesis and further discussion is provided in Chapter 5 (Section 5.1.3). 
1.6.4. CTA correlation with clinical outcome 
Choi and Chang found the expression of MAGE and SSX genes to be correlated with the 
presence of liver metastases in CRC (Choi and Chang, 2012).  In this study they used primer 
sets that were complimentary to several MAGE (MAGEA1-A6) and SSX (SSX1-9) genes; from 
37 samples tested a combined expression frequency of 51.4% was found for MAGE genes and 
32.4% for SSX genes.  Protein levels of another CTA, OY-TES-1, were found to correlate with 
tumour grade and invasion (Luo et al., 2013).  Interestingly, in this study low levels of gene 
activation (but not protein) were seen in normal adjacent colonic tissue but not normal control 
samples.  This fact has implications when considering the results of gene expression profiles 
and immunohistochemistry data, which will be presented later in this thesis. 
1.6.5. Therapeutic use targeting CTAs in CRC 
A phase II trial assessing the use of a therapeutic vaccine based on dendritic cells that have been 
pulsed with a tumour cell lysate (prepared from a MAGE-expressing melanoma cell line) 
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showed some promising results and low toxicity in patients with metastatic CRC (Burgdorf et 
al., 2008). However, in an earlier study a very weak overall clinical response rate of less than 
1% was found for the use of cancer vaccines to treat CRC, despite induction of an immune 
response in around half of patients (Noguchi et al., 2013b).  However, these vaccines were not 
all CTA derived and so CTA based vaccines may result in distinct and possibly higher clinical 
response rates, but this requires formal testing.  A partial clinical response with no major side 
effects of treatment to a cancer vaccine based on MAGE-A4 has also been observed in a single 
patient with metastatic colorectal cancer (Takahashi et al., 2012). 
 
1.7. CT gene expression in ovarian cancer 
1.7.1. Ovarian cancer overview 
Ovarian cancer is one of the leading causes of cancer deaths in women and the commonest 
cause of gynaecological cancer deaths (Siegel et al., 2015; Sung et al., 2014).  There have only 
been modest improvements in survival since the 1980s: in part this is due to a lack of effective 
screening methods as well as the vast heterogenous nature of the disease (Berns and Bowtell, 
2012; Erickson et al., 2013; Menon et al., 2014; Vaughan et al., 2011).  Although grouped as 
“ovarian cancer” due to the anatomical location of the tumours, there are five distinct subtypes 
of the disease and it is now widely accepted that many tumours do not in fact originate from 
the ovaries (Berns and Bowtell, 2012; Erickson et al., 2013; Nelson, 2015; Sorensen et al., 
2015).  The different molecular subtypes of ovarian carcinomas are: high-grade serous, clear-
cell, endometrioid, mucinous and low-grade serous.  Serous carcinomas for instance are thought 
to arise from the ovary, fallopian tube or peritoneum and mucinous carcinomas are often 
metastatic from the gastrointestinal (GI) tract (Erickson et al., 2013; Micci et al., 2014; 
Vaughan et al., 2011). 
Given the insidious nature of the presentation, coupled with the poor prognosis associated with 
the disease, there has been a drive to establish new biomarkers for the disease.  This has gone 
hand in hand with an improved understanding of the molecular events that occur in ovarian 
cancer pathogenesis (Berns and Bowtell, 2012; Micci et al., 2014).  CA-125 (see Table 1.3) has 
been used for many years to aid diagnosis but HE4 is the only new biomarker to establish itself 
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in recent years (Simmons et al., 2013).  HE4, or human epididymis protein-4, has too broad an 
expression in normal tissues to classify it as a testis-selective CTA. 
1.7.2. CT genes in ovarian cancer 
Numerous studies have shown CT genes to be expressed in ovarian cancer (reviewed in 
Mirandola et al., 2011(Mirandola et al., 2011).  Some studies have indicated that expression of 
CT genes predicts a less favourable clinical outcome in ovarian cancer (Daudi et al., 2014; 
Hasegawa et al., 2004; Sharma et al., 2005; Tammela et al., 2004; Tureci et al., 1998b; 
Yakirevich et al., 2003; Zimmermann et al., 2013).   It is certainly not a universal finding that 
the presence of CTAs or CT gene expression is associated with a worse prognosis.  Using a 
bioinformatics approach it has been shown that an immunoreactive subgroup of CTAs is 
associated with a favourable prognosis in ovarian cancer (Eng and Tsuji, 2014).  Immune 
responses to certain CTAs may result in the body’s ability to (partially) fight cancer and impact 
positively on prognosis; this has also been speculated as a possible reason contributing to the 
favourable prognosis of CRC that develops via the MSI pathway (Sammut et al., 2013).  The 
presence of tumour-infiltrating lymphocytes (TILs) has been associated with a better prognosis 
in various solid tumours, including ovarian cancer (Sato et al., 2005).  In this study by Sato and 
colleagues they did not see an association between CD8+ TILs (that were associated with the 
favourable prognosis) and the presence of three CTAs in the tumour.  Equally, however, they 
did not identify which TAAs were responsible for the TIL response. 
It could be that certain CTAs are able to predict a worse outcome in specific subsets of ovarian 
cancer; differentiating which CTAs are best for which subtypes requires further resolution.  It 
may well be that combining various biomarkers will prove of greatest clinical potential.  The 
presence of certain CTAs was found to accurately differentiate between borderline tumours and 
tumours of higher grade (Zimmermann et al., 2013) – such clinically relevant predictive power 
could be very useful when planning surgical intervention to remove tumours and how 
aggressive the resection should be.  It was over a decade ago that MAGEA4, detected using 
IHC, was found to be an independent predictor of survival in ovarian cancer (Yakirevich et al., 
2003).   More recently MAGEA4 has been suggested to be a central player, regulating the 
expression of other MAGE family members (Daudi et al., 2014).   
Combining CTA detection with conventional methods of disease stratification could 
conceivably increase the prognostic accuracy.  For instance, an even worse outcome has been 
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shown when looking at tumours that are both of higher grade and containing CTAs (Yakirevich 
et al., 2003).  Although not found to be an independent predictor of prognosis, sperm protein 
17 (SP17) was found in nearly half of the 70 ovarian cancer specimens examined in one study 
(Li et al., 2009).  More interestingly it was found in all cells isolated from the ascitic fluid of 
patients and in addition increased migration and resistance to chemotherapeutic agents of 
ovarian cancer cells in vitro.  Ovarian cancer often presents with clinically evident ascites.  
Isolating mRNA from peritoneal fluid samples and then using standard PCR amplification of 
different CT genes proved a very sensitive method for predicting that the fluid was a malignant 
exudate in another study (Hofmann and Ruschenburg, 2002).  Thus, using ascitic fluid as the 
source of biomarker development could potentially prove more useful than testing blood 
samples from patients and should be investigated further.  A similar approach could also be 
used for differentiating between benign and malignant causes of pleural effusions and appears 
to not have been extensively investigated.    
There has been a significant and increasing interest in the use of immunotherapy to treat ovarian 
cancer in the last decade (Tse et al., 2014; Wefers et al., 2015).  Immunotherapy has 
experienced resurgence itself (see Section 1.2) but our increased understanding of the 
pathogenesis of ovarian cancer coupled with the encouraging findings of CTAs being present 
has contributed to this increased interest.   Disappointingly, however, the results of early phase 
trials using immunotherapy have collectively shown little benefit, though the majority have not 
used CTAs as the target for antibody-based approaches (Leffers et al., 2014).  Recently, using 
xenograft and in vitro models of ovarian cancer, the use of a demethylating agent has been 
shown to not only induce CT gene expression but also enhance the effectiveness of an 
immunotherapeutic approach (Srivastava et al., 2015).  Such immunomodulatory effects of 
epigenetic manipulation may enhance the effectiveness of immunotherapy in the clinical setting 
in the coming years.  It has also been shown that the expression of some CT genes is associated 
with immunoreactive markers that are associated with a favourable prognosis in serous ovarian 
carcinoma (Eng and Tsuji, 2014).  The fact that other CT genes are expressed but not associated 
with this favourable ‘immunoreactive’ subgroup underlines the complex interplay between 
genes expression, antigen production and recognition, and anti-cancer immunomodulatory 
effects vs. oncogenic effects of CTAs. 
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1.8. CTAs and cancer treatment 
As discussed above, germline genes are a rich source of potential cancer-specific biomarkers.  
Clinically relevant biomarkers can be tremendously useful in developing and establishing 
treatment strategies in the clinical setting and tailoring them in a patient-specific fashion.  
Germline genes can also encode CTAs, which have been the target for effective immune-based 
treatments.  The most notable examples are in melanoma, where dramatic clinical responses 
have been seen in an adoptive therapeutic approach targeted at the CTA NY-ESO-1 (Hunder et 
al., 2008).  Another immunotherapeutic drug, Ipilimumab, has also shown considerable 
efficacy in the treatment of melanoma (Luke and Hodi, 2013) and mixed benefit in other tumour 
types such as ovarian cancer (Tse et al., 2014).  This drug does not directly target CTAs but has 
been shown to increase T-cell responses to NY-ESO-1 (Yuan et al., 2008) so this may partly 
explain the mixed clinical benefit observed in other tumour types with varying degrees of NY-
ESO-1 expression. Given the increasing evidence of germline factors being important in 
oncogenesis together with current knowledge of CTAs as both biomarkers and therapeutic 
targets, it is likely that in the coming years genes and proteins normally found in the germline 
will be of increasing importance in various aspects of cancer treatment. 
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1.9. Project aims 
The overarching aim of this project was to identify potential novel CT genes that could be used 
in therapeutics, diagnostics and/or disease stratification.  A number of related approaches were 
used in an attempt to fulfil the following subsidiary project aims. 
Firstly, we aimed to establish if there were any additional meiosis-associated cancer testis 
(meiCT) genes that could potentially act as cancer-specific biomarkers.  The MacFarlane group 
had set up and designed a computational pipeline which had already proved a useful method of 
identifying putative cancer-specific biomarkers (Feichtinger et al., 2012a; Feichtinger et al., 
2012b; Feichtinger et al., 2014).  There was a cohort of genes from this panel of genes which 
remained unvalidated.  We aimed to define the expression profile of these genes in a range of 
normal and cancerous tissues as a means of filtering out less promising candidates.  The genes 
as a group were loosely termed meiCT genes as it was predicted that some at least may be 
functionally related to meiosis.   
Secondly, we aimed to establish if there were any antigens (of meiCT genes) produced and 
present in normal testicular tissue.  This would serve as a route to establishing if the proteins 
were also produced in cancerous tissue.  Attempting to answer this question was an important 
next step with regards to potential use as an immunotherapeutic or drug target, as well as 
potential cell-surface marker for disease stratification purposes based on tissue and not only 
gene expression profile analysis.  We also aimed to investigate the potential immunogenicity 
of these proteins. 
Additionally, we aimed to draw-together information from the published literature to compile 
a list of candidate germline genes.  This is something that hitherto had not been done.  From 
this list, we aimed to go some way to establishing if there was a cohort of particularly promising 
candidates.  To fulfil this aim, the gene expression profiles for a larger cohort of genes would 
be tested in normal and cancerous tissue.  Further, a small biobank of tissue would be collected 
in which the expression or not of these germline genes could be compared directly in cancerous 
tissue as well as matched normal tissue from the same patients.  By focusing on CRC, we also 
aimed to establish if there was a subset of colorectal tumours that did express some of the 
germline-associated genes more widely, which would counter the generally held dogma that 
CTAs were infrequently found in CRC.  
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2. Materials and Methods 
2.1. Source of human cell lines  
The NTERA-2 (clone D1) cell line was gifted by Prof. P.W. Andrews (University of Sheffield) 
and the A2780 cell line was gifted by Prof. P. Workman (Cancer Research UK Centre for 
Cancer Therapeutics, Surrey, UK).  The following cell lines were purchased from the European 
Collection of Cell Cultures (ECACC); 1321N1, COLO800, COLO857, G-361, HCT116, HT29, 
LoVo, MCF7, MM127, SW480 and T84.  H460 and MDA-MB-453 were purchased from the 
American Type Culture Collection (ATCC), and two ovarian adenocarcinoma cell lines, PEO14 
and TO14, were obtained from Cancer Research Technology Ltd.  The T2 cells were gifted by 
Dr Steven Man (Cardiff University, Wales, UK).  Cell lines were regularly tested using the 
LGC Standards Cell Line Authentication service. 
2.2. Cell culture  
The cells were grown at 37˚C in a humidified incubator, in a CO2 enriched environment.  The 
media used for each cell line was supplemented with foetal bovine serum (FBS) from GIBCO, 
Invitrogen (Catalogue number; 10270, Lot 41Q6208K).  The cell lines and their growth 
conditions are detailed in Table 2.1.  All cell lines were routinely checked for mycoplasma 
contamination using the LookOut® Mycoplasma PCR Detection kit (Sigma Aldrich; MP0035) 
as per the manufacturer’s instructions.  Cell lines were authenticated following the key 
experiments through a short tandem repeat profiling technique, using LGC Standards Cell Line 
Authentication service – reports are provided in Appendix D (on CD).   
2.3. Preparation of frozen cell stocks  
Confluent cells were trypsinised using 1x trypsin-EDTA (Sigma-Aldrich; T3924) and collected.  
The cells were counted and then centrifuged for 5 minutes at 400 r.c.f.  The cells were then 
resuspended in freezing media (10% DMSO, 90% FBS) and transferred into a cryotube and 
placed at -80˚C for 24 hours before being transferred to liquid nitrogen for long term storage.  
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Table 2.1.  Description of the cells lines and their growth conditions  
 
Cell Line  Cell Line Description  CO2  Media  
  
1321N1  
NTERA-2  
(clone D1)  
  
SW480  
Human brain astrocytoma  
Caucasian pluripotent 
embryonal  
carcinoma  
Human colon 
adenocarcinoma  
5%  
 
10%  
  
5%  
Dubeco’s modified Eagle’s medium (DMEM) 
+ GLATAMAXTM (Invitrogen; 61965) + 10% 
FBS  
A2780  
MCF7  
Human ovarian carcinoma 
Human Caucasian breast 
adenocarcinoma  
5%  
5%  
  
DMEM + GLATAMAXTM + 10% FBS and 
1xNEAA (non-essential amino acids)  
COLO800  
COLO857   
H460  
Human melanoma  
Human melanoma  
Large cell lung carcinoma  
5%  
5%  
5%  
Roswell Park Memorial Institute 1640 
medium (RPMI 1640) + GLUTAMAXTM 
(Invitrogen; 61870) + 10% FBS  
PEO14*  
  
TO14*  
Ovarian Adenocarcinoma, 
peritoneal ascites  
Ovarian Adenocarcinoma, 
solid metastasis  
5%  
  
5%  
RPMI 1640 + GLUTAMAXTM + 10% FBS 
and 2 mM sodium pyruvate  
MM127  Human malignant melanoma  5%  RPMI 1640 + GLUTAMAXTM + 10% FBS 
and 25 mM HEPES  
T2 Cells T cell hybrid expressing 
HLA-A2 
5% RPMI 1640 + GLUTAMAXTM + 10% FBS + 
100 units penicillin and 100 µg streptomycin 
G-361  
  
HCT116  
HT29  
Human Caucasian malignant 
melanoma Human colon 
carcinoma Human Caucasian 
colon adenocarcinoma  
5%  
  
5%  
5%  
McCoy’s 5A medium + GLUTAMAXTM 
(Invitrogen; 36600) + 10% FBS  
T84  Human colon carcinoma  5%  Ham's F12 + DMEM (1:1) + GLUTAMAXTM 
(Invitrogen; 31331) + 10% FBS  
 DA-MB-453  Human breast carcinoma  0%  Leibovitz’s (L-15) medium + GLUTAMAXTM  
(Invitrogen; 31415) + 10% FBS  
* These cells lines were from the same patient, collected prior to treatment.  
2.4. Total RNA extraction  
Total RNA was extracted from human tissue samples using the RNeasy Mini Kit (Qiagen; 
#74104) according to the manufacturer’s instructions.  Briefly, 15-30 mg of RNAlater® 
(AmbionTM; #AM7020) stabilised tissue was added to 600 µl of Buffer RLT with 6 µl of 14.3 
M β-mercaptoethanol (β-ME) in a gentleMACSTM M-Tube (Miltenyi Biotec; #130-093-236).  
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The tissue was homogenised in a gentleMACSTM rotor-stator homogeniser (Miltenyi Biotec; 
#130-093-235) using the RNA_02 setting.  An optional DNase digestion step was routinely 
performed by adding 10 µl of DNase I stock solution (Qiagen; #79254) directly to the RNeasy 
spin column and leaving on the benchtop to incubate for 15 minutes at room temperature.  RNA 
was eluted from the RNeasy spin column into a fresh 1.5 ml collection tube by adding 30 µl of 
RNase-free water directly to the spin column membrane and centrifuging at 13,000 r.c.f.  This 
elution step was repeated once to produce a final volume of RNA of ~60 µl, which was then 
stored at -80˚C prior to use.  Total RNA extracts were prepared for all of the cancer cell lines 
grown in the lab (see Table 2.1) using a standard protocol (as described in Feichtinger et al. 
2012a).  The concentration and quality of RNA extracted from the cell lines was measured 
using a NanoDrop (ND_1000).    
2.5. cDNA synthesis  
2.5.1. cDNA synthesis for RT-PCR screening of mei-CT candidates 
Total RNA preparations from the human tissue panel (Clontech; #636643) and a range of 
tumour tissues and cell lines were purchased from Clontech and Ambion – refer to Appendix 
C (on CD) for details supplied by the company on this RNA.  The quantity of RNA was assessed 
as necessary using Nanodrop technology; 1.0 µg of total RNA was reverse transcribed into 
cDNA using the SuperScript III First Strand synthesis system (Invitrogen; #18080-051) as per 
the manufacturer’s instructions and the cDNA was then diluted eight times.  The quality of the 
cDNA was tested using a control RT-PCR using primers for ACTB.  
2.5.2. cDNA synthesis for qPCR screening on TLDA cards 
Total RNA preparations were from the human tissue panel (Clontech; #636643), a range of 
tumour samples purchased from Origene (see Appendix C, on CD) or extracted directly from 
tumour and adjacent normal tissue.  The quantity and quality of the RNA was assessed as 
necessary using BioRad Experion RNA analysis chip according to the manufacturer’s 
instructions.  RNA with RQI values lower than 7.5 were not used for TLDA card qPCR 
analysis.  1.0 µg of total RNA was reverse transcribed into cDNA using the SuperScript III First 
Strand synthesis system (Invitrogen; #18080-051 and #11752-250) as per the manufacturer’s 
instructions and the cDNA was then diluted five times.  The quality of the cDNA was tested 
using a control RT-PCR using primers for ACTB prior to use of the TLDA cards. 
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2.6. Reverse transcription (RT-) PCR  
The sequences for each of the genes analysed were obtained from the National Center for 
Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov/) and primers specific to each 
of the genes were designed to span introns where possible.  An oligonucleotide properties 
calculator (OligoCalc, available from: simgene.com/OligoCalc) and the NCBI primer-BLAST 
and primer designing tool (available from: http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi?LINK_LOC=BlastHome) were used to aid primer design.  
2.6.1. Method 1 
A volume of 2 µl diluted cDNA was used in the PCR with a final volume of 50 µl.  BioMixTM 
Red 2x (Bioline; BIO-25006) was used for the PCR amplification as per the manufacturer’s 
instructions.  Samples were amplified with a pre-cycling hold at 96°C for 5 minutes, followed 
by 40 cycles of denaturing at 96°C for 30 seconds, annealing for 30 seconds and extension at 
72°C for 40 seconds, followed by a final extension step at 72°C for 5 minutes.   For ACTB 
amplification a total of 35 reaction cycles was used. 
2.6.2. Method 2 
My Taq Red x2 (Bioline: BIO-25043) was also used for PCR amplification as per the 
manufacturer’s instructions.  Samples were amplified with a pre-cycling hold at 95°C for 1 
minute, followed by 40 cycles of denaturing at 95°C for 15 seconds, annealing for 15 seconds 
and extension at 72°C for 10 seconds, followed by a final extension step at 72°C for 5 minutes.  
Again, for ACTB amplification a cycle length of 35 was used instead of 40. 
 
Alternatively half the reaction volume was used (i.e. 1ul of cDNA to produce a final PCR 
volume of 25 µl).  RT-PCR for ACTB and NYESO-1 (a known X-CT gene) was carried out for 
all cancer and noncancer cDNA samples as controls.  The products were separated on 1% 
agarose gels stained with ethidium bromide or peqGREEN (Peqlab; 37-5000). 
2.6.2.1. Annealing temperatures used and RT-PCR cycling conditions 
Two reagents were used (BioMixTM Red 2x and MyTaqTM Red Mix, Bioline) for RT-PCR as 
described above.  The annealing temperatures used are shown in Table 2.2 – the letters 
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correspond to those used in Table 1 in Section 2 of Appendix, where the list of primers used is 
provided. 
 
Table 2.2.  Cycling conditions and annealing temperatures used for RT-PCR 
Bioline Mix Annealing temperature Cycling Code* 
BioMixTM Red 2x 52˚C A 
BioMixTM Red 2x 54˚C B 
BioMixTM Red 2x 55˚C C 
BioMixTM Red 2x 56˚C D 
BioMixTM Red 2x 60˚C E 
MyTaqTM Red 54˚C F 
MyTaqTM Red 55˚C G 
MyTaqTM Red 56˚C H 
MyTaqTM Red 58˚C I 
MyTaqTM Red 60˚C J 
*See Table 1 in Appendix for which conditions used for individual primer sets 
2.6.3. Purification of RT-PCR products using the Roche purification kit 
PCR products were run on a 1% agarose gel containing ethidium bromide and the band(s) were 
cut out of the gel using a sterile blade. The products were then purified using the High Pure 
PCR Product Purification Kit (Roche Applied Science; #11732676001), as per the 
manufacturer’s instructions. The purified PCR product was eluted from the column in nuclease 
free water. 
2.6.4.  Sequencing RT-PCR products 
A minimum amount of 5 ng/μl DNA was sent at room temperature in a clean Eppendorf tube 
to Eurofins MWG, with 15 pmol of the corresponding forward and/or reverse primers.  The 
sequencing results were blasted and aligned against the expected PCR product sequence, using 
the NCBI Basic Local Alignment Search Tool. 
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2.6.5. RT-PCR screening using the QIAxcel system 
PCR products were screened using QIAxcel DNA screening kit (Qiagen).  The QIAxcel was 
run as per the manufacturer’s instructions using the AM320 method.  The 15 bp – 1 Kb 
alignment marker and the 50-800 bp v2.0 size marker were used. 
2.7. Taqman Low Density Array 
After confirming RNA quality with BioRad ExperionTM analysis kit and performing cDNA 
synthesis as above, the cDNA was diluted approximately 1:5 with RT-PCR grade water 
(Ambion®, AM9935), producing a final volume of 110 µl.  RT-PCR was performed using 1 µl 
of this cDNA and ACTB primers to confirm reverse transcription was successful.  101-102 µl 
of the cDNA was mixed with an equal volume of Taqman® Universal Mastermix II, with UNG 
(Applied BiosystemsTM, #4440038) after allowing the reagent to equilibrate to room 
temperature for 30 minutes.  100 µl of this sample-specific PCR reaction mix was dispensed 
into the fill reservoir of the TLDA card.  The card was then spun down at 1200 r.p.m. for 1 
minute (Sorvall® Legent T centrifuge; HeraeusTM rotor 75006445) and repeated for a further 1 
minute spin.  The card was sealed using the Life Technologies mechanical sealing device; the 
ports were then cut off using scissors before loading on the Applied Biosystems® 7900HT Real-
Time PCR instrument.  Results were analysed using Life Technologies ExpressionSuite 
software. 
 
2.8. Western blot analysis 
2.8.1. Cell preparation 
Whole cell extracts (WCEs) were prepared from confluent or sub-confluent cell cultures.  The 
cells were trypsinised and the flask washed with approximately 10 ml of complete media to 
inactivate the trysin.  The pooled cells were transferred into Falcon tubes and spun at 1500 
r.p.m. for 3 minutes (Jouan C3 centrifuge: approximately 426 r.c.f.).  The supernatant was 
discarded and the cells were resuspended in approximately 10 ml of 1xPBS and spun again at 
1500 r.p.m. for 3 minutes.  This step was repeated once more.   
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2.8.2. Cell lysis 
The M-PER reagent was prepared (e.g., for 1 ml, 10 µl of x100 HALT protease inhibitor 
cocktail and 10 µl of x100 EDTA solution to 980 µl of M-PER® reagent).  The cell pellet from 
above was resuspended in 1-1.5 ml of cold 1xPBS and transferred into a 1.5 ml microcentrifuge 
tube.  This was centrifuged at 1500 r.p.m. (Thermoscientific HeraeusTM PICO 17 centrifuge) 
for 5 minutes at 4˚C and the supernatant removed carefully.  The pellet was weighed 
(subtracting the weight of an empty microcentrifuge tube) and 10µl of prepared M-PER reagent 
for every 1mg of dry pellet added.  The microcentrifuge tube was then placed on a rotary 
incubator and incubated for 10 minutes at room temperature.  After ‘full lysis’ the cell debris 
was pelleted by centrifugation at maximum speed (13,300 r.c.f./17,000 r.p.m. HeraeusTM PICO 
17 centrifuge) for 15 minutes.  The supernatant was then carefully removed and transferred into 
a new microcentrifuge tube.  The protein concentration was estimated by BCA (Thermo Fisher 
Scientific; #23277) method.  The lysis was flash frozen in liquid nitrogen and stored at -80˚C.  
2.8.3. Lysis sample preparation and running gel 
The samples were prepared as follows: 
 Lysate – correct volume for 30 µg 
 BoltTM LDS Sample Buffer (4X) – 5 µl  
 BoltTM Reducing Agent (10X) – 2 µl  
 Deionized water to make a final volume of 20 µl 
 
The samples were first incubated at 70˚C for 10 minutes and the 20 µl aliquots were then 
separated on SDS-polyacrylamide pre cast gels (BoltTM 4-12% Bis-Tris Plus Gels, 15 well, Life 
Technologies, BG04125BOX).  8 µl of Precision Plus ProteinTM Dual Color Standard (Bio-Rad, 
#161-0374) was used as a molecular weight marker.  The gels were run at 100V for 
approximately 60 minutes and subsequently electro-blotted onto a methanol-soaked PVDF 
membrane (Immobilon-P, Millipore, IPVH00010) at 500 mA for 120 minutes in 2x Towbin 
buffer (380 mM Glycine, 50 mM Tris). 
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2.8.4. Blocking, antibody and ECL 
The membranes were blocked in milk solution (10% milk/1xPBS/0.2% Tween) for 60 minutes 
at room temperature.  The blotted membranes were then probed with the primary antibody 
(diluted in milk solution) at 4˚C overnight.  The membranes were rinsed in milk solution, 
followed by two 10 minute washes before applying the secondary antibody (diluted in milk 
solution) for 60 minutes at room temperature.  Antibody detection was performed using Pierce 
ECL Plus/2 Western Blotting substrate (Thermo Scientific, #32132) and CL-XposureTM film 
(Thermo Scientific, 34091) in an enhanced chemiluminescence detection system according to 
the manufacturer’s instruction.  For GAPDH loading control, standard ECL substrate was used. 
2.9. siRNA (small interfering RNA) knockdown 
Subconfuent cells were seeded at 5x105 cells per well in 6-well plates that contained fresh 
complete media.  The cells were incubated under normal growth conditions.  The transfection 
mixture for each well was prepared as a mastermix in a clean Eppendorf tube and 106.6 µl was 
added to each well containing the cells.  The 106.6 µl contained 100 µl of serum free media, 6 
µl of HiPerFect transfection reagent (Qiagen; #301705) and 0.6 µl of the siRNA (Qiagen).  The 
list of the siRNAs used are shown in Table 2.3.  The mixture was incubated at room temperature 
for 20 minutes to allow formation of transfection complexes.  The transfection mixture was 
then added to the cells in the 6 well plate, which were then shaken gently within the incubation 
hood.  Untreated cells and negative-control siRNA (Qiagen) were used as controls.  Cells were 
treated with siRNA on day 0, with two further ‘hits’ at 24 and 48 hours, before harvesting the 
cells at 72 hours post transfection.   
 
 
Table 2.3.  siRNAs used for gene knockdown of C20orf201 
siRNA  Name Target Sequence (5’ to 3’) Catalogue number 
1 Hs_LOC198437_2 ACCGCCAAGAGGTGCAGACAA Sl00485135* 
2 Hs_LOC198437_5 CCCGTGGACGCAGTCGCTCGA Sl03186386* 
3 Hs_LOC198437_6 CCAGCCTCCCACATAAAGTTA Sl04258772* 
4 Hs_LOC198437_7 TCCCGCGGTGACGGCGACTGA Sl04319574* 
*From Qiagen 
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2.10. Immunohistochemistry (IHC) protocols 
2.10.1. Ventana automated IHC procedure 
Samples of human colon cancer and adjacent normal tissue was obtained from individuals 
undergoing colonic resection, following written informed consent.  The tissue samples were 
fixed in formalin and embedded in paraffin.  IHC was performed on 4 µm sections of this tissue.  
Staining was automated on a Ventana Benchmark XT IHC machine (Roche) using a standard 
IHC protocol (see Appendix A on CD).  3,3’-Diaminobenzidine (DAB) was used as the 
chromogenic substrate and the sections were counterstained with haemotoxylin.  Negative 
control was provided by addition of the antibody diluent without the primary antibody.  Images 
were obtained on Zeiss Axio Scan.Z1 digital slide scanner. 
 
Antibody optimization steps included both protease and heat methods of antigen retrieval.  
Standard Roche protocols were used in this regard – for full details see Appendix A (on CD).  
Heat retrieval produced the most consistent and reliable results both for performing IHC by 
hand and using the Ventana automated machine.  In addition to this a range of concentrations 
of the primary antibody were used, again both when performing IHC by hand and for the 
Ventana automated procedure to establish the optimum concentration.  For example, 1:50 to 
1:2000 dilutions of the primary antibody were used.  Preliminary work using TEX19 at a 1:500 
dilution had already been undertaken (Planells-Palop, unpublished data). It was discovered that 
lowering the TEX19 concentration from a 1:500 dilution to 1:800 still produced consistent 
results, so 1:800 dilution was used to minimise the chance of background staining. 
 
2.10.2. IHC by hand 
The tissue sections were cut on a microtome set at 4 microns thickness and mounted onto Leica 
sticky coat slides.  The slides were then baked in a dry oven at 60˚C for 30 minutes and allowed 
to cool to room temperature.  Deparaffinization with xylene was performed for 5 minutes and 
repeated three times in a fume hood.  The slides were then hydrated in 96% ethanol for 5 
minutes three times before washing them in dH2O prior to antigen retrieval.  450ml of dH2O 
was added to 50 ml of 10x DakoTM sodium citrate buffer (S1700; pH 6.0).  The 1x buffer 
solution was heated in a glass container on a heating platform to 95-99˚C before immersing 
slides (held in metal slide rack) into the buffer.  The buffer was maintained at a sub-boiling 
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temperature (98˚C +/- 2˚C) for 10 minutes.  The slides were then allowed to cool on the bench 
top (still immersed in the citrate buffer) for 20-30 minutes.  Alternative antigen retrieval with 
proteinase K was performed for 10 minutes.  The purpose of antigen retrieval was to unmask 
epitopes that were potentially hidden from the primary antibody and immunostaining without 
antigen retrieval was not attempted.  The slides were then immersed in DakoTM wash buffer 
(S3006) for 10-15 minutes on a gentle rotating platform; changing the wash buffer once during 
this time.  Enough blocking solution to cover the tissue section (e.g., 200-500 µl) was added 
and left to incubate in a humidified chamber.  The blocking solution used was either 5% normal 
serum/0.3% TritonTM X-100/1xPBS, or more commonly Dako mouse or rabbit serum (e.g., 995 
µl of the diluent mixed with 5 µl of rabbit serum, X0902) for at least 10 minutes at room 
temperature.  Overnight incubation with the primary antibody was at 4˚C in the humidified 
chamber, or alternatively at 30˚C for two hours.  DakoTM antibody diluent with background 
reducing components (S3022) was used to dilute the primary antibody.  Overnight incubation 
of the primary antibody at 4˚C was found to produce more consistent results so was used for 
the majority of IHC procedures performed by hand.  The slides were then washed for 10-15 
minutes in DakoTM wash buffer; changing the buffer once or twice over this time.  An optional 
step not usually carried out was to rinse briefly in methanol to remove excess water as a separate 
container was used.  In order to quench endogenous peroxidase, 3% hydrogen peroxide mix 
was made up (e.g., by adding 8 ml of 30% hydrogen peroxide to 72 ml of methanol).  The coplin 
jar was rinsed with methanol (to get rid of carryover water) if any doubt as to whether it was 
dry but a different container was usually used for quenching as opposed to washing so this was 
not generally carried-out.  The slides were then immersed (back to back) into the methanol/3% 
hydrogen peroxide mix for at least 7 minutes.  Enough secondary antibody to cover the 
specimen (e.g., 250 µl) at 1:1000 dilution was then added being careful not to allow the tissue 
to dry.  Incubation was for 30-60 minutes at room temperature.  The slides were then washed 
in DakoTM wash buffer for 10-15 minutes, again changing the wash buffer once or twice over 
this time.  The secondary antibodies used were purchased from Abcam (goat anti-mouse; 
ab47827 and goat anti-rabbit; ab6721).  After adding the secondary antibody the DAB substrate 
working solution was made up by adding 1 drop (or 20 µl) of the DAB Chromogen (Dako 
K3467) per ml of Substrate buffer.  The working solution was left at room temperature for at 
least 30 minutes before use.  The DAB solution was added to the slides and incubated for 
typically 4-5 minutes; or sometimes less according to the positive control sample on the day 
(i.e. DAB added to positive control first when appropriate and then visualised in real time under 
a light microscope).  The slides were placed on a rack and rinsed in a container with running 
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tap water for around 5 minutes before counterstaining with Haematoxylin (DakoTM; CS70030).  
Using a dropper the haemotoxylin was added and incubated for 10-15 seconds.  The slides were 
again rinsed in running tap water for 5 minutes before mounting.  Finally, the slides were 
dehydrated in 96% ethanol for 5 minutes three times (alternatively sequentially in 80%, then 
95% and then 100% ethanol for 2-5 minutes each).  The slides were then cleared by rinsing in 
xylene three times, leaving the slides in the final xylene solution before mounting for around 5 
minutes.  The coverslips were mounted with DPX mountant (Sigma; #06522) and allowed to 
dry on bench for at least 30 minutes before imaging. 
 
2.10.3. Variations to IHC protocol by hand 
2.10.3.1. Deparaffinization and hydration 
Rather than three 5 minute washes in xylene, the slides were dewaxed in fresh xylene for 60 
minutes in a fume hood.  The slides were then rinsed in a sequential series of 100%, 95%, 80%, 
70%, 50% ethanol for 2 minutes each.  The slides were then washed in dH2O prior to antigen 
retrieval as before. 
2.10.3.2. Antigen retrieval 
The DakoTM sodium citrate buffer was heated to 80˚C on a heating platform and the slides were 
immersed in the solution, which was then maintained at 80˚C (+/- 2˚C) for 60 minutes.  The 
slides were then allowed to cool on the bench top (still immersed in the citrate buffer) for at 
least 20 minutes or until less than 50˚C.   
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2.11. Immunofluorescence protocol 
The immunofluorescence (IF) protocol followed a similar approach to the IHC by hand method 
just described.  Tissue sections were cut on a microtome set at 4 microns thickness and mounted 
onto Leica sticky coat slides.  The slides were then baked in a dry oven at 60˚C for 30 minutes 
and allowed to cool to room temperature.  Slides were deparaffinised in xylene for 5 minutes 
three times, or alternatively for 60 minutes, in a fume hood.  The slides were then washed twice 
in 100% ethanol for 5 minutes and then twice in 95% ethanol for five minutes.  Alternatively, 
the same procedure as for IHC by hand version 2 above was used (i.e. 2 minute washes in 100%, 
95%, 80%, 70%, and then 50% ethanol).  The slides were then washed in dH2O prior to antigen 
retrieval.  Antigen retrieval was performed using heat-induced epitope retrieval by submerging 
slides in 10 mM sodium citrate buffer (DakoTM) pH 6.0 and maintaining at a sub-boiling 
temperature (95-99˚C on a heating platform for 10 minutes. Alternatively, the slides for held at 
80˚C (+/- 2˚C) for 60 minutes in the same solution. The slides were then allowed to cool on the 
bench top (still immersed in the citrate buffer) for 20-30 minutes, or until a temperature less 
than 50˚C had been reached.  The slides were then immersed in DakoTM wash buffer (S3006) 
for 10-15 minutes on a gentle rotating platform; changing the wash buffer once during this time.  
After rinsing with dH2O, the sections were incubated with 5% normal serum/0.3% Triton
TM X-
100/1xPBS, or Dako mouse/rabbit serum, for 1 hour at room temperature to block nonspecific 
binding and permeablize membranes, using a Dako pen (S2002) to draw around the tissue 
sections.  The slides were then incubated overnight with primary antibodies, diluted in DakoTM 
antibody diluent with background reducing components (S3022), or alternatively 1xPBS/1% 
BSA/0.3% TritonTM, at 4˚C in a humidified chamber.  Following washing for 10-15 minutes in 
1xPBS, the tissue sections were incubated with Alexa Fluor secondary antibodies, diluted in 
1xPBS/1% BSA/0.3% TritonTM X-100, for 2 hours in a humidified chamber in the dark.   A list 
of the primary and secondary antibodies used is provided in Table 2.4 and Table 2.5.  The slides 
were washed again for 10-15 minutes in 1xPBS.  Prolong® Gold Antifade Reagent with DAPI 
(Cell Signalling; #8961) was used to mount the coverslips on the slides, which were then sealed 
with nail varnish.  The slides were left overnight in the dark (e.g., in fridge) prior to visualisation 
on Zeiss confocal microscope or slide scanner.   Alternatively, DAPI was added to the slides 
and incubated in the dark for 10 minutes prior to coverslipping with Prolong® Gold Antifade 
Reagent (#9071).  Immunofluorescence was detected and imaged using a Zeiss LSM 710 
confocal microscope and ZEN lite software (Zeiss). 
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Table 2.4.  Primary Antibodies used for IHC and IF Procedures 
Antibody Clone Host Dilution Source Cat. No. 
Anti-C20orf201 Polyclonal Rabbit 1:250-1:500 Abcam ab108142* 
Anti-C20orf201 Polyclonal Rabbit 1:15-1:20 Abcam ab170783 
Anti-MAGEA1 Monoclonal Mouse 1:20 LSBio LS-C87868 
Anti-PIWIL1 Monoclonal Mouse 1:1000-1:2000 Sigma SAB4200365 
Anti-PIWIL2 Monoclonal Mouse 1:20-1:50 Abnova MAB0843 
Anti-SPO11 Polyclonal Rabbit 1:1000-1:2000 Abcam ab81695 
Anti-TEX19 Polyclonal Rabbit 1:400-1:800 Abcam ab185547 
*Lot: GR191628-1 and GR125175-1 
 
 
 
 
Table 2.5.  Secondary Antibodies used for IF 
Antibody Host Species 
Reactivity 
Label Dilution Source Cat. No. 
Anti-Mouse 
IgG 
Goat Mouse Alexa 
Fluor® 488 
1:400 Life 
Technologies 
A11029 
Anti-Mouse 
IgG 
Goat Mouse Alexa 
Fluor® 568 
1:400 Life 
Technologies 
A11031 
Anti-Mouse 
IgG 
Donkey Mouse Alexa  
Fluor® 647 
1:400 Life 
Technologies 
A31571 
Anti-Rabbit 
IgG 
Goat Rabbit Alexa 
Fluor® 488 
1:400 Life 
Technologies 
A11034 
Anti-Rabbit 
IgG 
Goat Rabbit Alexa 
Fluor® 568 
1:400 Life 
Technologies 
A11011 
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2.12. T-cell binding assay 
2.12.1. Peptide design 
T2 cells were donated by Dr Stephen Man (Cardiff University).  They are a TxB cell hybrid 
which express unstable HLA-A2 molecules and have been extensively used in biological assays 
to measure peptide binding to human leucocyte antigen (HLA) (Trojan et al., 2001).  Peptides 
were designed using different online tools including: Bioinformatics and Molecular Analysis 
Section (BIMAS) of the Center for Information Technology, National Institute of Health 
(http://www-bimas.cit.nih.gov/molbio/hla_bind/); SYFPEITHI Database (www.syfpeithi.de) 
(Rammensee et al., 1999); Immune Epitope Database (IEDB) Analysis Resource 
(http://tools.immuneepitope.org/mhci/result/); Zhiping’s Lab (http://www.umassmed.edu/zlab/ 
and http://zlab.bu.edu) (Peters et al., 2003).  The top ranking peptides and/or peptides that 
featured on multiple prediction results were chosen to take forward for the commonest HLA 
alleles for Caucasians. 
2.12.2. Peptide preparation and storage 
The peptides were ordered from Mimotopes (The Peptide Company) and 1mg of peptide was 
provided at a minimum of 94% purity.  Each peptide was dissolved in 20 µl of dimethyl 
sulfoxide (DMSO).  Alternatively 40 µl of DMSO was used if the peptide appeared not to 
dissolve well but this was only required for one peptide.  The peptide stock at a concentration 
of 50 mg/ml was stored at -80˚C.  2 µl of this stock peptide solution was added to 8 µl of RPMI 
1640 (+ Glutamax/2mM L Glutamine + 100 units per ml penicillin and 100 µg per ml of 
streptomycin) for a 1 in 5 dilution.   The positive control peptide was M1 (supplied by Stephen 
Man, Cardiff University) and was not diluted 1 in 5 as above for the custom peptides because 
the stock was at a lower concentration (10 mg/ml). 
2.12.3. Peptide incubation 
The T2 cells were cultured in complete RPMI 1640 media (+ 2mM L Glutamine + 
Penicillin/Streptomycin + 10% foetal calf serum) at 37˚C with 5% CO2.  The cultured cells 
were counted and 1x105 cells were added to the wells of a 96-well culture plate in a final volume 
of 200 µl media.  1 µl of the resuspended and diluted peptides were added separately to the 
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individual wells containing the T2 cells, which were then covered and incubated overnight at 
37˚C with 5% CO2. 
2.12.4. Addition of anti-human HLA-A2 antibody and flow cytometric read-out 
The T2 cells were harvested from the 96-well plate by pipetting up and down several times and 
transferred to separate 5 ml Falcon tubes.  The cells were washed by adding a similar volume 
(200-400 µl) of Flow Cytometry Staining (FACS) Buffer (1xPBS + FCS).  The tubes were then 
centrifuged at 1200 r.p.m. for 4 minutes in a Heraeus Megafuge 1.0R centrifuge.  The 
supernatant was removed from the cell pellet by inverting the tube.  5 µl of FITC anti-human 
HLA-A2 antibody (Biolegend, Clone: BB7.2, 400 µg/ml, #343304) was added to the 
resuspended cells (approximately 100 µl of supernatant remained on the cells after inverting 
the Falcon tube).  The cells were incubated with the antibody for 30-40 minutes at 4˚C in the 
dark.  Following this incubation, the cells were washed again with FACS buffer and the tubes 
then centrifuged at 1200 r.p.m. for 4 minutes.  The supernatant was removed in the same fashion 
by inverting the Falcon tubes, leaving approximately 100 µl of supernatant and cell suspension 
within the tube.  The Falcon tubes were tapped gently to dislodge the cell pellet before 
measuring on a FACS machine.  The viable T2 cells were identified on the basis of forward and 
side scatter, then gated using the negative control sample (T2 cells only).  HLA-A2 expression 
was determined for 20,000 cells. 
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3. Analysis of testis-specific genes as potential novel CT-genes 
3.1. Introduction 
In contrast to mitotic cell division that results in two identical daughter cells, meiosis results in 
four genetically distinct haploid cells termed gametes.  Mitosis occurs throughout our bodies to 
generate, renew and remodel tissues.  This allows organised growth during a child’s 
development, as well as enables tissue homeostasis and repair.  Meiosis and gametogenesis, on 
the other hand, are restricted to the germline.  The production of gametes in the cells of the 
germline is essential for successful reproduction, whereby ploidy is maintained in the offspring 
as the haploid cells combine during fertislisation to re-establish the diploid state in the zygote.  
Both mitosis and meiosis are tightly regulated processes orchestrated by a variety of proteins 
(Civelekoglu-Scholey and Cimini, 2014; Duro and Marston, 2015).  Some proteins are unique 
to meiosis.   
Dysregulation of mitosis can result in uncontrolled proliferation of cells that is a fundamental 
hallmark of cancer (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011).  Equally 
errors that occur during cell division could lead to chromosome segregation defects and 
aneuploidy or polyploidy.  The chromosome dynamics that occur during meiotic cell division 
are particularly complex, such as meiotic recombination, bouquet formation and sister 
centromere monopolarity (some of these details have been discussed in the Introduction).  If 
the genes regulating these processes become activated in somatic cells they could contribute 
greatly to genetic instability and in this way contribute to oncogenesis (McFarlane et al., 2015).  
Indeed, genetic instability is now considered a hallmark, or enabling characteristic, of cancer 
(Hanahan and Weinberg, 2011).   
A prognostic correlation in cancers has been shown for the expression of many CT genes (Choi 
and Chang, 2012; Luo et al., 2013; Yakirevich et al., 2003).  However, it remains unclear 
whether the (worse) clinical outcome observed for patients who have tumours which express 
CT genes are caused by their expression.  It is conceivable that the activation of CT genes is a 
consequence of increased genetic instability seen in certain tumours.  Despite the strong 
mechanistic reasons that would result, in theory, from the expression of testis- or meiosis-
specific genes, experimental evidence for a direct mechanistic link to cancer has been lacking.  
However, recent evidence from independent sources has added greatly to evidence in support 
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of a direct link between activation of such genes and cancer formation (Cho et al., 2014; Janic 
et al., 2010; Watkins et al., 2015). 
Proteins known to be essential for homologous chromosome conjoining in meiosis have been 
shown to be required for the alternative lengthening of telomeres (ALT) (Cho et al., 2014).  
Telomerase is an enzyme that enables elongation and maintenance of the telomere length.  This 
is the most common method for promoting immortalisation in cancer cells by preventing 
telomere shortening (Bertorelle et al., 2014; O'Sullivan and Karlseder, 2010).  There is an 
alternative method for the lengthening of telomeres in the absence of telomerase activity, 
termed ALT.  It has recently been shown that a heterodimer of two meiotic proteins interacts 
with RAD51 to promote directional movement of ALT telomeres and recombination of non-
sister telomeres to maintain telomere length and thus promote immortality (Cho et al., 2014).  
HORMAD1 is a meiosis-specific protein that was identified as a potential CTA over a decade 
ago (Chen et al., 2005).  HORMAD1 is involved in partner bias during homologous 
recombination (HR) events in meiosis.  More recently is has been shown that HORMAD1 
suppresses RAD51-dependent HR in triple-negative breast cancers, further supporting a role 
for meiotic proteins in oncogenesis (Watkins et al., 2015). 
Janic and colleagues identified that germline factors were oncogenic drivers in a Drosophila 
melanogaster brain tumour model (Janic et al., 2010).  It was subsequently shown that the 
orthologues of these genes were widely activated in human cancers and proposed that a ‘soma-
to-germline’ transition may be a key feature in many cancer types (McFarlane et al., 2014).  
These latest studies add to the evidence that tumour cells induce a gametogenic programme to 
promote the development of cancer hallmarks, as has been postulated (McFarlane et al., 2015; 
Simpson et al., 2005).  Meiosis-specific genes may be important drivers of this transition and 
understanding their function may help us understand important oncogenic mechanisms.  
Moreover, the same genes and protein products could be clinically useful biomarkers and/or 
targets for immunotherapeutics in oncology.  For these reasons, we set out to identify potential 
meiosis-specific genes as a source of novel CT genes.  Manual curation of the literature to 
identify candidate genes is both time-consuming and likely to miss meiosis-associated genes 
that have not yet been characterised in humans.  Thus, we set out to establish a more systematic 
approach as outlined below using a bioinformatics pipeline (developed in the McFarlane 
group). 
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3.2. Selection of candidate genes from a bioinformatics pipeline 
A bioinformatics pipeline was previously established to identify putative human meiosis-
specific genes that could potentially encode CTAs (Feichtinger et al., 2012b).  This was based 
initially on a cohort of mouse genes predicted to be associated specifically with spermatocyte 
development (Chalmel et al., 2007).  This study by Chalmel and colleagues identified 744 genes 
in mice, many of which would be expected to have roles during meiosis and potentially be 
meiosis and/or spermatocyte-specific.  The human orthologues of these genes were then 
identified with a high degree of stringency, revealing 408 candidate genes.  Figure 3.1 
summarises the pipeline specific to this research, which has been adapted from the pipeline 
described in detail elsewhere (Feichtinger et al., 2012b). 
The 408 human orthologue genes that had been identified were checked for expression in 
mitosis using MitoCheck (www.mitocheck.org).  MitoCheck was a project to identify genes 
and proteins involved in the cell division and chromosome segregation in humans – for more 
information see website.  Genes identified in this project will be expected to be expressed 
widely in somatic cells.  Thus, if any of our candidate genes were included in the MitoCheck 
list they were excluded at this stage as we wanted to identify genes restricted to meiosis or the 
germline.  This filtering step excluded 33 genes, leaving a list of 375 candidates (see Figure 
3.1).  These genes were then challenged against a bioinformatics tool, based on expressed 
sequence tag (EST) identifiers from the Unigene database (Feichtinger et al., 2014a).  ESTs are 
short nucleotide sequences (up to 500 bp) that are clustered and counted following a single-
pass nucleotide sequence read (Nagaraj et al., 2007).  EST databases have been utilised to 
identify potential new CTAs (Bettoni et al., 2009; Chen et al., 2005a; Chen et al., 2005b; 
Hofmann et al., 2008).   
If a candidate gene was represented in a non-testis/non-central nervous system (CNS) normal 
tissue EST library, then it was excluded.  The remaining genes were assessed further to see if 
they were represented in cancer EST libraries.  From the original 375 potential meiosis-specific 
genes the EST analysis identified 177 candidate genes that fulfilled these criteria.  These 177 
genes were sub-categorised into different classes based on the EST expression profiles.  Class 
1 genes, which contained 9 candidates, were found in cancer EST libraries and normal testis.  
Class 2 genes, which contained 75 candidates, had EST signatures seen in normal testis only.  
Class 3 genes had EST signatures seen in normal testis and central nervous system (CNS) 
tissues as well as being present in cancer EST libraries – 21 candidate genes fell into this 
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category.  Class 4 gene candidates, for which there were 72, were expressed in normal testis 
and CNS tissues but not found in the cancer EST libraries.  The 105 genes within class 1, 2 and 
3 formed the basis for the initial study from our group (Feichtinger et al., 2012b).  The aim of 
the work reported in this chapter was to validate the expression profile of a cohort of the 
remaining class 4 genes as potential CT genes (Sammut et al., 2014).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Schematic flow diagram of the bioinformatics pipeline used to identify potential novel 
CT genes.   
The initial pipeline was designed by McFarlane and Feichtinger (Fechtinger et al. , 2012b).  744 genes 
were identified as being meiosis-specific in mice; 408 human orthologues were then identified.  33 genes 
were excluded by MitoCheck, leaving 375 candidate human meiosis-specific genes.  All these genes 
were fed into an EST analysis pipeline, along with 3 positive control genes known already to encode 
CTAs.  The positive controls were included to assess whether known CTAs were not excluded by the 
pipeline and displayed appropriate expression profiles using the samples that were used for PCR 
validation. This returned 177 candidate genes; 72 which fell into a testis/CNS restricted category.  A 
cohort of these genes were then subject to RT-PCR expression validation, which formed the basis of the 
work presented in this chapter (Sammut et al., 2014).  Adapted from (Feichtinger et al., 2012b). 
Identification of human 
orthologues 
Filtering with 
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EST screen 
Validation with RT-PCR 
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408 genes 
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3.3. Identification and validation of potential novel CT genes predicted 
through an EST pipeline 
The candidate meiosis-specific genes were subjected to an EST filtering pipeline as outlined 
above.  This process categorised the genes into 4 groups.  Our group had previously validated 
the expression profiles of the candidate genes that fell into categories 1-3 of the EST pipeline 
(Feichtinger et al., 2012b).  Within the initial class 1-3 predicted gene sets RT-PCR validation 
revealed that a number were actually expressed in extensive somatic tissues (Feichtinger et al., 
2012b).  Given this, we re-analysed our predicted class 4 genes using updated CancerEST and 
CancerMA pipelines (Feichtinger et al., 2012a; Feichtinger et al., 2014a) and from this we 
identified 54 putative class 4 genes, those with expression signatures only in the testis and CNS 
of healthy tissue (see Table 3.1).  This cohort of genes totalled approximately two thirds of all 
the class 4 genes identified.   
The tissue specificity of these candidate genes was assessed by analysing the expression profiles 
of these genes in 20 different normal human tissue types.  The cDNA was generated from total 
RNA preparation from normal tissue samples, including testicular RNA, obtained post-mortem 
from Clontech and Ambion (see Appendix C, on CD, for further details).  The cDNA quality 
was assessed using PCR amplification of ACTB.  ACTB was chosen as a simple and practical 
way of assessing that the cDNA synthesis had worked and there was not massively varying 
quantities across our samples.  We were not undertaking quantitative PCR in these experiments, 
so a range of normalisation or ‘housekeeping’ control genes were not used. NY-ESO-1 was used 
as a control CT gene: this is a well characterised CT gene that encodes one of the most 
immunogenic CTAs.  Where possible, intron-spanning primer sets were designed to avoid 
amplification of possible contaminating genomic DNA.  40 cycles of PCR was used with the 
aim of detecting low levels of gene expression within the tested samples (except for ACTB 
where 35 cycles were used). 
 
The PCR validation acted as a crude but important step to try and identify genes with expression 
profiles consistent with germline predominant expression and equally to exclude genes that 
were expressed widely in somatic tissues.  Not all the PCR data is presented here but a sample 
of the genes from each of the following groups, as well as some of the genes that were excluded 
from further analysis.  It does not detract from the overarching message and conclusions drawn, 
which have inherent limitations as discussed again later.  A summary of the positive PCR data 
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is provided in Figure 3.6.  Based on the RT-PCR expression profile from the normal somatic 
tissues, the candidate genes were classified into different groups: 
 
 If the RT-PCR indicated that there was expression in more than two normal tissues 
(excluding testis and CNS tissues) then the genes were dismissed (see Figure 3.2).  
These genes were not subjected to further analysis within the cancer panel of tissues/cell 
lines. 
 
 The gene was classified as testis-restricted if expression appeared limited to the testis 
within normal tissues (see Figure 3.3). 
 
 If the RT-PCR indicated expression within the testis and normal CNS tissues only then 
the gene was classified as testis/CNS-restricted (see Figure 3.4). 
 
 Testis-selective genes were those which were seen in the testis, as well as one or two 
normal tissues.  Testis/CNS-selective genes were considered an additional category of 
genes (see Feichtinger et al., 2012b).  These were genes which the PCR indicated were 
expressed in testis and CNS tissues, as well as one or two other normal somatic tissues; 
none of the genes tested here exhibited this type of expression profile (see Figure 3.6). 
 
 
Table 3.1. List of the 54 potential meiCT genes. 
Gene name Ensembl ID Unigene 
cluster ID 
Chromosomal location with 
GRC coordinates 
ACTL9 ENSG00000181786 Hs.209206 19: 8,807,747-8,809,172 in 
GRCh37 coordinates 
ADAM2 ENSG00000104755 Hs.177959 8: 39,601,254-39,695,808 in 
GRCh38 coordinates 
ASB17  ENSG00000154007 Hs.125423 1: 75,918,873-75,932,431 in 
GRCh38 coordinates 
BOLL ENSG00000152430 Hs 692026  2: 197,726,879-197,786,762 in 
GRCh38 coordinates 
C1orf141* ENSG00000203963 Hs.666621 1: 53,916,574-53,945,929 in 
GRCh38 coordinates 
C2orf61 ENSG00000239605 Hs.531575 2: 47,045,538-47,155,378 in 
GRCh38 coordinates 
C3orf22 ENSG00000180697 Hs.178210 3: 126,245,842-126,277,808 in 
GRCh37 coordinates 
C3orf30  ENSG00000163424 Hs.271580 3: 119,146,150-119,160,042 in 
GRCh38 coordinates 
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C6orf81 ENSG00000157343 Hs.533066 6: 35,704,809-35,716,856 in 
GRCh37 coordinates 
C8orf74* ENSG00000171060 Hs.371776 8: 10,530,147-10,558,103 in 
GRCh37 coordinates 
C9orf153 ENSG00000187753 Hs.632073 9: 88,835,180-88,874,572 in 
GRCh37 coordinates 
C10orf67 ENSG00000179133 Hs.522360 10: 23,267,195-23,344,845 in 
GRCh38 coordinates 
C12orf50 * ENSG00000165805 Hs.112930 12: 88,373,812-88,427,814 in 
GRCh37 coordinates 
C16orf78  ENSG00000166152 Hs.125875 16: 49,373,823-49,399,431 in 
GRCh38 coordinates 
CAPZA3* ENSG00000177938 Hs.131288 12: 18,891,035-18,892,121 in 
GRCh37 coordinates 
CCDC116  ENSG00000161180 Hs.131615 22: 21,632,716-21,637,327 in 
GRCh38 coordinates 
CCDC63 ENSG00000173093 Hs.437141 12: 111,284,573-111,345,339  in 
GRCh37 coordinates 
CCDC73 ENSG00000186714 Hs.706808 11: 32,602,246-32,794,658 in 
GRCh38 coordinates 
CCIN ENSG00000185972 Hs.115460 9: 36,169,392-36,171,332 in 
GRCh38 coordinates 
DDI1  ENSG00000170967 Hs.591941 11: 104,036,580-104,039,194  in 
GRCh38 coordinates 
DNAJC5G  ENSG00000163793 Hs.116303 2: 27,498,289-27,504,367 in 
GRCh37 coordinates 
DYDC1 ENSG00000170788 Hs.407751 10: 82,095,861-82,116,511 in 
GRCh37 coordinates 
FAM170A* ENSG00000164334 Hs.713304 5: 119,629,559-119,635,822 in 
GRCh38 coordinates 
FAM194A  ENSG00000163645 Hs.147128 3: 150,659,885-150,703,971 in 
GRCh38 coordinates 
FAM71B* ENSG00000170613 Hs.666099 5: 157,161,846-157,166,264 in 
GRCh38 coordinates 
FIGLA ENSG00000183733 Hs.407636 2: 70,777,310-70,790,643 in 
GRCh38 coordinates 
GK2 ENSG00000196475 Hs.98008 4: 80,327,506-80,329,447 in 
GRCh37 coordinates 
H2AFB1 ENSG00000198082 Hs.592246 X: 154,113,247-154,113,833 in 
GRCh37 coordinates 
HEATR7B* ENSG00000 Hs.97714 5: 40,998,017-41,071,342 in 
GRCh38 coordinates 
HMGB4 ENSG00000176256 Hs.568628 1: 33,860,475-33,864,791 in 
GRCh38 coordinates 
IQCF1 ENSG00000173389 Hs.671210 3: 51,928,892-51,937,351 in 
GRCh37 coordinates 
KLF17* ENSG00000171872 Hs.567674 1: 44,118,850-44,135,140 in 
GRCh38 coordinates 
LYZL6  ENSG00000161572 Hs.97477 17: 35,934,518-35,943,699 in 
GRCh38 coordinates 
PDHA2  ENSG00000163114 Hs.131361 4: 95,840,088-95,841,474 in 
GRCh38 coordinates 
PDILT  ENSG00000169340 Hs.376025 16: 20,359,170-20,404,737 in 
GRCh38 coordinates 
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Note: emboldened genes are those for which RT-PCR on a range of normal human tissues indicated that 
gene expression was present in two or fewer somatic tissues other than testis and CNS tissues.  
*Signifies genes that had no expression in cancer cells/tissues as assessed by RT-PCR validation using 
34 cancer cell/tissue RNA sets. 
PPP3R2 ENSG00000188386 Hs.151167 9: 101,591,615-101,595,001 in 
GRCh38 coordinates 
PRPS1L1 ENSG00000229937 Hs.169284: 7: 18,026,782-18,027,863 in 
GRCh38 coordinates 
RBM44 ENSG00000177483 Hs.720233 2: 238,707,032-238,751,451 in 
GRCh37 coordinates 
RNF133 ENSG00000188050 Hs.126730 7: 122,337,766-122,339,210 in 
GRCh37 coordinates 
SATL1* ENSG00000184788 Hs.640783 X: 85,092,287-85,109,048 in 
GRCh38 coordinates 
SHCBP1L* ENSG00000157060 Hs.497034 1: 182,899,865-182,953,525 in 
GRCh38 coordinates 
SLC25A31* ENSG00000151475 Hs.149030 4: 127,730,378-127,774,293 in 
GRCh38 coordinates 
SPDYA ENSG00000163806 Hs.511956 2: 29,005,383-29,073,477 in 
GRCh37 coordinates 
SPZ1  ENSG00000164299 Hs.519403 5: 80,319,625-80,321,842 in 
GRCh38 coordinates 
TBC1D21* ENSG00000167139 Hs.124512 15: 74,165,949-74,181,555 in 
GRCh37 coordinates 
TGIF2LX  ENSG00000153779 Hs.592220 X: 89,176,881-89,177,882 in 
GRCh37 coordinates 
TMEM146* ENSG00000174898 Hs.631842 19: 5,720,688-5,778,745 in 
GRCh37 coordinates 
TRIM42* ENSG00000155890 Hs.343487 3: 140,396,881-140,419,992 in 
GRCh37 coordinates 
TSGA13 ENSG00000213265 Hs.592266 7: 130,668,648-130,687,432 in 
GRCh38 coordinates 
TSSK2 ENSG00000206203 Hs.694070 22: 19,130,808-19,132,621 in 
GRCh38 coordinates 
UBL4B ENSG00000186150 Hs.374027 1: 110,112,440-110,113,947 in 
GRCh38 coordinates 
UBQLN3 ENSG00000175520 Hs.189184 11: 5,507,300-5,509,985 in 
GRCh38 coordinates 
UMODL1 ENSG00000177398 Hs.242520 21: 42,062,959-42,143,453 in 
GRCh38 coordinates 
ZSWIM2  ENSG00000163012 Hs.375054 2: 187,692,562-187,713,935 in 
GRCh37 coordinates 
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Of the 54 genes, 21 were expressed in more than two non-testis/non-CNS normal tissues and 
were therefore dismissed at this stage.  Of the remaining 33 genes (bold in Table 3.1), 30 had 
expression limited to the testis in normal tissue, 2 had expression limited to the testis and normal 
CNS tissues and 1 further gene had expression in two normal tissues in addition to testis.  These 
33 genes, were then analysed by RT-PCR in a range of cancer tissues/cell lines – see Figures 
3.5 and 3.6.  Following this analysis, 14 of these genes were shown to have no expression in 
any of the cancerous material/cells.  For a further 16 genes expression was indicated in at least 
one cancerous tissue/cell line and no expression in normal tissues other than the testis (Figure 
3.6, class B).  Of the remaining 3 genes, 2 were cancer/testis/CNS restricted [i.e. expressed in 
at least one cancer cell type, in addition to the testis and normal CNS tissues (Figure 3.6, class 
C)] and 1 was cancer/testis-selective [i.e. expressed in one or two normal tissues other than 
CNS, as well as the testis and at least one cancer type (Figure 3.6, class D)].   
The SW480 cell line, which is a colorectal cancer cell line, stands out as expressing several of 
the candidate genes though weakly.  Although intron-spanning primer sets were used where 
possible it may be that genomic contamination accounts for some of these positive results.  
Further, it was identified by a member of our group that there was genomic contamination 
within this cell line cDNA (Jones-Hutchins, unpublished data). Intron-spanning primer sets 
could not always be designed – the sets that were not intron spanning are highlighted in Table 
1 in the Appendix.  On this basis the positive results for ACTL9, PDHA2, PRPS1L1, SPZ1 and 
TGIF2LX in the SW480 cell line should be viewed with caution.  However, we do not feel 
genomic contamination was a wide-spread problem in our samples and largely mitigated 
through the use of intron-spanning primer sets as described.  There was no expression in normal 
tissues for these primer sets and limited expression elsewhere suggesting a lack of genomic 
DNA contamination in these samples.  In addition, genomic DNA controls proved negative 
when these were tested on a limited group of samples where cDNA had been synthesised 
following human tissue collection for data presented elsewhere in this thesis.  These possible 
false-positive results in the SW480 cell line do not detract from the overall message and the 
relevant genes would still have been taken forward had these findings been shown to be 
negative.  The primary aim of the PCR validation was to exclude the genes that were widely 
expressed in somatic tissues.    
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Figure 3.2. RT-PCR analysis of candidate genes that were expressed in somatic tissues.   
Agarose gels showing the expression profile of the candidate genes in a range of normal tissue samples.  
cDNA was generated from the RNA extracted from these tissues post mortem.  A number of the 
candidate genes, examples of which are given here, were found to be expressed in a range of somatic 
tissues.  If expression was indicated in more than two normal tissues (other than CNS tissues) then the 
genes were excluded from further analysis.  All the examples here fell into this category.  ACTB gene 
was used as a positive control for the cDNA samples and NY-ESO-1 as a comparison to a known CTA.  
The DNA marker used in the agarose gel for RNF133 was hyperladder 1 (Bioline), rather than 
hyperladder 2 (Bioline) which was used in the other gels. 
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Figure 3.3.  RT-PCR validation of putative meiosis-associated genes that were restricted to testis 
in normal tissues.   
Agarose gels showing the expression profile of the candidate genes in a range of normal tissue samples.  
cDNA was generated from the RNA extracted from these tissues post mortem.   NY-ESO-1 is a known 
CT-gene which has a testis-restricted expression in normal tissues.  A number of the candidate genes 
were found to be expressed only in the testis and categorised as testis-restricted.  ACTB gene was used 
as a positive control for the cDNA samples.  C16orf78 appeared to express a band, though slightly 
shorter than the expected product size, in normal heart tissue but this was sequenced and found to show 
no significant similarity to this gene.  The DNA marker used in the agarose gel for PDHA2 is a more 
recent version of the Hyperladder 2, displaying intense marking bands at 300bp and 1000bp, rather than 
500bp and 1000bp. 
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Figure 3.4. RT-PCR analysis of putative CT genes that indicated limited expression in somatic 
tissues other than testis.   
cDNA was generated from the RNA extracted from a range of normal tissues post mortem.  Agarose 
gels were then run to visualise the expression profile of the candidate genes.  A number of the candidate 
genes (e.g., HMGB4 and SATL1) indicated that there was testis/CNS-restricted expression; that is 
expression in normal testis and CNS tissues but none of the other normal tissues tested.  Other candidate 
genes were classed as testis-selective if it was indicated that there expression profile was limited to two 
or less somatic tissues other than CNS – for example, BOLL above.  ACTB gene was used as a positive 
control for the cDNA samples and NY-ESO-1 as a comparison to a known CTA.  The DNA marker used 
in the agarose gel for SATL1 was hyperladder 1, rather than hyperladder 2 which was used in the other 
gels and on the gel assessing HMGB4 above a more recent version of hyperladder 2 was used which has 
a strong band at 300bp rather than 500bp. 
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Figure 3.5. RT-PCR analysis of candidate genes in cancer cell lines and tissues.   
Genes which passed the screening of gene expression and displayed limited activation in a panel of 
normal tissues, were subjected RT-PCR analysis in a range of cancer tissues and cell lines.  cDNA was 
generated from the RNA extracted from a range of cancer tissues obtained post mortem or extracted 
from various cancer cell lines.  Agarose gels were then run to visualise the expression profile of the 
candidate genes.  A number of the candidate genes displayed here showed no expression in any of the 
cancer samples.  Others, examples of which are given here, indicated limited expression in some cancer 
types. ACTB gene was used as a positive control for the cDNA samples and NY-ESO-1 as a comparison 
to a known CTA.  The DNA marker used in the agarose gel for PDHA2 and HMGB4 was a more recent 
version of hyperladder 2 that has a strong band at 300bp rather than 500bp. 
Chapter 3: Results 
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Grid representation of the gene expression profiles for the 19 genes for which RT-PCR 
indicated expression in at least one cancer type.   
Each gene has a row allocation on the grid; the presence of a filled square in any column indicates that 
a positive RT-PCR signal was obtained.  The shade of the blue indicates the intensity of the visualised 
signal seen on the agarose gel relative to the intensity of the band seen for the testis sample; the shade 
is not a reflection of the relative expression levels, rather it is a simple qualitative representation of PCR 
product intensity.  The columns represent the tissue/cell type tested: normal tissues in left hand panel 
and cancer tissues/cells on the right side of the grid.  The expression profiles for four previously 
characterised X chromosome encoded CT genes are shown as a positive control (set A: GAGE1, 
MAGEA1, NY-ESO-1, SSX2).  The majority of the newly identified putative CT genes had expression 
restricted to the testis in normal tissues.  Three of the genes had expression profiles consistent with 
limited expression in normal tissues as well as testis and at least one cancer type (sets C and D).  The 
chromosomal location of the genes is given in the column to the right of the gene names; only one of 
the novel genes is X-encoded. 
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3.4. Meta-analysis of candidate genes expression profiles 
In order to explore the possible clinical relevance of the newly identified genes, we conducted 
meta-analyses using patient-derived cancer microarray data, including 13 cancer types in a 
range of 80 microarray data sets (Feichtinger et al., 2012a).  Full details of the arrays included 
in this pipeline and how they were chosen are provided in the original publications from the 
McFarlane group (Feichtinger et al. 2012a; Feichtinger et al. 2012b). It is a limitation of this 
study that more cancer types and more arrays were not included but the selection of high-quality 
arrays that was conducted previously is a trade-off here and has been discussed further in the 
relevant publication describing the design of this tool (Feichtinger et al., 2012a). 
 
Microarray data was collated from the various array sets for which a given gene was present 
and the combined data was then meta-analysed to investigate whether there was a statistically 
significant upregulation in gene expression.  This meta-analysis was conducted using a freely 
available resource (CancerMA) that stemmed from work previously conducted by the 
McFarlane group (Feichtinger et al. 2012a).  An example of a significant meta-upregulation of 
an individual gene (SPZ1) is given in the Forest plot profile for ovarian cancer in Figure 3.7.  
The additional Forest plots are provided in the Appendix (Figures 14-19). 
 
First, we investigated the expression profiles of 18 of the 19 genes that exhibited expression in 
at least one of the cancer cell types tested by RT-PCR (one gene, TGIF2LX, was not present on 
the microarrays).  Of these, 9 (50%) of the genes showed meta-upregulation in either ovarian 
and/or prostate cancers (see Figure 3.8).  The circos plots, like those displayed in Figure 3.8, 
summarize the Forest plot information for multiple genes.  The microarray datasets were chosen 
as they provided good quality information on the gene expression in cancerous tissue compared 
to normal tissue. If a gene displayed statistically significant upregulation in a given cancer type 
compared to normal tissue, as summarised in the Forest plots, then a line linking that gene to 
that cancer type is displayed within the Circos plot.  The thickness of the connecting line is 
representative of the strength of this meta-upregulation (i.e. the thicker the line, the greater the 
strength of the statistical increase in gene expression in the cancer) but the thickness of the 
connecting line is also relative to the number of genes contained within the plot (i.e. the more 
genes displayed the thinner the lines become).  A maximum of approximately 300 genes can 
be challenged against cancerMA in a single ‘job’ and it becomes difficult to read the circos 
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plots if too many genes are contained within the plots, which is why additional plots are 
provided in the Appendix for data presented in Chapter 5 (see Figures 1-3 in the Appendix). 
 
Of the 33 genes with meiCT gene potential (based on expression patterns in normal tissue), 14 
genes did not appear to be expressed in any of the cancer cell types analysed by RT-PCR (see 
Table 3.1).  To further explore the possibility that these genes are CT genes, we used 11 of the 
14 genes for meta-analyses using the 80 cancer gene expression microarray data sets (3 of the 
genes, C1orf141, HEATR7B and SATL1, were not present on the microarrays) and found 
expression profiles for 5 of these genes were indicative of a cancer type marker for ovarian and 
prostate cancers (45.5%; Figure 3.9).  So, nearly half of the genes that were present on the 
arrays appeared to be potentially relevant biomarkers for these cancer types.  A further 5 (10 
genes in total) were expressed in at least one single cancer data set (see Figure 3.10), indicating 
the potential to mark a specific sub-group of tumours within a cancer type.  Only C8orf74 
exhibited no measurable expression in cancer cells / tissues (although C1orf141, HEATR7B and 
SATL1 could not be analysed via meta-analysis due to their absence on the arrays). 
 
Whilst the meta-analysis revealed 9 genes to be upregulated for two given cancer types (ovarian 
and prostate cancer), analysis of single cancer data sets from the 80 cancer data sets used reveals 
evidence for activation of a total of 15 of the 18 candidate genes in at least one patient-derived 
sample set (83.3%; Figure 3.10).  So, the range of possible cancer types for which these genes 
are potentially relevant is broader than the meta-analysis indicates.  For the genes that lack a 
statistically significant upregulation it suggests that they are less likely to be good biomarkers 
for the cancer type as a whole (e.g., for screening purposes) but this does not mean that there 
may be a subset of tumours within the cancer type for which individual genes could be clinically 
relevant. 
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Figure 3.7.  An example of a Forest plot for one of the identified meiCT genes, SPZ1.   
The Forrest plot indicates that SPZ1 is upregulated in ovarian cancers with an approximate 1.8 log-fold 
change over matched normal vs. cancer array sets.  The upper five squares illustrate the individual 
microarray studies, with the confidence intervals for the individual studies represented by the horizontal 
lines.  The size of the squares is proportional to the weight assigned to the individual study.  The upper 
diamond is a summary of all five data-sets showing significant upregulation for ovarian cancer.  When 
all the cancer-types on the arrays were meta-analysed there was no significant change in expression over 
normal tissues (lower diamond).  The additional Forest plots for the genes displaying significant meta-
upregulation are provided in the Appendix (Figures 14-19). 
  
Chapter 3: Results 
84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Circos plot showing the meta-change in gene expression by cancer type.   
The Circos plot links the individual genes which displayed a significant upregulation in expression when 
combined microarray data-sets were meta-analysed to the corresponding cancer type (ascribed by tissue 
type).  Only the identified putative CT genes that were indicated to have expression in at least one cancer 
cell type as assessed by RT-PCR (sets B-D in Figure 3.6) are displayed here.  One of the 19 genes that 
fell into this category, TGIF2LX, was not on the arrays and as such not subject to the meta-analysis.  The 
plot shows 9 genes exhibit meta-upregulation in ovarian and/or prostate cancers. The weight of the 
connection corresponds to the magnitude of the meta-change in gene expression. 
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Figure 3.9.  Circos plot showing the meta-change in gene expression in relation to corresponding 
cancer types (ascribed by tissue type) for identified genes that did not exhibit expression in any of 
the cancer cells or tissues assessed by RT-PCR.   
Three of these 14 genes, C1orf141, HEATR7B, SATL1, were not subjected to the meta-analysis as they 
were not present on the arrays.  The plot shows that 5 genes exhibit meta-upregulation in ovarian and/or 
prostate cancers. The weight of the connection corresponds to the magnitude of the meta-change in gene 
expression. 
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Figure 3.10.  Circos plot of single microarray analysis for identified meiCT genes exhibiting 
expression in cancer cells/tissues as revealed by RT-PCR.   
The expression of the genes is given corresponding to the data set in which a statistically significant 
upregulation was observed for the tumour vs. normal array analysis.  For data set designations see 
(Feichtinger et al., 2012a; Feichtinger et al., 2012b).  TGIF2LX was not present on the arrays.  The plot 
shows 15 of the remaining 18 genes analysed are statistically significantly upregulated in at least one 
cancer data set.  Three genes (ACTL9, CCDC116, RBM44) show no significant upregulation in any of 
the array sets and so are not shown on the Circos plot. 
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3.5. Discussion 
CTAs are cancer-specific biomarkers with considerable potential as prognostic and diagnostic 
markers as well as being therapeutic targets.  The current classification system for CTA genes 
continues to be based on that put forward by Hoffman and colleagues (Hofmann et al., 2008).   
It has since been proposed that a sub-category of CT genes that are associated with meiosis 
exists.  These genes, termed meiCT genes, were identified from an in-silico pipeline originating 
with putative meiotic genes (Feichtinger et al., 2012b; Sammut et al., 2014).  A further 29 
meiCT-genes have now been identified (Sammut et al., 2014).  As was the case for previously 
characterised meiCT genes, most of these genes are autosomally encoded (28 out of 29; see 
Table 3.1).  This finding is consistent with the transcriptional inactivation of the X chromosome 
during male meiosis (Turner, 2007).  Many of the previously identified CT genes are encoded 
by the X chromosome and expressed in spermatogonial mitotic cells (Almeida et al., 2009). 
 
An additional commonality with the previously characterised meiCT genes was the fact that 
many of this new cohort were shown to be upregulated as a general marker for ovarian cancers: 
10 of the new cohort displaying a meta-change increase in gene expression were in ovarian 
cancer.  This again raises the possibility of using the meiCT genes to improve the diagnosis of 
this diverse and pernicious cancer type.  It may be the case that genes that have a normal 
biological function (i.e. meiotic role) in the foetal ovary are preferentially reactivated in cancers 
of this tissue type.  However, a significant proportion of ovarian cancers are believed to be 
extra-ovarian in origin (Berns and Bowtell, 2012; Erickson et al., 2013; Sorensen et al., 2015).  
So the picture is complex and the reason for this finding is not entirely clear.  The possibility 
of stimulating meiotic gene expression via oncogenic paracrine signalling mechanism, even if 
the tumour originates outside of the germline tissue, still exists.   
 
Ovarian cancers are currently most frequently treated with cytoreductive surgery and 
chemotherapy, although these types of tumours are immunoreactive and there is currently 
extensive work ongoing to explore the application of immune-based therapies for their 
treatment (Nelson, 2015; Tse et al., 2014). Thus, the identification of ovarian cancer-specific 
biomarkers such as these is of considerable potential clinical importance.  
 
Recent work has demonstrated that sub-groups of 26 germline and placental specific genes can 
be used to delineate aggressive metastasis-prone lung cancers (Rousseaux et al., 2013b).  The 
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ability of these 26 germline genes to act as surrogates for a worse clinical outcome was 
independent of other traditional methods of disease stratification.  This indicates that small sub-
groups of tissue-specific genes can serve as accurate biomarkers in the stratification of complex 
and heterogeneous cancers.  The clinical implications of this are far reaching as they offer 
extensive potential in establishing optimal treatment strategies and both preventing unnecessary 
or unefficacious treatment as well as identifying patients who would benefit from a particular 
strategy when they would not be offered the treatment according to established methods of 
guiding therapeutic decisions.  This work provides a paradigm for how germline gene 
expression in cancers can be applied to clinical stratification of complex disease.  Having a 
definitive on/off expression profile, as observed with many of the meiCT genes, greatly 
enhances the potential simplicity of the application of these genes in novel prognostics 
technologies.  
 
A number of studies have now specifically explored the potential of expression of human 
germline genes as cancer biomarkers.  Interestingly, whilst common genes have been identified, 
the various studies have all identified additional distinct genes indicating that the full mining of 
data sets of this magnitude require multiple and diverse approaches.  For example, this current 
study has identified 29 new genes with tight germline and germline/CNS tissue-specific 
expression restrictions; however, a recent seminal and extensive study of human male 
germline/placental genes only identified 16 of the 29 (55.1%) genes reported here as 
germline/placental-specific (Rousseaux et al., 2013b).  A similar trend is seen when analysing 
previously reported meiCT genes (Feichtinger et al., 2012b).  This highlights how the 
investigative approach used will impact on the research findings and the need to establish a 
definitive list of germline genes.  The issue of creating a definitive list of germline genes will 
be revisited later in this thesis. 
 
In addition to serving as cancer biomarkers the meiCT genes may serve as therapeutic targets 
via a variety of routes.  Firstly, the immunogenicity of the gene products of the meiCT genes 
remains very poorly characterised.  Their highly stringent tissue specificity infers that their gene 
products could potentially serve as tumour-specific immunotherpeutic targets.  Given the 
heterogeneity of cancer, both intra- and inter-tumour, the development of a large bank of 
biomarkers will be of increasing importance in the development of personalised treatment 
strategies (Jamal-Hanjani et al., 2015; Mendelsohn, 2013; Seoane and De Mattos-Arruda, 
2014).  
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Germline genes in Drosophila melanogaster have been shown to serve to drive the oncogenic 
programme (Janic et al., 2010).  The human orthologues of these genes are also widely activated 
in human tumours (Feichtinger et al., 2014b) supporting the notion that a soma-to-germline 
transition is a hallmark of many cancers.  Additionally, other CT genes have been demonstrated 
to be required for cancer cell proliferation and their depletion can serve to sensitise cancer cells 
to standard therapeutic agents (Cappell et al., 2012; Whitehurst et al., 2007).  Thus, not only 
can germline gene products potentially offer direct targets for drug therapies, but depletion of 
their activity can also serve to enhance the efficacy of existing therapies potentially enabling 
reduced dose regimens, which will limit undesired drug toxicities.  The cancer-specific nature 
of meiCT gene expression makes these genes exceptionally attractive for further exploration in 
drug targeting and drug sensitisation.  
 
The suggestion that germline genes are oncogenic infers that some of the genes identified here 
could play a tumour initiating and/or progression role.  One of the genes validated here is a 
member of the ADAM gene family - ADAM2.  The ADAM proteins often exhibit proteolytic 
activity and have emerging roles in the invasive properties of specialist cells within the placenta 
(Pollheimer et al., 2014).  Such proteolytic functions may promote invasion and metastasis of 
solid tumours.  A putative role for other members of the adamalysins in the aetiology and 
pathology of colorectal cancer and melanoma has been proposed (Moro et al., 2014; 
Przemyslaw et al., 2013).  This might indicate that not only are germline genes required for 
oncogenesis, they might drive metastasis and thus offer cancer-specific intervention points to 
stop the lethal spread of tumours.  
 
SPZ1 was shown to be testis-specific in our normal tissue panel, a finding previously shown by 
Hsu and colleagues (Hsu et al., 2001).  In their study, they further showed that the gene was 
expressed both in the testis and epididymis.  We found a positive expression signal in a colon 
and ovarian cancer cell line and on meta-analysis there was a significant upregulation in ovarian 
cancer.  It has since been shown by Hsu and colleagues that SPZ1, which encodes a transcription 
factor, acts as a proto-oncogene to promote cellular proliferation and tumour formation in a 
mouse model (Hsu et al., 2005).   Despite this, SPZ1 has not previously been recognised as a 
CT gene (Almeida et al., 2009). 
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It has been suggested that another of the novel meiCT genes identified here, SHCBP1L, encodes 
a protein with strong homology to a mouse protein present in proliferating cells and may have 
similar physiological effects (Sood et al., 2001).  It remains unexplored whether this protein 
indeed acts through similar signal transduction pathways to promote proliferation but as the 
gene has shown a statistically significant meta-change upregulation, again in ovarian cancer, 
makes this possibility worthy of further exploration.  The protein product of this gene has been 
found in normal testis but not normal ovarian tissue and through an interaction with HSPA2 
contributes to spindle stability during meiosis (Liu et al., 2014).  Thus, it would be worth 
investigating whether the protein is indeed present in ovarian cancer. 
 
The fact that the cDNA used in the PCR validation was synthesized from RNA extracted post 
mortem has potential limitations.  The RNA may have degraded prior to extraction.  Limited 
information is provided from the companies about the patients from which the RNA was 
extracted – details that were provided by the company are supplied in the Appendix C (on CD).   
In a study aimed at identifying novel CT genes using a massively parallel signature sequencing 
technique Chen and co-workers showed that distinct sources of ‘normal’ tissues produced 
sometimes widely varying results in terms of whether a gene was expressed in that tissue type 
(Chen et al., 2005).  RNA extracted post-mortem will often be from the elderly population, in 
which there will be increased likelihood of an occult cancer that had not been diagnosed prior, 
or contributing, to the death of the individual.  Even if the tissue that had occult neoplasia had 
not been sampled, given what is known about field cancerization, an occult cancer could cause 
genetic changes in cells distant from the site of the tumour.  Some of the commercially sourced 
RNA was pooled from tissues from a number of individuals; this would increase the likelihood 
of containing cancerous material within the sample.  It is a major limitation of this work that 
the experiments were in general not repeated.  Ideally experiments should be repeated at least 
three times to improve the validity of the results and when dealing with post mortem samples 
this becomes even more important.  However, our screen was crude and basic and limited by 
the practicalities of cost and time.  Some genes may have been included that would have not 
passed more vigorous validation steps but equally we may have been too quick to exclude other 
candidates.  
 
The results of the meta-analysis (using the cancerMA tool) should not be over-interpreted.  
There are limitations of this approach and the fact that many of the upregulations in gene 
expression may be random should not be ignored.  As can been seen in the circos plots shown 
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in Appendix Section 3 (Figure 20), when a random selection of genes are chosen a similar 
proportion display upregulations – this suggests that the upregulations presented here may also 
be random.  Further, when PCR control (‘housekeeping’) genes are chosen these also display 
meta-upregulations in the cancer datasets included (see Figures 21 and 22, in Section 3 of 
Appendix).  Cancer is, however, a very heterogeneous disease and the fact that ‘housekeeping’ 
genes that are supposed to be present at roughly equal levels are not, is not unduly surprising.  
This fact has indeed been highlighted by others (e.g., Cicinnati et al., 2008).  Not all control 
genes will be present in equal amounts in all cancer types or sample groups.  Additionally, we 
selected some genes known to be upregulated in cancer – the circos plot for this list of genes is 
also shown in Section 3 of the Appendix (Figure 23).  Many of the genes do display 
upregulations but the information is limited by the number of cancer types included on 
cancerMA.  The data produced by cancerMA is further limited by the quality of the raw data of 
the original research on which the meta-analysis is based on.  The findings and conclusions 
drawn must not be over-interpreted.   
 
The concentration and purity of the RNA was assessed using NanoDrop (ND-1000) 
spectrophotometry technology prior to cDNA synthesis.  This is a widely used and accepted 
technique but there are limitations in terms of the limited information about the possible 
degradation of the RNA and this is a limitation of this study.  RNA extracted from human tissue 
samples that were collected for this research project (data presented later in thesis) were subject 
to more robust analysis using the ExperionTM RNA analysis kit (BioRad), which does provide 
a greater degree of reassurance that the RNA is of good quality and not degraded.  The fact that 
the RNA was not subjected to more robust analysis prior to cDNA synthesis is a further 
limitation of the results presented in this chapter. 
 
Data on The Human Protein Atlas (HPA) is freely available on www.proteinatlas.org (Uhlen et 
al., 2005) and provides a useful reference point for what has been established about gene 
expression and protein levels in certain tissues.  The data does have limitations, for example, in 
that some antibodies have not been fully validated but our results will be compared to the data 
presented on HPA for the most promising candidate genes put forward here.  ADAM2 and SPZ1 
have been mentioned already above. 
 
Data on HPA indicates that mRNA is present in normal testis but not in other tissue types for 
ACTL9.  The antibodies used are polyclonal and the website states that they have not been 
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externally validated.  Immunohistochemistry (IHC) indicates that the protein is present in 
normal renal tubular cells as well as cytoplasmic staining within hepatocytes.  The website 
acknowledges that the presence of the protein within the normal kidney and liver is not 
consistent with the gene expression data.  ACTL9 has recently been implicated as playing a 
possible role in eczema (Hirota et al., 2012).  It is acknowledged that the function of ACTL9 
remains obscure. 
 
ADAM2 is expressed in normal testis and this is consistent with the strong cytoplasmic staining 
seen in developing spermatocytes/spermatids within the seminiferous tubules of normal testis.  
The presence of mRNA or the protein was not demonstrated in other normal tissues according 
to HPA, which is consistent with our findings and those of other groups (Cho, 2012, Choi et 
al., 2016, Pollheimer et al., 2014).  Thus, it would appear likely that the antibody used for HPA 
is specific.  The protein is believed to play a role in sperm-egg interactions and may additionally 
be present within the placenta (Cho et al., 2012, Pollheimer et al., 2014) and as postulated above 
could conceivably play a role in tumour cell migration and/or invasion if expressed in cancer.  
However, the function of ADAM2 may be different in primates compared to mice and the 
precise function of this gene in humans remains unclear (Choi et al., 2016). 
 
Consistent with our findings ASB17 is expressed in normal testis only according to HPA, though 
no information on protein expression is provided.  There are no further references to this gene 
in humans and its function remains obscure. 
 
Again, consistent with our data the expression of BOLL is restricted to testis in normal tissues 
according to HPA.  The polyclonal antibody used also displayed presence only in the testis 
(developing spermatocytes) consistent with the gene expression data.  Additionally, there was 
weak staining on IHC of thyroid cancer.  Despite the fact that the HPA antibody appears to 
display specificity for the protein and be present in thyroid cancer, no further reference to the 
possible role of this gene in thyroid cancer has been identified – it is however, worthy of further 
scientific exploration.  BOLL has been implicated in lung and colorectal cancer and as such can 
be considered a CTA due to its germline-restricted expression pattern (Kim et al., 2011; 
Tessema et al., 2009).  As BOLL has been implicated in a rare syndrome in which there is 
marked hypomethylation in specific regions of the genome (Simo-Riudalbas et al., 2015), it 
could be predicted that this was the mechanism for reactivation in cancer.  However, 
hypermethylation of its promotor region in cancer appears more common (Tessema et al., 2009; 
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Kang et al., 2015).  The encoded proteins may be involved in cell cycle progression in normal 
testis and though a functional role in cancer has not been elucidated, it has been suggested it 
may be a useful biomarker for the detection of early CRC (Kang et al., 2015).   
 
C3orf22 is an uncharacterised gene for which no published scientific papers proposing a 
function or linking it to cancer have been identified.  The gene expression data present on HPA 
is consistent with the data presented here, in that it does appear to be germline restricted.  
Moreover, a polyclonal antibody which has not been independently validated but does display 
consistent results in that the protein is only found in normal testis according to HPA.  Moreover, 
HPA include IHC data indicating that the protein is found in colorectal, head and neck, lung, 
urothelial, testicular cancers and melanoma.  So, a possible oncogenic role for this gene would 
certainly appear possible. 
 
C16orf78 is another uncharacterised gene.  HPA mRNA data is consistent with our assertion 
that expression is limited to the testis in normal tissues.  A polyclonal antibody, as yet to be 
externally validated indicates that the protein is present in many cancer types as well as normal 
testis.  However, given the wide presence in cancer, as well as strong staining throughout the 
testis, the antibody may lack specificity.  Very little is known about this gene and it was not 
shown to have any upregulations in cancer vs. normal tissue according to CancerMA 
(Feichtinger et al., 2012a).  However, it has been shown that the protein may interact with other 
proteins known to be associated with prostate cancer, so this would be worthy of further 
exploration to establish a possible oncogenic link (Tao et al., 2012). 
 
The gene expression data included on HPA for CCDC116 is broadly in agreement with our data 
indicating a testis-selective expression pattern with very low levels of mRNA in some other 
normal tissues.  A polyclonal antibody used by HPA displays strong cytoplasmic staining in 
pancreatic islet cells.  The majority of cancer samples tested using IHC displayed negative or 
weak staining.  The strongest staining was seen in carcinoid tumours.  Thus, a possible 
relevance for this gene in neuroendocrine tumours of the gut is worthy of further exploration, 
especially in light of a possible normal physiological role in specialised cells of the pancreas.  
Tsolakis and colleagues have in fact further characterised the antibody in a range of pancreatic 
tumours, finding it to be present quite widely (Tsolakis et al., 2012).  The polyclonal antibody 
used by HPA has not been externally validated; though some external validation was carried 
out by Tsolakis and colleagues (2012), they did not correlate the presence of the protein with 
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gene expression data in the specific tissues in which it was shown to be present.  More recently, 
CCDC116 has been shown to be a constitutive part of the centrosome of sperm cells (Firat-
Karalar et al., 2014).  Further knowledge about its normal physiological role may help shed 
light on possible functional roles in cancer. 
 
DNAJC5G displays a testis selective expression with a much higher abundance of mRNA in 
the testis according to data on HPA.  The HPA polyclonal rabbit antibody against the protein 
displayed moderate staining within the seminiferous tubules of the testis as well as occasional 
positive staining in follicular adenocarcinoma of the thyroid, urothelial and some lung cancers.  
This antibody has not been externally validated.  DNAJC5G remains largely uncharacterised, 
though it belongs to a wider gene family of heat shock proteins.  These proteins are implicated 
in numerous disease processes and are important with regards to ‘protein stress’ that has the 
potential to lead to somatic mutations (Dekker et al., 2015).  The gene has been shown to be 
expressed in a neuroblastoma cell line and upregulated following ethanol treatment (Ferns et 
al., 2012). The possible relevance of an upregulation or reactivation of this gene in cancer 
remains obscure. 
 
The IHC data included on HPA is inconsistent with the gene expression data for GK2 indicating 
normal expression restricted to the testis; the latter result being consistent with our findings.  A 
polyclonal antibody lacking external validation was used displaying moderate, predominantly 
cytoplasmic staining in several normal tissue types (strongest in hepatocytes).  There was also 
positive staining in numerous cancer types but most strongly and widely in endometrial, 
hepatocellular, prostate and thyroid cancer.  Given the widely different results of the IHC to 
gene expression results it is likely that the antibody lacks specificity for the protein and this 
requires clarification. GK2 has recently been identified through a serological analysis of 
recombinant cDNA expression libraries (a technique used previously to identify many CT 
genes – for example, Mashino et al., 2001) as a potential biomarker and therapeutic target for 
early breast cancer (Zuo et al., 2016).  Thus, although the HPA antibody may lack specificity 
for the antigen, further exploration of this gene and its potential relevance in a subset of cancers 
would appear worthwhile.  According to cancerMA, however, the gene is not significantly 
upregulated in any cancer type when the included array data are meta-analysed. 
 
IHC data for HMGB4 is consistent with the gene expression data indicating the gene is only 
switched on in the testis.  Normal testis but no other normal tissue or indeed cancer types stained 
Chapter 3: Results 
95 
 
positively.  Additionally, the protein has been validated, showing consistent single band on 
Western Blotting.  Very little research has linked this gene to cancer, though one important 
paper has suggested the protein may be the binding site for cisplatin and one of the main reasons 
that testicular germ cell tumours display such high levels of response to cisplatin chemotherapy 
(Park and Lippard, 2012).  Our preliminary PCR data indicate that HMGB4 is expressed at 
moderate levels in leukaemia cell lines, so further investigation of a link between this gene and 
blood cancers would be worth investigating.  The presence of the antigen in a subset of tumours 
may pave the way to targeted cisplatin-based treatment for these tumours, though initial data 
suggest few tumours express this gene. 
 
Data from HPA is consistent with ours showing that IQCF1 has expression limited to the testis 
in normal tissues.  No antibody has been tested and protein analysis for this gene is lacking on 
HPA.  Few studies have investigated the function of this gene and no link to cancer has yet been 
formally identified.  However, a functional role in sperm capacitation has been postulated (Fang 
et al., 2015). 
 
LYZL6 has been stained positively in normal testis using IHC using two separate polyclonal 
antibodies, consistent with gene expression data indicating testis restriction expression.  Weak 
to moderate cytoplasmic staining was seen in some ovarian, pancreatic and stomach cancers 
according to HPA.  No formal link to cancer for this gene has been identified.  Functionally it 
may have immune and antibacterial properties within the testis (Wei et al., 2013).  A possible 
role in cancer remains obscure. 
 
PDHA2 has been shown to be testis restricted both at an mRNA and protein level on HPA.  The 
gene expression data is consistent with our data showing expression limited to the testis in 
normal tissues.  HPA used three separate polyclonal antibodies, none of which have been 
externally validated.  These antibodies displayed varying cytoplasmic localisation in 
developing spermatocytes within the seminiferous tubules as well as Leydig cells located 
between the seminiferous tubules.  IHC staining was generally negative in the cancer samples 
for one of the antibodies but staining for the other two was moderate both cytoplasmic and 
nuclear across many cancer types.  So, the picture for this gene and its relationship to cancer is 
not clear and some of the antibodies may lack specificity for the antigen.  Given that this gene 
is intronless, our PCR data in the cancer samples, where expression was indicated in a 
colorectal, ovarian and melanoma cancer cell line, needs to be treated with caution.  It is a major 
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limitation of this work that genomic DNA contamination controls were not used but intron-
spanning primer sets were used where possible.  Functionally PDHA2 may be involved in the 
acrosome reaction and sperm capacitation (Kumar et al., 2008).  It has also been shown that 
demethylation of the promotor region for this gene can induce expression in somatic tissues 
(Pinhiero et al., 2012), so this could provide a route to aberrant gene expression in cancer. 
 
PPP3R2 forms part of a regulatory subunit of calcineurin and is testis specific; it is important 
for the acrosome reaction as well as sperm motility (Miyata et al., 2015).  HPA state that the 
polyclonal antibody they used targeted antigen from more than one gene and the IHC data 
should be treated with caution; the antibody has not been externally validated.  Gene expression 
data for PPP3R2 presented on HPA is consistent with ours in that the gene is testis restricted 
and this is also consistent with the findings of previous studies (Liu et al., 2005; Miyata et al., 
2015).  We did not find convincing expression in any cancer cell type tested and no further 
studies have linked this gene to cancer.  Thus, the HPA data displaying moderate to strong 
cytoplasmic as well as nuclear immunoreactivity widely in endometrial and renal cancers in 
additional to less common but positive staining in several other cancer types, requires further 
exploration to establish a definite link to cancer.  Unrelated to cancer but of interest to note, it 
has been proposed PPP3R2 may form part of a drug target for a reversible male contraceptive 
(Miyata et al., 2015).   
 
No antibody against PRPS1L1 has been tested by HPA and no other reference to cancer has 
been identified in the literature.  However, HPA do provide gene expression data consistent 
with our own that expression is restricted to the testis in normal tissues.  The coding region of 
this gene is intronless and the suggested expression in a colorectal cancer cell line should be 
treated with caution for this reason; there may have been genomic DNA contamination within 
the SW480 cell line as stated previously.  There were no meta-upregulations in any cancer types 
included on cancerMA and a possible link to cancer for this gene is at present very tenuous. 
 
RBM44 is a highly conserved intercellular bridge protein that interacts with TEX14 in the testis 
(Iwamori et al., 2011).  Gene expression and IHC data presented on HPA is consistent with our 
data also indicating testis restriction in normal tissues.  However, the polyclonal antibody used 
by HPA has not been externally validated and presumed off-target binding was disregarded.  
Within cancer samples, moderate cytoplasmic immunoreactivity was observed in carcinoid 
tumours and gliomas, as well as some thyroid cancers.  Occasional melanoma samples also 
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tested positive, which is perhaps consistent with gene expression indicated in one melanoma 
cell line in our PCR experiment.  
 
Overexpression of Spz1 has been shown to stimulate cellular proliferation and induce 
infertitilty in mice (Hsu et al., 2004).  No studies linking SPZ1 to cancer in humans has been 
identified, however as a transcription factor that can induce cellular proliferation if the gene 
were switched on it could have significant adverse consequences.  HPA gene expression data, 
like ours, indicates that the gene is expressed only in the testis.  Our data indicated expression 
in a colorectal and ovarian cancer cell line.  Positive IHC staining was seen in some colorectal 
and ovarian cancer samples tested on HPA but stronger staining was observed for melanoma, 
glioma, breast and cervical cancers.  The polyclonal antibody used by HPA has not been 
externally validated.  Moreover, it is stated that expert annotation of the IHC results in normal 
tissues, where immunoreactivity was demonstrated quite widely, could not be performed due 
to inconsistent results.  In light of the gene expression data, it is likely that the HPA antibody 
lacks specificity. 
 
TGIF2LX is a testis-specific gene present on the X-chromosome and testis restricted expression 
in normal tissues is shown by our data and that presented on HPA.  IHC data included on HPA 
for TGIF2LX shows nuclear staining in developing spermatocytes.  There was very occasional 
but strong nuclear or cytoplasmic observed in colorectal, head and neck and urothelial cancers.  
It may be of clinical relevance in a limited subset of cancers but this requires further 
clarification.  Further discussion about related genes is provided in Chapter 5 (Section 5.3.5.1). 
 
The function of ZSWIM2 remains obscure but it is thought to be a testis-restricted protein, 
which may regulate apoptosis during germ cell differentiation via paracrine or autocrine means 
(Nishito et al., 2006).  Gene expression data on HPA is, like ours, also consistent with ZSWIM2 
being a testis-restricted gene.  Our preliminary PCR data suggest the gene is activated in two 
separate ovarian cancer cell lines, though the gene was not meta-upregulated when ovarian 
cancer microarray datasets were metaanalysed.  HPA used two polyclonal antibodies, which 
both displayed positive staining in some normal tissues inconsistent with the expected result.   
Serous ovarian cancer was the most common cancer type displaying positive staining on IHC, 
with very occasional positivity in endometrial and lung cancer, and negative staining in other 
cancer types.  The HPA antibodies may lack specificity for ZSWIM2 but it is interesting to note 
that the IHC staining in the cancer samples broadly correlates with our PCR data.  Thus, it is 
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possible that ZWIM2 is a relevant biomarker for certain ovarian adenocarcinomas but this 
requires substantiation through further focussed research. 
 
3.6. Closing remarks 
Germline genes are emerging as important cancer-specific factors.  The extent of their clinical 
importance is only now starting to come into focus, either as biomarkers for stratification and 
diagnosis, as oncogenic activators and as drug or immunotherapeutic targets.  What is becoming 
increasingly apparent is the heterogeneity of tumour cell populations.  This is the driver for the 
need to identify a large cohort of cancer cell markers that individually or in combination can 
target and mark a large number of tumour types and cell populations.  The list of genes 
identified in this chapter contributes to the growing catalogue of cancer-specific biomarkers. 
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4. Characterisation of two novel CT antigens and evaluation of 
their immunogenic potential 
4.1. Introduction 
So far I have presented work looking at the gene expression of germline and CT genes.  As has 
been demonstrated by Rousseaux and colleagues, such analysis alone can serve as a powerful 
stratification or predictive tool for patients with cancer (Rousseaux et al., 2013b).  Gene 
expression analysis has also been used to categorise cancers into clinically relevant subgroups 
(for example, Marisa et al., 2013; Sadanandam et al., 2014; Tan et al., 2013).  Such an approach 
may be increasingly used across a wide array of cancer types to help guide therapy from an 
early stage.  However, as anti-cancer therapies are often targeted at a biological 
function/antigen, it is the protein products that are in general of the most interest.  
Immunotherapeutic approaches also rely on (tumour-associated) antigen production.  Indeed, 
one of the most attractive attributes of CT, and many germline, genes is that they may encode 
antigens that are highly specific for the cancer which produces them and in so targeting these 
antigens (e.g., with immunotherapies), the treatment should not result in deleterious side effects 
in healthy tissues as the antigen will, so far as the body’s immune system is concerned, be 
unique to the cancer. 
 
So, gene expression experiments are very useful but generally, in terms of therapeutics, there 
is a need to establish that a protein is produced by the cancer cells which express the genes.  
This makes it important and relevant to establish whether CT genes do result in antigen 
production.  If this is the case for the novel CT genes which have been identified, then this 
would make them bona fide novel CTAs.  This is of fundamental importance as the proteins 
may have a functional (i.e. oncogenic) role in the cancer.  Additionally the antigens may be 
recognised by the immune system. Thus, the two subsequent questions following confirmation 
of antigen production are: is there a functional role for these proteins, and are they 
immunogenic?  Either, or both, of these questions may reveal an antigen with therapeutic 
potential.  For example, the biological function of the protein may be disrupted to halt the 
progression of cancer or result in regression of disease.  Tumour associated antigens (TAAs) 
can also be the target for immunotherapeutic approaches if they are recognised by the immune-
system.  The function of the immune system can then be harnessed to kill cancer cells that 
present such antigens when they are recognised as non-self (Mellman et al., 2011).  This also 
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requires a deeper understanding of the mechanisms that create a site of immune-privilege within 
the tumour microenvironment, which prevent the innate function of the immune system from 
achieving this. 
 
Antibodies are commonly used to detect the presence of antigens within biological material.  
The presence of the antigen can also be inferred indirectly using enzyme-linked immunosorbant 
assay (ELISA), which detects circulating antibodies in the serum that have been produced by 
the patient in response to a particular antigen.  ELISA tests also suggest the antigen may be of 
interest as an immunotherapeutic target, as the antigen must have been able to evoke an immune 
response in order to test positive using this technique. 
 
Previously in this thesis I have presented work predominantly looking at the expression of 
germline or CT genes.  Here, I took forward two novel candidate CT genes (C20orf201 and 
TEX19) to see if the antigens were produced and present in cancer tissue.  These genes were 
chosen as our group had identified them as promising cancer-specific markers (Feichtinger et 
al., 2012) and we also had antibodies that had been validated for detecting the antigen of 
interest.  An additional CT gene, SPO11, was also investigated as this had been identified as a 
candidate meiCT gene as well as being previously described as a CTA but there remained 
uncertainty about its function or indeed presence within cancer (Almeida et al., 2009; Hofmann 
et al., 2008; Litvinov et al., 2014).  SPO11 is also an interesting protein given its known 
physiological functions during meiosis (see Section 1.4.5).  Germline specific augonaute 
proteins were also investigated as one member, PIWIL1, was shown to be of potential interest 
from the gene expression analysis conducted on CRC samples.  Finally, the potential 
immunogenicity of the novel CTAs were investigated using a T-cell binding assay. 
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4.2. C20orf201 as a potential biomarker in ovarian cancer 
C20orf201 was described as a meiCT gene, which had a testis/CNS restricted expression profile 
in normal tissues (Feichtinger et al., 2012b).  It was additionally shown in this study to be 
clearly expressed in ovarian cancer and leukaemia cell lines.  The data presented in Chapter 5 
are broadly consistent with these previous findings but weak expression in foetal liver, bone 
marrow and trachea were shown in addition to testis and CNS tissues, questioning how tightly 
restricted the expression of this novel CT gene is (see Figure 5.16).  However, it remained a 
promising candidate as it was expressed in a colon cancer sample, one melanoma sample, both 
lung cancer samples and more strongly in ovarian cancer samples.  In addition to this, 
expression of this gene displayed a significant upregulation in gene expression when ovarian 
cancer microarray datasets were meta-analysed (Feichtinger et al., 2012). 
 
Thus, it appeared a promising novel CTA candidate but it was unclear if it was present at the 
protein level.  Using an antibody purchased from Abcam® I tested to see if the protein was 
present in various cancer cell lines, which appeared to be the case (see Figure 5 in Appendix).  
I went on to test the specificity of this antibody by using siRNA knockdown targeting this gene.  
As shown in Figure 4.1, four different siRNAs reduced the intensity of the band detected on a 
Western Blot, indicating that the antibody was detecting the C20orf201 protein.  There was a 
further band detected at ~50kDa, which was not affected by the siRNA treatment. 
 
To look into the presence of C20orf201, I then used normal testis as a positive control for 
detection using immunohistochemistry (IHC).  Although, the function of this protein is 
unknown, it was predicted to play a role during spermatogenesis and shown to be expressed 
strongly in the testis.  Moreover, a requirement of its classification as a CTA would require 
presence of the protein in the normal testis.  This initial data revealed positive staining in the 
testis, and although the staining pattern varied depending on the experimental variables and 
tissue section used, stronger staining was present in the spermatogonial layer of the testis and 
appeared predominantly nuclear (see Figure 4.2 and Figure 6 in Appendix).  Positive staining 
was also revealed using immunofluorescence (IF) in the testis using a different antibody (see 
Figure 7 in Appendix) but the staining was not localised to the spermatogonial layer of the 
seminiferous tubules but more dispersed throughout the tissue section and developing germ 
cells.  MAGEA1 is a spermatogonial protein with very tight expression limited to basal layer 
of the testis in healthy tissues and was used as a control to co-stain in the IF experiments. 
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Figure 4.1  Western Blot indicating the presence of C20orf201 in A2780 cells following siRNA 
treatment.   
The expected size was 26kDa and a clear reduction in band intensity was seen using four different 
siRNA treatments that were carried-out over three days before conducting cell lysis.  ab108142 Abcam 
antibody (Lot. GR191628-1; 1:1000 dilution) for detection of C20orf201.  Secondary antibody: anti-
rabbit IgG, HRP-linked (Cell Signaling, #7074; 1:3000 dilution).  A band is also visible at around 50 
kDa but this did not respond to siRNA knockdown.   GAPDH is shown as a loading control. 
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Figure 4.2. IHC staining of C20orf201 in normal testis.   
IHC was performed on the semi-automated Ventana machine (Roche) using the rabbit polyclonal 
antibody to C20orf201 (ab108142, Abcam).  Positive staining in these examples was stronger in the 
basal or spermatogonial compartment of the seminiferous tubules and appeared nuclear (indicated by 
arrows).  An example of a different tissue section is shown in Figure 6 in Appendix.  Images acquired 
on an AMG EVOS® xl Core microscope. 
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Given that there was an indication from combined sources that C20orf201 may be expressed 
strongly in ovarian cancer, I tested for the presence of this protein in ovarian cancer samples.  
Ten ovarian cancer samples were purchased from ProteoGenex, which were supplied with 
matched normal surrounding tissue from the same patient.  On purchase, Proteogenex indicated 
that the normal tissue was also ovarian but subsequent analysis of H+E staining of the tissue 
sections revealed that the majority of the samples contained non-ovarian tissue.  The 
pathological and clinical information supplied by the company is supplied in Appendix C (on 
CD).  The H+E stains for each specimen were assessed by two consultant pathologists.  Most 
of the cancer samples tested displayed clear positive staining for C20orf201, though in general 
the staining pattern was classified as weak to moderate when assessed by a trained pathologist.  
A selection of these examples are shown in Figures 4.3 to Figure 4.5.  There was weak staining 
in the normal ovarian tissue that was tested, but there was in general clear differential staining 
compared to normal adjacent tissue that was negative for the majority of the samples tested.  A 
summary of the staining patterns seen, independently verified by two consultant pathologists 
(Dr M Atkinson and Dr H Shawki), are provided in Table 4.1.  
 
Next, I went on to test tissue microarray (TMA) slides, which contained a variety of normal 
tissue.  The aim of this was to show the staining pattern was limited within the normal tissue, 
as was expected from the gene expression analysis that had suggested this gene was a novel CT 
gene.  The staining of the TMA section proved problematic as a large proportion of the tiny 
cores that were present were displaced by the staining process.  I attempted staining the TMAs 
by hand, again with limited success and could not reproduce the positive staining pattern 
previously obtained using the Roche Ventana® automated machine in the testis sections.  
  
I obtained TMAs from three separate sources and the best results were obtained using the TMA 
supplied by the Co-operative Human Tissue Network (CHTN).  The results indicated that there 
was positive staining using this antibody against some normal tissues, including colon, as well 
as breast cancer (see Table 4.2).  Some examples of the staining patterns obtained on the TMA 
is provided in the Appendix (see Section 3, Figure 8).  Separate staining of the colon tissue that 
I had collected further corroborated this finding of positive staining within normal colon.  There 
was no indication from the gene expression analysis previously conducted that C20orf201 was 
expressed in normal colon (see Figure 4.18).   
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Figure 4.3.  C20orf201 staining in ovarian carcinoma and adjacent normal tissue.   
(A) Ovarian sample 032036 (see Table 4.1) contained a small focus of serous ovarian carcinoma and is 
shown here to depict the staining pattern seen in the cancer (top right of image A) compared to the 
normal para-tubal tissue surrounding the cancer.  Staining for C20orf201 was following heat retrieval, 
using Abcam antibody (ab108142).  A higher power magnification of the paratubal tissue (B) and a 
higher power magnification of the carcinoma is shown in (C).  It can be seen that there is stronger, 
predominantly nuclear staining in the section containing cancer.  Images obtained on a Zeiss Axio 
Scan.Z1 digital slide scanner. 
A
B 
C 
 
 
B 
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Figure 4.4. C20orf201 staining in normal ovary and ovarian cancer tissue.  
(A) Shows negative or very weak staining of C20orf201 in normal ovarian tissue (sample 031890T1 in 
Table 4.1).  The staining pattern seen in the serous ovarian carcinoma from the same patient is shown 
in (B) – sample 031890T2 in Table 4.1.  Very weak nuclear staining can be seen on higher magnification 
in the normal ovary shown in higher magnification (C) but this was considered negative by the 
pathologist who looked at this independently. Weak cytoplasmic staining in the high grade ovarian 
cancer and stronger nuclear staining seen in the carcinoma, shown in higher magnification in (D).  
Staining following heat retrieval for C20orf201 (Abcam, AB108142).  Images obtained on a Zeiss Axio 
Scan.Z1 digital slide scanner. 
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Figure 4.5. C20orf201 staining in ovarian carcinoma and matched normal adjacent tissue.   
Here the staining of C20orf201 in a high-grade serous carcinoma of the ovary (B) is shown together 
with normal surrounding connective tissue (see samples 031603T2 and 031603T1 in Table 4.1).  
Staining was with the rabbit polyclonal antibody raised against C20orf201 (Abcam, ab108142).  
Negative staining was seen in the surrounding connective tissue, shown in higher power magnification 
in (C).  Weak cytoplasmic and patchy/focal moderate nuclear staining seen in the ovarian cancer, shown 
in higher magnification in (D).  Images obtained on a Zeiss Axio Scan.Z1 digital slide scanner. 
  
A
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Table 4.1. C20orf201 staining in serous ovarian cancer and matched normal tissue. 
Sample description 
(sample code*) 
Staining pattern Matched normal 
description (code*) 
Staining pattern 
Adenocarcinoma 
(possibly high grade) 
(Sample: 032050T2) 
Focal weak nuclear 
staining 
Normal cervix  
(Sample: 032050T1) 
Weak to moderate 
nuclear staining in 
epithelial cells 
High grade serous 
carcinoma 
(Sample: 032036T2) 
Moderate nuclear and 
cytoplasmic staining in 
cancer 
Paratubal tissue and 
small focus of ovarian 
carcinoma  
(Sample: 032036T1) 
Weak to moderate 
predominantly 
nuclear staining in 
carcinoma only 
Serous carcinoma 
(possibly low grade) 
(Sample: 031940T2) 
Moderate but variable 
nuclear and cytoplasmic 
staining  
Normal cervix 
(Sample: 031940T1) 
Weak to moderate 
nuclear staining in 
epithelium 
High grade serous 
carcinoma 
(Sample: 031985T2) 
Moderate nuclear and 
weak cytoplasmic 
staining 
Myometrium and 
endometrium  
(Sample: 031985T1) 
Negative 
High grade serous 
carcinoma 
(Sample: 031890T2) 
Focal moderate positive 
nuclear and weak 
cytoplasmic staining 
Normal ovary  
(Sample: 031890T1) 
Negative 
High grade serous 
carcinoma 
(Sample: 031827T2) 
Weak cytoplasmic and 
focal moderate nuclear 
staining 
Smooth muscle and 
connective tissue 
(Sample: 031827T1) 
Focal weak staining 
in some endothelial 
cells 
High grade serous 
carcinoma 
(Sample: 031772T2) 
Very sparse and weak 
nuclear staining 
Normal cervix 
(Sample: 031772T1) 
Patchy positive 
nuclear staining 
High grade serous 
carcinoma 
(Sample: 031722T2) 
Moderate nuclear 
staining 
Myometrium  
(Sample: 031722T1) 
Very weak focal 
nuclear staining 
Serous carcinoma 
(possibly high grade) 
(Sample: 031666T2) 
Weak nuclear and 
moderate cytoplasmic 
staining 
Normal ovary  
(Sample: 031666T1) 
Very weak scanty 
nuclear staining in 
stromal cells 
Serous carcinoma 
(Sample: 031603T2) 
Moderate nuclear and 
cytoplasmic  
Normal Fallopian tube  
(Sample: 031603T1) 
Weak cytoplasmic 
and patchy nuclear 
staining 
*Details of the individual samples supplied by Proteogenex are provided in Appendix C (on CD). 
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Table 4.2.  Summary of TMA staining for C20orf201 using IHC 
Tissue Staining Pattern* 
Normal Prostate Scanty nuclear staining in myoepithelial cells.  Negative in epithelium 
Normal Liver Negative 
Smooth Muscle Negative 
Breast Cancer Patchy (<30%) positive nuclear staining 
Breast Cancer Patchy (15-20%) positive nuclear staining 
Smooth Muscle Negative 
Normal Liver Negative 
Normal Prostate Very weak and scanty nuclear staining (consider negative) 
Normal Colon Positive predominantly cytoplasmic staining of glandular epithelium 
Normal Colon Cytoplasmic staining in colonic crypt.  Weak staining of lymphocytes but 
negative central region of Peyer’s patch 
Normal Prostate Scanty nuclear staining in myoepithelial cells only. 
Normal Liver Negative 
Smooth Muscle Negative 
Breast cancer Very weak and scanty nuclear staining 
Breast cancer Nuclear staining in 30-50% of cancerous tissue 
Smooth Muscle Negative 
Normal Liver Negative 
Normal Prostate Negative 
Normal Colon Very weak cytoplasmic staining. 
Normal Spleen Scanty nuclear staining in lymphocytes 
Normal Spleen Very occasional positive staining of lymphocytes 
Normal Spleen Negative 
Normal Spleen Negative 
Normal Spleen Very occasional weak positive 
Normal Colon Very weak surface and cytoplasmic staining in glandular cells 
Normal Prostate Very weak and scanty nuclear staining in stroma (epithelium negative) 
Normal Liver Negative 
Myometrium Negative 
Normal Prostate Negative 
Normal Colon Very weak cytoplasmic staining in glandular epithelium 
Breast Cancer Patchy (~10%) focal nuclear staining 
Breast Cancer Patchy (5-10%) nuclear staining 
Normal Colon Weak cytoplasmic staining in glandular epithelium and weak nuclear staining 
in stroma 
Normal Spleen Occasional positive staining in some lymphocytes 
Normal Spleen Negative 
*Example IHC images are provided in the Appendix (see Figure 8).  The IHC findings were confirmed 
with a consultant pathologist (Dr Mark Atkinson). 
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4.3. TEX19 localisation in normal testis and colonic tissue 
Our group previously identified TEX19 as a novel mei-CT gene with expression seen in the 
majority of cancer samples tested but restricted to the testis and thymus in normal tissues 
(Feichtinger et al., 2012b).  TEX19 appeared to be a promising candidate on my TLDA analysis 
also, with expression restricted to the testis but also seen in colon and lung cancer (see Figure 
4.18).  Little is known about the function or localisation of TEX19 in humans, though it is 
known to be expressed in the germline as well as pluripotent stem cells (Kuntz et al., 2008).  
Deletion of TEX19 resulted in impaired or absent spermatogenesis in mice (Ollinger et al., 
2008).   
 
Argonaute proteins interact with the major sub-classes of small RNAs (Watanabe and Lin, 
2014).  In the germline members of the PIWI group of argonaute proteins interact with PIWI-
interacting RNA (piRNA).  Together these complexes functionally interact to repress the 
expression of retroelements via epigenetic silencing (Crichton et al., 2014).  Although TEX19 
has not been linked directly to the PIWI-piRNA pathway (Crichton et al., 2014) it remains 
possible that there is an interaction between these proteins.  Deletion of TEX19 resulted in 
activation of retroelements and it was thought that TEX19 may function to maintain genomic 
stability during sperm production and development (Ollinger et al., 2008).  PIWIL1 is a known 
germline gene: it also was shown to be a potential biomarker in colon cancer on the TLDA 
analysis.  Of the four colon cancer samples that expressed TEX19, three also expressed PIWIL1 
at moderate to high levels (see Figures 5.18 and Figure 5.22).  Both genes had limited 
expression in normal tissue samples, though PIWIL1 expression was seen more commonly than 
TEX19.  The expression of PIWIL1 was limited to normal colon tissue that had been obtained 
adjacent to colon cancer, so it is possible that PIWIL1 expression was influenced in these cells 
by the neighbouring tumour.   
 
In order to investigate the localisation of TEX19 within the testis and possible association with 
PIWI proteins, IF experiments were performed – see Figures 4.6-4.8.  First of all TEX19 was 
co-stained with MAGEA1 that is known to localise to the spermatogonial layer of the testis and 
the monocoloncal antibody produced a very clean and consistent signal, thus acting as a positive 
control.  As shown in Figure 4.6, TEX19 associated with MAGEA1 in and close to the 
spermatogonial compartment but the two proteins did not exactly co-localise.  TEX19 appeared 
to localise around the stem cell and developing spermatocytes with a tapering of less intense 
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staining towards the adluminal compartment and region where post-meiotic cells would reside.  
Thus, staining for TEX19 appeared to be in an ill-defined matrix between the spermatogonial 
cells or perhaps more likely within the cytoplasm of the Sertoli cells that envelope developing 
spermatocytes.   
 
As can be seen in Figures 4.6 and 4.8 (see also, Figure 9 in Section 3 of the Appendix), this 
staining pattern for TEX19 was consistent.  In some cases there was weak staining seen in the 
cytoplasm of developing spermatocytes in the adluminal compartment (e.g., Figure 4.7) but in 
general the most consistent appearance was that just described above.  In Figure 4.7 there were 
some cells, in the adluminal compartment of the seminiferous tubule, in which TEX19 and 
PIWIL1 did co-localise.  In a second example provided in Appendix (Figure 9) there did not 
appear to be co-localisation of the proteins and the presence of TEX19 within the cytoplasm of 
some spermatocytes within the adluminal compartment was not seen.  However, the regions of 
the tubule that expressed the proteins more strongly were the same, suggesting that a functional 
interaction may still exist.  A way of confirming the cellular localisation of TEX19, or any other 
candidate germline protein, would be to co-stain with other known spermatocyte (and Sertoli) 
cell markers and observe for any co-localisation.  
 
As can be seen in Figure 4.7, as was the case with MAGEA1, TEX19 also did not co-localise 
exactly with PIWIL1.  PIWIL1 appeared to be present throughout the seminiferous tubules but 
stronger staining was seen in the adluminal compartment where many of the cells will be 
undergoing meiosis at various stages of sperm cell development.  The staining pattern for 
PIWIL2 was less consistent but more of this protein appeared to be present in the 
spermatogonial layer of the seminiferous tubules (see Figure 4.8).  An additional example of 
the staining seen for PIWIL2 in the testis is shown in Figure 10 in Section 3 of the Appendix.  
The negative controls for these and subsequent IF experiments are shown in the Appendix 
(Figures 11-12).  Co-localisation of the PIWI proteins with each other, or with MAGEA1, could 
not be performed as all three of the antibodies used were raised in mice.   
 
The presence of TEX19 was also assessed using IHC and a consistent staining pattern was seen 
in the basal area of the seminiferous tubule.  As with the IF experiments, the staining appeared 
to surround the germ cells close to the spermatogonial compartment and staining was weaker 
towards the adluminal compartment (see Figure 4.9).   
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Figure 4.6.  IF of TEX19 and MAGEA1 staining in normal testis (x40).   
IF was carried out on FFPE tissue blocks of normal testis showing MAGEA1 (red) staining detected by 
the mouse monoclonal antibody (LSBio, LS-C87868) localised to the spermatogonial layer of the 
seminiferous tubule.  The staining for TEX19 (green) was with the rabbit polyclonal antibody (Abcam, 
ab185547).  Although there was a strong correlation between the regions of the seminiferous tubule that 
stained positive for the two proteins, both being towards/in the basal or spermatogonial compartment, 
there was no exact co-localisation.  Images acquired on Zeiss LSM 710 confocal microscope. 
Combined MAGEA1
d 
TEX19 DAPI 
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Figure 4.7.  TEX19 and PIWIL1 staining in normal testis (x40).   
IF was carried out on FFPE tissue blocks of normal testis showing TEX19 (green) staining detected by 
the rabbit polyclonal antibody (Abcam, ab185547), which localised between developing spermatocytes 
but towards the basal compartment of the seminiferous tubule.  The co-staining for PIWIL1 was with 
the mouse monoclonal antibody (Sigma, SAB4200365).  The staining for PIWIL1 appeared stronger in 
the adluminal compartment where a higher proportion of cells would be undergoing meiosis and once 
again there was no exact co-localisation with TEX19, except in the cytoplasm of the occasional germ 
cell in the adluminal compartment.  The cytoplasmic staining of TEX19 within developing germ cells 
was not consistently reproducible and another example of IF staining for TEX19 and PIWIL1 in normal 
testis is shown in Figure 9 of Appendix.   Images acquired on Zeiss LSM 710 confocal microscope. 
TEX19 DAPI 
Combined PIWIL1 
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Figure 4.8.  TEX19 and PIWIL2 staining in normal testis (x40).   
IF was carried out on FFPE tissue blocks of normal testis showing PIWIL2 (red) staining detected by 
the mouse monoclonal antibody (Abnova, MAB0843).  Weak and patchy staining was present 
throughout the seminiferous tubule and occasional surrounding cells but stronger, predominantly 
cytoplasmic, staining was present in the spermatogonial layer of the testis.  TEX19 (green) appeared to 
stain a region surrounding the germ cells predominantly towards the spermatogonial layer of the 
seminiferous tubule.  See Figure 10 in Section 3 of the Appendix for a repeat experiment, where the 
staining in the spermatogonial layer of the seminiferous tubule was more distinct for PIWIL2 but on that 
occasion co-staining for TEX19 was not performed.   Images acquired on Zeiss LSM 710 confocal 
microscope. 
  
Combined 
TEX19 
PIWIL2 
DAPI 
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Figure 4.9.  IHC staining of TEX19 in normal testis.  
IHC was performed on 4 µm tissue sections cut from FFPE tissue blocks of normal testis (Abcam, 
ab185547).  Stronger staining was seen towards the spermatogonial layer of the seminiferous tubules 
but the staining appeared predominantly between the spermatogonial cells; at least no nuclear positivity 
was present within the germ cells.  The IHC findings were consistent with the IF experiments shown 
above.  Image obtained on a Zeiss Axio Scan.Z1 digital slide scanner. 
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I went on to test for the presence of the protein in colon cancer samples.  Here, a common 
finding in the normal adjacent tumour (NAT) tissue was limited cytoplasmic staining in the 
adluminal columnar epithelial cells (for example, see Figure 4.10 and Figure 4.11).  Expression 
was seen more widely in the cancer samples, an example of which is shown in Figure 4.10.  In 
the region of cancer, TEX19 appeared to display nuclear as well as cytoplasmic staining, raising 
the possibility that the protein shuttles to the nucleus to have differing consequences when 
present in cancer.  The staining pattern was seen with some consistency across the normal 
colonic mucosa and appeared cytoplasmic and predominantly confined to the epithelial cells 
immediately adjacent to the bowel lumen.  Although the example shown in Figure 4.10 was 
directly adjacent to a tumour (on the same slide), it was fairly typical of the staining seen in 
other (though more distant) NAT colonic mucosa tissue sections that I tested.  All the normal 
samples stained were from patients with colonic tumours.  A summary of the staining pattern 
seen is provided in Table 4.3.   
 
The staining pattern was not strongly positive in any of the colon cancer samples, though there 
was a trend to stronger staining seen compared to the NAT tissue.  This was particularly true 
with regards to the nuclear staining.  One cancer sample (C40) had an area of mucinous 
carcinoma that displayed stronger cytoplasmic staining for TEX19 but the adjacent normal 
colonic mucosa also displayed areas of moderate staining adjacent to the lumen (see Table 4.3).  
Also, sample 45 which was a poorly differentiated tumour displayed widespread nuclear 
positivity that was not seen in the adjacent normal tissue.  Both these tumours were also found 
to express TEX19 (see Figure 5.16) and suggest a possible functional relevance in these tumours 
that carry a poor prognosis.  However, somewhat confusingly two other tumours that displayed 
stronger differential staining in the cancer (samples 26 and 35) did not clearly express TEX19 
(see again Figure 5.16).  This could be accounted for by the heterogeneity of expression of the 
gene within individual tumour samples.  The weak cytoplasmic staining seen in the majority of 
the NAT colonic samples tested is not entirely inconsistent as very weak/borderline expression 
was seen in some of the NAT colon samples tested on the TLDA cards, though this generally 
fell below the threshold I had set for determining definite gene expression.  The localisation of 
TEX19 within the adluminal cells is of uncertain significance and it is possible that this also 
represents an artefact or ‘edge effect’ of the IHC procedure.  It should be remembered that all 
the normal colon samples stained were from patients with colonic tumours, so in certain 
respects they may not be representative of normal colonic mucosa in patients without cancer.   
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Figure 4.10.  IHC staining of TEX19 on colon cancer.    
IHC was performed on 4 µm tissue sections of sample C26.  (A) Displays the entire tissue section and 
(B) shows a higher-power magnification of the transition from cancer to normal epithelium, which 
becomes progressively more normal from a left to right direction.  It is clear from (A) that stronger 
staining was present in the portion of the tissue section containing cancer.  Images obtained on a Zeiss 
Axio Scan.Z1 digital slide scanner. 
B 
A 
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Figure 4.11.  TEX19 staining in colon cancer and adjacent normal mucosa assessed by IHC.   
Higher power magnification of the same sample shown in Figure 4.10.  (A) Shows a histologically 
normal area displaying weak positive cytoplasmic staining in the glandular cells closest to the luminal 
surface of colon.  (B) Higher power magnification of the area of cancer: here again cytoplasmic staining 
is seen but there is also weak to moderate nuclear staining of the cancer cells. Nuclear staining was 
present in the abnormal epithelial cells but also the stromal cells of the tumour, neither of which were 
seen in the normal areas of colon adjacent to the cancer.  Images obtained on a Zeiss Axio Scan.Z1 
digital slide scanner. 
 
A 
B 
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Table 4.3.  Summary of the IHC staining results for TEX19 in colon cancer and adjacent normal 
tissue. 
Sample Tumour staining pattern Normal adjacent tissue staining pattern  
C7*  Weak cytoplasmic and patchy weak nuclear 
staining  
Weak cytoplasmic and nuclear staining in 
glandular epithelium  
C9  Weak cytoplasmic staining  Weak cytoplasmic in adluminal epithelium 
C12*  Weak to moderate focal nuclear and weak 
cytoplasmic staining  
 
Scanty weak nuclear staining in epithelial 
and stromal cells; weak to moderate cyto-
plasmic staining in adluminal epithelium  
C22  Weak focal nuclear staining  
 
Weak cytoplasmic staining in adluminal 
epithelium; scanty focal mucosal nuclear  
C26  Moderate cytoplasmic and moderate focal 
nuclear staining in adenoma and focal 
nuclear staining in stroma  
Moderate cytoplasmic staining in 
adluminal epithelium and patchy weak 
nuclear staining  
C27  Scanty moderate nuclear staining and weak 
cytoplasmic staining  
Weakly cytoplasmic positive adluminal 
epithelial cells  
C31*  Scanty weak predominantly nuclear staining  
 
Very weak and patchy nuclear and 
cytoplasmic adluminal glandular staining  
C32*  Patchy moderate nuclear staining and weak 
cytoplasmic staining  
Very weak cytoplasmic adluminal 
epithelial staining  
C33  Weak cytoplasmic staining with patchy 
areas of both weak/moderate nuclear and 
cytoplasmic staining  
Weak cytoplasmic staining in adluminal 
epithelium and scanty focal nuclear 
positivity  
C35  Moderate nuclear and weak cytoplasmic 
staining  
 
Weak adluminal cytoplasmic epithelial 
staining and very weak focal nuclear 
staining in stroma  
C36*  Weak and patchy nuclear and cytoplasmic 
staining  
Weak to moderate cytoplasmic staining in 
adluminal epithelium  
C40  Weak nuclear and cytoplasmic staining with 
focal areas of moderate cytoplasmic staining 
in area of tumour with mucinous component  
Weak to moderate cytoplasmic staining in 
adluminal epithelium  
C45  Weak to moderate nuclear staining and weak 
cytoplasmic staining  
Weak to moderate cytoplasmic staining in 
adluminal epithelium  
Sample names in bold denote cancer samples for which the TLDA analysis indicated that TEX19 was 
expressed.  *TEX19 gene expression not assessed on the TLDA cards for these samples.  Please refer 
to Table 5.2 for details relating to the cancer from which the samples were taken. 
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To further validate the presence of TEX19 in normal tissues, I also conducted IHC using the 
same experimental conditions, on a TMA containing numerous types of normal tissues.  As was 
the case with my previous attempts at staining TMA slides, there was some loss of the cores 
during the process.  However, the majority of the cores were intact and most of these displayed 
negative staining for TEX19.  A summary of the positive staining seen is provided in Table 4.4 
and example images are displayed in the Appendix (see Figure 13 in Section 3).  Consistent 
with my findings in the NAT colon samples that I had collected, there was similar staining in 
the cytoplasm of the intestinal epithelial cells present on the array.  Thus, the possibility of the 
staining being the result of the mucosa being close to a tumour is very unlikely.  
 
 
 
Table 4.4.  Summary of positive IHC staining patterns seen for TEX19 on a normal TMA 
Tissue type Positive staining pattern description 
Amniotic membrane Weak cytoplasmic 
Aorta (smooth muscle) Very weak and scanty cytoplasmic 
Appendix (MALT) Weak cytoplasmic staining in cells adjacent to lumen 
Bladder Very weak and scanty cytoplasmic staining (adluminal) 
Colon Weak cytoplasmic staining (adluminal) 
Endometrium (secretory) Very weak cytoplasmic staining in glandular cells 
Eosophagus Very weak and scanty cytoplasmic staining 
Epididymis Weak to moderate adluminal cytoplasmic positivity 
Fallopian Tube Very weak glandular cytoplasmic staining  
Gallbladder Weak cytoplasmic staining 
Intestinal smooth muscle Very weak cytoplasmic staining 
Kidney (cortex) Very weak cytoplasmic 
Lung (bronchial epithelium) Very weak and scanty cytoplasmic staining 
Pancreas Focal weak nuclear and cytoplasmic staining 
Placenta Very weak and scanty cytoplasmic positivity 
Seminal vesicle Very scanty cytoplasmic staining 
Small Intestine Weak to moderate cytoplasmic in adluminal epithelium 
Spleen Very weak and scanty cytoplasmic staining 
Stomach (oxyntic mucosa) Weak cytoplasmic staining 
Testis (seminiferous tubules) Moderate cytoplasmic in basal compartment 
MALT – mucosa associated lymphoid tissue.  Other tissue types included on the TMA, for which TEX19 
staining was considered negative, included: adrenal gland, breast, heart, parathyroid gland, cervix, 
ovary, prostate, liver, lymph node, thymus, mesothelium, brain, peripheral nerve, salivary gland, tonsil, 
skin (squamous epithelium), synovium, skeletal muscle, uterine smooth muscle, kidney (medulla).  
There was significant loss of tissue limiting the interpretation for: breast, oesophagus, ovary, prostate, 
skin and synovium; in addition, there was complete loss of all 3 cores of articular cartilage.  
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4.4. SPO11 and PIWIL1 localisation in testis and colonic tissue 
DSBs are generated in meiosis by the topoisomerase II-like enzyme SPO11.  SPO11 is a highly 
conserved protein without known physiological roles outside of meiosis/meiotic recombination; 
it is thus widely believed to have a testis/germline restricted expression profile (de Massy, 
2013).  The TLDA analysis revealed that SPO11 was only expressed in the testis, with no 
expression seen in any other normal or cancer samples tested using two different assays.  
However, SPO11 is considered a CTA and has been described as such by at least two groups 
(Almeida et al., 2009; Litvinov et al., 2014).  The specificity of SPO11 to the testis has been 
called into question by others (Hofmann et al., 2008).  We also remained interested in this gene 
given its important physiological roles during meiosis and work had already been conducted by 
other group members to validate a polyclonal antibody that detected SPO11.  Thus, the presence 
of SPO11 was investigated as an example of a known CTA but also to reveal its localisation 
within the testis and possible presence in cancerous tissue.   
 
The antibody for SPO11 produced a very strong signal and proved difficult to optimise using 
IHC.  Thus, IF was used as the main technique to establish where the protein could be detected 
in normal testis.  As shown in Figure 4.12 and Figure 4.13, SPO11 appeared to be present in a 
large proportion of developing spermatocytes consistent with its known physiological roles 
during meiosis.  Co-staining with MAGEA1 is displayed in Figure 4.12 and although there 
appeared to be some focal positivity in the spermatogonial compartment, SPO11 staining was 
strong throughout the germ cells within the seminiferous tubules.  In Figure 4.13, co-
localisation with PIWIL1 is shown – it can be seen that many of the same cells tested positive 
but SPO11 appeared to have predominantly nuclear localisation, whereas PIWIL1 was largely 
cytoplasmic.  PIWIL1 staining using IHC in normal testis is shown in Figure 4.17, which again 
showed stronger staining in the adluminal compartment of the seminiferous tubule.  Nuclear 
localisation of SPO11 in developing spermatocytes would be expected given the known 
function of SPO11 in initiation of meiotic recombination by causing DNA DSBs.  In the colon 
specimens tested, there appeared to be very weak staining in the normal adjacent cancer 
specimens (see Figure 4.14 and 4.16).  In Figure 4.14, nuclear localisation was limited to a 
specific cell within the colonic crypt – this was at the interface between the stem cell and 
progenitor zone.  In the cancer samples tested there was stronger staining but this was non-
specific.  Similarly for PIWIL1 there was positive but non-specific staining and no clear co-
localisation of these proteins (see Figure 4.15 and 4.16).   
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Figure 4.12.  SPO11 and MAGEA1 staining in normal testis (x40).   
IF was carried out on FFPE tissue blocks of normal testis showing MAGEA1 (red) staining detected by 
the mouse monoclonal antibody (LSBio, LS-C87868) localised to the spermatogonial layer of the 
seminiferous tubule.  The staining for SPO11 (green) was with the rabbit polyclonal antibody (Abcam, 
ab81695).   Although there was some clear focal positivity for SPO11 within the basal compartment of 
the seminiferous tubule, there were very few cells which displayed exact co-localisation with MAGEA1.  
Moreover, staining for SPO11 was stronger within developing germ cells in the adluminal compartment.  
Images acquired on Zeiss LSM 710 confocal microscope. 
DAPI SPO11 
Combined MAGEA1 
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Figure 4.13.  SPO11 and PIWIL1 staining in normal testis (x40).   
IF was carried out on 4 µm sections of FFPE tissue blocks of normal testis showing SPO11 (green) 
staining detected by the rabbit polyclonal antibody (Abcam, ab81695).  The staining for PIWIL1 (red) 
was with the mouse monoclonal antibody (Sigma, SAB4200365).  The staining pattern was similar in 
distribution but SPO11 appeared to have a predominant nuclear localisation within developing 
spermatocytes, whereas PIWIL1 as before demonstrated stronger cytoplasmic staining.  There were 
some cells that stained SPO11 only but for PIWIL1 positive cells, they appeared also to stain positive 
for SPO11.  Some mature spermatids are also seen, which are weakly positive for SPO11 only.  Images 
acquired on Zeiss LSM 710 confocal microscope. 
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Figure 4.14. IF staining of SPO11 and PIWIL1 in normal adjacent colonic mucosa.   
IF was carried out on 4 µm sections of FFPE tissue blocks of normal colon sample B9 showing SPO11 
(green) staining detected by the rabbit polyclonal antibody (Abcam, ab81695).  The staining for PIWIL1 
(red) was with the mouse monoclonal antibody (Sigma, SAB4200365).  Staining for PIWIL1 was 
negative and there was weak positive nuclear staining for SPO11 in a cell at the interface between the 
progenitor and stem cell zone.  In other regions of normal adjacent colonic tissue there was patchy 
staining for SPO11 in occasional cells just beneath the basement membrane of the colonic crypt.  Images 
acquired on Zeiss LSM 710 confocal microscope. 
SPO11 
Combined PIWIL1 
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Figure 4.15.  IF staining of SPO11 and PIWIL1 in colon cancer.   
IF was carried out on FFPE tissue blocks of colon cancer sample C9 (matched adjacent tumour to Figure 
5.14) showing SPO11 (green) staining detected by the rabbit polyclonal antibody (Abcam, ab81695).  
The staining for PIWIL1 (red) was with the mouse monoclonal antibody (Sigma, SAB4200365).  
Staining for PIWIL1 was weakly positive in the adenomatous crypt as well as tumour stroma.  SPO11 
staining appeared stronger in the adenomatous tissue and weaker in the stroma but there was likewise a 
lot of non-specific staining as seen for PIWIL1.  There was no clear co-localisation for SPO11 and 
PIWIL1 but some overlap in staining that was not surprising given the high amount of non-specific 
staining seen.  Images acquired on Zeiss LSM 710 confocal microscope. 
 
  
SPO11 
Combined PIWIL1 
DAPI 
Chapter 4: Results 
126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16.  IF staining of SPO11 and PIWIL1 in colon cancer and normal adjacent colonic tissue.   
IF was carried out on 4 µm sections of FFPE tissue blocks of colon cancer sample C45 and adjacent 
normal tissue.  The normal colonic tissue section in shown in (A) and the colon cancer sample shown in 
(B).  A higher power magnification of the maximum intensity projection image for the poorly 
differentiated adenocarcinoma is shown in (C).  SPO11 (green) staining was detected using the rabbit 
polyclonal antibody (Abcam; ab81695).  The staining for PIWIL1 (red) was with the mouse monoclonal 
antibody (Sigma; SAB4200365).  Staining for PIWIL1 was weak and appeared to be have nuclear 
localisation but this was not clear.  SPO11 staining was slightly stronger but patchy and appeared to 
localise to both the cytoplasm and nucleus.  Again there was no clear co-localisation for SPO11 and 
PIWIL1.  Images acquired on Zeiss LSM 710 confocal microscope.  
C
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The weak and suggested nuclear staining for PIWIL1 in colon cancer using IF (as displayed in 
Figure 4.16) was investigated for confirmation by IHC.  Attempts to stain for SPO11 using IHC 
displayed a lot of background staining and I did not manage to produce interpretable results due 
to the strong staining seen.  However, for PIWIL1 there was more consistent results using the 
monoclonal antibody used in the IF experiments (Sigma; SAB4200365, Lot. 111M4781).  As 
was seen on IF, IHC on normal testis produced positive and relatively clean staining in the 
adluminal compartment of the seminiferous tubules (see Figure 4.17).  A selection of the colon 
cancer and NAT colon samples that I had collected were also tested: I chose to stain some based 
on the strength of expression indicated by the gene expression analysis in the matched samples 
(see Chapter 5 for details).  The colon samples appeared negative, though there was perhaps 
some focal weak nuclear positivity in a poorly differentiated adenocarcinoma which the PCR 
results had indicated expressed PIWIL1 strongly (see Figure 4.18).  This result was broadly 
consistent with what the IF experiments had shown on the same tissue sample (see Figure 4.16).  
It may however be the case that despite the PIWIL1 gene being expressed in several colon 
cancers tested, the protein is not translated or the experimental conditions used were unable to 
detect the presence of the antigen.  PIWIL1 did appear to be present in breast cancer samples 
that were included on a TMA slide used to test the PIWIL1 antibody – see Figure 4.18.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17.  IHC staining for PIWIL1 in normal testis.   
IHC was performed on 4 µm section of normal testis using the mouse monoclonal antibody targeting 
PIWIL1 (Sigma, SAB42000365).  Image obtained on a Zeiss Axio Scan.Z1 digital slide scanner. 
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Figure 4.18.  IHC staining of PIWIL1 in normal colon, colon cancer and breast cancer.   
IHC was performed on 4 µm tissue sections of colon cancer sample 45 and adjacent normal tissue from 
the same patient (A).  There was a suggestion of some weak scanty nuclear positive staining in this 
poorly differentiated adenocarcinoma shown in (B) but the majority of the tissue sections stained 
negative, despite previous results indicating that PIWIL1 was expressed at reasonable levels in some 
tissue samples.  There was more obvious patchy nuclear positivity in a breast cancer sample.  Images 
obtained on a Zeiss Axio Scan.Z1 digital slide scanner. 
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4.5. Assessment of the potential immunogenicity of TEX19 and C20orf201 
From the gene expression analysis I conducted and previous work to identify novel meiosis-
associated CT genes, TEX19 and C20orf201 appeared two of the most promising candidates.  
The attempts to establish the localisation and presence of the proteins in normal and cancer 
tissues produced mixed but broadly encouraging findings.  To establish the immunogenic 
potential of these two proteins, customised peptides from each protein were produced and used 
to see if they could bind to T-cells by utilising a cell binding assay in specialised T2 cells.  An 
example of the flow cytometry result is shown in Figure 4.19 and a summary of all the results 
is displayed in Table 4.5.  Three repeat experiments were performed. 
 
If the peptide binds to the T cell, then there will be a change in the mean fluorescence intensity 
(MFI).   It can be seen in Table 4.5 that several peptides produced a positive result – an increase 
of at least 30% above the MFI for the control is significant.  Five of the TEX19 peptides 
appeared of potential immunogenic interest, with the most significant change in intensity seen 
for two peptides that produced in excess of a 100% change in the MFI value: these were 
LEDAGLDPHF and YLYASWMYQL that were both predicted to bind to HLA-A2 molecules 
strongly.   
 
Nine of the C20orf201 peptides appeared to be potentially immunogenic (i.e. resulted in an at 
least 30% increase in the MFI).  Three of these peptides produced an increase in the MFI of 
over 100% over the control cell population.  It should be noted that the T-cell binding assay 
does not prove that the peptide will be immunogenic in vivo and the ‘strong binders’ (i.e. the 
peptides which produce the largest change in MFI) do not always turn out to be the most 
immunogenic (Nunes et al., 2011).  It does, however, give a good indication of which peptides 
would be good candidates to take forward for a given human population.   
 
  
Chapter 4: Results 
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19.  Flow cytometry result for T-cell binding assay.   
T2-cells were cultured overnight with dimethyl sulfoxide (DMSO) only as a control or with customised 
peptides dissolved in DMSO.  A flow cytometric readout was performed – the vertical red line indicates 
the mean fluorescence intensity (MFI) for the DMSO only treated cells.  The red line is indicated in the 
same position for the two peptides below this: for the middle peptide there is a shift in the fluorescence 
intensity to the right and the bottom peptide the MFI is very similar to that of the control.  The middle 
peptide (YLYASWMYQL) for TEX19 can be thus seen to bind strongly to the T2 cells and result in a 
shift in the MFI.  Results analysed using FCS Express 4 Flow Research Edition software. 
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Table 4.5.  Summary of T-cell responses to the tested peptides 
Peptide Sequence Protein MFI-1 MFI-2 MFI-3 % mean 
increase 
1 YLYASWMYQL TEX19 253037.67 635064.04 1239791.90 395.25 
2 QLSICFTCFK TEX19 71341.99 116117.48 287597.33 18.25 
3 ELWPQEAVPL TEX19 99752.60 97660.75 350629.75 41.19 
4 LPWRFEELL TEX19 82306.63 112726.43 220123.91 1.43 
5 WPQEAVPLGL TEX19 128830.05 104999.47 375714.32 54.33 
6 YEEEGMSYLY TEX19 83743.93 79100.43 282640.05 14.00 
7 EEEGMSYLY TEX19 65562.28 91430.40 284992.98 15.84 
8 LEDAGLDPHF TEX19 151888.31 108245.03 376706.04 58.28 
9 GLPWRFEEL TEX19 217289.02 298953.73 374186.61 103.53 
10 QLQHGDQLSI TEX19 93827.72 104864.29 288924.77 23.12 
11 RMPDPRPWT C20orf201 91464.79 88398.82 333698.49 33.21 
12 LLFGDLLEDV C20orf201 124848.21 343677.00 1519956.95 456.73 
13 DPRPWTQSL C20orf201 71370.35 85626.57 352472.44 36.14 
14 EARGRVRAL C20orf201 157674.73 161374.24 337502.72 57.25 
15 FLPPQLKPA C20orf201 444807.22 595682.71 1060447.52 405.33 
16 RLLGVLKAA C20orf201 241931.96 482995.83 505697.68 185.48 
17 ATEPPKPGW C20orf201 136002.64 148423.50 335763.63 51.52 
18 RPWTQSLEL C20orf201 71109.13 77902.70 264482.76 7.44 
19 EENVDGTIF C20orf201 88822.55 91225.62 300866.52 22.84 
20 LPAQRHRHL C20orf201 116007.56 110243.22 334121.90 40.78 
21 ELFLPPQLK C20orf201 79095.62 87739.02 287653.44 17.75 
22 LPAQRHRHLL C20orf201 127779.12 121689.59 219097.34 8.74 
23 AEARGRVRAL C20orf201 153480.42 139289.74 274059.40 32.09 
24 Positive control M1 79882.06* 193124.10 265955.81 48.02* 
N/A Negative control N/A 87734.06 112603.19 213555.36 N/A 
MFI – Mean Flourescence Intensity.  * - MFI1 result excluded as M1 peptide diluted inappropriately.  
% mean increase refers to the percentage mean increase in MFI taken from the three repeat experiments. 
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4.6. Discussion 
The search for more precise methods of cancer stratification is as important as ever.  As we 
enter an era of more personalised treatment strategies, a vast array of biomarkers will be 
required to meet the clinical need of accurate stratification, which may use a combination of 
markers and approaches to reach the desired degree of predictive accuracy.  The work presented 
in this chapter makes the initial steps towards a translational research outcome at the antigenic 
level for some novel and poorly characterised germline genes.  Despite the encouraging initial 
findings of the staining pattern in ovarian cancer samples and the validation of the antibody 
using siRNA knockdown, the antibody against C20orf201 (Abcam, ab108142) did appear to 
produce positive staining in tissue for which we did not expect to see positive staining.  This 
may relate to a lack of specificity of this polyclonal antibody.  Alternatively, very low levels of 
gene expression may produce a protein that is translated and stable in vivo.  Weak expression 
was in fact seen on the TLDA card analysis in a few normal tissue samples, which was more 
than indicated by the previous RT-PCR analysis by our group in which expression was limited 
in normal tissues to the testis and CNS (Feichtinger et al., 2012b).  So, the gene may not have 
such tight tissue specificity as we originally thought and this is reflected in the positive staining 
patterns seen on IHC.   
 
As far as developing a novel therapy (e.g., immune-based) targeting C20orf201 is concerned, 
the fact that weak staining was seen in normal ovarian tissue is perhaps not of particular 
significance.  If the surrounding tissues do not contain the protein, as the IHC experiments 
indicated, then damage to normal ovarian tissue is unlikely to be of concern to the patient, 
especially if they are of post-menopausal age as is often the case.  However, given that 
immunotherapeutics are given systemically, an antigen present anywhere in the body could 
potentially be targeted by such an approach and result in adverse/unwanted consequences.  
Given that staining of the normal TMAs revealed staining in some other normal tissues outside 
of the ovaries, this would potentially prevent the protein being used as an immunotherapeutic 
target.  However, a TAA that is present at very low levels in normal healthy tissues may still 
be a potential target of novel immunotherapies if present to a far higher degree in the cancer 
being targeted.  Given the differential staining seen in serous ovarian cancer samples tested in 
this, it may be possible to use the presence of C20orf201 as a predictive marker to help guide 
certain therapies, even if low level presence in certain somatic tissues could obviate its use as 
an immunotherapeutic target. 
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Also, I experienced some reproducibility problems when ordering a new batch of the C20orf201 
antibody, which highlights the problems and importance of reproducibility in experimental 
research.  This is particularly true when attempting to translate the findings into the clinical 
setting.  Another issue with antibody production is the specificity of antibodies.  Although 
polyclonal antibodies can be 100% specific for the target protein, there is an increased 
likelihood (over monoclonal antibodies) that other proteins could be detected.  To deal with the 
reproducibility issues of using animals to produce antibodies, some have urged a shift-change 
in the way antibodies are produced with the antigenic sequences being defined at the DNA level 
and produced within engineered cells (Bradbury and Pluckthun, 2015).  The process and issues 
surrounding antibody validation have recently been discussed (Baker, 2015; Bordeaux et al., 
2010).  One reasonable conclusion is that, given staining was seen in tissues not expected to 
contain the protein, the antibody should be “abandoned”, as specified in the final validation step 
described by Bordeaux and colleagues (Bordeaux et al., 2010).  C20orf201 may still be an 
interesting TAA with therapeutic potential but the antibody I have been using may lack the 
rigour required to take the findings forward into the clinical setting.  Since we published our 
initial findings highlighting C20orf201 as a potential meiCT-gene (Feichtinger et al., 2012b) 
another group have provided evidence that the antigen is produced in patients with prostate 
cancer (Kamata et al., 2013).  I did not test for the expression of the gene in prostate cancer.  
Together these combined findings suggest the C20orf201 may be of relevance in certain cancer 
types and warrants continued experimental exploration. 
 
The other novel meiCT gene that I investigated for antigen production was TEX19.  Deletion 
of TEX19 has been shown to result in activation of retroelements, or transposable elements 
(TE), in mice (Ollinger et al., 2008).  The PIWI proteins, which form complexes with piRNAs, 
together repress the expression of TEs in the germline and guard against unwanted genetic 
alteration as a result of TE activation (Siomi et al., 2011; Watanabe and Lin, 2014).  Our group 
has shown that knockdown of TEX19 in a colorectal cancer cell line resulted in upregulation of 
PIWIL1 (Planells Palop, unpublished data).  IF data here has shown both proteins to be present 
in the seminiferous tubules without significant co-localisation.  It may be the case that in cancer, 
if TEX19 is present it could promote activation of the TEs that promote oncogenic change.  
However, in the testis there is competition from piRNAs and PIWI proteins to protect against 
this effect.  The physiological effects may also depend on the localisation and magnitude to 
which the protein is present in the cell.  For example, cytoplasmic staining appeared to be 
present in the seminiferous tubules of the testis and weak cytoplasmic staining also present in 
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some normal colonic epithelial cells adjacent to the luminal surface.  Whereas, in colon cancer 
samples, stronger cytoplasmic as well as nuclear staining for TEX19 was seen in some instances 
(for example, see Figure 4.11).   
 
Somewhat confusingly, the IHC example showing perhaps the clearest differential staining 
within the same specimen, did not appear to display expression of TEX19 in the TLDA analysis 
(see Figure 5.18).  This may be because the RNA was extract from a non-cancerous portion of 
the specimen.  This highlights a deficiency of the sampling and experimental technique.  It can 
be seen from Figure 4.10 that under half of the specimen contained cancer, so it is quite possible 
given that not the entire sample was homogenised for RNA extraction that the invasive cancer, 
and region where TEX19 may have been expressed more strongly, was inadvertently excluded.   
 
TEX19 displayed consistent staining pattern on both IHC and IF experiments and appeared to 
stain a ‘matrix’ between the germ cells.  An alternative possibility is that the staining pattern 
seen was in the cytoplasm of specific spermatocytes close to the BTB; nuclear staining was 
never observed.  There was more intense staining towards the spermatogonial or basal 
compartment of the seminiferous tubules.  One distinct possibility is that TEX19 is not in fact 
present within the germ cells and may be present within the cytoplasm of Sertoli cells which 
are known to be critical for regulating spermatogenesis.  A staining seen predominantly outside 
of the germ cells, does raise questions about what functional role it may play during germ cell 
development.  Perhaps it acts via interaction with cell surface receptors to regulate 
spermatogenesis but does not play a direct role in meiosis.  The stronger staining towards the 
basal compartment where the stem cells of the germline reside, would suggest a possible link 
to pluripotency for which a functional role has already been suggested (Kuntz et al., 2008).  Co-
staining for known cytoplasmic markers of Sertoli cells should be performed to investigate if 
TEX19 does co-localise with these markers.  Similarly, IF experiments with known 
spermatocyte subtype-specific cell markers may reveal an association with specific germ cells 
within the testis but I believe the staining pattern observed and presented here is less consistent 
with this possible cellular localisation. 
 
SPO11 is responsible for the formation of DNA DSBs and the initiation of meiotic 
recombination.  The protein was shown to have predominantly nuclear localisation within 
germline cells in the testis (see Figure 4.13).  IF experiments also indicated that very low levels 
of protein expression may be present in normal colonic tissue.  The nuclear staining of a 
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possible stem cell in the region of a normal colonic crypt (as shown in Figure 4.14) was not a 
consistent finding and no co-localisation with known stem cell markers was performed.  It was 
found some time ago that the Drosophila orthologue of SPO11, mei-W68, was present in 
somatic cells and appeared to have a mitotic role (McKim and Hayashi-Hagihara, 1998).  This 
finding has not been corroborated in humans and it is widely regarded as a meiosis-specific 
protein where it regulates other aspects of chromosome dynamics in addition to forming DNA 
DSBs (Celerin et al., 2000; Murakami and Keeney, 2008).  SPO11 may also play a role in 
check-point signalling and the targeting of cells with mitotic errors for destruction following 
entry into meiosis (Stevens et al., 2013).  SPO11 is considered a CTA and may be present in 
limited amounts in cervical cancer, melanoma, colorectal cancer and lymphoma (Almeida et 
al., 2009; Eldai et al., 2013; Koslowski et al., 2002; Litvinov et al., 2014).  In general there has 
been limited confirmation of the presence of either mRNA or protein in human cancers; for 
example, for squamous cell carcinoma of the head and neck region and acute myeloid 
leukaemia the gene has been found not to be expressed in patient samples, and the only sample 
that did contain SPO11 in these studies was a single leukaemia cell line (Atanackovic et al., 
2006; Atanackovic et al., 2011).  In the samples I tested I found the gene to have a testis-
restricted expression profile (see Figure 5.20).   
 
Despite the apparent lack of expression of SPO11 in the cancer samples I had tested, I went on 
to test a selection of colon cancer samples using IF.  SPO11 had been described as potentially 
relevant in CRC (Eldai et al., 2013) and I co-stained for the presence of PIWIL1 in some colon 
cancer samples (see Figure 4.15 and Figure 4.16).  PIWIL1 did appear to be expressed in an 
increased number of colon cancer samples, compared to the adjacent normal tissue (see Figure 
5.23).  PIWIL1 was not present in NAT colonic tissue when assessed using IF, whereas SPO11 
displayed possible and very limited staining as just described.  In the cancer samples there was 
non-specific staining for both proteins.  This could be due either to low levels of protein present 
in the cancer or non-specific binding of the antibody to other antigens within the tissue.  The 
presence of SPO11 appeared stronger in general in the cancer samples compared to PIWIL1, 
despite an indication from the TLDA analysis that PIWIL1 was activated in some of the colon 
cancer samples, whereas SPO11 was not.  One explanation for this, and for the lack of 
confirmation of SPO11 expression more generally in cancer, could be the lack of 
polyadenylation in the mRNA encoding SPO11.  Oligo-dT was used as the complementary 
primary for all cDNA synthesis reactions in my experiments.  
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4.7. Conclusions 
C20orf201 and TEX19 are germline associated genes that appear to be upregulated in certain 
cancers.  It has been shown that they have potential as immunogenic biomarkers and thus may 
serve as targets for immune-based treatments against cancer.  The function of these genes is yet 
to be established, although TEX19 may interact with or influence the function of PIWI proteins 
in the germline and could via a gene activating role cause the upregulation of other oncogenic 
genes when present in cancer.  C20orf201 has been shown to be a potential biomarker in ovarian 
cancer and shown to be present in the majority of serous cancers tested by IHC.  TEX19 
likewise appears to be present in increased amounts in colon cancer, though not clearly 
associated with a particular tumour grade or stage.   
 
Both proteins appear to be present in some normal tissues not expected from their gene 
expression profiles.  We have validated the antibodies used by siRNA knockdown but a 
common feature seen with these polyclonal antibodies may be the detection of multiple 
antigens, leading to a lack of specificity and detection of a different protein in the tissue samples 
when using IHC and IF.  This is an historical and ongoing issue in the field of cancer research 
and molecular biology more widely (Bordeaux et al., 2010).  Validating and profiling the 
behaviour of antibodies on an appropriate platform that can be easily translated into the clinical 
setting is important.  PIWIL1 appears to be upregulated in some colon cancer and could 
potentially via epigenetic mechanisms influence expression of other genes in cancer.  There are 
emerging roles for PIWI-proteins and piRNAs in cancer, including colorectal cancer (Li et al., 
2010; Siddiqi and Matushansky, 2012; Tan et al., 2015); these should be investigated further 
along with a possible role for TEX19 via related, opposing or independent mechanisms. 
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5. Germline gene expression in colon and other cancers 
5.1. Introduction 
5.1.1. Classification and staging of colorectal cancer 
At least three recognised ‘routes’ to the development of CRC exist (i.e. the CIN, MSI and CIMP 
pathways) although there is some degree of overlap between these various pathways (Al-
Sohaily et al., 2012; Fearon and Vogelstein, 1990; Tamas et al., 2015).  Most cases of CRC are 
sporadic and generally occur in middle-aged people and the elderly.  The Vogelstein model for 
carcinogenesis, which remains representative of the most common CIN pathway (see Figure 
1.13), served as a paradigm for our understanding of molecular pathways in other cancer types.   
 
Traditional staging was based on the Duke’s staging system, which groups CRC in 4 groups (A 
to D).  This system remains in use today, although it has been largely superseded by the tumour-
node-metastasis (TNM) system that is used more widely across a variety of solid tumours 
internationally (Compton and Greene, 2004).  The tumour stage is numbered I to IV according 
to the TNM staging system and this correlates to the Duke’s staging A to D.  A summary of 
these staging systems is provided in Table 5.1, along with the approximate associated survival 
rates.  This does not take into account the importance of the degree of differentiation, as well 
as other molecular characteristics related to intra- and inter-tumour heterogeneity (Compton 
and Greene, 2004; Hu et al., 2011).  Undoubtedly the staging system will continue to evolve 
and undergo more accurate refinement; survival rates will also change as treatment efficacy 
improves over time.  Indeed, there have been recent studies based on the genetic signature of 
the disease, which attempt to classify the disease more accurately into clinically meaningful 
subgroups (Marisa et al., 2013, Sadanandman et al., 2014).  These alternative classification 
systems are inextricably linked to our better understanding of tumour heterogeneity. 
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Table 5.1. Staging and survival in colorectal cancer 
Stage Tumour Node Metastasis Duke’s 1 year 
survival 
5 year 
survival 
I T1 or T2 N0 M0 A ~95% ~90% 
IIA T3 N0 M0 B ~90% ~85% 
IIB T4 N0 M0 B ~80% ~65% 
IIIA T1 or T2 N1 M0 C ~90% ~80% 
IIIB T3 or T4 N1 M0 C ~80% ~65% 
IIIC Any T N2 M0 C ~80% ~55% 
IV Any T Any N M1 D ~40% ~10% 
T1 – Tumour invades submucosa; T2 – Tumour invades muscularis propria; T3 – Tumour invades through the 
muscularis propria; T4 – Tumour invades other organs or perforates the visceral peritoneum; N0 – no lymph node 
metastases; N1 – Metastasis in one to three lymph nodes; N2 – Metastasis in four or more lymph nodes; MX – 
presence of distant metastasis cannot be assessed; M0 – No distant metastasis; M1 – Distant metastasis present.  
Adapted from American Cancer Society (www.cancer.org – accessed 30th July 2015) and (Compton and Greene, 
2004). 
 
5.1.2. Alternative classification and heterogeneity of colorectal cancer 
Recent studies have characterised CRC into distinct molecular subtypes based on their gene 
expression profiles, which correlated with known signalling pathways and clinical outcomes 
(Marisa et al., 2013; Sadanandam et al., 2013; Sadanandam et al., 2014).  As the cost and speed 
of transcriptomic profiling continues to improve it would appear likely that such classification 
systems will become widely used to complement existing stratification methods such as TNM 
staging.  A major challenge in developing such stratification methods in a clinical practice will 
be dealing with intratumour heterogeneity, as well as inter- and intra-metastatic heterogeneity 
(Jamal-Hanjani et al., 2015).  The analysis of circulating factors may prove to be the optimal 
strategy to overcome this problem, as they could be representative of the entire cancer landscape 
for a given patient.  However, the detection of circulating tumour cells and cell-free (cfDNA), 
which occur at low concentrations provides an additional level of analytical challenge.  The 
extent of tumour heterogeneity certainly raises questions as to the validity of existing biopsy 
methods to accurately stratify patients to optimal treatment approaches.  Although there is 
concordance in some important genetic mutations (e.g., KRAS), there are also genetic 
differences between CRC metastases and the primary tumours from which they originate 
(Sylvester & Vakiani, 2015).  Thus, despite the fact metastatic deposits and primary tumours 
are clonally related to each other, the evolution and complexities of the cancer stem cell models 
of tumour formation and metastatic spread are increasingly apparent (Visvader & Lindeman, 
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2012).  Moreover, tumour heterogeneity is not purely determined by genetic difference between 
and within tumours; there are important additional factors to consider.  The impact of 
epigenetics, the tumour microenvironment and the inherent random variability of cellular 
biological processes all contribute to tumour heterogeneity (Caiado et al., 2015). 
5.1.3. Melanoma associated antigen genes in colorectal cancer 
The melanoma associated antigen (MAGE) family of germline genes serve as a good example 
of the variability of CT gene expression in CRC.  It can also be seen that some CRCs do co-
express several genes, which suggests these tumours may respond to specific therapeutic 
approaches.  The MAGE family of CTAs were the first to be described (van der Bruggen et al., 
1991).  They have tightly restricted expression limited to the testis in normal tissues and are 
among the most immunogenic of the known CTAs (Chomez et al., 2001; Meek and Marcar, 
2012; van der Bruggen et al., 1991).  They are encoded by a large paralogous gene family of 
over 60 genes that are located on the X chromosome (Chomez et al., 2001), and whilst their 
function in testis germ cells is poorly understood, they are known to possess oncogenic activity 
(Bhan et al., 2012; Ladelfa et al., 2012).  Several of the MAGE gene family members are 
expressed in CRC with expression frequencies generally ranging between 5-20% (reviewed in, 
Sammut et al., 2013).  Others genes, such as MAGEB1 and MAGEB2 may not be expressed at 
all in CRC but this has not been extensively corroborated (Lurquin et al., 1997).  Burgdorf et 
al. tested the expression of various MAGE genes in liver biopsy specimens from nineteen 
patients with metastatic CRC (Burgdorf et al., 2008).  In contrast to a previous study showing 
no MAGEA12 expression in primary tumours (Dakshinamurthy et al., 2008), Burgdorf and 
colleagues found this gene to be expressed in many of the specimens tested.  Although the exact 
frequency of MAGEA12 expression was not stated, 47% of the specimens were shown to 
express all six of the MAGE genes tested for.  Overall 79% of liver biopsy specimens were 
found to express at least one of the MAGE gene family members (Burgdorf et al., 2008).  In a 
separate study a subset of CRC samples were found to express MAGEA3 with relatively high 
frequency compared to other known CT genes (Shantha Kumara et al., 2012).  This could imply 
that more aggressive or advanced forms of CRC (i.e. that have metastasised) express MAGE 
genes more widely and that they may even be contributing to the metastatic process.  Taken 
together these findings illustrate the great variability seen between studies that have assessed 
CT gene expression in tumours.  Differences in the site and technique for tissue sampling, post 
sampling tissue handling and subsequent analytical techniques all potentially impact on the 
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expression frequency detected.  The further complicating factor in gene expression profiling is 
the extent of (intra-)tumour heterogeneity (Swanton et al., 2010); CT gene expression profiles 
and differences between studies should also be viewed in this light.   
The extent of MAGE gene co-expression and collective expression of at least one family 
member within a cohort of primary tumours has not been extensively investigated for 
comparison to the Burgdorf study (2008) that assessed CRC liver metastases, therefore limiting 
the conclusions that can be drawn from these findings.  The largest set of samples tested found 
90 out of 250 CRC specimens to express at least one of six MAGE-A genes (Chen et al., 2010).  
Li et al. also tested for the expression of ten well characterised CTA genes, including four 
members of the MAGE family, in a cohort of 121 CRC patients (Li et al., 2005).  Over half 
(56.2%) of patients expressed at least one CT gene and around one quarter co-expressed two or 
more of the CT genes; the four assessed MAGE genes were relatively widely expressed in this 
cohort. These figures are not dramatically different to the study investigating liver metastatic 
specimens, which importantly looked at a different set of MAGE genes making a direct 
comparison of limited value (Burgdorf et al., 2008).  An even higher co-expression frequency 
(approaching 90%) of one or more of ten MAGE genes was seen in a study of eighty CRC 
specimens (Hasegawa et al., 1998).  It is interesting to note that MAGEA8 was found to have 
the highest expression frequency (44%) in this study and this gene has not been as widely 
investigated as some of the other MAGE genes.  
The highly stringent tissue specificity of germline-specific and meiCT genes implies that their 
gene products could potentially serve as tumour-specific immunotherpeutic targets.  Equally as 
important could be their ability to enhance the accuracy of transcriptomic profile to predict 
disease outcome.  Given the heterogeneity of cancer, both intra- and inter-tumour, the 
development of a large bank of biomarkers will be of increasing importance in personalised 
treatment strategies (Jamal-Hanjani et al., 2015; Mendelsohn, 2013; Seoane and De Mattos-
Arruda, 2014).  In this chapter some preliminary work on expression profiling of genes 
associated with the germline, principally focussing on colon cancer samples, in presented.  Our 
approach started from the initial tissue collection of colon cancer samples and adjacent normal 
tissue.  The data provide some resolution of which genes may be useful biomarkers; we included 
both meiCT genes that had been identified as possible biomarkers previously by our group, as 
well as other germline genes identified and reported in the literature.  There is a huge variability 
in the expression of CT genes in CRC and it is generally considered a disease of low germline 
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gene expression levels (Almeida et al., 2009; Caballero and Chen, 2009; Cheng et al., 2011; 
Costa et al., 2007; Fratta et al., 2011; Hofmann et al., 2008; Simpson et al., 2005; Viphakone 
et al., 2015).  The variability, as illustrated above with regards to the MAGE gene family, is 
poorly understood and a principal hypothesis in which we were interested was that there may 
be a subgroup of CRCs with higher levels of germline gene expression contrary to this generally 
held view.   
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5.2. Part I - Results 
5.2.1. Establishment of biobank and examples of tissues collected 
In order to obtain good quality RNA for gene expression screening, an application was made 
for research and development and ethical approval.  Ethical approval was sought from the North 
West Wales Research Ethics Committee following this application (Ethical approval reference 
number 12/WA/0042).  In brief the study outline involved: 
 Attending multidisciplinary team meetings to identify potential patients for the study.  I 
liaised with nurse specialists and other members of the clinical team to distribute 
information leaflets to the patients in advance of their operation, giving them time to 
consider if they wished to take part. 
 Patients were then approached and consented individually, usually when they were 
admitted to hospital for the operation.  Written informed consent was obtained. 
 Prior to surgery (usually in the anaesthetic room) a blood sample was obtained.  This 
was spun the same day at 3600 r.p.m. for 3 minutes and the serum extracted.  This was 
stored at -20˚C before transferring for long term storage at -80˚C. 
 Following surgical resection, the specimen was inspected and a sample of the tumour 
and adjacent normal tissue at least 5 cm distant from the tumour was sampled with a 
sterile scalpel.  This was split into three small pieces: one placed directly in formalin; a 
second placed in RNAlater®; and a third was flash frozen in isopentane that had been 
cooled in liquid nitrogen.  Some sections were frozen in OCT embedding media as well 
for approximately 20 seconds that could subsequently be used for frozen sectioning and 
immunofluorescence if required. 
 The tissue in RNAlater® solution was left in the fridge for 24 hours before transferring 
to -20˚C or -80˚C for long-term storage. 
 
Below is a selection of haemotoxylin and eosin (H+E) stains for the colon cancer and normal 
adjacent tumour (NAT) samples collected in this study.  The H+E stains shown are for some of 
the samples tested for gene expression of various germline genes and there are also comparative 
IHC data presented in Chapter 4.  A full list of the pathological classification and related clinical 
variables is provided in Table 5.2.  The mean age of the patients for the cohort of samples 
collected for this research was 71.2 years old and the male to female ratio was 1.67:1.  This is 
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comparable to the known statistics of CRC in this region, with an overall male to female ratio 
of 1.43:1 (White et al., 2015). The figures depict the heterogeneity, even at the macroscopic 
level between tumour samples (see Figures 5.1 to 5.7).  Although the sampling method provided 
assurance and knowledge of the tissue processing and RNA quality for example, it did not 
always guarantee that invasive cancer had been sampled.  However, overall the tissue collection 
provided a reasonable selection of cases for which to perform the screening of potentially 
relevant germline genes.   
The importance of EMT in cancer is well established; epithelial-derived cancer cells that 
acquire mesenchymal phenotype have a greater propensity to invade and metastasize.  For 
instance, the gene expression methods of CRC classification both identified a subtype with 
worse prognosis that was associated with stem-cell or mesenchymal-like properties (Marisa et 
al., 2013; Sadanandam et al., 2013).  Greater resolution of how the tumour stroma is crucially 
important in contributing to oncogenesis has recently been provided in a study that isolated 
different subpopulations of cells in CRC (Calon et al., 2015).  They provided evidence that 
genes were expressed in the tumour stroma that were responsible for the unfavourable gene 
expression-classified subtype and could be the main drivers of oncogenic processes.   
It can be appreciated in some of the following H+E-stained examples how a reasonable 
proportion of some solid tumours samples/biopsies are made up of stromal cells.  This has 
implications in the development of novel therapeutic approaches targeting these gene products 
and also in creating valid predictive gene expression signatures to guide therapy.  An alternative 
approach would be to view the tumour stroma and epithelial cancer cells as a single entity and 
use both for either of these translational research aims.  As long as the genes are differentially 
expressed (i.e. either in normal stroma vs. tumour stroma and/or normal epithelial vs. carcinoma 
cells), and important in oncogenesis, then the diagnostic or therapeutic endpoint is unchanged.   
It can also be seen that many of the NAT colonic cancer samples contained a high proportion 
of non-epithelial/mucosal cells.  So, in this study, it cannot be confirmed to what extent the 
genes are expressed in the supporting tissues.  It would be interesting to investigate whether 
there is differential expression of germline genes in the stroma surrounding the tumour that may 
be contributing to tumorigenesis.  The sampling method and RNA extraction technique adopted 
in this study did not permit this degree of resolution. 
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Figure 5.1. Haemotoxylin and eosin stain of colorectal sample 9.  
(A) Normal colonic tissue section displaying normal crypts mainly in cross section, submucosa and a small region 
of muscularis propria. (B) Higher magnification of the normal colonic mucosa, with the muscularis mucosa 
immediately beneath this and then the submucosa.  A small region of muscularis propria is also visible as well as 
part of a Peyer’s patch.  (C) Shows the tissue section obtained from the cancer from the same patient – no normal 
mucosa is visible.  The section is a high grade tubular adenoma, and a higher power magnification is shown in 
(D).  Although the tissue section is not deep enough to display invasion, there is a prominent desmoplastic reaction 
seen on the left side of the tissue section, which is pathognomonic of an underlying cancer.  A higher power 
magnification of this desmoplastic reaction is shown in (E).  Thus, it can be concluded that the high grade adenoma 
is part of an adenocarcinoma. 
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Figure 5.2. Haemotoxylin and eosin stain of colorectal sample 28.   
(A) Normal tissue section with mucosa and submucosa visible; no muscularis propria is contained in this section.  
The crypts of the mucosa are seen predominantly in cross section – a higher power magnification is shown in (B).  
The tissue sample from the tumour from the same patient is shown in (C).  There is no normal mucosa contained 
within this section but no features that are diagnostic of invasive cancer.  A higher power magnification of the 
tubular adenoma is shown in (D). 
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Figure 5.3. Haemotoxylin and eosin stain of colorectal sample 33.   
Normal colonic mucosa with submucosa but no muscularis propria is seen in (A).  A higher power magnification 
of some of the colonic crypts is shown in (B); the muscularis mucosa is seen immediately beneath the crypts and 
the submucosa beneath this – an area of submucosa is also seen in the top right of this image, due the tissue being 
folded on itself.  Tissue from the tumour of the same patient is shown in (C).  This section contains entirely invasive 
adenocarcinoma with no normal colonic mucosa.  The cancer can be seen invading the muscularis propria; a high 
power magnification of the invasive carcinoma is shown in (D).  
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Figure 5.4. Haemotoxylin and eosin stain of colorectal sample 35.   
(A) Normal tissue section displaying normal colonic crypts in cross section and an area of muscularis propria in 
the bottom left of the image.  A higher power magnification of the normal mucosa is shown in (B), which also 
contains muscularis mucosa and a small lymphoid aggregate.  (C) Displays tissue obtained from the tumour of the 
same patient.  No normal colonic mucosa is seen but there is also no evidence of invasive cancer in this specimen.  
Higher power magnification of the fragmented low grade villous adenoma displayed in (B) is shown in (D).  The 
adenoma was part of a caecal tumour that was a moderately differentiated adenocarcinoma (see Table 5.2). 
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Figure 5.5. Haemotoxylin and eosin stain of colorectal sample 38.  
(A) Normal colonic tissue section showing a large rim of normal colonic mucosa and a central section of 
muscularis propria.  A higher power magnification of the normal colonic crypts seen in cross section adjacent to 
the muscularis propria (B): note, this is not the normal anatomical arrangement but rather a result of the tissue 
processes technique.  (C) Displays a matched cancer tissue sample from the same patient.  No normal colonic 
mucosa is seen but regions of low grade tubular adenoma are seen interspersed by lymphocytes and muscle in the 
upper portion of the tissue section; a higher power magnification of the adenoma is shown in (D) which 
corresponds to the white dotted square within (C).  The region outlined by a dark blue dotted line is shown in 
higher magnification in (F) and contains invasive cancer; a higher power magnification of this invasive cancer is 
shown in (E). 
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Figure 5.6.  Haemotoxylin and eosin stain of colorectal sample 40.   
(A) Entirely histologically normal colon sample displaying colonic mucosa, some submucosa and a small amount 
of muscularis propria in the left central region of this section. (B) High power magnification of the normal colonic 
mucosa from the tissue section in (A); the normal colonic crypts seen here are shown in cross-section.  (C) Matched 
sample of the colorectal cancer from the same patient: an area of normal colonic mucosa is seen in the lower 
portion of this tissue section and a higher power magnification is shown in (D).  Two distinct areas of carcinoma 
are shown in the upper central and left portion of the section: mucinous type on the left with a region containing 
muscularis propria below this; and intestinal type carcinoma in the central portion, both shown in higher 
magnification in (E) and (F), respectively.  An area of low-grade tubular adenoma is seen in the upper right portion 
of the cancer sample, shown in higher magnification in (G).   
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Figure 5.7.  Haemotoxylin and eosin stain of colorectal sample 45.   
(A) Normal colon tissue section, displaying a rim of normal colonic mucosa shown in higher magnification in (B) 
and a larger area of submucosa and muscularis propria beneath this.  A Peyer’s patch is seen in the upper left of 
the tissue section in (A).  A matched section of carcinoma from the same patient is shown in (C).  Only a very 
small area of histologically normal colonic mucosa is seen, displayed in higher magnification in (D).  The vast 
majority of the tissue section in (C) is taken up by an adenocarcinoma of high grade (poorly differentiated), a 
representative section of which is shown in higher magnification in (E).  This cancer is of particularly high grade, 
displaying few characteristics to guide the tissue of origin (i.e. if the small section of normal colon was removed 
from the section).  
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Table 5.2. Pathological and demographic characteristics of sampled colonic tumours 
Age Gender Case Site Differentiation Duke’s 
Stage 
T N Positive/ 
identified 
M EVA 
71 M C1 Ascending Moderate B 3 0 (0/10) X No 
63 M C2 Ascending Moderate C 3 1 (1/16) X Yes 
67 M C3 Caecum Moderate C 3 1 (2/10) X Yes 
76 M C4 Caecum Moderate C 3 1 (1/12) X No 
85 F C5 Caecum Moderate B 3 0 (0/16) X No 
65 M C6 Ascending TVA* N/A N/A 0 (0/8) N/A N/A 
74 M C7 Ascending Moderate B 3 0 (0/7) X Yes 
85 F C8 Caecum Moderate C 3 2 (7/21) X No 
61 F C9 Descending Moderate B 3 0 (0/4) X No 
75 F C10 Sigmoid No tumour N/A N/A 
  
X N/A 
54 F C11 Descending Moderate B 3 0 (0/17) X No 
69 F C12 Transverse Moderate B 2 0 (0/10) X No 
78 M C13 Caecum X X X X X 1 X 
76 M C15 Transverse Moderate B 3 0 (0/10) X Yes 
64 F C16 Ascending Moderate A 1 0 (0/16) X X 
60 M C17 Transverse Moderate B 3 0 (0/13) X No 
X M C18 Caecum Moderate C 3 1 (2/20) X No 
71 M C19 Sigmoid   Moderate C 3 2 (7/18) X Yes 
53 M C20 Recto-sigmoid Moderate C 2 4 (4/12) X No 
79 F C21 Ascending Poor B 3 0 (0/6) X No 
72 M C22 Ascending Moderate B 3 0 (0/7) X No 
78 F C23 Recto-sigmoid Moderate B 2 0 (0/50) X No 
73 M C24 Caecum Moderate C 3 1 (3/14) X No 
79 M C25 Caecum Moderate B 3 0 (0/14) X No 
76 F C26 Ascending Moderate B 3 0 (0/6) X No 
60 F C27 Sigmoid  Moderate B 3 0 (0/8) X Yes 
74 M C28 Descending Moderate A 2 0 (0/11) X No 
74 M C29 Caecum VA** N/A N/A 0 (0/2) N/A N/A 
85 M C30 Sigmoid Poor C 3 1 (1/34) X No 
81 M C31 Ascending Moderate A 2 0 (0/12) X No 
84 M C32 Ascending Moderate B 3 0 (0/7) X No 
79 M C33 Ascending Moderate B 3 0 (0/13) X No 
78 M C34 Caecum Moderate B 3 0 (0/3) C No 
77 F C35 Caecum Moderate B 3 0 (0/18) X No 
84 F C36 Descending Moderate C 3 1 (3/8) 1 Yes 
65 M C38 Sigmoid  Moderate B 3 0 (0/8) X No 
81 F C39 Appendix Moderate B 4 0 (0/9) X X 
67 M C40 Transverse Moderate B 3 0 (0/4) X No 
70 F C44 Caecum Moderate B 2 0 (0/14) X No 
90 M C45 Ascending Poor B 3 0 (0/18) X No 
*TVA – Tubulovillous Adenoma (high degree of atypia); **VA – Villous Adenoma (severe dysplasia); T – 
Tumour; N – Node; M – Metastasis; EVA – Extramural Vascular Invasion; X – denotes unknown. 
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5.2.2. Expression of germline genes in colon cancer investigated by RT-PCR 
RNA was extracted from the colonic tissue that had been preserved in RNAlater® solution.  This 
was quantified and an equal amount was reverse transcribed into cDNA.  The expression of 
germline genes, mainly members of the meiCT gene group that we had previously identified 
were tested using a 40-cycle RT-PCR.  As shown in Figure 5.8 the germline genes tested were 
not measurably expressed in either the normal or cancerous colonic tissue.  Other than several 
of the meiCT genes appearing to be expressed in the SW480 colorectal cancer cell line, there 
was no strong indication that the genes were transcribed in this cancer type. 
Qaixcel gels were used in part as they provided a slightly higher throughput screening for gene 
expression as compared to RT-PCR screening using agarose gels.  They also provide a higher 
degree of resolution for smaller product sizes.  There appeared to be very limited expression of 
germline genes in the colon cancer samples that I had obtained; a finding which is perhaps not 
unexpected given what is known about CT gene expression and CRC in the literature (Sammut 
et al., 2013).  CRC is considered to have generally low expression of CT genes as opposed to 
other cancer types such as melanoma or lung cancer (Dakshinamurthy et al., 2008; Sammut et 
al., 2013).  The melanoma sample tested (see Figure 5.9) did not express either of the germline 
genes investigated but this was only one melanoma sample and two germline genes not known 
to be strongly associated with melanoma.   
 
The screening of samples using RT-PCR was time consuming and it was becoming clear that a 
new approach was needed to increase the throughput of the screening process in the hope of 
identifying potentially relevant germline genes associated with this cancer type – see Part II of 
this chapter.  PIWIL1 did emerge as one possible marker in colon cancer as it appeared to be 
expressed in 6 out of the twelve cancer samples tested but only 2 of the adjacent normal tissues 
(see Figure 5.9). 
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Figure 5.8.  RT-PCR of meiCT genes in colon tissues.   
RT-PCR was performed for different germline genes using cDNA generated from RNA extracted from colon 
tumour and normal adjacent tumour tissue samples from the patients listed in Table 5.2.  Qaixcel gels shown here 
were used as a slightly higher throughput method of screening a larger number of samples at the same time.  cDNA 
was generated from RNA extracted from colonic tissue obtained immediately post-operatively.  Various meiCT 
genes were tested and were not shown to be expressed using a 40-cycle PCR amplification.  Two separate primer 
sets were used for SPO11.  The rows alternate between normal adjacent cancer colonic samples and colon cancer 
samples. Testis, in the first column, was used as a positive control sample. 
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Figure 5.9. RT-PCR of germline genes in colon cancer samples and melanoma.   
Qaixcel gels were used to explore the expression, using a 40-cycle PCR amplification.  Here two germline genes 
identified as predictive markers in lung cancer (Rousseaux et al., 2013a) were tested using the primers sets used 
in the paper (see Table 1 in Section 2 of Appendix).  Testis, was used as a positive control samples in column 1.  
cDNA was synthesised from RNA obtained commercially from a melanoma sample and from a selection of the 
colonic samples I had obtained.  VCY was found to be expressed in testis only.  PIWIL1 was found in testis but not 
the melanoma sample.  However, some of the colonic samples did express this gene.  Most of these samples were 
from the cancer samples (e.g., C23, C26, C29, C31, C35 and C45) but two of the normal adjacent cancer samples 
also appeared to express this gene (B21 and B22).  Interestingly, in the corresponding cancer sample a PCR product 
could not be detected.  This may be due to lower cDNA content in this sample as the ACTB control band was 
weaker in C21 compared to B21 and other samples.  The lower green marker line is at 15 bp and the upper green 
line corresponds to 1000 bp. 
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5.2.3. Developing a definitive list of germline-associated genes  
Knochbin and colleagues (Rousseaux et al., 2013b) provided the first description of how 
germline genes can be used for identifying patients who had a worse outcome and may benefit 
from particular forms of therapy.  In this paper they identified genes which had expression 
limited to the testis or placenta.  The crucial finding of this work was that the gene expression 
signature profile alone was enough to identify patients with a higher likelihood of suffering an 
early demise from lung cancer.  The gene expression profile of a limited panel of germline 
genes (26 in total) could predict an unfavourable outcome independently of accepted 
stratification methods, such as TNM staging, grade, or cancer type.  This has considerable 
implications for patient management. 
 
We had adopted a different approach to identify genes associated with spermatogenesis, which 
may have been meiosis-specific or at least be expected to be germline in origin (Feichtinger et 
al., 2012b; Sammut et al., 2014).  Although there was considerable overlap in the approaches 
used, there were several of our genes that were not present on the Knochbin group panel of 
germline genes and vice versa (see Appendix B, on CD for complete lists).   
 
These differences, together with the increasing evidence supporting a major role of germline 
factors in cancer both as predictive markers and oncogenic drives, provided a rational to 
develop a definitive list of germline genes.  There is no agreed or definitive list of germline 
genes in the literature.  Some of the genes will be expressed and have roles in somatic cells as 
well as those of the germline, whereas others will have expression (and function) limited 
entirely to the germ cells.  When expression is limited in somatic cells, this forms the basis for 
the identification of CT genes, which can also be considered cancer/germline genes.   
 
With this aim in mind, five sources from the literature were compiled to produce what we 
believe at present to be the closest to a definitive list of germline-associated genes.  These five 
sources were: 
   
 We used the original list of gene candidates that had been identified as orthologues of 
mouse spermatocyte specific genes (Feichtinger et al., 2012b).  This list comprised 400 
genes, many of which had been tested for expression in a range of normal tissues as well 
as cancer tissue/cell lines and from which the meiCT genes, of which 85 have now been 
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described, were identified (Feichtinger et al., 2012b; Sammut et al., 2014).  Rather than 
limit ourselves to the 85 meiCT genes, for the purpose of compiling the ‘definitive’ list 
I included all the orthologues that had originally been identified, although we knew that 
a significant proportion of these genes were expressed widely in somatic tissues and 
perhaps only had upregulation in the germline. 
 
 The second list of genes was the testis and/or placental genes that were described by the 
Knochbin group (Rousseaux et al., 2013b).  This comprised 506 genes, of which 439 
were testis-specific and 67 were associated with the placenta.  
 
 At the time of compiling the list 285 CT genes had been accepted and compiled on 
‘CTDatabase’ (Almeida et al., 2009).  I did not attempt, by manually searching the 
literature, to include other genes that had been proposed as CT genes but not 
corroborated by others.  
 
 Janic and colleagues reported 49 germline genes to be over-expressed in Drosophila 
melanogaster l(3)mbt tumors and may in fact be oncogenic drivers for these tumors 
(Janic et al., 2010).  28 human orthologues of these genes were identified; the list of 
genes totalled 48 when all paralogs were included (Feichtinger et al., 2014a).  This paper 
provided support to the notion that a soma-to-germline transition exists during the 
development of many human cancers. 
 
 Finally, Hoffman and colleagues described 53 genes as CT genes based on their 
expression profile which they validated as restricted to the testis and brain in normal 
tissues; the majority of these genes were X-encoded (Hofmann et al., 2008). 
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When presenting the data on gene expression below (see Section 5.3.1) I have categorised the 
final list of germline genes tested according to the sources just described.  These are the 
groupings used – it should be noted that several of the genes selected for gene expression 
analysis appeared in more than one of these groups:   
 
 Group A – genes previously categorised as meiCT genes (Feichtinger et al., 2012b; 
Sammut et al., 2014) 
 
 Group B – CT genes identified as testis/brain restricted (Hofmann et al., 2008) 
 
 Group C – all human orthologues of the mouse spermatocyte/meiosis-associated genes 
(Chalmel et al., 2007; Feichtinger et al., 2012b) 
 
 Group D – all human orthologues of the Drosophila melanogaster germline genes, 
which drove oncogenesis in a brain tumour model (Feichtinger et al., 2014a; Janic et 
al., 2010) 
 
 Group E – known CT genes according to CTdatabase (Almeida et al., 2009) 
 
 Group F – all the germline-specific genes, identified as testis-specific or placenta-
specific by the Knochbin (Rousseaux et al., 2013b) 
 
 Group G – the cohort of 26 genes taken from group F that were predictive of a poor 
prognosis in lung cancer patients (Rousseaux et al., 2013b). 
 
We attempted to conduct a systematic review but this did not identify additional relevant papers.  
Moreover, not all the above papers included for the list generation were identified through this 
approach.  We acknowledge that our approach here is open to selection bias but it remains as 
close to a definitive list of potential germline-specific genes as we are aware of in the literature.  
Further details are provided in Appendix B in the folder entitled “Germline gene lists with 
source”, on the CD. 
  
Chapter 5: Results 
 
158 
 
5.2.3.1. Validation of germline gene expression of a panel of genes identified as predictive 
markers in lung cancer 
 
These five sources of germline genes produced a list of 1292 genes; this number was reduced 
to 1060 once duplications had been removed.  The degree of overlap between the different 
sources varied somewhat – full details are provided in Appendix B (supplied on CD).  Just over 
half of the meiCT genes which we had identified appeared in the germline gene list compiled 
by Knochbin’s group and all were from the testis-specific, not placental gene list (Rousseaux 
et al., 2013b).  There was a much higher degree of overlap proportionally between the meiCT 
list and the Knochbin group gene list (see Appendix B, on CD) than with the original list from 
which the meiCT genes were derived.  There was, however, no overlap between the final 26 
genes which they identified as independent predictors of a worse outcome in lung cancer 
patients and the meiCT genes.  In fact only 4 of the 26 genes appeared on the original list of 
genes which our group had identified as orthologues of mouse spermatocyte-specific genes.  
Partly for this reason, I validated the expression profile of the 26 Rousseaux genes using RT-
PCR in the normal panel of tissue that we had used to validate the expression profiles for the 
meiCT genes (i.e. as in Chapter 3).  In their paper they described the genes as having tightly 
restricted expression profiles to the germline (Rousseaux et al., 2013b).  As shown in Figure 
5.10 and Figure 5.11, not all the genes appeared to have such tightly restricted tissue expression 
in our panel of normal tissues. 
 
We would have excluded over one quarter (7 of the 26) of the Knochbin group panel of genes 
from further analysis.  This shows how varying degrees of stringency can impact on the findings 
as we may have been excluding clinically relevant genes due to our more stringent approach.  
It also perhaps raises questions about the normality of our ‘normal’ panel.  The tissues were 
obtained post-mortem and it is possible that the individuals had an undiagnosed cancer prior to 
their death, though given how extensively the 7 Knochbin group genes were represented in the 
normal panel, this possibility is unlikely to affect the overall conclusion.  It would be interesting 
to see if the 7 genes were excluded from the Rousseaux list, whether the remaining 19 genes 
would still hold predictive power of a worse outcome in lung cancer.  
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Figure 5.10. RT-PCR of genes identified as predictive markers in lung cancer in a panel of 
normal tissues.   
A 40-cycle amplification in a panel of normal tissues was conducted using the PCR primers used in the study by 
Knochbin and colleagues (Rousseaux et al., 2013b).  The higher resolution of the Qaixcel gels used for this allowed 
identification of the PCR bands in the majority of cases; testis was used as a positive control (far left column).  
Several genes, for examples MAGEB6 and RMB46 shown here were restricted to the testis only.   RFX4 was 
restricted to the testis and central nervous system and would have passed through the validation/screening process 
that we employed for the meiCT genes but classified as testis/CNS-restricted and not testis-restricted.  The 
testis/CNS-restricted expression was also confirmed using a separate assay/primer set on the TLDA analysis – see 
Figure 5.22.  Other genes, for example C10orf82, would have been excluded as it appeared to be widely expressed 
in the normal tissue panel and again this was confirmed on the TLDA analysis. 
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Figure 5.11. Grid representation of the gene expression profiles for germline genes that had been 
shown to be associated with a worse outcome in lung cancer patients.   
The primers used for PCR amplification were taken from the paper identifying this cohort of genes (Rousseaux et 
al., 2013b).  RNA was obtained from commercial sources for a range of normal tissue types and reverse 
transcribed; the cDNA was subject to 40-cycle PCR amplification.  Two of the genes did not produce a visible 
product on the Qiaxcel gel (category G).  7 genes appeared to be widely expressed across the tissue panel (category 
F).  A further 7 were testis-selective or testis/CNS-restricted (see categories C-E) and the remaining genes appeared 
to have expression restricted to the testis (category B).  The category A genes above are known CT genes that had 
previously been screened in the same samples and included here for comparison purposes. Results can be compared 
directly to Figure 5.22, which acts as a further validation of these findings through similar experimentation using 
a different approach and assays. 
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Despite my finding that some of the predictive germline genes identified by the Knochbin group 
(Rousseaux et al., 2013b) appear to be expressed in somatic tissues, we did not exclude them 
from consideration and kept them all within the list of germline-associated genes at this stage.  
Using the CancerMA pipeline we investigated how many genes displayed a meta-upregulation 
in any cancer type included in the pipeline.  Around 20% of the germline genes were not present 
on the arrays included for this analysis.  The definitive list of germline genes included genes 
with Hs.xxx and LOCxxx identifiers (these are generally transcribed regions of the genome but 
without known gene function or assigned name).  The data from which CancerMA was based 
did not consider genes with these number identifications so it is not surprising that a significant 
proportion were not present on the arrays.  CancerMA can only deal with ~300 genes of interest 
at a time, so challenging of array data with the complete list produced 4 separate circos plots 
(for example, see Figure 5.12).  See also Figures 1-3 in Section 3 of the Appendix for the 
additional circos plots analysed in the same fashion.  Brain and ovarian cancers were the most 
common cancer types displaying statistically significant meta-upregulations.  When 
considering only the ‘meiCT’ genes identified by the McFarlane group (Feichtinger et al., 
2012b; Sammut et al., 2014), ovarian cancer was by far the most common cancer type 
displaying meta-upregulation of these genes (see Figure 4 in Section 3 of Appendix).   
 
Over 250 CT genes, from over 100 separate gene families, have been identified although not 
all of these meet the strict CT gene expression criteria (Almeida et al., 2009; Hofmann et al., 
2008).   This is consistent to some degree with the findings presented here (i.e. from TLDA 
results).  We chose not to include genes which Hofmann (2008) reported as not testis or 
testis/CNS restricted, though many of the testis-selective group were included from the list 
taken from ‘CTDatabase’ (Almeida et al., 2009). 
 
Around half the germline genes displayed at least one statistically significant upregulation in 
gene expression when the microarray datasets were meta-analysed (for examples, see Figure 
5.12).  After feeding all the germline genes through CancerMA, I then challenged the genes 
displaying meta-upregulations in any cancer type against CancerEST.  I filtered for EST 
signatures restricted to immunologically privileged tissues (i.e. testis, placenta, brain and other 
CNS tissues) and then additionally cancer.  This resulted in a list of 78 genes – see Figure 5.13 
and Appendix B (on CD).  Further explanation of the degree of overlap and how the list of 
candidate genes was generated is provided in the folder “germline gene lists with source” in 
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Appendix B, on the CD.  No claim is made with regards to the clinical or biological significance 
of the gene lists generated (e.g., in Figures 5.12 and 5.13) – indeed as highlighted in Chapter 3 
and Figure 20 in Appendix, some of the upregulations may be stochastic in nature.  One must 
be careful not to over-interpret the findings but the selected genes provided a rational approach 
on which to focus down on a more practical and manageable list on which to base initial gene 
expression analyses.  Ideally, all genes would be taken forward but this was not deemed 
practical for the purpose of this research, limited in part by the costs of screening over 1000 
gene targets.  A further limitation of this research and the results of the TLDA analyses is that 
the results were not duplicated (i.e. n=1 for the majority of the following experiments).  We 
accept this is a major limitation but the purpose of this research was a ‘first look’ exploratory 
study.  We included control genes based on previous experiments and no internal validation 
was performed for our sample population.  This is also a weakness to some degree but the 
quantitative nature of the TLDA experiments was an added bonus rather than purpose of the 
research.  We were interested primarily in “on/off” answers (i.e. was a given gene switched on 
in a certain cancer but not expressed in normal tissue).  Such “on/off” gene signatures may 
ultimately prove to be useful therapeutic targets or in disease stratification due to lack of 
presence in normal tissues.  We included testis as a positive control for the experiments, as all 
genes should have been switched on in normal testis.  As shown in the Appendix B (on CD – 
file entitled “TLDA repeat for Testis Sample”), the single repeat performed on a separate day 
for the positive control sample, displayed very consistent results.  This is reassuring and 
suggests there is not a high rate of false positive or false negative results.  However, it is 
important that additional repeat experiments are conducted before further exploratory work is 
conducted. 
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Figure 5.12. Germline genes displaying meta-change upregulation in cancer.   
The definitive list of germline genes (comprising over 1000 genes) were assessed using CancerMA (Feichtinger 
et al., 2012a).  The website is limited to ~300 targets on a single run, so the results for a selection of the germline 
genes are shown here; genes beginning with the letter S through to Z are included.  The picture was broadly similar 
for the other germline genes when challenged against the same pipeline (see Figures 1-3 in Section 3 of the 
Appendix).  Brain cancer and ovarian cancer feature most commonly as cancer types displaying a statistically 
significant upregulation in gene expression when the microarray datasets were meta-analysed.  Lung cancer was 
the third most common cancer type displaying meta-upregulations and colorectal cancer the fourth most common. 
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Figure 5.13.  Circos plot showing genes with EST signatures restricted to immunological 
privileged tissues and cancer.   
The germline genes that were meta-upregulated in CancerMA were then challenged against CancerEST and the 
genes with signatures limited to immunologically privileged tissues as well as cancer are displayed here. The 
thickness of the lines is representative of the magnitude of the expression found for a given gene in a given tissue.   
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5.3. Part II – Results and Discussion 
5.3.1. TLDA analysis of germline gene expression in human tissues 
Using a combination of approaches I identified 192 targets that could be analysed using Taqman 
Low Density Array (TLDA) technology.  The full list of targets and the TLDA assays used for 
each target is provided in Appendix B (on CD).  If a gene appeared on more than one germline 
gene list (see Section 5.2.3 and Appendix B on CD) then this increased the likelihood of 
selection.  I also attempted to include the majority of the meiCT genes as well as the 26 targets 
that Knochbin and colleagues had identified as predictive markers in lung cancer (Feichtinger 
et al., 2012b; Rousseaux et al., 2013b; Sammut et al., 2014). 
 
Based on the Ct values for each sample I assigned the gene expression as followed: 
 Group 1 – highest expression (Ct value <23)  
 Group 2 – moderate-strong expression (Ct value 23-26) 
 Group 3 – moderate expression (Ct value 26-29) 
 Group 4 – weak-moderate expression (Ct value 29-32)  
 Group 5 – not expressed (Ct value >32) 
 
The Ct value cut-off of 32 was based on advice given by Life Technologies on when gene 
expression can be considered positive.  Due to the TLDA microfluidics, a Ct value of 32 is 
equivalent to a Ct value of 35 seen during most standard qPCR experiments.  Such borderline 
results should be subject to more rigorous testing to establish if the genes are truly expressed.  
To provide as clear a representation as possible of whether the gene was expressed we chose 
the more stringent cut-off of 32 recommended by the company, especially as the samples were 
not run in triplicate as would normally be the case for qPCR experiments.  The colours in 
Figures 5.15 to 5.20 depict these different levels of expression, as shown in the key above – the 
darker the shade of blue, the stronger the level of gene expression.  An example of the readouts 
from the TLDA cards from which these Ct values are based is provided in Figure 5.14.  The list 
of Ct values is provided in Appendix B (on CD).  Figure 5.15 is a heatmap of all the gene 
expression data obtained in a range of normal and cancer tissues.  RNA extracted from 
melanoma, lung and ovarian cancers were obtained from Origene – information supplied by the 
company for these samples is provided in Appendix C (on CD).   
 
5 
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      +++++
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Figure 5.14.  Gene expression of six target genes in colon cancer and adjacent normal tissue.   
This is an example of the TLDA analysis for colon sample 26. The red arrows indicate the cutoff Ct value 
indicating definite gene expression.  The upper two plots are two endogenous control genes: (A) 18s; (B) RPS13, 
which are both highly expressed.  The Ct values for both control genes are very similar indicating equal amounts 
of cDNA were loaded onto the card.  The amplification plot for C20orf195 is shown in (C); in this case the curve 
shifted to the left for the cancer sample compared to the normal sample.  However, both Ct values fell within the 
same range: categoriesed as weak expression (Ct between 29 and 32).  (D) is the amplification plot for CEP55, 
which again indicates higher expression in the cancer sample but this gene is expressed more strongly than for 
C20orf195: both samples in this case are categorised as moderate expression (i.e. Ct between 26 and 29).  (E) is 
the amplification plot for C20orf201 – here the Ct value for the cancer sample falls just below the cutoff but for 
the normal sample the Ct value is above the cutoff, which meant in this case it was categorised as not expressed.  
(F) is the amplification plot for IQCF1 – here the gene has weak expression in the cancer sample but is not 
expressed in the normal adjacent tissue and the curve fails to cross the threshold even up to 40 cycles. 
  
B A 
C D 
F E 
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Figure 5.15.  Heatmap of the expression of germline-associated genes in human tissues.   
The thicker grey lines divide the normal from cancerous tissues and/or the categories the genes were grouped into. 
The genes generally and as expected had moderate-high levels of expression (darker blue) in the testis (far left 
column).  The heatmap is ordered according to expression levels in normal tissues.  Around half had expression 
restricted to the testis in normal tissues: group I.  Group II genes had testis/CNS restricted expression; group III 
genes had testis-selective expression pattern; group IV genes had testis/CNS-selective expression; whereas group 
V were expressed in three or more normal tissues excluding the testis and CNS tissues.  These groups are ordered 
according to the strength of gene expression seen and/or alphabetically. A “-“ within a cell means that gene 
expression for that sample was not tested for the corresponding gene.  The arrows mark results for two TEX19 
assays – see main text for discussion.  NAT – Normal adjacent tumour; M – Melanoma; O – Ovarian; L – Lung. 
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5.3.2. Co-expression of germline genes in colorectal cancer samples 
Colon cancer samples 20, 28 and 40 (see Table 5.2) expressed several of the germline-
associated genes.  When considering group I-IV genes in Figure 5.15 (i.e. the more promising 
CT gene candidates), sample 20 expressed 8 of the germline genes and colon cancer sample 40 
expressed 10 of the genes.  Typically, the colon cancer samples only expressed 2 or 3 genes 
from these groups and in a couple of cases none of these genes appeared to be expressed.  
Sample 20 was from a patient with more advanced stage disease that had already metastasized 
to the regional lymph nodes (Duke’s C cancer).  Although sample 40 was not a metastatic 
tumour, interrogation of the H+E stain for the sample collected from this patient revealed a 
region within this adenocarcinoma to have a mucinous component (see Figure 5.6).  Mucinous 
adenocarcinomas of the colon generally carry a worse prognosis and are resistant to certain 
forms of cancer therapy (Lee et al., 2013).  Demethylation of DNA may be a common feature 
leading to the activation of multiple genes in these tumours (Adair and Hogan, 2009; Shen et 
al., 2007) or alternatively the activation of a certain oncogene (or genes) acts as a catalyst for 
the activation of others.  Whether the activation of these germline genes is correlated with an 
unfavourable outcome in CRC would need to be established by a more focussed investigation 
in a larger cohort of samples.   
 
Colon cancer sample 28 expressed 5 of the germline-selective genes (i.e. groups I-IV); this 
cancer also expressed PIWIL1 strongly.  This was an early stage cancer (Duke’s A) and there 
was no evidence of either metastasis to the regional lymph nodes on the pathological staging or 
distant metastasis at the time of surgery on the radiographic staging.  Patients with Duke’s A 
tumours have a 5-year survival of over 90% and their long-term prognosis is good.  There was 
no indication on any of the pathological characteristics that this patient should have an adverse 
outcome.  However, on a follow-up computerised tomography scan the patient was discovered 
to have an adrenal metastasis.  Two years after their initial surgery, the patient remains alive.  
It is possible that the expression of these half-dozen germline genes could have predicted this 
unforeseen outcome, in a similar fashion to how 3 or more of the panel of 26 germline genes 
predicted an unfavourable outcome in lung cancer patients in the Knochbin study (Rousseaux 
et al., 2013b).  It is possible that adjuvant (e.g., chemo- or immuno-) therapy would have 
reduced the chances of such recurrence/metastasis occurring and the germline genes could be 
the basis of tailored personalised therapy for such patients. 
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5.3.3. General comments and differences to previously published work 
With the exception of the normal adjacent tumour (NAT) samples, the other normal tissues 
were the same as those used in the PCR experiments in Chapter 3 and subject to the same 
limitations of using post-mortem samples as highlighted previously.  All the genes were 
selected from a cohort that was associated with the germline.  It may have been expected that 
most should have displayed testis-restricted or testis-selective expression.  One of the striking 
features when looking at the heatmap above (see Figure 5.15) was the fact that a significant 
cohort of the genes did not exhibit a testis-specific expression pattern; approximately half fell 
into the tightly restricted category.  Around one third of the germline genes selected were 
expressed in more than 2 normal tissue samples excluding the CNS, although a couple of these 
genes were restricted to two or less normal tissue types.  This is due to testing three normal 
ovarian tissues and several NAT colon samples, which collectively only represent two tissue 
types.  We would have discarded the majority of these genes from further analysis if we had 
seen this expression profile on RT-PCR.  The final 20% were testis-selective in their expression 
profiles (see groups II-IV in Figure 5.15).  Group II genes were expressed in CNS tissues only 
in the normal panel as well as normal testis.  Group III genes were expressed in up to 2 normal 
tissue samples and not in the CNS.  Finally, group IV genes were expressed in testis and CNS 
and in addition up to a maximum of 2 other normal tissue samples. 
5.3.3.1. Germline-associated genes with expression in normal tissues 
Some of the findings were somewhat contradictory to what has been described previously in 
the literature.  For example, CCDC79 has been described as a meiosis-specific gene with an 
expression profile limited to male and female germ cells (Daniel et al., 2014).  Moreover, we 
validated this gene previously as a meiCT gene and it was included in the germline gene list 
developed by the Knochbin group (Feichtinger et al., 2012b; Rousseaux et al., 2013b).  
Although this gene was not widely expressed across the tissue samples tested, it was shown to 
have high levels of expression in a selection of normal and cancer tissues, including normal 
liver, ovary and colon samples (see Figure 5.16, category ACF).  It may be that the primers 
lacked specificity for this gene, or alternatively the gene is not as germline-restricted in its 
expression profile as previously thought.  In general, however, it was reassuring to see that a 
large proportion of the genes (~70%) did have a limited expression profile in the normal tissues.  
Moreover, some of the genes that did not have a testis-restricted or selective expression pattern 
in normal tissues are known to be expressed in somatic tissues. 
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Rousseaux and colleagues described 506 genes that were said to be germline-specific: 439 were 
testis-associated and 67 were placenta-associated (Rousseaux et al., 2013b).  As depicted in 
Figure 5.21 the majority of these genes were not widely expressed in normal tissues, though 
EBI3 stood out as a gene that was widely expressed.  This gene we had shown separately to be 
expressed widely in normal tissues using the primers that Rousseaux et al. provided in the 
supplementary materials for this study (see Figure 5.10), confirming a degree of consistency 
between the experiments.  Thus, it may be that the different experimental approach adopted by 
Rousseaux and colleagues did not adequately filter out all somatically expressed genes. 
 
TGIF2 and related genes are discussed below in Section 5.3.5.1.  Some other examples of genes 
that had high and/or frequent expression within the normal tissues tested on the array were 
TUBA1A and RPS5.  These genes were mapped as orthologues of mouse and fly genes 
respectively, being associated with spermatogenesis in mice or brain tumour development in 
Drosophila melanogaster (Feichtinger et al., 2012b; Feichtinger et al., 2014a).  Both genes 
have recently been described as useful normalisation genes for qPCR in specific tissues (Mehta 
et al., 2015; Park et al., 2013), which is consistent with the expression profile displayed across 
all the tissues tested in this study.  Again and as for TGIF2, these genes may have been 
inappropriately mapped as human orthologues of the respective Drosophila melanogaster 
germline genes. 
 
TRIP13 was identified as an orthologue of a mouse spermatocyte-associate gene (Feichtinger 
et al., 2012b).  Although it is required for HR in meiosis and interacts with other meiosis-
specific proteins such as HORMAD1, the gene is also expressed in somatic tissues (Wang et 
al., 2014a; Wojtasz et al., 2012).  This is again consistent with the expression profile 
demonstrated in this study (see Figure 5.17, group C).  There was generally higher expression 
of the gene in cancer samples, which is also consistent to what has been shown in various 
malignancies (Banerjee et al., 2014; Larkin et al., 2012).  The expression levels of TRIP13 were 
able to predict recurrence of prostate cancer when used in combination with established 
methods of disease stratification (Larkin et al., 2012).  Interestingly, TRIP13 promotes error 
prone NHEJ, rather than HR, as a form of DNA repair, as well as malignant transformation in 
head and neck cancer (Banerjee et al., 2014).  Wang and colleagues have identified a mitotic 
checkpoint-silencing function of TRIP13 and suggested this may be an important mechanism 
promoting chromosomal instability in cancer (Wang et al., 2014a).  Thus, this gene has complex 
Chapter 5: Results 
 
171 
 
and different impacts on DNA repair and chromosome stability in the normal and malignant 
state, which appears to depend to some degree on the level of expression.  It would be interesting 
to establish whether similar mechanisms occur to promote oncogenesis and/or treatment 
resistance in CRC.  Although TRIP13 may be germline-associated, it should not be considered 
a germline-specific gene or a CT gene but does appear to be an important oncogene when it is 
upregulated.  It is unlikely to be useful as an immunotherapeutic target, though it is possible 
that as yet ill-defined oncogenic functions could be targeted in other forms of cancer therapy. 
 
CEP55 is considered a CTA according to CTDatabase, though this gene did not appear on any 
of the other germline gene lists we identified (Almeida et al., 2009).  It has been shown in 
numerous cancer types to be associated with survival and/or more aggressive forms of disease 
(reviewed in, Jeffery et al., 2015).  The gene was widely expressed in both the normal and 
cancerous tissues tested in this study, though to a greater degree in the cancerous tissue where 
it was expressed in moderate-high levels in all but one tested cancer sample (an ovarian cancer).  
It is known to be expressed at much higher levels in the germline, which is presumably why is 
has been classified as a CTA (perhaps due to a fold-increase in expression over normal).  
However, there are now well established roles during mitosis (Jeffery et al., 2015), so the 
classification of this gene even as a testis-selective CTA should be revisited.  This does not 
mean it does not have important oncogenic functions and/or therapeutic potential, though again 
unlikely to be a useful target for immunotherapies. 
5.3.3.2. Meiosis-associated genes in normal and cancerous tissue 
The TLDA analysis served as a ‘revalidation’ of the expression profiles of genes which we had 
previously identified as possible cancer-specific biomarkers and termed meiCT genes given 
their putative association with meiosis (Feichtinger et al., 2012b; Sammut et al., 2014) but went 
further to investigate the expression of these genes in clinical tissue samples.  The results, 
summarised in Figure 5.16, in general were consistent with our previous findings and RT-PCR 
validation of gene expression profiles.  Exceptions to this appeared to be TDRD1 and CCDC79, 
though in terms of tissue the highest number of separate tissue types for which any of the meiCT 
genes were expressed was 4 (excluding the testis and CNS).   
 
We previously validated IQCF1 as a meiCT gene which had weak expression in a colorectal 
and ovarian cancer cell line (Sammut et al., 2014).  Here it was shown that this gene had a 
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testis/CNS restricted expression profile in normal tissues.  Additionally, there was expression 
in one colon cancer sample and clear expression in one melanoma sample (see Figure 5.16, 
group AC).  This gene has recently been implicated in sperm capacitation and the acrosome 
reaction that are both essential processes for successful fertilisation (Fang et al., 2015).  A 
functional role in cancer has not been established, though it can be postulated that the protein 
could promote invasion if present aberrantly in cancer, as some acrosomal proteins are involved 
with ‘invasion’ of the zona pellucida to permit fertilisation. 
 
MBD3L1 has been shown previously to have upregulated expression in the testis and acts as a 
transcriptional repressor in a methylation dependant fashion (Jiang et al., 2004).  The protein 
product of this gene forms a complex that has high affinity for methylated DNA and may be 
involved in a targeted mechanism of tumour suppressor gene inactivation in cancer (Rauch et 
al., 2006).  We found the gene to be expressed in a melanoma and ovarian cancer sample, with 
expression restricted to the testis in normal tissues (see Figure 5.16, group ACF).  The 
McFarlane group had previously validated this gene as a meiCT with a testis-selective 
expression profile and expression also seen in an endometrial and ovarian cancer cell line 
(Feichtinger et al., 2012b).  The gene was also identified independently by Rousseaux and 
colleagues as a testis-associated germline gene, though it was not a member of the final panel 
of genes used to predict a worse outcome for lung cancer patients (Rousseaux et al., 2013b).  It 
would be interesting to investigate whether this gene does have a functional role in cancer, for 
example, by reducing the expression of tumour suppressor genes. 
 
The topoisomerase encoding meiosis-specific gene SPO11 was not shown to be clearly 
expressed in any tissue other than the testis and was tested using two separate assays (see Figure 
5.17, group CE); very weak/borderline expression was seen in foetal liver and a colon cancer 
sample only.  The colon cancer sample which appeared to express SPO11 at very low levels 
was an aggressive mucinous histo-type (see Figure 5.6).  However, additional experimentation 
would be needed to confirm whether this protein, which causes DNA DSBs during meiosis, is 
in fact present in a subset of colon cancers, though it is a recognised CTA (Almeida et al., 
2009).  It has recently been shown that SPO11, along with other meiosis-specific proteins may 
be present in cutaneous T-cell lymphoma (Litvinov et al., 2014). 
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Figure 5.16. Gene expression of germline genes in normal and cancerous tissues previously 
categorised as meiCT genes (group A genes).   
The letters on the far left indicate which groups the genes were included in and depict overlap between these 
groups – see Section 5.2.3.  The grey vertical line divides the normal from cancerous samples.  
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NUTM1 15 - - - - - - -
PRDM9 5 - - - - - - -
A RAD21L1 20 - - - - - - -
SHCBP1L 1 - - - - - - -
SMC1B 22 - - - - - - -
ACTRT1 X - - - - - - -
ASB17 1 - - - - - - -
C17orf98 17 - - - - - - -
C19orf67 19 - - - - - - -
C20orf201 20 - - - - - - -
CATSPER1 11 - - - - - - -
CXorf27 X - - - - - - -
DUSP21 X - - - - - - -
FABP9 8 - - - - - - -
FAM170A 5 - - - - - - -
FTMT 5 - - - - - - -
AC IL31 12 - - - - - - -
IQCF1 3 - - - - - - -
PFN3 5 - - - - - - -
RBM44 2 - - - - - - -
STRA8 7 - - - - - - -
SYCP3 12 - - - - - - -
TCTE3 6 - - - - - - -
TDRD1 10 -
TEPP 16 - - - - - - -
TEX19 17 -
TEX19 17 -
TRIM42 3 - - - - - - -
TRIML1 4 - - - - - - -
ACD TGIF2LY;TGIF2LXX -
ACDE SYCP1 1 -
ACDF BOLL 2 -
DDX4 5 -
ACE ODF3 11 -
ODF4 17 -
ADAM2 8 -
ACEF BRDT 1 -
LUZP4 X -
ACTL9 19 -
ADAD1 4 -
C12orf50 12 -
C16orf78 16 -
C1orf65 1 -
C3orf22 3 -
C4orf17 4 -
C5orf47 5 -
C8orf74 8 -
CAPZA3 12 -
CCDC116 22 -
CCDC38 12 -
CCDC79 16 -
CST8 20 -
CYLC1 X -
CYLC2 9 -
ACF DNAJC5G 2 -
FAM71B 5 -
GK2 4 -
IQCF3 3 -
KLF17 1 -
LYZL6 17 -
MBD3L1 19 -
NT5C1B 2 -
PAPOLB 7 -
PDHA2 4 -
PPP3R2 9 -
PRPS1L1 7 -
SEPT12 16 -
SPZ1 5 -
TBC1D21 15 -
TSSK1B 5 -
ZCCHC13 X -
ZSWIM2 2 -
AF HMGB4 1 -
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LUZP4 has been identified in multiple myeloma cell lines and enriched specifically in sub-
populations of these cells with stem-cell characteristics (Wen et al., 2014).  It is possible that 
LUZP4 expression was already high in the primary tumour before the melanoma recurred in 
this patient, although the study by Wen et al. hints at an association with stem cells in support 
of the theory postulated above, though this was seen in a different cancer type.  Wen and 
colleagues additionally demonstrated that knockdown of LUZP4 enhanced the sensitivity of 
myeloma cells to chemotherapeutic agents and reduced their colony-forming ability prior to 
treatment with these agents (Wen et al., 2014).  LUZP4 was expressed in the only recurrent 
malignant melanoma sample that we analysed; indeed this was the only sample of either cancer 
or normal tissues other than testis that expressed this gene (see Figure 5.16, group ACEF).  This 
gene was identified as a testis-specific germline gene, though not included in the 26 predictive 
genes for lung cancer which they narrowed down to (Rousseaux et al., 2013b).  We additionally 
identified and validated it as a meiCT gene that had displayed a meta-upregulation in ovarian 
cancer (Feichtinger et al., 2012b).  LUZP4 is considered a CT gene where expression has been 
shown most commonly in melanoma, lung, brain and ovarian cancers (Tureci et al., 2002).  
Given that expression was seen on the TLDA analysis in a recurrent malignant melanoma 
sample only, it may be the case that the CSC population expressed this gene which then became 
enriched in the tumour cell population when the cancer recurred.  It is possible that the presence 
of this gene confers a survival advantage to the stem cell population or contributes to resistance 
to treatment, though a mechanism for this would need to be established and this remains purely 
speculative.  Recently, it has been shown that LUZP4 can bind to RNA and interacts with other 
known mRNA export receptors and associated proteins (Viphakone et al., 2015).  It was further 
shown that LUZP4 could reconstitute the RNA export deficiency produced when a known 
mRNA adaptor was repressed and consequently promote proliferation of melanoma cells.  
Thus, there is growing evidence LUZP4 functions as an oncogenic driver in cancer. 
 
Also included on the TLDA cards we designed were a cohort of genes that were present on the 
original list of human orthologues of the mouse genes associated with meiosis/spermatogenesis 
(Chalmel et al., 2007; Feichtinger et al., 2012b).  The results for this group of genes are shown 
in Figure 5.17 – it is immediately apparent when comparing to Figure 5.16 that the expression 
profile for these genes was more widely seen in somatic tissues, which confirms that our 
previous experimental validation process was sound (Feichtinger et al., 2012b; Sammut et al., 
2014).  It is interesting to observe that the category C genes in Figure 5.17 (i.e. the genes that 
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did not overlap with any other groups and were restricted to group C) had the most extensive 
expression in normal tissues; some of these genes had been excluded as meiCT candidates 
previously during our validation process (Feichtinger et al., 2012b).  A similar observation was 
also seen for the group D genes, where 4 out of the 5 genes, which did not overlap with any 
other groups/sources of germline genes, were widely expressed in the normal samples – see 
Figure 5.20.  These observations also display how if candidate genes did overlap between the 
groups they do generally appear to be more promising targets to take forward and investigate 
further as potential cancer-specific biomarkers.   
5.3.3.3. Testis-expressed (TEX) genes 
TEX101 has been accepted as a CTA gene but not widely investigated across different cancer 
types (Almeida et al., 2009).  It was identified as a human orthologue of a mouse gene 
associated with meiosis/spermatogenesis but not validated as a meiCT gene (Feichtinger et al., 
2012b).  It was identified as being associated with small cell lung cancer but not seen in cell 
lines derived from non-small cell tumour types (Tajima et al., 2003).  Both the lung cancer 
samples we tested were of a non-small cell type (one squamous cell and the other an 
adenocarcinoma) and consistent with this previous finding, which found it to be present in small 
cell lung cancer only, we found this gene not to be expressed in the tested samples.  The gene 
was found to be expressed but no antibodies against the protein could be detected in the serum 
of patients with chronic myeloid leukaemia (Ghafouri-Fard et al., 2012).  TEX101 expression 
was not detected in breast cancer samples tested in a further study (Dianatpour et al., 2012).  It 
has not been described as a CT gene in colorectal cancer but a novel finding here is that two of 
the colon cancer samples expressed this gene (see Figure 5.17, group CE).  However, one of 
the NAT colonic samples also expressed the gene, although the gene was otherwise restricted 
to the testis in the normal tissue samples.  Interestingly, it has been shown that NYD-SP8 (an 
alias for TEX101) was shown to suppress the activity of various proteases involved in 
extracellular matrix (ECM) degradation, and have a stronger association with earlier stages of 
hepatocellular carcinoma (Yin et al., 2009).  The effect of suppressing ECM degradation took 
place despite the fact that this protein shares homology with the urokinase plasminogen 
activator receptor, which is known to promote ECM breakdown (Smith and Marshall, 2010).  
The association with early stage or better prognostic tumours would also be at odds with its 
expression being associated with small cell lung cancers, which carry a very poor prognosis.  
However, consistent with the suppression of tumour invasion (Yin et al., 2009), the presence 
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of the protein in squamous cell carcinomas of the head and neck was associated with a lower 
rate of lymph node metastasis (Yoshitake et al., 2012).  Thus, there may be a differing role of 
this gene in different tumours and at different stages of tumour development.   
 
In addition to TEX101 other TEX genes were included on the TLDA cards, namely TEX14, 
TEX15 and TEX19.  TEX14 and TEX15 were both expressed in more than two of the normal 
tissues other that testis.  Stronger expression was seen in melanoma for both genes and for 
TEX15 in an ovarian cancer sample also (see Figure 5.17, group CE).  TEX15 has been proposed 
previously as a CT gene that is preferentially expressed in cancer stem-like cells (Yamada et 
al., 2013).  Knockout experiments in mice have revealed a functional role for TEX15 in DSB 
repair and chromosomal synapsis during meiosis (Yang et al., 2008).  Both genes appear to 
have expression in normal tissue to an extent which may hinder their use as immunotherapeutic 
targets, though it may be the case that in the instances of low gene expression seen in normal 
tissue, translation of the protein does not take place.  In the samples tested, however, if there 
was upregulation of TEX14 or TEX15 in the cancer samples, it appeared to be minimal. 
 
TEX19 displayed a tighter restriction of its expression in normal tissues.  We used two separate 
assays for this gene and it was only expressed in one NAT sample in one of these assays (see 
Figure 5.16).  Consistent with our previous findings but where we used predominantly cancer 
cell lines (Feichtinger et al., 2012b), the gene was expressed in several cancer samples and in 
all cancer types tested.  We used two separate primer sets for this revalidation and although 
there was a slightly wider expression pattern for one of the primer sets, the results were broadly 
similar between the two (see Figure 5.16 as well as the rows marked by black arrows in Figure 
5.15).  There was also an indication of very weak expression in more cancer samples, as well 
as some normal tissues; though it is worth pointing out that this very weak/borderline expression 
TEX19 in normal tissues was almost entirely limited to the NAT samples.  In mice, TEX19 is a 
placenta and germline specific protein, which associates with the stem cell compartment and is 
essential for spermatogenesis (Kuntz et al., 2008; Tarabay et al., 2013).  It has not been 
described as a CTA other than its potential highlighted by our group (Feichtinger et al., 2012b) 
and although other TEX genes were, it was not present on the list of ~500 germline genes (group 
F) identified by the Knochbin group as either testis- or placenta-specific (Rousseaux et al., 
2013b). 
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Figure 5.17.  Gene expression of group C genes, which had not been confirmed as meiCT genes 
previously, in normal and cancerous tissues.   
This grid represents all the genes that were identified as orthologues of mouse spermatocyte-specific that were 
included on the arrays and not already included in Figure 5.16.  Again, the letters on the left hand column indicate 
which groups the gene also appeared in.  Most of the genes overlapped with another group but some were restricted 
to this group and these genes displayed the highest frequency of expression in the normal tissues (category C 
above). 
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BCEF HORMAD1 1 -
C16orf46 16 - - - - - - -
C19orf45 19 - - - - - - -
C20orf195 20 - - - - - - -
C2orf70 2 - - - - - - -
CCDC113 16 - - - - - - -
CEP72 5 - - - - - - -
LRRC6 8 - - - - - - -
C MND1 4 - - - - - - -
PBX4 19 - - - - - - -
PLD6 17 - - - - - - -
RANBP17 5 - - - - - - -
SYNGR4 19 - - - - - - -
TCFL5 20 - - - - - - -
TDRD5 1 - - - - - - -
TRIP13 5 - - - - - - -
TUBA1A 12 - - - - - - -
CD DAZ1 Y -
DAZ1 Y - - - - - - -
CDE PIWIL2 8 -
TDRD1 10 -
CDEF MAEL 1 -
DAZL 3 -
CDF PIWIL1 12 -
RNF17 13 -
ARMC3 10 -
CAGE1 6 -
CCDC110 4 -
GPAT2 2 -
HSPB9 17 -
LEMD1 1 -
LEMD1 1 - - - - - - -
NLRP4 19 -
NOL4 18 -
CE NXF2B;NXF2 X -
PTPN20A;PTPN20B1 -
SPO11 20 -
SPO11 20 -
SSX5 X -
SYCE1 10 -
TEX101 19 -
TEX14 17 -
TEX15 8 -
TSSK6 19 -
AKAP3 12 -
HORMAD2 22 -
PRSS54 16 -
CEF SPACA3 17 -
SPATA19 11 -
TEKT5 16 -
TULP2 19 -
BTG4 11 - - - - - - -
CF C10orf82 10 - - - - - - -
STK31 7 - - - - - - -
TKTL2 4 - - - - - - -
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One of the genes which stood out as a good candidate CT gene was C20orf195 (see Figure 5.17, 
group C).  This gene was expressed in testis and none of the normal tissues tested but was also 
expressed in two melanoma samples and one ovarian cancer sample.  The gene encodes an 
uncharacterised protein with unknown function.  It was identified as an orthologue of a mouse 
spermatocyte/meiosis-associated gene but it was not validated as a meiCT.  The same gene also 
appeared on the EST filter for meta-upregulated genes in cancer (see Figure 5.13).  Together 
these findings provide a strong indication this gene may be a clinically relevant gene that should 
be investigated further.  The gene was not expressed in any of the CRC samples collected for 
this research, so appears not to be candidate marker for this cancer type but it could be for other 
cancer types such as melanoma or ovarian cancer as the data suggests. 
 
Another interesting gene was C16orf46, which had a testis-selective expression profile but 
appeared to be expressed in several of the cancer samples tested (see Figure 5.17, group C).  In 
fact, 14 of the 20 cancer samples tested expressed this gene.  Despite this no previous 
association with cancer has been described in the medical literature and the gene has unknown 
function.  Further investigation of this gene would certainly appear warranted. 
 
SYNGR4 has unknown physiological functions, though is a member of the synaptogyrin gene 
family which encode proteins that are involved in exocytosis (Shin, 2014).  The gene was 
identified as an orthologue of a mouse gene characterised as being associated with 
spermatogenesis (Feichtinger et al., 2012b).  The gene has a statistically significant 
upregulation in expression when ovarian cancer microarray datasets were meta-analysed (see 
Figure 5.12).  The gene had a testis/CNS-selective expression pattern in normal tissues, being 
expressed commonly at low levels in NAT colon samples and having higher expression in 
normal brain and testis (see Figure 5.17).  There was also higher expression in 3 colon cancer 
samples and the gene was also expressed in melanoma, lung and ovarian cancer (in 4 out of the 
7 samples tested for these cancer types).  It may well be worth exploring the function of this 
gene and expression pattern further in cancer and normal tissues as well as investigating the 
normal function of this gene. 
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Figure 5.18. Gene expression of group E genes in normal and cancerous tissues.   
All these genes had previously been identified as CT genes according to ‘CTdatabase’ (Almeida et al., 2009).  As 
Hofmann and colleagues (2008) had previously discovered several CT genes are selective in their expression 
profile with a preference for the testis/germline and upregulated in cancer.  Some genes, for example GPAT2, 
appeared to be equally strongly expressed in normal tissues questioning its categorisation as even a testis-selective 
CTA though it was strongly expressed in an ovarian cancer sample.   
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ACDE SYCP1 1 -
ACE ODF3 11 -
ODF4 17 -
ADAM2 8 -
ACEF BRDT 1 -
LUZP4 X -
BCEF HORMAD1 1 -
MAGEA1 X - - - - - - -
BE MAGEA2 X - - - - - - -
MAGEA9;MAGEA9B X - - - - - - -
CPXCR1 X -
CTAGE1 18 -
DDX53 X -
BEF DKKL1 19 -
MAGEB3 X -
MAGEB4 X -
MAGEB6 X -
SPANXE;SPANXC X -
CDE PIWIL2 8 -
TDRD1 10 -
CDEF MAEL 1 -
ARMC3 10 -
CAGE1 6 -
CCDC110 4 -
GPAT2 2 -
HSPB9 17 -
LEMD1 1 -
LEMD1 1 - - - - - - -
NLRP4 19 -
NOL4 18 -
CE NXF2B;NXF2 X -
PTPN20A;PTPN20B 10 -
SPO11 20 -
SPO11 20 -
SSX5 X -
SYCE1 10 -
TEX101 19 -
TEX14 17 -
TEX15 8 -
TSSK6 19 -
AKAP3 12 -
HORMAD2 22 -
PRSS54 16 -
CEF SPACA3 17 -
SPATA19 11 -
TEKT5 16 -
TULP2 19 -
ATAD2 8 - - - - - - -
CASC5 15 - - - - - - -
CEP290 12 - - - - - - -
CEP55 10 - - - - - - -
MAGEA12 X - - - - - - -
MAGEA12 X - - - - - - -
MAGEA4 X - - - - - - -
NR6A1 9 - - - - - - -
E OIP5 15 - - - - - - -
OTOA 16 - - - - - - -
PBK 8 - - - - - - -
PLAC1 X - - - - - - -
RQCD1 2 - - - - - - -
SPAG4 20 - - - - - - -
SPAG9 17 - - - - - - -
TMEFF1 9 - - - - - - -
TTK 6 - - - - - - -
CCDC83 11 - - - - - - -
EF RBM46 4 - - - - - - -
ROPN1 3 - - - - - - -
TPTE 21 - - - - - - -
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5.3.4. Analysis of genes previously described as CT genes 
Several genes included on the TLDA cards had previously been described as or suggested to be 
CTA genes (Almeida et al., 2009).  The expression profiles for these genes are shown in Figure 
5.18.  Discussion of specific examples is detailed below (see also Section 1 of Appendix for 
additional discussion). 
5.3.4.1. PLAC1 and PLAC1-like genes 
PLAC1 is a known CT gene and it has been suggested that it may be a marker of stemness in 
epithelial ovarian cancer (Almeida et al., 2009; Tchabo et al., 2009).  The gene is considered a 
trophoblast-associated gene where it is thought to play an important role in placental 
development but low levels of expression have been seen in testis and cerebellum (Fant et al., 
2010).  The suggested roles this gene plays in cancer relate to the processes involved with 
invasion of trophoblastic cells that normally occur during placental development (Devor et al., 
2014; Fant et al., 2010; Tchabo et al., 2009).   Expression of this gene has been linked to many 
cancers, for example, ovarian, endometrial, colorectal and breast cancer; PLAC1 has also been 
recommended as a potential target for immunotherapies (Devor et al., 2014; Liu et al., 2014; 
Liu et al., 2012b; Shantha Kumara et al., 2012; Tchabo et al., 2009).  PLAC1 expression has 
been shown to be induced by Epstein-Barr virus (EBV) (Wang et al., 2014b), providing further 
evidence for a link between infections/inflammation, CT genes and cancer.  PLAC1 was 
expressed in a proportion of each cancer type tested in the TLDA cards but not clearly in any 
normal tissue other than the testis (see Figure 5.18), confirming its existence as a CT gene 
across many cancer types.  The gene is believed to be held in a transcriptionally-repressed state 
in somatic cells due to its promotor region being in a heterchromatic state (i.e. outside the 
germline/placenta).  Mutations in TP53 and RB have been identified as possible routes to the 
transcriptional upregulation of PLAC1 in tumour cells (Chen et al., 2013).  Although high levels 
of PLAC1 are found in many cancer cell lines, the model in vitro system used in that study was 
transformed primary fibroblasts.  Given the increasing realisation of the importance of the 
tumour stroma in driving oncogenesis (Calon et al., 2015; Isella et al., 2015), it could be that 
fibroblasts associated with tumours experience an upregulation in PLAC1, which is then able 
to exert tumorigenic effects.  This would require in-depth analysis of gene expression in tumour 
cell subpopulations as has been recently described in CRC (Calon et al., 2015).   
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PLAC1L encodes the PLAC1-like protein.  It shares no significant homology with the known 
CT gene PLAC1 and very little is known about this gene’s function.  PLAC1L was identified as 
a testis-associated germline-specific gene, though interestingly PLAC1 was not identified as a 
germline gene despite being classified as a placental-associated gene (Rousseaux et al., 2013b).  
PLAC1L was identified as an interacting partner with the BRCA1 C terminus (BRCT) domain 
(Woods et al., 2012) so potentially could impact on DNA repair pathways if upregulated in 
cancer.  It would be interesting to investigate if this gene is expressed in cancer but I did not 
include this gene on the TLDA cards. 
5.3.4.2. Previously validated tissue-specific CTA-genes 
A cohort of the ‘known CTA-genes’ (see Figure 5.18) were separately validated by Hofmann 
and colleagues as germline restricted or selective (Hofmann et al., 2008).  It can be seen in 
Figure 5.19 that all but 3 of these genes conformed to the testis-restricted or testis/CNS-
restricted expression profile in normal tissues as had been previously described (Hofmann et 
al., 2008).  None of the genes were found to be widely expressed in normal tissues, and all 
would still be classified as CT genes though some with a testis-selective expression pattern.  
One of the genes, HORMAD1, appeared on our list of spermatocyte-associated genes (group C) 
but it was excluded as a meiCT gene as weak expression was seen in a range of normal tissues 
in previous work by the McFarlane group (Feichtinger et al., 2012b).  A greater proportion of 
the genes from this group overlapped with group F genes, which were germline tissue-restricted 
genes identified by the Knochbin groups (Rousseaux et al., 2013b).  The consistency of our 
results with the cohort put forward by Hofmann and colleagues (2008) is reassuring that our 
experiments, although not repeated, have a certain degree of validity.  The experiments should 
however be repeated. 
 
DKKL1 is expressed during spermatogenesis and during placental development, where it plays 
a role in implantation of the blastocyst as well as promoting the ability of sperm to penetrate 
the zona pellucida during fertilisation (Kohn et al., 2010).  Thus, it may well interact with 
proteolytic factors and could conceivably play a role in tumour invasion if ectopically expressed 
in cancer.  Due to the fact that microarray data suggested this gene was upregulated in certain 
brain tumours, Sibbe and Jarowyj (2013) investigated whether the protein was present in the 
brain of mice.  They found that it was present in low abundance, with highest levels in cortical 
neurons and postulated a role in oncogenesis as well as neurodegenerative disorders (Sibbe and 
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Jarowyj, 2013).  The gene was categorised as testis-selective given limited expression in normal 
tissues (see Figure 5.19, group BEF).  Borderline or very low expression was seen in CNS 
tissues but this did not meet the criteria we set (i.e. Ct value <32) to say the gene was definitely 
expressed in this tissue type but the previous findings of others suggest this low expression in 
the CNS may be real (Sibbe and Jarowyj, 2013).  It was observed that foetal liver, as well as 
normal ovarian tissue did express low-moderate levels of this gene.  None of the NAT colonic 
samples clearly expressed the gene but one of the colon cancer samples did.  Moreover, the 
gene was widely expressed in the melanoma, ovarian and lung cancer samples, with only one 
of the tested ovarian cancer sample not clearly expressing this gene.  It is possible that this gene 
plays an important oncogenic role in many cancers and more widely than is currently 
appreciated despite it being recognised as a CTA; it may also be a good therapeutic target for 
these cancers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19.  Gene expression of germline genes previously categorised as CT genes and 
validated by Hofmann and colleagues as testis or testis/CNS-restricted.   
All these genes overlapped with category E genes (known CT genes), which is not surprising as Hofmann et al. 
(2008) were analysing genes thought to belong to this category of genes.   Consistent with their acceptance as CT 
genes, none of the genes analysed fell outside what would classify them as such, although some were testis-
selective in their expression profile in normal tissues. 
 
 
HORMAD1, for which a functional role in breast cancer has recently been proposed (Watkins 
et al., 2015), displayed a tight testis-restricted expression pattern in normal tissues but was 
likewise not found to be expressed in any of the cancer samples we tested (e.g., see Figure 5.19 
and Figure 5.21, group BCEF).  HORMAD2, displayed a testis/CNS-restricted expression 
pattern and was shown to be expressed reasonably strongly in a lung adenocarcinoma sample 
(e.g., see Figure 5.18, group CEF).  HORMAD2, along with its sister HORMA domain protein 
HORMAD1, play critical roles during meiosis and meiotic recombination (Kim et al., 2014).  
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HORMAD2 has recently been characterised as a CT gene in lung cancer patients (Liu et al., 
2012a).  This is consistent with the findings from our PCR experiment, where lung cancer and 
not colon, ovarian and melanoma cancer samples expressed this gene.  It has further been shown 
that single-nucleotide polymorphisms of this gene impact significantly on the clinical outcome 
in a Chinese population with lung cancer (Zhang et al., 2014).  Thus, it is possible that such 
genetic testing of this CT gene could facilitate disease stratification and guide therapy 
accordingly for this cancer type.  
 
5.3.5. Analysis of germline genes previously identified as oncogenic drivers in 
Drosophila melanogaster 
The paper by Janic and colleagues (2010) was very important in that it provided evidence for a 
direct role for germline factors acting as oncogenic drivers in a brain tumour model in 
Drosophila melanogaster.  It was subsequently shown that the human orthologues of these 
genes were frequently upregulated in human cancers and speculated that a soma-to-germline 
transition may be a hallmark of many cancer types (Feichtinger et al., 2014a).  Several of these 
human orthologues were included on the TLDA cards and the genes overlapped with several 
other germline gene lists (see Figure 5.20).  All but one of the genes that did not display an 
overlap with other gene lists (category D in Figure 5.20) were widely expressed in both the 
normal and cancerous tissue samples tested; some of these are discussed below in Section 
5.3.5.1 and Section 5.3.6.   
 
It has recently been shown that the meiosis-associated gene, FKBP6, that is known to play a 
role in male fertility, is also associated with cervical cancer (Brebi et al., 2014).  Through 
genome wide DNA methylation analysis this gene was identified as being associated with 
cervical cancer and in particular precancerous lesions (Brebi et al., 2014).  It was shown in the 
TLDA analysis that the gene was expressed in the testis and a melanoma sample only, 
categorising it as a novel CT gene (see Figure 5.20, group DF).  A role for this gene in both 
melanoma and cervical cancer is thus worthy of further exploration.  The gene was identified 
as a testis-specific germline gene by the Knochbin group but not included in the predictive panel 
of 26 genes for lung cancer patients (Rousseaux et al., 2013b).  FKBP6 was not identified as 
an orthologue of mouse spermatocyte/meiosis-associated gene but it should be noted that 
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orthologues for every mouse gene listed by Chalmel and colleagues could not be identified 
(Chalmel et al., 2007; Feichtinger et al., 2012b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20. Gene expression of group D genes in normal and cancerous tissues.  
These genes had all previously been identified as ortholgues of germline genes that drove oncogenesis in brain 
tumours in Drosophila melanogaster (Feichtinger et al., 2014a).  In a similar observation to Figure 5.17, the genes 
that were only found in this group (category D) were more widely expressed in the normal panel, although 
NANOS2 was an exception but this gene was not expressed in any of the cancer samples. 
 
5.3.5.1. TGIF2 and related genes 
TGIF2 was identified as the human orthologue of the Drosophila melanogaster germline gene 
zpg that had been implicated in contributing to oncogenesis in a brain tumour model in 
Drosophila melanogaster (Feichtinger et al., 2014a; Janic et al., 2010).  It was originally 
identified as a transcription factor upregulated in ovarian cancer cell lines (Imoto et al., 2000).  
It was shown in this earlier study that the gene was expressed across all normal tissue tested but 
at a lower levels than the ovarian cancer samples; consistent with the finding that the gene was 
expressed widely in the normal tissues analysed on the TLDA cards (see Figure 5.20, group D).  
TGIF2 has more recently been revealed as a target for microRNAs (miRNAs) and implicated 
in metastasis formation (Lujambio et al., 2008; Suzuki and Yoshino, 2008).  TGIF2 has also 
been identified as one of the most highly upregulated genes when comparing rectal adenomas 
to carcinomas (Lips et al., 2008).  Again, consistent with this finding we found generally higher 
expression in the colon cancer samples compared to the matched normal tissue.  High levels of 
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expression were also seen in all the melanoma, ovarian and lung cancer samples tested, though 
similar levels of expression were also seen in normal ovarian tissue.  TGIF2 is undoubtedly 
important in the pathogenesis of many cancer types but it is one gene to exclude from further 
analysis if trying to identify cancer-specific germline genes with a clear on-off signal.  The 
mapping of this gene as a human orthologue of a Drosophila melanogaster gene may not have 
been entirely accurate. 
 
TGIF2LX and TGIF2LY on the other hand are testis/germline-specific genes and the expression 
profile seen on the TLDA array was consistent with this finding.  The assay used on the array 
did not differentiate between these two genes.  It was further shown that the gene was expressed 
clearly in a melanoma sample, with weaker expression in two ovarian cancer samples and the 
metastatic lung cancer sample tested (e.g., see Figure 5.16 and Figure 5.20, group ACD).  The 
gene did not appear to be expressed in any of the colon cancer samples.  Interestingly the 
melanoma sample displaying the strongest expression among the cancer types was a recurrent 
cancer, raising the possibility of expression of this gene playing a role in drug resistance or 
cancer-stem-like cell characteristics.  Clearly this would need to be corroborated by further 
studies and is very speculative on the basis of the current evidence provided.  However, it has 
been suggested to have a functional role in regulating spermatogonial stem cells in the testis 
(Aarabi et al., 2008).  TGIF2LX has been shown to display similar functions in a fly model to 
that of TGIF2, although expression of both genes inhibited rather than promoted cell growth 
and proliferation (Wang et al., 2008).  Interestingly, TGIF2LY did not display the same effect 
on fly tissues despite its close relation to TGIF2LX.  Thus, TGIF2LX may have tumour 
suppressor functions but given the functional overlap with TGIF2, which is implicated in 
various oncogenic processes, it also raises the possibility of as yet uncharacterised functions.  
Little is known about its function within the testis, though it is believed to play important roles 
in spermatogenesis and is implicated in infertility (Aarabi et al., 2008; Wang et al., 2008).   
 
We identified TGIF2LX as a meiCT gene (Sammut et al., 2014) and it was also shown, along 
with TGIF2LY, to be an orthologue of a Drosophila melanogaster gene that had been implicated 
as having oncogenic functions in brain tumours (Feichtinger et al., 2014a; Janic et al., 2010).  
Adding to the possible role of these genes in driving oncogenesis in the brain, TGIF2LY was 
shown to have statistically significant upregulation in brain tumours when clinical datasets were 
meta-analysed (see Figure 5.12).  TGIF2LX was not present on the arrays (i.e. that contributed 
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to CancerMA) so it cannot be stated that this upregulation is specific for TGIF2LY (Feichtinger 
et al., 2012a).  The only other reference specifically linking these two related genes to cancer 
in the literature that we are aware of is a study showing that more aggressive forms of prostate 
cancer commonly expressed either TGIF2LX or TGIF2LY (Ousati Ashtiani et al., 2009).  Given 
its expression in three separate cancer types in this study, this raises the possibility of either or 
both of these genes playing an oncogenic role more widely than is currently appreciated. 
5.3.5.2. Expression profiles of genes that contribute to the synaptonemal complex 
SYCP1 and SYCP3 are constituent members of the synaptonemal complex (SC) (Fraune et al., 
2012).  The genes encoding these proteins were both identified as meiCT genes; SYCP3 
displayed a significant upregulation in ovarian cancer on the microarray datasets and SYCP1 in 
ovarian and brain cancer (Feichtinger et al., 2012b).  SYCP1 is additionally considered a CT 
gene and was also identified as an orthologue of germline oncogenic driver gene of brain 
tumours in Drosophila melanogaster (Almeida et al., 2009; Feichtinger et al., 2014a; Janic et 
al., 2010).  On the TLDA analysis SYCP1 was only expressed in the testis (e.g., see Figures 
5.16 and 5.20, group ACDE).  SYCP3 on the other hand was expressed strongly in the testis, 
with weak to moderate expression in normal brain and ovary as well as a melanoma, colon and 
lung cancer sample (e.g., see Figure 5.16, group AC).  Interestingly neither of these genes 
appeared to be expressed in ovarian cancer, which was the cancer type displaying significant 
upregulation in expression on the microarrays (Feichtinger et al., 2012b), although both genes 
did display very weak/borderline expression when the lower threshold for expression was 
considered.  SYCP3 has been shown to inhibit BRCA2 function and consequently HR, lead to 
increased DSB formation and aneuploidy in vitro, providing a mechanism for contributing to 
chromosomal instability in cancer (Hosoya et al., 2011).  The expression of SYCP3 has also 
recently been shown to correlate with a worse outcome in lung and cervical cancers (Cho et al., 
2014; Chung et al., 2013).  Such gene expression analysis could be a relatively simple way of 
identifying patients who would benefit from more aggressive forms of treatment at an earlier 
point in their treatment, before the disease had progressed to a stage where cure cannot be 
achieved.  Rousseaux and colleagues (2013b) were the first to demonstrate the potential power 
of combining a relatively small number of germline genes to predict poor outcome in lung 
cancer patients.  Similar cohorts of genes, for which SYCP1 and SYCP3 may well be useful 
members, could be identified and prove useful in different types of cancer.  Such predictive 
groups of genes would be of considerable clinical benefit at relatively low cost.  For example, 
Chapter 5: Results 
 
187 
 
gene expression profiling using both germline, including SYCP1, and somatic genes has been 
shown to predict disease progression in cutaneous T-cell lymphoma, once again displaying the 
power of relatively simple stratification approaches that could have wider clinical applications 
(Litvinov et al., 2015). 
 
SYCE1 also forms part of the central element of the SC – see Section 1.4.5 (Fraune et al., 2012).  
It is considered a CTA (Almeida et al., 2009) and the gene encoding this protein was identified 
as a candidate meiCT gene but found to be expressed in several normal tissues, thus excluding 
it being classified as a meiCT gene (Feichtinger et al., 2012b).  In the ‘revalidation’ of this 
genes tissue expression using the TLDA cards, the gene was shown to have testis/CNS 
restricted expression pattern, so on this basis should not have been excluded, possibly 
suggesting the negative 40-cycle PCR validation was in this case too stringent.  It should be 
noted that although we tested the expression in more normal tissues, the expression was in fact 
tested in slightly fewer individual tissue types than the McFarlane group had originally 
performed.  The gene appeared only to be expressed in one NAT tissue sample.  Thus, the gene 
may indeed be a (meiosis-associated) CT gene and our previous classification was perhaps 
over-stringent in some instances.  A benefit of this ‘over-stringency’ should be the identification 
of highly-specific cancer biomarkers.  Others have recently provided evidence suggesting 
SYCE1, along with VCX/Y and other CT genes, do encode CTAs of potential importance in lung 
adenocarcinomas (Taguchi et al., 2014).  We found strong expression in one of the ovarian 
cancer samples in this study (e.g., see Figure 5.18, group CE), suggesting the gene may be 
clinically relevant in a subset of patients with this cancer type. 
5.3.6. Previously identified tissue-specific germline genes 
CCDC83 appeared on the extended list of germline genes identified by Rousseaux and 
colleagues and also in the list of known CT genes (Almeida et al., 2009; Rousseaux et al., 
2013b).  This gene was shown to have restricted expression to the testis in the normal tissues 
tested and one of the colon cancers tested also displayed moderate expression levels (e.g., see 
Figure 5.21, group EF).  These findings were consistent with CCDC83 being a CT gene.  In 
support of this it was shown through an immunoscreening technique using sera obtained from 
patients with CRC, some displayed IgG antibodies against this protein (Song et al., 2012).  They 
also confirmed a gene expression profile consistent with it being a CT gene.  Together with our 
findings this adds further support to this protein being of real significance for a subset of CRC 
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patients.  In addition to the clear expression of the gene in one of the colon cancer samples, 
three other colon cancer samples had very weak/ borderline expression.  Borderline expression 
of this gene was also seen in two of the NAT sample (though interestingly the corresponding 
cancer sample did not display borderline expression) and two ovarian cancer samples that were 
tested.  In the study by Song et al. they also found a weak IgG response to the protein in a small 
cohort of the normal patients tested (Song et al., 2012).  This may limit the use of this CTA as 
a target for immunotherapeutic approaches in the clinical setting.  
5.3.6.1. The genes previously identified as predictive markers in lung cancer 
The genes depicted in Figure 5.22 all belong to the group of gene identified by the Knochbin 
group as predictive of a worse outcome in lung cancer (Rousseaux et al., 2013b).  The genes 
were not widely expressed in the two lung cancer samples tested on the TLDA cards.  However, 
the prediction of a poor outcome was based on 3 or more of any of the 26 genes being expressed 
in a given tumour.  So in fact, on this basis, both the tumours from which the RNA was extracted 
and used in this study would be expected to carry a poor prognosis given the fact that 5 and 3 
of the 26 gene were expressed respectively.  The lung cancer specimen expressing 5 of the 26 
predictive genes was a metastatic tumour.  
 
In comparison to my RT-PCR findings (see Figures 5.10 and 5.11) the results are broadly 
similar, displaying consistency between the different assays/primer sets, which is reassuring.  
ROPN1 was shown on the RT-PCR to be testis-selective but on the TLDA analysis showed 
more expression in the normal tissues to the point that its classification as a CT gene is called 
into question.  The other example of a discrepancy is for OR7E156P, for which it was suggested 
as having a weak expression pattern in normal tissues on RT-PCR but here the gene was 
expressed in the testis only.  Given that the strength of expression in the testis was weaker than 
many of the other germline genes tested in this study, this might suggest the primers/assay is 
not efficient in this instance and as a consequence of this perhaps failed to detect weak 
expression that may be present in other tissues.  It would be worth repeating the analysis with 
an alternative assay and confirming expression with DNA sequencing. 
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Figure 5.21. Gene expression of group F genes in normal and cancerous tissues.   
All these genes had previously been identified as tissue-specific germline (placental or testis-associated) genes 
(Rousseaux et al., 2013b).  EB13 was the only gene from this group that was widely expressed in the normal 
samples; a finding that concurred with the previous RT-PCR analysis (see Figures 5.10 and 5.11).  Interestingly, 
this was one of the predictive genes of a poor outcome in lung cancer. 
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LGALS14 is a placental-associated gene that was also identified as a predictive marker in lung 
cancer patients (Rousseaux et al., 2013b).  It did not appear on other germline lists (perhaps 
due to its placental and not testis-association) but was meta-upregulated in cancer, as well as 
being EST restricted when the germline list was challenged against these pipelines (see Figure 
5.13).  It did display a restricted expression profile in the normal tissues and also displayed only 
very weak/borderline expression in the testis.  It was additionally expressed in one colon cancer 
sample and one ovarian cancer sample (see Figure 5.22, group F).  Interestingly it was not 
shown to be expressed in lung cancer samples for which it was identified as a predictive marker, 
though it should be noted that it was not universally expressed in lung cancer or even the group 
with the worst prognosis in the Knochbin group study (Rousseaux et al., 2013b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22.  Gene expression of group G genes in normal and cancerous tissues.   
These genes belong to the group of 26 that Rousseaux and colleagues identified as predictive markers of a poor 
prognosis in lung cancer patients (Rousseaux et al., 2013b); the genes are also included in Figure 5.21 as they were 
taken from the category (F) genes.  Four of targets were not included on the TLDA cards: these were TPTE2P2, 
FLJ43944, Hs.601545 and C12orf37.  When considering the NAT samples as a single tissue type, the majority of 
these genes did display an expression pattern consistent with testis-restricted or testis-selective CT genes. 
 
 
HIST1H3C was shown to be testis-selective in normal tissues; expression was seen in bone 
marrow as well as one of the NAT colonic samples.  This gene had previously been described 
as having a testis only expression profile in normal tissues and it was one of 26 genes that 
predicted a poor prognosis in lung cancer (Rousseaux et al., 2013b).  In the cancer samples 
tested, four of the colonic cancer samples indicated that the gene was expressed and in addition 
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TPTE 21 - - - - - - -
CPA5 7 - - - - - - -
DPEP3 16 - - - - - - -
EBI3 19 - - - - - - -
HIST1H3C 6 - - - - - - -
ISM2 14 - - - - - - -
KIAA1257 3 - - - - - - -
F LGALS14 19 - - - - - - -
LOC441601 11 - - - - - - -
NBPF6;NBPF41 - - - - - - -
OR7E156P 13 - - - - - - -
RFX4 12 - - - - - - -
TUBA3C 13 - - - - - - -
VCY;VCY1B Y - - - - - - -
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one of the ovarian samples and one of the lung cancer samples also expressed this gene (see 
Figure 5.22).  Little is known about this gene’s association with cancer but it has been shown 
that methylation of this gene was associated with overall survival in neuroblastoma patients 
(Decock et al., 2012).  It was further shown that DNA methylation of this gene together with 
three other genes could predict which patients were more likely to survive from the cohort of 
patients collectively grouped as already being in a high risk, more aggressive disease category 
(Decock et al., 2012).  This highlights not only the important of epigenetic factors but also how 
traditional methods of stratifying disease are not entirely accurate.  In a similar way to that 
which Rousseaux and colleagues discovered (Rousseaux et al., 2013b), ectopic activation of 
tissue specific genes together with analysis of epigenetic alterations may prove a useful 
discriminator and selector for specific forms of therapy.  Both studies also highlight how 
combining factors (for example, gene expression and DNA methylation status) increases the 
accuracy of, or even enables, accurate stratification.  Validating appropriate combinations of 
such factors to accurately predict response to treatments or survival across the range of cancer 
types will be an ongoing challenge for scientists and clinicians into the future.  The methylation 
status of HIST1H3C was not investigated in the Knochbin group study (Rousseaux et al., 
2013b).  
5.4. Conclusions 
With reference to colorectal cancer C19orf67, CCDC83, DAZ1, IQCF1, ISM2, KLF17, 
LGALS14, ODF4, PLAC1, SPZ1, TEX19, TEX101, TKTL2, and various members of the MAGE 
family of CT genes appear to be potentially relevant CT genes.  All these genes were expressed 
in at least one colon cancer sample and displayed an expression profile in normal tissues 
consistent with a CT gene.  Many of these are not widely recognised as CT genes in colon 
cancer.  In addition to this, PIWIL1 and C16orf46 emerged as interesting candidate genes with 
limited expression in normal tissues but expression seen across many cancer samples tested.  
PIWIL1 displayed weak to moderate expression in some NAT colonic samples but expression 
was otherwise restricted to the testis in normal tissues, including normal non-adjacent cancer 
colonic tissue.  This is consistent with earlier findings using RT-PCR (see Figure 5.9).  The 
importance of PIWIL1 as a stem cell marker in colorectal cancer has recently been described 
(Litwin et al., 2015).  TEX19 and PIWIL1 were discussed previously in Chapter 4.  Consistent 
with the findings of previous studies two of the colon cancer samples were shown to co-express 
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several members of the MAGE family, suggesting a common mechanism of transcriptional 
activation.  It should be noted that this is a large gene family and we included relatively few 
members on the TLDA cards.  The two colon cancer samples that expressed the most candidate 
CT/germline genes were of an aggressive histological type, or had displayed the ability to 
metastasise (to the regional lymph nodes).  By focusing on a smaller cohort of genes, it may be 
possible to predict a worse outcome and/or guide therapy from biopsies taken early on during 
the diagnostic and staging process.  
 
Over 100 genes appeared as potential candidates for the development of immunotherapies given 
their limited expression in normal tissues.  All these genes could also potentially be utilised to 
improve cancer diagnostic and/or stratification techniques; though many of them display a very 
limited or no expression in the cancer samples tested in this study.  Additional discussion for 
some of these candidate genes is provided in the Appendix (Section 1).  As already mentioned, 
a major limitation of this work is that the experiments were not repeated and this is something 
that should be done before further exploratory work is carried out but the consistency seen 
between the findings of others and the separate RT-PCR and TLDA experiments is reassuring 
that the results can be trusted to some degree.   
 
The most promising of the genes selected and tested in this study are listed in the Table 5.3 
below.  These genes were selected on the basis that they displayed an expression profile 
consistent with a CT gene (i.e. tightly restricted to testis in the normal tissues tested or were 
testis-selective) and were also expressed in at least one of the cancer samples tested in this 
study.  Some well characterised CT genes are included (e.g., members of the MAGE family).  
This list provides a more focussed list of genes, which could be taken forward and tested on a 
larger cohort of cancer samples.  Statistical analysis could then be applied to test the possible 
predictive power of these genes in different cancer types but the smaller number of genes will 
both decrease the costs of gene expression profiling and reduce the problems related to 
‘statistical noise’ when dealing with a larger cohort of genes.  It should be remembered that 
potentially relevant genes have not been included in this list, as the limited number of samples, 
and indeed cancer types, tested may have failed to reveal expression of certain genes that does 
exist.  The cost of screening a large cohort of genes in a large cohort of cancers would be 
prohibitive, so the list provides a more manageable number to investigate further.   
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Some genes that display limited expression in normal tissues (perhaps excluding them as 
putative CT genes) but appear to be expressed with increased frequency in cancer have also 
been highlighted.  For example, C16orf46 is an uncharacterised gene but appears to be 
expressed frequently in cancers and is certainly worthy of further investigation.  Likewise, other 
genes (e.g. DAZL and SPACA3) appear to be expressed with increased frequency in colon 
cancer samples but their expression in normal tissues means they may not serve well as genes 
that have an “on-off” cancer detection signal and/or as targets for immunotherapy. 
 
 
Table 5.3.  Possible germline genes to focus further research on 
Germline-restricted Germline-selective* Colon cancer 
germline-restricted 
Colon cancer 
germline-selective* 
ARMC3 CCDC110 C19orf67 C20orf195 
C1orf65 DDX4 CCDC83 DAZ1 
CAPZA3 GK2 IQCF1 DDX53 
CTAGE1 HMGB4 KLF17 DKKL1 
FKBP9 ISM2 LGALS14 HIST1H3C 
HORMAD2 NBPF6 MAGEA1 MAGEA12 
LUZP4 PRSS54 MAGEA2 PIWIL1 
LYZL6 RBM46 MAGEA4 SPANX 
MBD3L1 SEPT12 MAGEA9 STK31 
NFX2 SMC1B MAGEB6 SYCP3 
NT5C1B TEX15 ODF4 SYNGR4 
PFN3  PLAC1 TEKT5 
PPP3R2  SPZ1 TEX101 
RAD21L1  TKTL2 TEX19 
STRA8    
SYCE1    
TGIF2LX    
TPTE    
TUBA3C    
VCY    
*Expression in up to two normal tissue types (i.e. testis-selective or testis/CNS-selective). NAT colonic samples 
are considered collectively as a single tissue type for this purpose.  The genes in the third and fourth columns are 
more promising potential biomarkers for colorectal cancer based on increased frequency or level of expression in 
the colon cancer samples tested compared to the normal samples in this study. 
 
 
Several candidate germline-associated genes that may be of relevance in cancer have been 
identified and the findings here with regards to previously identified cancer-associated genes 
are generally consistent, which confirms the validity of this exploratory study.  Some genes 
have been associated with cancers that have not been described previously.  For example, 
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LYZL6 with melanoma, TEX101 with colon cancer, and TPTE with melanoma and ovarian 
cancer.  The findings provide a platform on which to conduct further focussed research and the 
suggested list of germline genes on which to focus on is provided in Table 5.3.  This research 
should attempt to clarify the functional relevance of these often poorly characterised genes, as 
well as investigate their predictive power, for example, in transcriptomic profiling of cancer, 
which can potentially improve the classification/stratification of tumours with real clinical 
benefit.  
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6. General Discussion 
6.1. A move towards more precise personalised treatment in medicine 
The emergence and expansion of omics technologies together with the increased computational 
power of bioinformatical techniques is heralding what could be a paradigm shift in the way 
medicine is practiced in the modern world.  Historically medicine is driven by the symptoms of 
the patient to reach a diagnosis and then formulate a treatment plan.  However, the increased 
predictive power of combining various disease stratification approaches is likely to lead to 
personalised treatment strategies for patients and particularly so in the field of oncology (Duffy, 
2015; Vockley and Niederhuber, 2015).  This so called ‘precision medicine’ or ‘personalised 
medicine’ approach will clearly be expensive but the reduction in waste it could bring about, 
coupled with an improvement in the efficacy of treatments, could well make it not only 
affordable but in fact desirable (Duffy, 2015).  The same predictive tools that indicate treatment 
will not be effective for a certain group of patients, will at the same time reserve treatment 
strategies for patients that it is known will obtain clinical benefit.  Such an approach would 
reduce the morbidity associated with treatments and promote rational decision making in cases 
where the therapy is of marginal or no benefit.  In order to reach the goal of tailoring therapy 
effectively for the many different cancer types, it is likely that a considerable array of 
biomarkers will be needed.  Work presented here will contribute to the growing list of putative 
cancer-specific biomarkers that may help form part of personalised treatment strategies.  Close 
collaboration between clinical statisticians and bioinformaticians will be essential, as numerous 
sources of data are screened for this information, if we are to fulfil the promise of precision 
medicine.   
 
One problem of screening such vast and expanding data sources is being able to see through 
the ‘haze’ to reach clinically relevant predictive endpoints.  Rousseaux and colleagues (2013b) 
provided an example of how such problems can be overcome.  In this study they focussed on a 
limited number of genes that ultimately led to identifying a manageable list of 26 genes that 
were of considerable predictive value in lung cancer patients.  Similar gene lists for different 
cancer types may prove equally as powerful.  The cost of such an approach could also be widely 
affordable – it is conceivable that ‘omic-chips’ that analyse expression (and mutation) profiles 
for a limited number of genes could be developed and analysed relatively cheaply.  For 
example, if a diagnosis is suspected one ‘chip’ could be used (e.g., using a blood sample) or a 
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different one selected to screen a biopsy sample once a provisional diagnosis has been made.  
As the costs and accuracy of next generation sequencing using both liquid and FFPE samples 
improves (Pasquale et al., 2015; Sakai et al., 2015), it is conceivable that disease or cancer-type 
specific gene lists will not in fact be required.  Companies are already trying to cash-in using 
such liquid biopsy techniques (for example, Biocept Inc.) highlighting that the approach 
provides the most up-to-date information to clinicians about the state of the patients’ cancer.  
Mutations can evolve over the duration of disease and differ when cancer recurs following 
treatment – liquid biopsies can monitor this in real-time and help both guide therapy during 
treatment as well as pick-up on recurrences at an earlier stage.  Such approaches could even be 
used for screening certain at-risk populations.   
6.2. Germline genes in cancer 
Work here has focussed on germline-associated genes.  First I investigated a novel cohort of 
putative testis-specific genes and using clinically-derived cancer microarray datasets confirmed 
that some were significantly upregulated in prostate and ovarian cancer.  More genes were 
upregulated in individual datasets from a wider degree of cancer types, indicating that they 
could be relevant markers for sub-categories of cancers.   Dissecting the complexities of tumour 
subtypes together with intratumour heterogeneity is an ongoing challenge in the field of 
oncology and precision medicine (Blagden, 2015; Jamal-Hanjani et al., 2015; Seoane and De 
Mattos-Arruda, 2014).  The use of liquid biopsies to detect circulating free DNA and/or 
circulating tumour cells may help provide some degree of resolution without the need for 
detailed analysis of numerous areas of a given tumour.  Given the often very low frequency of 
expression of many germline genes in cancer makes it very challenging to attempt to reliably 
detect these genes from a liquid biopsy. 
 
It is possible that relevant genes were excluded in the validation process adopted in this 
research.  This is highlighted by the fact that there was a relatively poor overlap between genes 
that have been identified by the McFarlane group (Feichtinger et al., 2012; Sammut et al., 2014) 
and germline gene lists identified by the Knochbin group (Rousseaux et al., 2013).  It was hoped 
that a more stringent approach would enable us to identify genes that had a clear on/off signal 
that could be used in a relatively simple test enabling more ready translation into the clinical 
setting.  I attempted to collate a definitive list of germline genes and from this selected a cohort 
to investigate in normal and cancerous (predominantly CRC samples) human tissues.  A clear 
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subpopulation of CRC did not emerge expressing germline genes more widely.  This is possibly 
a limitation of the relatively small numbers of samples included in this study.  However, it does 
act as an indicator of how similar technology can potentially be utilised.  This list of genes 
proposed (see Table 4.8) may prove to be useful as a predictive panel of genes in different 
cancer types.  This would require screening of a much larger number of cancer samples.  This 
smaller list of ~50 targets makes such screening less financially constrained and provides a 
rational basis from which to take the exploratory study further. 
 
There is mounting evidence for a functional role of germline and meiotic factors in cancer 
biology.  Janic and colleagues (2010) were the first to establish that germline factors were 
oncogenic drivers in D. melanogaster.  Specific proteins known to play important roles in 
meiosis have now been shown to have a cancer-phenotype promoting effect when present in 
tumours: Hop2 and Mnd1 promote maintenance of telomere length via the ALT pathway and 
HORMAD1 promotes genetic instability through inhibition of the most effective DNA repair 
pathway (Cho et al., 2014; Watkins et al., 2015).  It has also been demonstrated that the human 
orthologues of the genes identified by Janic el al. (2010) are widely upregulated in human 
cancers suggesting a broader role of germline genes in cancer that is currently realised 
(Feichtinger et al., 2014).  Two novel germline proteins, TEX19 and C20orf201, have been 
shown here to be present and potential immunological targets for cancer therapy.  A functional 
role for these proteins in cancer, or indeed in normal physiology, remains to be clarified.  It is 
possible that TEX19 contributes to genetic instability when present in cancer and although a 
putative meiosis-associated protein, it may not play a direct role in meiosis. 
6.3. Concluding remarks and future directions 
Precision, or personalised, medicine is based on the predictive power of existing biomarkers 
and stratification techniques.  Gene expression is one important facet on which to focus 
stratification efforts and germline factors are emerging as useful in this regard.  Future work 
should screen a larger cohort of cancer samples and attempt to link germline gene expression 
to clinical outcomes in a range of cancer types.  A putative list of genes is proposed for further 
investigation based on their limited expression in the cancer samples tested in this research.  An 
alternative approach would be to screen a larger number of genes but the cost of such an 
approach is likely to be prohibitory.   
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The function of many germline and CT genes remains poorly characterised despite the interest 
in CTAs as targets for immunotherapy for some time, some of which have already been targeted 
(Hunder et al., 2008; Simpson et al., 2005; Whitehurst, 2014).  Establishing physiological roles 
for certain genes (for example, TEX19 and C16orf46) which appear to be widely expressed in 
human cancers should be a priority.  This may hint at important oncogenic roles.   Two novel 
putative CTAs (C20orf201 and TEX19) with immunogenic potential have been investigated.  
The tissue-specificity of the presence of these antigens in human cancers and normal tissues 
should be tested through the development of monoclonal antibodies, which may facilitate their 
transition to use within the clinical setting either as predictive biomarkers and/or therapeutic 
targets.  
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Appendix 
Section 1 – Further discussion  
Discussion of additional germline genes assessed using TLDA cards 
MeiCT genes 
PFN3 and PPP3R2 were both identified by our group as meiCT genes but have not otherwise 
been described as CTAs.  The normal physiological role of PFN3 remains unclear but it 
interacts with proteins close to the acrosome of developing sperm and its functions are 
believed to be distinct from other somatic members of this protein group (Behnen et al., 
2009).  Low-moderate levels of expression were seen in three separate cancer types on the 
TLDA arrays, though not clearly expressed in any of the colon cancer samples (see Figure 
5.16, group AC).  PPP3R2 has previously been shown to be a testis-specific gene, which may 
have a role in calcium-mediated signal transduction pathways and like many CT genes is 
activated by demethylation of its promoter region within the testis (Liu et al., 2005).  The 
TLDA array analysis revealed this gene to have a testis/CNS restricted expression pattern and 
in addition be expressed in one ovarian cancer sample.  The TLDA result therefore concurs 
with our previous validation of these genes as CT genes that may be of clinical relevance in a 
subset of cancers. 
 
We characterised TRIM42 as a novel meiCT gene, which was not detectable in any cancer 
tissues or cell lines but had a significant upregulation in prostate cancer when microarray 
datasets were meta-analysed (Sammut et al., 2014).  No other studies linking this gene to 
cancer have been identified in the literature and the TLDA analysis confirmed our previous 
findings of the gene expression being restricted to testis only; there was no expression in any 
of the cancer types we tested but those did not include prostate cancer for which an 
upregulation had been suggested by the microarray datasets (see Figure 5.16, group AC).  
C20orf201 is another poorly characterised gene, which had been identified previously as a 
meiCT gene that was testis/CNS restricted in normal tissue and significantly upregulated in 
ovarian cancer in the clinical datasets (Feichtinger et al., 2012b).  The TLDA gene expression 
results revealed testis/CNS-selective expression, with additional expression in at least one 
sample of each of the four cancer types tested (see Figure 5.16, group AC). 
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ODF3 and ODF4 are testis-specific genes that have not been extensively investigated in 
cancer though both are considered CT genes (Almeida et al., 2009).  We had also 
characterised these genes as candidate meiCT genes, with both genes appearing to be 
upregulated in ovarian cancer though only ODF4 displayed a statistically significant 
upregulation in gene expression when combined clinical datasets were meta-analysed 
(Feichtinger et al., 2012b).  ODF4 has been found to be expressed in chronic myeloid 
leukaemia (Ghafouri-Fard et al., 2012).  Neither gene was found to be expressed in prostate 
cancer samples but SPATA19 was, in 40% of the samples tested, in a separate study 
(Ghafouri-Fard et al., 2010); this gene was present on the extended germline gene lists 
compiled by the McFarlane and Knochbin groups (e.g., see Figure 5.17, group CEF).  ODF3 
was not expressed in a small cohort of breast cancer samples tested in another study 
(Dianatpour et al., 2012).  We found ODF3 to be expressed in testis but none of the other 
samples tested.  ODF4 on the other hand was testis-restricted in the normal tissues but was 
strongly expressed in one colon cancer and one lung cancer sample (e.g., see Figure 5.16, 
group ACE).  It has not been previously identified as a candidate CTA in either of these 
cancer types, which makes this a novel finding of this research; its possible role in 
tumorigenesis remains obscure.   
 
SMC1B and RAD21L are meiosis specific genes, which encode subunits of the cohesin 
complex (Strunnikov, 2013).  We identified both of these genes as potential CTAs previously 
and a possible role for these genes in contributing to chromosomal instability through 
reactivation of their meiotic function in cancer has been postulated (Feichtinger et al., 2012; 
Strunnikov, 2013).  SMC1B was revealed as having a micro-RNA binding site single 
nucleotide polymorphism associated with recurrence in head and neck cancers (Zhang et al., 
2010).  SMC1B has been shown to be present in pancreatic cancer and to interact with p53 
(Ansari et al., 2015).  Increased expression levels have also been observed in a radiotherapy-
resistant non-small cell lung cancer cell line compared to a radiosensitive lung cancer cell line 
(Kim et al., 2011).  Expression of SMC1B has also been linked to more aggressive forms of 
breast cancer (Hsiao et al., 2010).  The TLDA analysis revealed testis-selective expression in 
normal tissue.  Expression was seen in foetal liver and also a NAT colonic sample; this latter 
finding was made more surprising by the fact that the corresponding cancer sample did not 
express the gene (see Figure 5.16, group A).  Two melanoma samples and one ovarian cancer 
sample also expressed the gene, so it may be contributing to oncogenesis/chromosomal 
instability in these cancer types. 
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SPZ1 has previously been shown to have an expression profile tightly restricted to the testis in 
normal tissues (Sha et al., 2003).  We independently found it to have a testis-restricted 
expression profile and classified it as a meiCT gene (Sammut et al., 2014).  Furthermore, 
meta-analysis of microarray datasets indicated this gene was significantly upregulated in 
ovarian cancer (Sammut et al., 2014).  The TLDA analysis once again revealed a testis-
restricted expression pattern in normal tissues.  In the cancer samples it was expressed in one 
colon cancer sample and two ovarian cancer samples (e.g., see Figure 5.16, group ACF).  This 
increases the evidence or likelihood that this gene is clinically relevant in ovarian cancer and 
this is certainly worthy of further exploration.  It has been shown using a mouse model that 
SPZ1 regulates PCNA expression and promotes cellular proliferation (Hsu et al., 2005).  It 
was further suggested that SPZ1 may act as an oncogene through interaction with the Ras 
signalling pathway.  KRAS mutations are common in colorectal cancers and given that SPZ1 
was found to be expressed in one of the colon cancer samples, it would be interesting to 
investigate if there is an interaction with Ras in a subset of patients with CRC. 
 
We characterised TRIML1 as a novel meiCT gene that has not otherwise been associated with 
oncogenesis (Feichtinger et al., 2012b).  It has been identified as a possible regulator of 
embryo development in its early preimplantation stage (Tian et al., 2009), which is consistent 
with its categorisation and inclusion here as a germline-associated gene.  The TLDA analysis 
revealed a testis-selective expression profile with weak-moderate expression in normal colon 
and ovarian samples (see Figure 5.16, group AC).  There was strong expression in one of the 
colon cancer samples only.  A possible oncogenic role for this gene remains obscure. 
 
STRA8 is involved in the early stages of meiosis and believed to be an inducer of meiosis in 
both the testis and ovary; retinoic acid (RA) promotes the expression of this gene in 
spermatogonia (Rossi and Dolci, 2013).  STRA8 was identified as a novel meiCT gene but has 
not otherwise been described as a CTA (Feichtinger et al., 2012b).  The TLDA analysis in 
this study has indicated, as expected, testis-restricted expression in normal tissues.  STRA8 
was expressed in all ovarian cancer samples tested (2 out of the 4 samples were not tested for 
this gene) and one of the lung cancer samples (see Figure 5.16, group AC).  This is a novel 
and potentially important finding, though an oncogenic or predictive role for this gene in 
these cancer types remains to be established.  It has been suggested that RA may, through 
STRA8 expression, drive mTORC1 activation in spermatogonial progenitor cells to influence 
cellular differentiation within the testis (Hobbs et al., 2015).  Given the importance of mTOR 
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signalling in cancer as well as stem cell self-renewal (Cargnello et al., 2015; Guertin and 
Sabatini, 2007; Xu et al., 2014), this raises the possibility of STRA8 impacting on such 
signalling pathways if ectopically activated in cancer.  This is somewhat speculative and 
would need to be investigated by further research but the confirmation of STRA8 expression 
in lung and ovarian cancer is important and interesting. 
 
TULP2 belongs to a family of genes that were originally thought to encode transcription 
factors and have been implicated as having roles in various biological and signal transduction 
processes primarily within the CNS (Boggon et al., 1999; Carroll et al., 2004).  TULP2 has 
high levels of expression in the testis and low levels of expression in the normal retina, which 
is another immunologically privileged site; its function remains poorly characterised (Carroll 
et al., 2004).  The gene was included in the spermatocyte-associated and germline-specific 
genes compiled by the McFarlane and Knochbin groups, respectively (Feichtinger et al., 
2012b; Rousseaux et al., 2013).  It is also listed as a CT gene but I am not aware of other 
researchers proposing this gene as a CTA or linking it to cancer (Almeida et al., 2009).  The 
TLDA analysis revealed that the gene was expressed in normal testis, foetal liver, ovary and 
CNS tissues, consistent with it being a testis/CNS-selective CT gene.  Within the cancer 
samples, one colon cancer, one melanoma and two ovarian cancers expressed this gene (e.g., 
see Figure 5.17, group CEF).  Its relevance as a biomarker or therapeutic target in these 
cancer types remains to be established but another member of this gene family TULP3, has 
recently been shown to be a predictive biomarker in pancreatic cancer (Sartor et al., 2014). 
 
LYZL6 is expressed in the male testis and belongs to a family of lysozymes that can cause 
bacterial cell wall disruption.  It has been confirmed, using a yeast expression system, that the 
protein has antibacterial properties (Zhou et al., 2014).  I found the gene to be expressed in a 
melanoma sample and testis only, suggesting that it may be a novel CT gene (see Figure 5.16, 
group ACF).  It was identified as a testis-specific germline gene but not associated with a 
worse outcome in lung cancer in the Knochbin group study (Rousseaux et al., 2013b).  It has 
not been previously described as a CTA and has no known oncogenic effects.  Different 
lysozymes have been shown to suppress proliferation of breast cancer cells (Mahanta et al., 
2015) but conversely the presence of the protein has been shown to be of differing prognostic 
significance in breast cancers in men and women (Serra et al., 2002; Vizoso et al., 2001).  It 
should be noted that these studies were not specifically investigating LYZL6 or the gene 
product but some degree of functional overlap between these proteins of the innate immune 
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system will be expected.  The possible relevance of LYZL6 in cancer requires further 
clarification but the expression of this gene in cancer is a novel finding of this research.  
 
Our group identified and classified SEPT12 as a meiCT gene that had a significant 
upregulation in ovarian cancer microarray datasets (Feichtinger et al., 2012b).  SPAG4 is 
considered a known CTA (Almeida et al., 2009), although we found this gene to be widely 
expressed in the normal tissues tested.  There was, however, more consistent and higher 
expression in the cancer samples.  Thus, it may be another example of a CT gene that is 
expressed in normal tissues but at low levels; it should be remembered that the fold change in 
gene expression in normal tissues compared to testis and cancer, is an alternative way of 
classifying CT genes as discussed in the introduction.  Consistent with our findings, it has 
separately been shown that normal heart, lung, kidney, spleen, uterus and placenta expressed 
SPAG4 but the strength of the bands on the agarose gel was much weaker in these tissues 
compared to testis (Yeh et al., 2015).  This confirms that the readout from the TLDA card is 
most likely accurate, even though SPAG4 is considered a CTA.  SEPT12 displayed a 
testis/CNS-selective expression pattern in the normal tissues we tested; in the cancer samples 
it was not expressed in the colon cancer but was found in a melanoma, ovarian and lung 
cancer sample.  There was moderately strong expression in the ovarian cancer and melanoma 
sample that expressed SEPT12 and SPAG4 (see Figure 5.16, group ACF and Figure 5.18, 
group E).  It has been shown that the products of these two genes co-localise in developing 
sperm cells and functionally interact (Yeh et al., 2015).  It is possible that there is a functional 
interaction when they are co-expressed in cancer, though this finding could also relate to a 
common mechanism of transcriptional upregulation, such as demethylation, in cancer.  
Known CTA-encoding genes 
Although SPANXC/E was expressed in three of the NAT colonic samples; this gene was also 
strongly expressed in the recurrent malignant melanoma sample and the metastatic squamous 
carcinoma of the lung (e.g., see Figure 5.21, group BEF).  SPANX was one of three CT genes 
previously shown to correlate with the presence of liver metastases in CRC (Chen et al., 
2010).  There are numerous members of this gene family and the promotor region is shared 
with other CT genes, including VCY, suggesting a common ancestry (Hansen et al., 2008).  
The specificity of primers to detect individual members of such paralogous gene families 
creates a difficulty in comparing expression profiles between studies (the assay selected for 
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the TLDA cards did not differentiate between SPANXC and SPANXE).  SPANX genes have 
previously been shown to be expressed in ovarian cancer cell lines, as well as melanoma cell 
lines and tumour specimens (Westbrook et al., 2004).  This is consistent with the expression 
seen in the melanoma and ovarian cancer samples in this research (see Figure 5.21).  More 
recently the presence of CT genes, including a member of the SPANX family, have been 
shown to negatively correlate with EMT markers and be associated with the epithelial rather 
than mesenchymal phenotype in a CRC cell line model (Yilmaz-Ozcan et al., 2014).  As the 
products of these genes have been shown to elicit immune responses in vivo they might be 
attractive targets for immunotherapy (Almanzar et al., 2009). 
 
CTAGE1 is a CTA gene that has been shown to be of potential importance in patients with 
lymphomas, glioma and melanoma (Akiyama et al., 2014; Liggins et al., 2010; Litvinov et 
al., 2014; Usener et al., 2003).  In this study CTAGE1 was confirmed as a gene with restricted 
tissue expression in the testis in normal tissues and was expressed in an ovarian cancer sample 
(e.g., see Figure 5.21, group BEF).  This raises the possibility of this CT gene being clinically 
relevant in ovarian cancer, which has not been described previously. 
 
DDX53 also belongs to the category of known CT genes and was also included in the 
extended list of germline genes compiled by the Knochbin group (Almeida et al., 2009; 
Rousseaux et al., 2013).  It was not present on the list of human orthologues from which the 
meiCT genes were derived.  From the TLDA analysis conducted here it would have been 
categorised as testis/CNS-selective, so would not have been discarded at this validation stage.  
Within the cancer samples there was moderately high expression in one of the colon cancer 
samples tested as well as an ovarian cancer sample (e.g., see Figure 5.21, group BEF).  The 
gene was not expressed in either of the two lung cancer samples tested, although it has been 
proposed and investigated as a possible diagnostic marker in lung cancer patients (Chapman 
et al., 2012; Wang et al., 2014).  Functionally DDX53, which is also known as CAGE and 
CT26, encodes the CAGE protein that has been shown to increase cellular proliferation by 
enhancing cyclin-dependant kinase activity (Por et al., 2010) and also contributes to drug 
resistance via a negative impact on p53 levels in hepatocellular and melanoma cell lines (Kim 
et al., 2010).  Thus, whenever the gene is expressed, it is potentially clinically important and 
may be a useful predictive biomarker in combination with other cancer-associated genes. 
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TTK has previously been described as a CT gene that is able to elicit a T-cell response in 
patients with squamous cell carcinoma of the oesophagus and was subsequently used as part 
of a cancer vaccine targeting multiple CTAs (Kono et al., 2012; Mizukami et al., 2008).  
Higher levels of TTK expression have also been linked with recurrent prostate cancer 
(Shiraishi et al., 2011).  The TTK antigen has been one of multiple targets of novel cancer 
vaccine therapies, evaluated in early phase clinical trials in lung cancer and 
cholangiocarcinoma (Aruga et al., 2013; Suzuki et al., 2013).  The gene was expressed in 
bone marrow, stomach and normal ovarian tissue as well as being widely expressed in NAT 
colonic tissue in this study.  Using our stringent screening approach, we would have excluded 
this gene from further analysis on this basis.  Higher levels of expression for this gene were 
seen in the colon cancer samples, as well as in melanoma, lung and ovarian cancer (see Figure 
5.18, group E).  Given that this CTA has been used as a target for immunotherapy without 
serious adverse side effects, implies that low levels of expression of this gene produce such 
low amounts of protein in these tissues that it is not clinically relevant.  It also highlights the 
complexity of selecting targets for disease stratification and/or treatment in cancer. 
 
SPAG9 is considered a CT gene (Almeida et al., 2009), though neither the McFarlane group 
nor the Knochbin group identified this gene as spermatocyte- or germline-associated in the 
list compiled independently (Feichtinger et al., 2012b; Rousseaux et al., 2013b).  It has been 
highlighted as a possible cancer biomarker and/or therapeutic target in many cancer types and 
implicated in promotion of tumour proliferation and invasion (Jilg et al., 2014; Mirandola et 
al., 2011; Yi et al., 2013).  It has been shown here that SPAG9 was widely expressed in both 
normal and cancerous tissues, although there was a more consistently high expression in the 
cancer samples (see Figure 5.18, group E).  However, the high levels of expression in the 
normal tissues is at odds with what is known about this gene and it could suggest a lack of 
specificity with the primers for this target.  The assay I chose for this gene was exon-spanning 
so this should obviate the possibility of genomic contamination but it would be important to 
repeat this using a different assay/primer set.  The alternative conclusion is that SPAG9 would 
not be a suitable candidate to take forward using a more focused list of genes using TLDA 
cards (i.e. looking for an “on-off” signal).  It has been shown recently that a fusion transcript 
occurs between SPAG9 and JAK2 in an aggressive form of acute lymphoblastic leukaemia 
(Kawamura et al., 2015).  It is possible that previous studies have detected SPAG9 as a fusion 
gene, which is why it was absent from our and the Knochbin groups expanded gene lists (see 
Appendix B, on CD for full lists). 
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TPTE is a well characterised CT gene that has been implicated as playing a role in several 
cancer types (Almeida et al., 2009; Dong et al., 2003; Simon et al., 2014).  It was first 
described as a CT gene not long after its initial discovery where it was shown to share 
significant homology to the tumour suppressor gene PTEN and gained its alias name as 
PTEN2 (Chen et al., 1999; Dong et al., 2003; Wu et al., 2001).  More recently several 
epitopes for this gene have been identified that may be important in targeting the TAA that is 
encoded by this gene (Simon et al., 2014).  TPTE was not identified as a candidate meiCT 
gene but Rousseaux and colleagues found that the expression of this gene along with 25 other 
germline genes predicted a worse outcome in lung cancer (Rousseaux et al., 2013b).  We 
found the gene to be expressed in a melanoma and ovarian cancer sample and as expected the 
gene expression was restricted to testis in normal tissue (e.g., see Figure 5.18, group EF).  The 
gene was not expressed in any of the colon cancer samples tested.  The expression of this 
gene in ovarian cancer and melanoma appears to be a novel finding as no reference in the 
English language linking the gene to these cancer types has been identified.  Mutations in 
TPTE have been shown to permit phosphatase activity and impact on cell migration (Leslie et 
al., 2007).  Clarification of a possible role for this gene as an oncogenic driver or predictive 
biomarker should be investigated further across a range of cancer types.  
Other tissue-specific genes identified by the Knochbin group 
We chose to include STK31 as it was present on both our extended list of spermatocyte-
associated genes and the list of germline tissue-restricted genes that Rousseaux and colleagues 
compiled (Feichtinger et al., 2012; Rousseaux et al., 2013b).  In normal tissues the gene was 
shown to have testis/CNS-selective expression, being expressed in ovarian and normal 
adjacent colonic cancer tissue types only.  In the cancer samples, the gene appeared to have 
higher expression in four of the colon cancer samples and in addition had moderate 
expression in both lung cancer samples and an ovarian cancer sample.  Although not included 
on CTdatabase (Almeida et al., 2009) it was proposed as a novel CT gene implicated in 
gastrointestinal tract cancer (Yokoe et al., 2008).  It was subsequently shown that 
overexpression of STK31 in a duodenal cancer cell line promoted invasive abilities but not 
proliferation and conversely knockdown led to apoptosis (Kuo et al., 2014).  STK31 localised 
with the centrosomes of this cell line and it was concluded that the protein may be involved in 
cell cycle regulation through an interaction with the spindle assembly checkpoint mechanism 
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(Kuo et al., 2014).  Through analysis of driver mutations in melanoma, STK31 has also been 
identified as a possible target for novel therapies in this cancer type (Xia et al., 2014).  We 
found the gene to be expressed in melanoma also.  The expression of the gene widely in 
normal adjacent colon cancer tissues may limit the use of the protein as a target for 
immunotherapeutic approaches.  Expression was not demonstrated in the commercially 
obtained normal colonic sample used, so it is possible that the gene activation results from 
field cancerisation within the colonic mucosa.  Further analysis is required to establish to 
what extent there is expression in normal tissues as my results indicate there may be higher 
expression than other groups have reported (Yokoe et al., 2008). 
 
We identified TKTL2 as an orthologue of a mouse spermatocyte-associated gene but did not 
validate it as a candidate meiCT gene (Feichtinger et al., 2012b).  Rousseaux and colleagues 
also identified this gene as being testis-specific and moreover, it was included in their final 
list of 26 genes that predicted an unfavourable outcome in lung cancer patients (Rousseaux et 
al., 2013b).  On the TLDA analysis the gene had a testis/CNS-restricted expression pattern 
and in addition one of the colon cancer samples expressed this gene (see Figure 5.17, group 
CF).  The Knochbin group study was the first to link this gene to cancer (Rousseaux et al., 
2013b).  A related gene, TKTL1, has been linked to various cancer types, including cervical 
and nasopharyngeal cancer where it promoted proliferation of cells in vitro and it was 
additionally correlated with disease progression in nasopharyngeal cancer (Chen et al., 2009; 
Zhang et al., 2008).  These studies did not find TKTL2 to be upregulated.  TKTL1, which is 
not testis-specific, has also been linked to adverse clinical outcomes in lung and CRC (Diaz-
Moralli et al., 2011; Kayser et al., 2011).  A plausible mechanism for the gene’s association 
with a worse outcome in solid tumours is through its effect on glucose metabolism and energy 
supply to tumour cells within a hypoxic tumour microenvironment (Bentz et al., 2013).  
Given that TKTL2 is a member of a group of genes that can independently predict a poor 
outcome in lung cancer and the gene appears to be expressed occasionally in colon cancer, 
further work should be conducted to both establish a function for this gene and assess whether 
it could form part of a predictive panel of genes across a wider range of cancer types. 
 
TUBA3C has been implicated as playing a pivotal role in sperm motility as well as autosomal 
dominant genetic syndromes (Mikelsaar et al., 2012).  There had been no report of a link to 
cancer in the medical literature for this gene until Knochbin and colleagues identified this 
gene as a member of a predictive cohort of genes in lung cancer (Rousseaux et al., 2013b).  
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Other members of the TUBA family were identified as orthologues of mouse spermatocyte-
associated genes but these were not validated as meiCT genes (Feichtinger et al., 2012b).  In 
this study we found the gene to be expressed in one of the lung cancer samples, which is 
consistent with the Rousseaux paper (see Figure 5.22, group F).  There was also very 
weak/borderline expression in all the melanoma samples tested (2 out of the 4 samples were 
not tested for this gene) providing the first evidence that this gene may be a biomarker for this 
cancer type also but this requires clarification through further research to confirm definite 
expression and clinical relevance.  None of the colon cancer samples expressed this gene and 
it was restricted to the testis in the normal tissues that were tested. 
 
VCY has been implicated in ribosomal assembly during spermatogenesis and was another 
gene identified as a predictor of poor outcome in lung cancer (Rousseaux et al., 2013b; Zou et 
al., 2003).  It has since been confirmed as a CTA with varying frequency in different lung 
cancer types (Taguchi et al., 2014).  It has not otherwise been described as a CT gene.  It had 
a testis-restricted expression profile in normal tissues and appeared to be expressed strongly 
in melanoma only within the cancer samples we tested (see Figure 5.22, group F).  Thus, it 
would be interesting to investigate the expression and function of this gene further in 
melanoma. 
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Section 2 – Primers used for RT-PCR 
Table 1.  List of primers used for RT-PCR, annealing temperatures and PCR 
cycling conditions
Gene/primer 
name 
Sequence (5’ – 3’) Length  CG
% 
Tm Size PCR 
cycle 
ACTB - F CAAACATGATCTGGGTCATCT 21 42.9 55.6 353 E 
ACTB – R GCTCGTCGTCGACAACGGCTC 21 66.7 66.0   
             
ACTL9 - F CAGTCGGTGCTGTCTGTCTA 20 55 59.1 488 E 
ACTL9 - R CCGCAGAGAAGCACGTTTTG 20 55 60.4  * 
             
ADAM2 – F CTGTGCTGAAGGACCATGCT 20 55 60.3 610 B 
ADAM2 – R GCCACTGTCAATACTCCCAC 20 55 58.3   
             
ASB17 – F GGGTCAGTGGGGATATCACT 20 55 58.2 327 B 
ASB17 – R GGGCTTGGACAGTATACTGG 20 55 57.4   
             
BOLL – F ATGACAGAGCTGGAGTATCC 20 50 56.1 657 A 
BOLL – R TGGCACTTGGAGCATAAACC 20 50 58.5   
        
BTG4 – F GCCTCATCAGACGTTTCCTC 20 55 58.4 125 F 
BTG4 – R AAGGGCTGTTTCAAGTTTTCAA 22 36.4 57.2   
             
C1orf141 – F1 CCCGTTGTGCTTTGAGGATG 20 55 59.5 565 I 
C1orf141 – R1 TGTGGGTATGCTCGTTGGTT 20 50 59.6   
             
C1orf141 – F2 ACATCCGCGTCTAAGGCAAT 20 50 59.8 367 B 
C1orf141 – R2 CAAAGCACAACGGGAGCAAG 20 55 60.3   
             
C10orf67 – F1 GCTTTTCCTCCTCCTTGAGG 20 55 57.9 293 E 
C10orf67 – R1 CCCAAAATCTACCTGGAGGG 20 55 57.3   
             
C10orf82 – F CTGCCAAGGAATGTCCAAGGA 21 52.4 60.3 134 H 
C10orf82 – R TGACAGGTTTCAGTTTCGGGG 21 52.4 60.5   
             
C12orf37 – F ATGGGATGCTTTGATTGCTC 20 45 56.4 143 F 
C12orf37 – R AGAGATGTGAGGCTGGCAGT 20 55 60.9   
             
C12orf50 – F ATGCTTCTGGGAAACTCAGC 20 50 58.2 539 A 
C12orf50 – R CAGTCTTTGGTTTCCCATGC 20 50 57.3   
             
C16orf78 – F CAGGGGAAGAAGAAACAAGC 20 50 56.6 405 A 
C16orf78 – R GTCTCTTATGAAGGTTGCCC 20 50 55.8   
             
C2orf61 – F2 GGGCAATACAACGTGCTTCC 20 55 59.8 204 C 
C2orf61 – R2 ACAGCTGGGCAAGAATCGAG 20 55 60.4   
             
C3orf22 - F CAGTGCCTGCAAGAAGTCTC 20 55 58.8 294 E 
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C3orf22 – R CAAAGGTTGCACAGTGGAGG 20 55 59.3   
             
C3orf30 – F GACCAGACTGACCACTTAGC 20 55 57.6 563 B 
C3orf30 – R AAATTCAGGGGGTCCTCTGG 20 55 59   
             
C6orf81 – F GCAAACAGGATGAGTATGCC 20 50 56.9 603 A 
C6orf81 – R GCAGGGACTGTTCGTTGTAA 20 50 58.1   
             
C8orf74 - F CCAGGTGGTCAAGTTCACAG 20 55 58.4 551 E 
C8orf74 - R GGTCCAAGATGGCGAATGTG 20 55 59.3   
             
C9orf153 – F1 GCCACCCTTCCTCAATGTTCA 21 52.4 60.6 711 C 
C9orf153 – R1 TGGAGATGGGGTCTTTCTATGTTTT 25 40 60   
             
C9orf153 – F2 ATGTTCCTCACTGGAGACACC 21 52.4 59.4 273 C 
C9orf153 – R2 ATGTTTTCCAGGCTTGTTCATT 22 36.4 57.0   
             
CAPZA3 - F GTACCACTCTGCATCGATGG 20 55 58.1 645 E 
CAPZA3 - R GTCAGAGAGTATCCTGTGCC 20 55 57.1  * 
             
CCDC116 – F1 TGTGAGGGACAAACTCCTGC 20 55 59.9 721 B 
CCDC116 – R1 GTGAGACATGCTGGACTTCG 20 55 58.7   
             
CCDC116 – F2 GCTTTCAGTGGACACAGGAG 20 55 58.5 555 B 
CCDC116 – R2 GCGGCTTCTTCTTCGTGAAC 20 55 59.8   
             
CCDC63 – F GGACACCTCTCAGTACAACC 20 55 57.3 614 E 
CCDC63 – R GCGGAAGGTTGATGTCAGTG 20 55 59.2   
             
CCDC73 – F TGAGCTGCAAAGGGAGAAGG 20 55 60 881 C 
CCDC73 – R GTTCTCGAGTCCCTGGAAGC 20 60 60.1   
             
CCDC83 – F AATCCTCGTCATCTGCTGCT 20 50 59.2 90 F 
CCDC83 – R TCCAGCAGCTTGGGTAAGATA 21 47.6 58.5   
             
CCIN – F CAGCGCACTCATCAATTGGG 20 55 59.9 369 C 
CCIN – R CTAAGTGCTGCTGCCCGATA 20 55 59.9  * 
             
CPA5 – F CAGCACCAACAGCTTCAGTT 20 50 59 76 G 
CPA5 – R CATTACAAAGTTGTCAATCCAGCTA 25 36 57.9   
             
DDI1 – F GAGCAGCAAAGGGAAAAGGC 20 55 60 591  A 
DDI1 – R GTCCGAAGACTCATCTTGCC 20 55 58.4  * 
             
DNAJC5G – F GATGAGCCTCTATGCAGTGC 20 55 58.5 464 B 
DNAJC5G – R GCTGACTCTGGACATTCTGC 20 55 58.6   
             
DPEP3 – F CCTGGACAGGCTTAGAGACG 20 60 59.5  72 H 
DPEP3 – R TCCTGGGACTGGCATGAG 18 61.1 58.3   
             
DYDC1 - F CCTTGGGGCCTGTTTAACTC 20 55 58.5  444 E 
DYDC1 - R CTGCTCAAGTTAGGTGCTCC 20 55 58.3   
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EB13 – F CCTGCAGTGGAAGGAAAGG 19 57.9 58.1 100  G 
EB13 – R AGGGTCCAGGAGCAATCC 18 61.1 58.3   
             
FAM170A – F1 CGTTTCTTCTTCACGCAAGC 20 50 58.3 305  A 
FAM170A – 
R1 
TCACTTCTTCCATCCTTGGC 20 50 57.5   
             
FAM170A – F2 TGAAGAGTCCCAGGAAACCG 20 55 59.3 305  B 
FAM170A – 
R2 
CTTCTTCCATCCTTGGCTGC 20 55 58.9 + 446  
             
FAM194A - F GCTGAACCTGAATGTCTGGC 20 55 59.2 413  B 
FAM194A - R GCTGCATGAGGGTCAATAGC 20 55 59.1   
             
FAM71B - F GCAGTTGTGTCCCTCTTCTG 20 55 58.5 537  E 
FAM71B - R GCCATGGACTTGCTGGATTC 20 55 59.3   
             
FIGLA – F CTCAACCGTGGTTTTGCCAG 20 55 60 371  C 
FIGLA – R TCCAGACTTCTGGTTGGGGA 20 55 60.1   
             
FLJ43944 – F ACTGTAATGCTCGGCAAGGT 20 50 59.7  X G 
FLJ43944 – R CTGAGTTTTCTGGGGAGGTGG 21 57.1 60.3   
             
GK2 – F TATTGGGAGCCCAGTGCAAG 20 55 60 309  C 
GK2 – R GCTCCAAACGCTTACTCCCT 20 55 60  * 
             
H2AFB1 – F CGAGCGGAGCTTTCGTTTTC 20 55 60.2 264  D 
H2AFB1 – R CAGGGCCACTTGAGAGATGG 20 60 60.1  * 
             
HEATR7B1 - F CAGCAGCCAGAATCTGATGG 20 55 58.7  633 E 
HEATR7B1 - 
R 
CAGGAACTTTGCCCACCTTG 20 55 59.3   
             
HIST1H3C – F GTCTAGTAATGAACCAATCAGTCTGG 26 42.3 59.2  X F 
HIST1H3C – R AGTCCCGCGCGATAAAAT 18 50 57.2  * 
             
HMGB4 – F CCAGCTAAAGCCTAAGGCAA 20 50 57.9 449  A 
HMGB4 – R CGAAGTACTTAGCTCTCAGG 20 50 54.8  * 
             
IQCF1 - F GAGCAGAGTCAAAGGCAGAG 20 55 58.3 481  E 
IQCF1 – R GAGTCCAGCAAGATCTCCAG 20 55 57.4   
             
ISM2 – F ACTCGGCCCTGTGGCTAT 18 61.1 60.4 87  H 
ISM2 – R GGTGTCCTTGTCCTCAGTGC 20 60 60.6   
             
KIAA1257 – F GACGATTCTTGGACGATTCAA 21 42.9 56.4 86  F 
KIAA1257 – R AATTCCTTGATCTCCATCATGC 22 40.9 56.5   
             
KLF17 – F1 CTCGACAGTACCTTCTGACG 20 55 57.5 461  E 
KLF17 – R1 CCCGCATATGTCGTCTAAGC 20 55 58.6   
             
KLF17 – F2 AGTAGAGAAGAACTCCAGGC 20 50 56 314 B 
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KLF17 – R2 GATGAGTCTTCTGGTGTTGC 20 50 56.5   
             
LGALS14 – F TCACTTTTGTCAAGGACCCAC 21 47.6 58.4 211  H 
LGALS14 – R TTGTGACGCACATAGATGCAC 21 47.6 59.3   
             
LOC441601 – 
F 
GCCAAAGCAGACACACTCAC 20 55 59.7  X I 
LOC441601 – 
R 
ACAATGTTCACCATTTTCAACTGT 24 33.3 58   
             
LYZL6 – F GGCGCTACTCATCTATTTGG 20 50 56.1 348  A 
LYZL6 – R CCGGACACAATCCTTTTTGC 20 50 57.9   
             
MAGEB6 – F TGAGCCTGAAAAGTGCTGTC 20 50 58.4 93  H 
MAGEB6 – R TGTGGGTAGGAAGACTAGGAAGG 23 52.2 60.6   
             
NBPF4 – F CATGCTGAGAGCGCAGAG 18 61.1 58.3 62  F 
NBPF4 – R TTTCATCCTGCCATCCTTTG 20 45 56   
             
NY-ESO-1 – F CTGAATGGATGCTGCAGATGC 21 52.4 60.0  279 E 
NY-ESO-1 – R CTGCGTGATCCACATCAACAG 21 52.4 59.6   
             
OR7E156P – F TGAGAATTCTCTTGCCTGCC 20 50 57.9 X  G 
OR7E156P – R GAGAAAAGGGTCCCAGAGAT 20 50 56.2   
             
PDHA2 – F1 CGAGTTGCCCAGAAATCAGC 20 55 59.6  374 B 
PDHA2 – R1 AGCTCTGCGAGAATGGATCG 20 55 60  * 
             
PDHA2 – F2 CTCACCTCAGCCCCAATTTC 20 55 57.2  679 B 
PDHA2 – R2 CCTATAGGGCTCATGGTGTG 20 55 58.5  * 
             
PDILT – F GACGAACCCAGAAATGGACG 20 55 58.9 404 B 
PDILT – R GCTGTGACATCGATCTTGGC 20 55 59.4   
             
PIWIL1 – F AGAGGTTACCAGACCAGAATGG 22 50 59.2  77 J 
PIWIL1 – R GTGTGGGAGAAACACTACCACTT 23 47.8 60.4   
             
PPP3R2 – F1 GGGCAGGAGGTTTAAGAAGT 20 50 57.1  401 A 
PPP3R2 – R1 CCACAGCACTGAATTCCTCA 20 50 57.8  * 
             
PPP3R2 – F2 GTCCACAATGGGAAACGAGG 20 55 58.8  509 B 
PPP3R2 – R2 GGACCAGCTTCTTGTGGATC 20 55 58.3  * 
             
PRPS1L1 – F GACGGAGTGCCTCTGGTAG 19 63.2 59.2 728  C 
PRPS1L1 – R CAGCTGCGAGGCAGATTGTA 20 55 60.5  * 
             
RBM44 – F CAGATGTGTCGTCGCCATTG 20 55 59.6  548 E 
RBM44 – R GAGACGTCAACTCCTGTCAG 20 55 57.7   
             
RBM46 – F GGAAATTTGGCGGTCCTC 18 55.6 56.1  70 G 
RBM46 – R CCTACAAAAACTTCACAGCCTCT 23 43.5 58.9   
             
RFX4 – F CATCACCAAGCAAACCCTTT 20 45 56.8  117 G 
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RFX4 – R GACTCGATGGGAGACTGCTC 20 60 59.6   
             
RNF133 – F GGTGGGGAGAAAGCACATCA 20 55 60  347 C 
RNF133 – R GGCATGTCCCATGGGGTAAA 20 55 60  * 
             
ROPN1 – F CCAAAGTGGATGGGGAGAT 19 52.6 56.4 89  I 
ROPN1 – R GATTATACCATCAGGGCCAATTA 23 39.1 55.9   
             
SATL1 – F GCTGGAGACTGCCCAGAAAT 20 55 60 228  C 
SATL1 – R CTTGCCAGTCCATGAGTCGT 20 55 60   
             
SHCBP1L – F CGTGTCGAGCTCATTGAGTA 20 50 57.5 471  A 
SHCBP1L – R GTCAGCTTTGGACACCACAA 20 50 58.6   
             
SLC25A31 – F GGTACAAAGGCATGGTGGAC 20 55 58.8 422   B 
SLC25A31 – R CCCTGTACCGCGAAGAACAT 20 55 60.1 + 695  
             
SPDYA – F AAGTTAAGGGACCAGCTCTG 20 50 56.8 293 A 
SPDYA – R TGTTTTTCTGTCACCCCTGC 20 50 58.6   
             
SPO11 – F1 TGGTAACCAGACTGTCGTCG 20 55 59.4 331  E 
SPO11 – R1 ATCAGGAACTCCCTTTCCCG 20 55 59.1   
             
SPO11 – F2 ACGGGAAAGGGAGTTCCTGA 20 55 60.5 324  J 
SPO11 – R2 TCTCCAAAATGGTTGGCAGGT 21 47.6 60.1   
             
SPZ1 – F CTGCTAAGTCAGCTGAGATG 20 50 55.7 403  A 
SPZ1 – R TTGTCTTCTTTCTCTGGGGC 20 50 57.4  * 
             
TBC1D21 – F CCCTCTCTCCTGAAAACAGC 20 55 57.9 419 B 
TBC1D21 – R CTTGTCGATGAGGACGTTGC 20 55 59.3   
             
TGIF2LX – F1 ACCAGAGCACAAGAAGAAGC 20 50 58.1 578 A 
TGIF2LX – R1 GCTCTTGCTTCTTCTCTAGC 20 50 56  * 
             
TGIF2LX – F2 GAGTCCGTTAAGATCCTCCG 20 55 57.2 532 B 
TGIF2LX – R2 GCTTCTTCTCTAGCTCCAGC 20 55 57.8  * 
             
TKTL2 – F ACGACCGGTTCATCCTCTC 19 57.9 58.8 61 F 
TKTL2 – R TCCACCCAAGCAGCATAGA 19 52.6 58.3   
             
TMC7 – F1 GCAAACCATCTGCTGGATCG 20 55 59.6 331 B 
TMC7 – R1 ATGGATGAAGGACTGCAGCG 20 55 60.5   
             
TMC7 – F2  GCGGTATAGCAGCAAGTCTT 20 50 58.1 971  A 
TMC7 – R2  GGATTGTCAGACGGATCTCA 20 50 56.7   
             
TMC7 – F3 TCCTCCAAGAATTGCCAAGC 20 50 58.5 396 A 
TMC7 – R3 CCAGGAATCTCAAGAAGGAG 20 50 54.9   
             
TMEM146 - F GGAAATACTGACCCCACTGC 20 55 58.3 485 E 
TMEM146 – R GGTCGCAGCCAACTGAAATC 20 55 59.8   
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TPTE – F AGGCACCTGCGAAAGAAAG 19 52.6 58.4 85 G 
TPTE – R CGTGCTAACACACTTTCACTGAT 23 43.5 59.5   
             
TRIM42 – F GAAGCTCCTCCATGTTGTCC 20 55 58.3 524 B 
TRIM42 – R CCACTTAGCTCGGTTCTTCC 20 55 58   
             
TSGA13 – F CCTGCAGACTAGCAACCCAA 20 55 60 379 B 
TSGA13 – R TGCCCGACTGCATCAGAAAT 20 50 60   
             
TSSK2 – F AAGAACCTGACCTGCGAGTG 20 55 60 363 C 
TSSK2 – R CTAGGTGCTTGCTTTCCCCA 20 55 60  * 
             
TUBA3C – F CGGAGGAGCTCAACATGC 18 61.1 58.2 82 J 
TUBA3C – R AGTTCCCAGCAGGCATTG 18 55.6 57.6   
             
UBL4B – F CACGCTGAAGAGACTGGTGT 20 55 60 352 D 
UBL4B – R CTCCTCTGCCAGGAGGTACT 20 60 60  * 
             
UBQLN3 - F GGAGATGATACGTAGCCAGG 20 55 57 573 E 
UBQLN3 – R CCAGTACTGTTCTCTGTGGG 20 55 57.3  * 
             
UMODL1 - F GTGAAAGGAAGGAGGACGAC 20 55 57.9 563 E 
UMODL1 – R CAGCAGGTCATTCTGGAAGG 20 55 58.3   
             
VCY – F GGCCAAGGAGACAGGAAAG 19 57.9 57.7 80 H 
VCY – R CGGCCACCTTGGTAGTCTT 19 57.9 59.3   
             
YI72E07 – F TGCTACTTGCTGTGTGACCTG 21 52.4 60.5 X H 
YI72E07 – R ATGGTGTGACTTCCTCCTCAG 21 52.4 59.1   
             
ZSWIM2 - F AAACACCTTGGGATTCCCTG 20 50 57.7 466 A 
ZSWIM2 -R GGCATGAATTGCACTTGTGG 20 50 58.3   
The letters in the right hand column refer to the PCR cycling conditions used – refer to Table 2.2. 
X denotes that expected product size uncertain. 
*In PCR cycle column indicates that primer set did not span an intron. 
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Section 3 – Additional Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Germline genes displaying meta-change upregulation in cancer.   
The definitive list of germline genes (comprising over 1000 genes) were assessed using CancerMA 
(Feichtinger et al., 2012a).  The website is limited to ~300 targets on a single run, so the results for 
only a selection of the germline genes were provided in Figure 4.14.  Here, genes beginning with the 
letter A through to C are included.  Brain cancer and ovarian cancer feature most commonly as cancer 
types displaying a statistically significant upregulation in gene expression when the microarray 
datasets were meta-analysed, with CRC and lung cancer being the next most common. 
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Figure 2. Germline genes displaying meta-change upregulation in cancer.   
The definitive list of germline genes (comprising over 1000 genes) were assessed using CancerMA 
(Feichtinger et al., 2012a).  The website is limited to ~300 targets on a single run, so the results for 
only a selection of the germline genes were provided in Figure 4.14.  Here, genes beginning with the 
letter D through to K are included.  Brain cancer and ovarian cancer were once again the most 
common cancer types displaying a significant upregulation in gene expression when the microarray 
datasets were meta-analysed, with breast cancer featuring more prominently in this cohort of genes. 
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Figure 3. Germline genes displaying meta-change upregulation in cancer.   
The final cohort of genes (not shown in Figures 1 and 2 above or Figure 5.12) is shown here, with 
names starting with the letter L through to R.  Brain cancer and ovarian cancer were once again the 
most common cancer types displaying a significant upregulation in gene expression when the 
microarray datasets were meta-analysed but for this cohort head and neck cancer featured more 
commonly than in the other examples.  The combined list of meta-upregulated genes provides one 
avenue on which to narrow down on a smaller cohort of genes for individual cancer types. 
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Figure 4. Circos plot displaying meta-upregulated meiCT genes in cancer.   
When challenging the entire list of meiCT genes against CancerMA (Feichtinger et al., 2012a), 
ovarian cancer stood out as the predominant cancer type displaying meta-upregulations.  The thickness 
of the line connecting individual genes to the associated cancer type in which they are upregulated 
corresponds to the degree of upregulation or strength of association.  The reason for the prominence of 
ovarian cancer is unclear, as many ovarian tumours are believed to originate outside of the ovaries, 
although dormant meiosis-associated genes could conceivably be reactivated in cancer.  
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Figure 5. Western Blot indicating the presence of C20orf201 in cancer cell lines.   
Western blot was performed on whole cell extracts from NTERA-2, A2780, G-361 and SW480 cells.  
Detection of C20orf201 was with the ab108142 antibody (Abcam; Lot. GR125175-1, 1:1000).  All the 
cells line lysates produced a band of the expected size, and some in addition a fainter band at ~50 kDa.  
Secondary antibody: anti-rabbit IgG, HRP-linked (Cell Signaling, #7074; 1:3000 dilution).   GAPDH 
is shown as a loading control. 
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Figure 6.  IHC staining of C20orf201 in normal testis.   
IHC was performed on the semi-automated Ventana machine (Roche) using the rabbit polyclonal 
antibody against C20orf201 (Abcam, ab108142).  Positive staining was seen in germ cells of various 
stages of development/differentiation with strongest positive staining seen in the spermatogonial cells 
(arrows).  There was also positive staining seen in some cells surrounding the seminiferous tubules, 
indicating that the protein (or antigen detected by the antibody) was not restricted to germ cells of the 
testis.  A few post-meiotic spermatid/sperm cells are visible with small nuclei that displayed negative 
staining.  Images acquired on an AMG EVOS® xl Core microscope. 
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Figure 7.  Immunofluorescence (IF) staining for C20orf201 and MAGEA1 in 
normal testis (x40).   
IF was carried out on FFPE tissue blocks of normal testis showing MAGEA1 (green) staining detected 
by the mouse monoclonal antibody (LSBio, LS-C87868) localised to the spermatogonial layer of the 
seminiferous tubule.  The staining for C20orf201 (red) was with the rabbit polyclonal antibody 
(Abcam; ab170783).  Similar but less distinct staining pattern was obtained using the rabbit polyclonal 
antibody to C20orf201 (Abcam; ab108142) and the stronger staining seen on IHC in the 
spermatogonial layer could not be reproduced.  C20orf201 stained developing spermatocytes more 
strongly and there appeared to be no clear co-localisation with MAGEA1.  Images acquired on Zeiss 
LSM 710 confocal microscope.   
DAPI MAGEA1 
C20orf201 Combined 
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Figure 8.  IHC staining of C20orf201 in human tissues.   
Selected images taken from IHC performed on a TMA (CHTN_TEST2).  IHC was performed on the 
semi-automated Ventana® machine (Roche) using the rabbit polyclonal antibody against C20orf201 
(Abcam; ab108142, Lot. – GR125175-1).  Negative staining was seen in normal liver, smooth muscle 
and spleen: images (A), (B) and (C), respectively.  Positive nuclear staining was seen in a proportion 
of the stromal cells in normal prostate (D) but the prostate epithelium displayed negative staining.  
There was weak positive staining in normal colon (E) that was largely cytoplasmic (the example 
shown here displayed stronger staining than what was generally seen).  There was also patchy positive 
nuclear staining seen in breast cancer samples, as shown in (F).  Images obtained on a Zeiss Axio 
Scan.Z1 digital slide scanner. 
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Figure 9.  TEX19 and PIWIL1 staining in normal testis (x40).   
IF was carried out on a 4 µm section of FFPE tissue blocks of normal testis showing TEX19 (green) 
staining detected by the rabbit polyclonal antibody (Abcam, ab185547), which again localised 
between developing spermatocytes but towards the basal compartment of the seminiferous tubule.  
The co-staining for PIWIL1 was with the mouse monoclonal antibody (Sigma, SAB4200365).  The 
staining for PIWIL1 appeared stronger in the adluminal compartment where a higher proportion of 
cells would be undergoing meiosis.  Although there was no clear co-localisation between these two 
proteins, there was a region on the interface between the spermatogonial and adluminal compartments 
where cytoplasmic staining in the germ cells for PIWIL1 was quite strong; this is the same region of 
the seminiferous tubule that TEX19 was consistently found (although not in the precise same cellular 
region).  Images acquired on Zeiss LSM 710 confocal microscope. 
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Figure 10.   PIWIL2 staining in normal testis (x40).   
IF was carried out on FFPE tissue blocks of normal testis showing PIWIL2 (green) staining detected 
by the mouse monoclonal antibody (Abnova, MAB0843).  In this example, more distinct staining was 
observed in the cytoplasm of germ cells in the spermatogonial compartment.  Comparison can be 
made to Figure 4.8 in Chapter 4, where co-staining for TEX19 was performed.   Images acquired on 
Zeiss LSM 710 confocal microscope. 
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Figure 11.  Negative control for IF analysis on normal testis (40x)  
Negative control for Figures 4.6-4.8, in Chapter 4.  Top left – DAPI staining.  Top right – Alexa Fluor 
488 (green) rabbit secondary antibody only.  Bottom left – Alexa Fluor 568 (red) mouse secondary 
antibody only.  Bottom right – maximum intensity projection of combined image. Images acquired on 
Zeiss LSM 710 confocal microscope.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.  Negative control for IF analysis on normal testis and colon (40x) 
Negative controls for Figures 4.12-4.16.  Negative control performed in normal testis shown in (A) 
and negative control in normal colon in (B).  Top left of each image – DAPI staining.  Top right of 
each image – Alexa Fluor 488 (green) rabbit secondary antibody only.  Bottom left of each image – 
Alexa Fluor 647 (red) mouse secondary antibody only.  Bottom right of each image – maximum 
intensity projection of combined image. Images acquired on Zeiss LSM 710 confocal microscope.   
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Figure 13.  IHC staining for TEX19 in human tissues.   
IHC was performed on the semi-automated Ventana® machine (Roche) using the rabbit polyclonal 
antibody against TEX19 (Abcam; ab185547) on a normal human TMA (CHTN_NORM2).  The 
majority of the tissues included on the array, which included 150 individual tissue cores, stained 
negative for TEX19.  Moreover, the majority of the remaining tissues stained only weakly positive – 
this was predominantly cytoplasmic staining.  Here an example of some of the staining patterns seen is 
provided.  (A) Shows an example of what was considered negative staining in a normal section of 
lymph node.  (B) Is a section of pancreas and this was considered to display weak focally positive 
nuclear and cytoplasmic staining.  Normal testis (C) was included on the array and produced a similar 
staining pattern to that seen previously with moderate staining seen towards the basal compartment of 
the seminiferous tubules; acting as a positive control.  Weak but consistently positive staining was 
seen in intestinal epithelial cells but predominantly adjacent to the lumen (i.e. adluminal); a sample of 
small intestine with stronger than typical staining is shown in (D).  Weak cytoplasmic staining also 
seen in amniotic membrane shown in (E) and in a sparse fashion within normal bronchial epithelium 
shown in (F).  Images obtained on a Zeiss Axio Scan.Z1 digital slide scanner. 
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Figure 14.  Forest plots for two of the identified meiCT genes, DNAJC5G and IQCF1.   
These Forrest plots display a statistically significant meta-upregulation in gene expression for 
both genes in ovarian cancer when combined microarray datasets are analysed.  There is an 
approximate 1.6 log-fold change over matched normal vs. cancer array sets for DNAJC5G (A) 
and an approximate 2.1 log-fold change for IQCF1 (B).  The upper five squares illustrate the 
individual microarray studies, with the confidence intervals for the individual studies 
represented by the horizontal lines.  The size of the squares is proportional to the weight 
assigned to the individual study.  The upper diamond is a summary of all five data-sets 
showing significant upregulation for ovarian cancer.  When all the cancer-types on the arrays 
were meta-analysed there was no significant change in expression over normal tissues (lower 
diamond). 
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Figure 15.  Forest plot for two of the identified meiCT genes, LYZL6 and PPP3R2.   
These Forrest plots display a statistically significant meta-upregulation in gene expression for 
both genes in ovarian cancer when combined microarray datasets are analysed.  There is an 
approximate 1.2 log-fold change over matched normal vs. cancer array sets for both genes.  
The upper five squares illustrate the individual microarray studies, with the confidence 
intervals for the individual studies represented by the horizontal lines.  The size of the squares 
is proportional to the weight assigned to the individual study.  The upper diamond is a 
summary of all five data-sets showing significant upregulation for ovarian cancer.  When all 
the cancer-types on the arrays were meta-analysed there was no significant change in 
expression over normal tissues (lower diamond). The Forrest plot for SPZ1, which also 
displayed a meta-upregulation in ovarian cancer, is shown in Figure 3.7. 
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Figure 16.  Forest plots for three of the identified meiCT genes: ACTL9, ADAM2 and ASB17.   
These Forrest plots display a statistically significant meta-upregulation in gene expression in 
prostate cancer when combined microarray datasets are analysed.  There is an approximate 
1.7 log-fold change over matched normal vs. cancer array sets for ACTL9 (A), an approximate 
2.9 log-fold change for ADAM2 (B), and a 1.8 log-fold change for ASB17 (C).  The upper two 
squares illustrate the individual microarray studies, with the confidence intervals for the 
individual studies represented by the horizontal lines.  The size of the squares is proportional 
to the weight assigned to the individual study.  The upper diamond is a summary of the data-
sets showing significant upregulation for prostate cancer.  When all the cancer-types on the 
arrays were meta-analysed there was no significant change in expression over normal tissues 
(lower diamond). 
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Figure 17.  Forest plots for three of the identified meiCT genes: C3orf22, DNAJC5G and 
PPP3R2.   
These Forrest plots display a statistically significant meta-upregulation in gene expression in 
prostate cancer when combined microarray datasets are analysed.  There is an approximate 
1.5 log-fold change over matched normal vs. cancer array sets for C3orf22 (A), an 
approximate 1.9 log-fold change for DNAJC5G (B), and a 1.1 log-fold change for PPP3R2 
(C).  The upper two squares illustrate the individual microarray studies, with the confidence 
intervals for the individual studies represented by the horizontal lines.  The size of the squares 
is proportional to the weight assigned to the individual study.  The upper diamond is a 
summary of the data-sets showing significant upregulation for prostate cancer.  When all the 
cancer-types on the arrays were meta-analysed there was no significant change in expression 
over normal tissues (lower diamond). 
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Figure 18.  Forest plots for two of the identified meiCT genes: C12orf50 and TRIM42.   
Forrest plots displaying a statistically significant meta-upregulation in gene expression in 
prostate and/or ovarian cancer when combined microarray datasets are analysed.  These genes 
did not appear to be expressed in the limited cancer samples we tested through PCR.  There 
was however an approximate 1.2 log-fold change over matched normal vs. cancer array sets 
for C12orf50 (A), an approximate 3.1 log-fold change in prostate cancer (B) and 1.9 log-fold 
change in ovarian cancer (C) for TRIM42.  The upper squares illustrate the individual 
microarray studies, with the confidence intervals for the studies represented by the horizontal 
lines.  The size of the squares is proportional to the weight assigned to the individual study.  
The upper diamond is a summary of the data-sets showing significant upregulation for 
relevant cancer type.  When all the cancer-types on the arrays were meta-analysed there was 
no significant change in expression over normal tissues (lower diamond). 
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Figure 19.  Forest plots for three of the identified meiCT genes: FAM71B, SHCBP1L and 
TMEM146.   
These genes did not appear to be expressed in the cancer samples we tested through PCR.  
However, there was a meta-upregulation in gene expression in ovarian cancer for all three 
genes when combined microarray data are analysed.  There was an approximate 1.3 log-fold 
change over matched normal vs. cancer array sets for FAM71B (A), an approximate 1.9 log-
fold change for SHCBP1L (B) and a 2.4 log-fold change for TMEM146 (C).  The upper 
squares illustrate the individual microarray studies, with the confidence intervals for the 
studies represented by the horizontal lines.  The size of the squares is proportional to the 
weight assigned to the individual study.  The upper diamond is a summary of the data-sets 
showing significant upregulation for relevant cancer type.  When all the cancer-types on the 
arrays were meta-analysed there was no significant change in expression over normal tissues 
(lower diamond). 
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Figure 20.  Circos plot displaying meta-upregulated randomly selected genes.   
100 genes were randomly selected from a list of protein-encoding genes provided by the HUGO gene 
nomenclature committee (HGNC) – www.genenames.org.uk (website accessed 18th May 2016).  59 of 
these randomly selected genes displayed a meta-upregulation in at least one cancer type.  23 of the 
genes were not included on the arrays, so overall 76.6% displayed at least one upregulation in at least 
one cancer type.  Brain, ovarian and lung cancer displayed the most upregulations but in comparison 
to Figure 4 above, there was not a striking preponderance for ovarian cancer as was seen for the 
meiCT gene cohort.  The thickness of the line connecting individual genes to the associated cancer 
type in which they are upregulated corresponds to the degree of upregulation or strength of 
association.    
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Figure 21.  Circos plot displaying meta-upregulated randomly selected ‘housekeeping’ genes.   
Housekeeping genes are expressed in both normal and pathological tissues and some display fairly 
constant expression in both normal and pathological states (Eisenberg and Levanon, 2013).  They are 
thus useful for quantitative PCR experiments, acting as a normalisation factor, though should ideally 
be optimised for each disease state or sample cohort.  100 genes were randomly selected from a list of 
housekeeping genes, freely available at www.tau.ac.il (website accessed 10th June 2016).  Of the 100 
randomly selected housekeeping genes, 73 were shown to have a meta-upregulation in at least one 
cancer type.  However, only 6 of these genes were not included on the arrays.  So, overall 77.6% 
displayed at least one up-regulation in at least one cancer type.  The thickness of the line connecting 
individual genes to the associated cancer type in which they are upregulated corresponds to the degree 
of upregulation or strength of association.    
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Figure 22.  Circos plot displaying meta-upregulated selected ‘housekeeping’ genes.   
Eleven housekeeping genes were put forward as the most consistent genes displaying constant 
expression in different tissue states (Eisenberg and Levanon, 2013).  When subject to analysis through 
the cancerMA pipeline (Feichtinger et al., 2012a), seven of the genes displayed a meta-upregulation in 
at least one cancer type.  One of the genes was not present on the arrays, so overall 70% displayed at 
least one upregulation in at least one cancer type: only slightly lower than the randomly selected 
cohort of genes.  Although these genes would be expected to show constant expression, the fact they 
do in selected cancers is still not unsurprising given the heterogenous nature of the disease.  The 
proportion of genes displaying upregulations is slightly lower when compared to other gene cohorts.  
As acknowledged in the text, there are limitations of cancerMA as there are with other existing 
pipelines and the results produced should not be over-interpreted.  The thickness of the line connecting 
individual genes to the associated cancer type in which they are upregulated corresponds to the degree 
of upregulation or strength of association.    
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Figure 23.  Circos plot displaying meta-upregulated genes previously shown to be upregulated in 
ovarian cancer.   
Seven genes have recently been shown in one study to be upregulated in ovarian cancer samples (Gao 
et al., 2016).  When subject to analysis through cancerMA, 3 of these 7 genes displayed a meta-
upregulation in ovarian cancer.  As highlighted in the text cancerMA has limitations, one being the 
restricted number of arrays included and the inherent weaknesses of the raw microarray data on which 
it is based.  It is not surprising that there is not an exact correlation to other published work using 
different methodologies in different samples.  BCL6 was shown in a separate study to be upregulated 
in different subtypes of ovarian cancer (Wang et al., 2015b), so it is reassuring to see that cancerMA 
displays a meta-upregulation for this gene.  The thickness of the line connecting individual genes to 
the associated cancer type in which they are upregulated corresponds to the degree of upregulation or 
strength of association.    
 
